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ABSTRACT 
PART I - TOTAL SYNTHESIS OF (−)-PF-1018 
The family of polyketide natural products arising from 1,3,5-cyclooctatriene intermediates has grown 
significantly in the last decade. The oldest and most famous members of this family are the endiandric acids, 
and more recently natural products such as the elysiapyrones, kingianins and ocellapyrones have been 
isolated and synthesized. The reaction cascades that yield these compounds commence from conjugated 
E,Z,Z,E tetraenes, which undergo an 8π/6π electrocyclization sequence leading to bicyclo[4.2.0]octadienes. 
For some of these natural products, such as endiandric acid C, this cascade is followed by an intramolecular 
Diels−Alder reaction. (−)-PF-1018 can also be considered a member of this family, since this polyketide 
originates from a 1,3,5-cyclooctatriene precursor. However, (−)-PF-1018 is obtained through a variation of 
the 8π/6π/Diels−Alder cascade: the cyclooctatriene intermediate is intercepted by a dienophile in an 
intramolecular [4+2] cycloaddition, bypassing the 6π electrocyclization step. This unique reactivity defines 
the unprecedented structure of (−)-PF-1018, which comprises a tricyclic 8/6/5 ring system bearing 6 
contiguous stereocentres. This core is linked to a bicyclic tetramic acid by an ethylene linker. 
 
 
The first part of this thesis describes the total synthesis of (−)-PF-1018. The key cascade reaction started 
with a polyene bearing a doubly protected syn-diol responsible for the divergent reactivity that led to the 
[4+2] cycloaddition. In the absence of these hydroxy groups the corresponding polyene underwent the 
“classical” 8π/6π electrocyclization cascade. The tricyclic core was further elaborated by means of a 
Barton−McCombie reaction which yielded the desired product together with an unexpected tetracycle. 
Both intermediates reconverged into an aldehyde which was transformed into (−)-PF-1018 via a 
Horner−Wasworth−Emmons reaction. 
 
VIII 
 
PART II – DEVELOPMENT OF PHOTOSWITCHABLE GABAA RECEPTOR POTENTIATORS 
GABAA receptors are ionotropic receptors ubiquitous in the central nervous system which are activated by 
gamma-aminobutyric acid (GABA). The binding of two molecules of GABA induces pore opening causing a 
flow of chloride anions into the cell which inhibits neurotransmission. The activity of these receptors can be 
modulated by different drugs, the most prevalent of which are benzodiazepines and Z-drugs. These 
compounds induce current potentiation by increasing the affinity of the GABAAR for the GABA 
neurotransmitter. Benzodiazepines and Z-drugs show low specificity for the different GABAAR subtypes, and 
therefore cause undesired side effects such as drowsiness, anterograde memory loss and ataxia. Although 
the binding site and binding modes of benzodiazepines have been recently elucidated, other binding 
pockets for these drugs exist. In the case of Z-drugs, it is known that they bind the benzodiazepine binding 
site, but their binding mode has yet to be described. 
 
 
In the second part of this thesis we describe the principles of design and the synthesis of a photoswitchable 
benzodiazepine. The azo-extension approach on the benzodiazepine scaffold relied on the early 
introduction of the azobenzene moiety at the ortho-position of the pendant phenyl ring. This resulted in the 
isolation of new azobenzophenone intermediates as well as the envisioned azobenzodiazepine. 
 
We also describe the design and synthesis of the first reported photoswitchable Z-drugs. The design was 
built on a lead compound found in a virtual screening campaign based on the benzodiazepine binding 
model. Given the high affinity of the parent compound for the GABAAR and the presence of an “azostere” 
in its structure, we decided to synthesize a series of photochromic ligands using an azologization approach. 
Again, the strategy relied on the early introduction of the azobenzene moiety, giving rise to new types of 
heterocyclic azobenzenes. 
IX 
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J coupling constant (NMR 
spectroscopy) 
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KR   ketoreductase 
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λ  wavelength 
L   ligand 
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spectroscopy 
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LED  light emitting diode 
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o  ortho 
p  para 
PAM   positive allosteric modulator 
PBS  phosphate-buffered saline 
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1. Introduction 
1.1 1,3,5-Cyclooctatriene: Thermal Electrocyclizations 
and Historical Perspective 
 
The first synthesis of 1,3,5-cyclooctatriene (1.4 or simply cyclooctatriene) was reported by Richard 
Willstätter and Hans Veraguth in 1905 as an intermediate in the synthesis of cyclooctatetraene (1.7).[1] 
Starting from pseudopelletierine (1.1), a natural product present in the root-bark of the pomegranate tree, 
1.4 could be obtained through ketone reduction and dehydration of the resulting alcohol followed by two 
consecutive Hofmann eliminations of the amino bridge present in 1.2 (Scheme 1.1, A). Three decades later, 
American chemists including Hurd, Drake, Horning, Goldwasser or Taylor, who could not reproduce these 
results argued that the product isolated by Willstätter could not be identified as cyclooctatetraene.[2–5] In 
1947 however, Arthur C. Cope reproduced Willstätter’s results and corroborated the structure of 
cyclooctatetraene (1.7) by comparison to a sample obtained by the method of Walter Reppe from BASF 
Ludwigshafen, who synthesized 1.7 from acetylene in the presence of a nickel catalyst at high pressures.[6,7] 
The previous laborious synthesis of 1,3,5-cyclooctatriene from pseudopelletierine did not allow for isolation 
of large quantities of 1.4, but by Reppe’s method significant amounts of cyclooctatetraene, a near 
precursor, could be readily prepared. This prompted Cope and others to develop a method in which 1.7 was 
transformed into a mixture of 1,3,5-cyclooctatriene and 1,3,6-cyclooctatriene under Birch conditions. 
Treatment of the mixture with potassium tert-butoxide yielded solely the conjugated isomer (Scheme 1.1, 
B).[7,8] 
Years later, in 1965, coinciding with the publication of Woodward and Hoffman’s article which established 
the rules for pericyclic reactions, the first synthesis of 1,3,5-cyclooctatriene from a linear precursor was 
developed by Ziegenbein using a method by Meister, which consisted of partial hydrogenation of diyne 1.8, 
obtained by Glaser coupling of vinylacetylene, (Scheme 1, C) followed by an 8π electrocyclization.[9,10] This 
sequence was later used in the synthesis of endiandric acids by Nicolaou, as described in Chapter 1.2.1. 
 
Scheme 1.1. Overview of the different synthetic routes towards cyclooctatriene in chronological order. 
 
In 1950, Cope was intrigued by the slight variations found in the refractive indices of different samples of 
1,3,5-cyclooctatrienes. Upon distillation of 1.4 at unusually high temperatures (80 ºC instead of 40 ºC), which 
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presumably triggered a 6π electrocyclization, and treatment of the fractions with the lowest refractive index 
with silver nitrate, bicyclo[4.2.0]octa-2,4-diene (1.10) was isolated.[11] Its structure was confirmed by 
hydrogenation to bicyclo[4.2.0]octane and by separate Diels−Alder reaction with succinic anhydride. Cope 
recognized that the 6π electrocyclization was a reversible reaction since upon heating 1.10 various amounts 
of cyclooctatriene were obtained. 
After the first description of the valence isomerization of cyclooctatriene by Cope and given its now easy 
access, many chemists studied the 8π/6π reaction cascade of octatetranes,[12,13] with Huisgen being the 
most prolific for several years. 
 
 
Scheme 1.2 and Figure 1.1. Top. Activation energies for 8π and 6π electrocyclizations of 1.9 and 1.4 obtained 
by Huisgen experimentally(a) and calculated by Houk.(b) Bottom. Transition states for both transformations 
calculated by Houk (included with his permission).[20] 
 
Huisgen focused on the kinetics and thermodynamics of these electrocyclizations providing the first 
activation energy values, (1.9→1.4 = 17.0 kcal/mol and 1.4→1.10 = 27.8 kcal/mol, Scheme 1.2), reaction 
constants, distribution of the different species at different temperatures and substituent effects on the 
electrocyclization processes.[14–17] In the case of 2,4,6,8-decatetraene for example, he described that the 
(E,Z,Z,E)-isomer cyclized fastest, followed by the (E,Z,Z,Z)-isomer and the all cis (Z,Z,Z,Z)-isomer, which was 
the slowest.[18] He also noted that the processes were conrotatory for the 8π electrocyclization and 
disrotatory for the 6π, in agreement with the Woodward−Hoffman rules. At high temperatures (>140 ºC), 
however, “forbidden” processes occurred to some extent.[19] 
 
Scheme 1.3. Torquoselectivity in cyclooctatriene ring opening. The lowest energy transition state is the one 
in which the biggest substituent points out of the ring (outward), which in this case involves a clockwise 
rotation along the C-C axis next to the breaking sigma bond. Note that for ring closure, the positioning of 
the substituent in the transition state is predefined by the Z- or E- configuration of the terminal double bond. 
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Major contributions based on computational chemistry were later made by Kendall N. Houk. He reported 
the structures for transition states and made systematic studies on the influence of terminal substituents 
in the outcome of the cyclization cascade.[20–23] The torquoselectivity of the retro 8π electrocyclization was 
one of the main subjects of study in these articles. This concept coined by Houk is defined as the preference 
of the terminal substituents to occupy an inward or an outward position during the transition state (Scheme 
1.3).[24,25] 
Unlike for cyclobutene, the electronic influence of the terminal substituents is not relevant in 8π 
electrocyclizations given the low orbital overlap in the transition state.[21,25–27] Steric bulk, however, plays an 
important role in determining the direction of rotation of the side chains, with the outward preferred in a 
vast majority of cases. Interestingly, Houk also provided an explanation as to why no natural products with 
a disubstituted endo-syn pattern at C7 and C8 in bicyclo[4.2.0]octadienes have been found. The transition 
state for such compounds is too high in energy due to the steric clash of the substituents with the hexadiene 
ring and with each other (Scheme 1.4 and Figure 1.2). 
 
 
 
Scheme 1.4 and Figure 1.2. Activation energies for the 6π electrocyclization of triene 1.12 and calculated 
structures of the transition states by Houk (included with his permission).[20] The energy difference of 4 
kcal/mol can explain why no disubstituted endo-C7,C8-syn natural products have been found. 
 
Regarding other electrocyclizations of cyclooctatriene, the relative energies of the transition states for 6π 
and 4π thermal electrocyclizations are respectively 18 and 32 kcal/mol higher than the activation energy 
for the 8π process.[27] This explains why such reactivities are scarcely observed (Scheme 1.5, Top).[28] The 
photochemical 8π electrocyclization is outcompeted by [4+2] cycloaddition, yielding vinyl 
bicyclo[3.1.0]hexene.[28–31] 
As a closing remark on Houk’s studies on the 8π/6π electrocyclization cascade, substitution at the 
octatetraene termini strongly influences the outcome of the cyclization process (Scheme 1.3). When R ≠ H, 
the activation energy for the 8π electrocyclization increases, especially for terminal (Z)-configured 
tetraenes. The presence of substituents at terminal positions also increases the instability of the resulting 
cyclooctatriene intermediates, (especially if they are syn-configured, such as 1.12, Scheme 1.4) lowering the 
activation energy for the 6π electrocyclization. Therefore, the equilibrium of the 8π/6π electrocyclization 
cascade is generally shifted towards the bicyclo[4.2.0]octadienes (1.13 in Scheme 1.4), except for 
unsubstituted cyclooctatriene (1.4, Scheme 1.2), isolable at room temperature. 
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1.2 Cyclooctatriene-Derived Natural Products 
 
As shown in Chapter 1.1, cyclooctatrienes arise from octatetraenes upon 8π electrocyclization, but this is 
not the only reactivity available to octatetraenes, since photochemically induced intramolecular Diels−Alder 
reactions and 6π disrotatory electrocyclizations can also take place. These reactivities have been exploited 
for the synthesis of different natural products (NPs), many of which are thought to share common 
precursors. For example, ocellapyrone A (1.15), photodeoxytridachione (1.16) and 9,10-deoxytridachione 
(1.17) can be traced back to the same precursor 1.14 (Scheme 1.5, bottom).[31–33]In some occasions this 
reactivity has led to undesired side products or frustrated synthetic approaches, as later discussed with 
regard to Trauner’s early attempts towards SNF4435.[34] Moreover, these reaction pathways can be 
responsible for the relatively low yields in many of the 8π/6π cyclization cascades which follow. 
In this chapter we will provide an overview on the total syntheses of most members of the Cyclooctatriene-
Derived natural product family. The polyketide nature of these NPs together with the ubiquitous presence 
of cyclooctatriene derivatives as key intermediates in their total syntheses (and presumably also in the 
corresponding biosyntheses), justifies in our opinion the inclusion of these NPs, together with PF-1018 in 
the aforementioned family.  We also include the syntheses of three sesquiterpene natural products which 
do not belong to this family but entail a cyclooctatriene key intermediate.  
 
Scheme 1.5. Top. Octatetraene and its different pericyclic reactions. Bottom. Natural products which 
originate from the linear precursor 1.14 as a result of the processes shown above.[31–33] 
 
1.2.1 Endiandric acids 
Until recent years, cyclooctatrienes had only been scarcely used as intermediates in total synthesis. The first 
and most remarkable use of cyclooctatrienes in natural product synthesis was reported by Nicolaou in his 
biomimetic synthesis of various endiandric acids.[35] This work was inspired by Black’s brilliant 1980 
biosynthetic proposal, in which he hypothesized that the endiandric acids A, B and C, isolated from 
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Endiandra introrsa (Lauraceae) were formed from linear polyenes.  He posited that these polyenes 
underwent an 8π electrocyclization to deliver functionalized cyclooctatrienes (Scheme 1.6),[36] which was 
followed by a 6π thermal disrotatory electrocyclization to yield bicyclo[4.2.0]octadienes, known as 
endiandric acids E-G (Scheme 1.6).[36–38] Finally, upon intramolecular Diels−Alder reactions, the intrincate 
structures of endiandric acids A, B, and C, bearing 8 stereocentres could be obtained. Black observed that 
these natural products were all racemic, and therefore suggested that no enzymes took part in the 
cyclization steps. 
 
Scheme 1.6. Biosynthesis of endiandric acids A-C as proposed by D. St. C. Black. 
 
As mentioned in Chapter 1.1, linear polyenes such as 1.27 (Scheme 1.7) bearing 1,3,5,7-tetraene entities 
(where C3-C4 and C5-C6 olefins must be Z) undergo 8π thermal conrotatory electrocyclization via transition 
state 1.27TS delivering cyclooctatriene 1.21. This compound exist as a mixture of two conformers, 1.21a 
and 1.21b, which interconvert by a ring flip with an energy barrier of 4-7 kcal/mol (Scheme 1.7).[39] Each 
conformer, 1.21a or 1.21b, yields a different diastereomer upon 6π electrocyclization, which in the case 
depicted in Scheme 1.7 are endiandric acids D and E. 
 
Scheme 1.7. Biosynthesis of endiandric acids D-E as proposed by D. St. C. Black showing one of the two 
possible transition states for the 8π electrocyclization and the two conformers of the resulting 
cyclooctatriene. 
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Following Black’s reasoning, Nicolaou envisioned a biomimetic synthesis of endiandric acids using simpler 
substrates for the 8π/6π cascade, which would be further functionalized prior to the Diels−Alder reaction.[40] 
Thus, starting from symmetric diyne 1.30 obtained through Glaser alkyne coupling of enyne 1.29, partial 
reduction with Lindlar´s catalyst presumably led to the non-isolable octatetraene 1.31, which after the 
8/6 cascade yielded bicyclo[4.2.0]octadiene 1.32 (Scheme 1.8). Selective protection of the exo-alcohol 
was achieved by regiospecific iodoetherification of the endo-alcohol followed by TBDPS protection of the 
remaining primary alcohol and reversal of the etherification by treatment with Zn dust and acetic acid. Appel 
reaction followed by nucleophilic substitution of the resulting bromide by sodium cyanide in HMPA allowed 
for isolation of the key intermediate 1.34, which could be further elaborated affording endiandric acids A-
G (Schemes 1.8 and 1.9). Subsequent DIBAL reduction of 1.34 and condensation of the resulting aldehyde 
with diethyl trans-cinnamylphosphonate yielded the Diels−Alder precursor 1.35. The desired [4+2] 
cycloaddition was achieved in refluxing toluene, which smoothly yielded the core structure 1.36. This was 
elaborated into the common precursor of endiandric acids A and B, 1.37 by TBAF deprotection, Appel 
reaction and one-carbon homologation via nucleophilic attack of sodium cyanide. 1.37 was finally converted 
into endiandric acids A and B by simple cyanide hydrolysis for endiandric acid A (1.25) and Wittig olefination 
with phosphonium salt 1.38 and ester hydrolysis for endiandric acid B (1.26). 
 
Scheme 1.8. Total synthesis of endiandric acids A and B by Nicolaou. 
 
Starting from the key intermediate 1.34, Nicolaou also accomplished the synthesis of endiandric acids C-G 
(Scheme 1.9).  At the time, only endiandric acids C and D had been found in nature.[41] 
Bicyclo[4.2.0]octadiene 1.43 was prepared from 1.34 in 7 steps and was condensed with dimethyl E-
cinnamylphosphonate to yield endiandric acid D. Endiandric acid D was then transformed into its 
corresponding methyl ester by treatment with diazomethane, and was further reduced to give aldehyde 
1.44, which was coupled with phosphonate 1.38 and hydrolysed to yield endiandric acid G. Aldehyde 1.39 
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was obtained from the key intermediate 1.34  by DIBAL reduction and was submitted to a HWE reaction 
which yielded tetraene 1.42, from which endiandric acids E and F were obtained in 5 steps each. 
Aldehyde 1.39 was also an intermediate in the synthesis of endiandric acid C. After condensation with 
phosphonate ester 1.38, an intramolecular Diels−Alder reaction took place in excellent yield by refluxing 
triene 1.40 in toluene for 12 hours. The resulting tetracycle 1.41 was converted into endiandric acid C in 6 
steps using similar chemistry as previously described. 
 
Scheme 1.9. Total synthesis of endiandric acids C-G by Nicolaou. 
 
Having achieved the first total syntheses of endiandric acids A-G, Nicolaou provided another approach 
towards these natural products in a strictly biomimetic fashion.[42] Now the main goal was to give evidence 
to corroborate Black’s hypotheses. Based on their previous experience, two initial considerations were 
taken as guidelines: 1) The central (Z,Z)-diene should be masked until a late stage to avoid undesired 8π 
electrocyclization. 2) For practical reasons, the carboxylic acid groups would be exchanged by methyl esters. 
 
Scheme 1.10. Preparation of the building blocks for the biomimetic syntheses of endiandric acid methyl 
esters A-G. 
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As depicted in Scheme 1.10, alkylation of deprotonated thioether 1.45 with alkyl iodide 1.46 led to silyl 
ether 1.47, which was subsequently deprotected and oxidized to deliver aldehyde 1.48. Condensation of 
1.48 with dimethyl trans-cinnamylphosphonate yielded thioether 1.49, which was converted to the 
corresponding sulfoxide by treatment with m-CPBA. Thermally induced elimination and TMS deprotection 
with silver nitrate and potassium cyanide then provided triene 1.50 as a 1:1 mixture of E/Z isomers. Upon 
purification, the E-isomer was independently submitted to two Glaser couplings with alkynes 1.51 and 1.52, 
both derived from thioether 1.47. A further oxidation/elimination sequence led to diynes 1.53 and 1.54, 
which could be separated by flash chromatography. 
 
Scheme 1.11. Biomimetic synthesis of the methyl ester derivatives of endiandric acids A-G. 
 
Finally, the linear endiandric acid precursors 1.53 and 1.54 were successfully submitted to semi-reductive 
conditions with Lindlar’s catalyst in the presence of hydrogen affording the desired endiandric acid methyl 
esters.[43] Thus, when 1.53 was stirred for few hours at room temperature under these conditions, the semi-
reduction of the diyne was followed by an 8π/6 π electrocyclization sequence delivering endiandric acid 
analogues D and E (1.55, 1.56) in low yields without any trace of the Diels−Alder product 1.57. However, if 
the mixture was heated up to 100 ºC for a few minutes under the previously described conditions, the 8π 
electrocyclization was followed by a [4+2] cycloaddition resulting in the isolation of endiandric acid A methyl 
ester (1.57) as the single product. 
In the case of polyene 1.54, the same reaction at room temperature led to the isolation of the respective 
methyl esters of endiandric acids F and G (1.58, 1.59. When the reaction mixture was heated up for few 
minutes at 100 ºC, the previous sequence was followed by a Diels−Alder reaction, which delivered 
endiandric acid methyl esters B and C (1.60, 1.61). 
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Finally, a NMR study of the thermal conversion of these compounds was performed at 70 ºC. The equilibrium 
between endiandric acid methyl esters E and D and the transformation of the former into endiandric acid A 
was monitored showing a half-life of 1.3 hours for 1.56, with 1.57 being the major component after 6 hours. 
When pure endiandric acid F methyl ester was submitted to the same conditions, build-up of G took place 
quickly in the first 2 hours and then slowly decayed. Unlike the latter, endiandric acid B methyl ester slowly 
enriched the mixture and turned into the major isomer after 6 hours. Finally, endiandric acid C methyl ester 
slowly built-up and only represented 10% of the mixture after 14 hours. 
This extensive work by Nicolaou proved Black’s hypothesis for the biosynthesis of endiandric acids and 
described an elegant and high yielding synthesis of these complex natural products. It also established a 
new type of cascade that would be used in the future for the synthesis of other intricate natural products 
such as the kingianins and the elysiapyrones. The question of how the Diels−Alder reaction takes place in 
nature without the assistance of enzymes would remain an intriguing question until a possible explanation 
was provided with the total synthesis of kingianin A.[44] 
 
1.2.2 SNF4435 
A remarkable case of a total synthesis race took place with the immunosuppressant natural products 
SNF4435C and SNF4435D.[45–47] Unlike the endiandric acids, these pyrones, isolated by Kurosawa from 
Streptomyces spectabilis were found as single enantiomers.  
 
Scheme 1.12. Proposed biosynthesis of SNF4435 C and D. 1.67 and 1.68 represent a pair of isomers not found 
in nature, presumably due to the torsional strain between the contiguous nitrobenzene and methyl groups 
(the tetrahydrofuran ring was omitted for clarity). 1.71 represents the misassigned structure of SNF4435 D 
by Kurosawa and 1.70 the real structure as corrected by Trauner. 
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SNF4435C and SNF4435D showed unprecedented potent selective immunosuppressive activity towards B-
cell proliferation without affecting T-cell production, suggesting a new mode of action. This interesting 
bioactivity together with their attractive bicyclo[4.2.0]octadiene core prompted several research groups to 
pursue their total synthesis, reviving a cascade sequence which had not been utilized for 20 years. The main 
participants in this race were Christopher M. Beaudry and Dirk Trauner from UC Berkeley; Jack E. Baldwin, 
John E. Moses, Robert M. Adlington, Mikkel F. Jacobsen and Rodolfo Márquez for Oxford University; and 
Kathlyn A. Parker and Yeon-Hee Lim from Stony Brook University, New York. 
The first article was released in April 2002 from the Trauner group[34] and included synthetic studies, a 
proposed biosynthesis and a corrected structure for SNF4435D based on the logic of the 8π/6π cascade. 
The synthesis portion consisted of two linear routes which failed to provide a cascade precursor and one 
elegant and simple modular approach which yielded a bicyclo[4.2.0]octadiene with a methyl ester handle 
for further functionalization (Scheme 1.13). 
 
Scheme 1.13. Synthetic approaches towards SNF4435 by Trauner. A, B. failed attempts towards the 
bicyclo[4.2.0]octadiene core. C. Successful approach towards bicyclic precursor 1.86 via 8π/6π 
electrocyclization cascade. 
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The first explored route started with aldehyde 1.72, which was elongated via Still−Gennari olefination 
followed by DIBAL reduction and HWE reaction to install the ethyl ester handle. Although the labile ester 
1.73 underwent spontaneous 6π electrocyclization yielding undesired cyclohexadiene 1.74, it could be 
reduced to alcohol 1.75 upon treatment with DIBAL. However, 1.75 was also unstable and could not be 
further oxidized to aldehyde 1.76. 
A second-generation approach was inspired by biogenetic considerations. Since the biosynthesis of 
polyenes is achieved by a series of reduction and dehydration steps,[48] this strategy was translated to the 
synthesis by the hydration of one of the double bonds in search for increased stability. Thus, starting with 
aldehyde 1.77, an intermediate in the previous route, an Evans aldol reaction afforded oxazolidinone 1.78, 
which was transformed into advanced intermediate 1.79 in 5 steps. Unfortunately, all attempts to 
dehydrate this compound led to decomposition. 
The final approach relied on a late-stage Stille coupling of vinyl iodide 1.81 with stannane 1.83. The former 
was synthesized by a Stork−Zhao olefination of aldehyde 1.72, and the stannane was obtained by a 
carbocurpation of propargyl alcohol followed by trapping of the metalated species with iodine to give the 
branched product 1.82. Oxidation of the alcohol followed by Wittig olefination and metalation with 
hexamethylditin yielded 1.83. The tandem Stille coupling between 1.81 and 1.83 followed by the 8π/6π 
cascade took place at room temperature in the presence of Pd(MeCN)Cl2 yielding exclusively 
bicyclo[4.2.0]octadiene 1.86. The high stereoselectivity could be assigned to the torsional strain between 
the adjacent aromatic and methyl groups, analogous to the repulsion present in 1.65b and 1.66b (Scheme 
1.12). 
Four months later Moses and Baldwin published their studies on the biomimetic synthesis of SNF4435 C.[49] 
Starting with the same aldehyde as Trauner, 1.72, Moses and Baldwin aimed for the total synthesis of the 
natural product spectinabilin,[50] thought to be natural precursor of 1.69 and 1.70 via double bond 
isomerization and 8π/6π electrocyclization cascade[34,49] (Scheme 1.14). 
 
Scheme 1.14. Top. Biomimetic strategy followed by Moses and Baldwin for the synthesis of SNF4435 C from 
spectinabilin. A double olefin isomerization of spectinabilin would give the right stereochemistry to induce 
the 8π/6π cascade. Bottom. Proof of principle with a simplified system using esters 1.90 and 1.91. 
 
Chain extension of aldehyde 1.72 was performed by a series of E-selective Wittig olefinations with stabilized 
ylide 1.89. Once the conjugated tetraene was obtained, Pd(II)-induced E/Z isomerization at room 
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temperature triggered the electrocyclization process yielding the desired bicyclo[4.2.0]octadiene core in 
35% and 48% yield for the ethyl (1.93) and methyl ester analogues (1.86), respectively. Interestingly, all 
thermal and photochemical attempts to convert the all-E tetraene 1.91 into hexadiene 1.93 failed, 
suggesting that the isomerization requires metal catalysis. 
Parker’s approach was published one year later.[51] Noting that the works by Trauner and Baldwin yielded 
only the diastereomer leading to SNF4435 C, she pursued a systematic study of the cascade. Using the 
successful domino Stille/8π/6π electrocyclization developed by Trauner, a series of vinyl stannanes with 
different substitution patterns were synthesized to evaluate whether they could give access to the skeleton 
of SNF4435 D (Scheme 1.15). 
 
Table 1.1. Screening of different substituents at the terminal end of the vinyl stannane participating in the 
Stille coupling with vinyl iodide 1.81. 
 
Parker was the first to explore the 8π/6π cascade with two substituents, here called RE and RZ, present at 
one terminus of the tetraene. In contrast to the previous work by Trauner and Baldwin (Schemes 1.13 and 
1.14, compound 1.86) where only the endo product was obtained, when the reaction was run with diene 
1.94 bearing a silyl ether (Table 1.1, Entry 1), a complete lack of selectivity for “endo” or “exo” products was 
observed. The torsional strain between the silyl ether chain and the cyclohexene ring presumably equals 
that of the aromatic ring with the adjacent methyl group, which previously governed the stereoselectivity 
of the 6π electrocyclization. To compare with Trauner’s and Balwin’s work, the reaction was run with 
stannane 1.83 (Entry 2), confirming the previous findings (exclusive endo selectivity) and increasing the yield 
from 48% (Baldwin) to 60%. When running the reaction with a terminal Z ethyl ester (Entry 3), E/Z 
isomerization occurred, affording product 1.100 with the same relative configuration found in entry 2 (100% 
endo). When replacing the hydrogen by a methyl group, the stereoselectivity gained in Entries 2 and 3 was 
lost once again (Entries 4 and 5). As for Entry 1, this could be explained by the steric clash between the RZ 
substituent and the cyclohexadiene ring, which destabilizes the endo transition state. Finally, when using 
the small linear cyano group, the mentioned torsional strain in the endo transition state was greatly 
diminished and a 9:1 endo/exo ratio was obtained. The nitrile was also a potential handle for future work 
in the installation of the tetrahydrofuran and the pyrone.  
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Scheme 1.15. Synthesis of the advanced intermediate 1.107 by Parker. 
 
Thus, after having established the cyanide as suitable group, the advanced intermediate 1.107 was 
synthesized starting from diol 1.104, which was monoprotected with TBS chloride followed by mesylation 
and SN2 displacement to install the required phosphonate ester. Horner−Wasworth−Emmons reaction of 
phosphonate 1.105 with aldehyde 1.106 followed by Stille coupling at room temperature yielded the 
stannane required for the cascade, which delivered bicyclo[4.2.0]octadiene 1.107 in 40% yield from 1.105. 
One year later, Parker published the first total synthesis of (–)-SNF4435 C and (+)-SNF4435.[44] The route 
took advantage of the previously developed Stille coupling and installed the enantiopure tetrahydrofuran-
pyrone moiety prior to the cascade reaction (Scheme 1.16). 
 
 
Scheme 1.16. Total synthesis of (−)-SNF4435 C and (+)-SNF4435 by Parker. 
 
The synthesis started with the functionalized phosphonate ester 1.108, analogous to 1.105 (Scheme 1.15), 
which was converted into vinyl iodide 1.109 in 4 steps (Scheme 1.16). Sharpless epoxidation of the allylic 
alcohol followed by ester hydrolysis triggered a 5-exo-tet cyclization, which was followed by oxidative 
cleavage of the resulting 1,2-diol by treatment with sodium periodate delivering aldehyde 1.110. Oxidation 
of 1.110 by treatment with silver nitrate followed by activation of the acid with carbonyldiimidazole yielded 
acylimidazole 1.111. This was condensed with 1.112 and heated to reflux in benzene to induce 
transesterification yielding 1,2-pyrone 1.113. SNF4435 C and D were synthesized by the conversion of 1.113 
into the desired 1,4-pyrone by treatment with methyl fluorosulfonate followed by Stille coupling, which 
yielded the required stannane for the reaction cascade. The Stille/8π/6π sequence was performed with vinyl 
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iodide 1.81 under palladium catalysis at room temperature, yielding (−)-SNF4435 C and (+)-SNF4435 D in a 
very similar ratio as in nature. 
7 months later, Trauner and Beaudry published their total synthesis of these natural products featuring a 
biomimetic convergent synthesis which included a [3,3]-sigmatropic rearrangement and the tandem Stille 
coupling/8π/6π electrocyclization cascade (Scheme 1.17).[52] This approach started with vinyl iodide 1.106, 
which instead of engaging in a Wittig olefination as for the previous synthesis (Scheme 1.15), was alkylated 
with dianion 1.114. The resulting primary and secondary alcohols were protected with TBS chloride and 
acetic anhydride respectively. The resulting diene 1.115 underwent an Ireland−Claisen rearrangement upon 
treatment with LDA and TMSCl. The resulting acid was esterified, brominated at the α-position and 
subjected to a transetherification after TBS deprotection, affording diene 1.116. This route afforded pyrone 
1.116 in 10 steps from commercially available starting materials vs 11 steps for Parker’s synthesis. Following 
the method developed by Parker, vinyl iodide 1.117 was prepared in 4 more steps and purified by chiral 
HPLC. Vinyl iodide 1.81 was stannylated with hexamethyl ditin under palladium catalysis and subsequently 
coupled to vinyl iodide 1.117 under Baldwin’s conditions[53] affording  1.69 and 1.70 in a remarkably high 
89% combined yield. Again, the product ratio was similar to the mixture of isomers found in nature. 
 
Scheme 1.17. Total synthesis of (−)-SNF4435 C and (+)-SNF4435 by Trauner. 
 
Interestingly, a publication by Trauner and Hertweck published one year later showed that the 8π/6π 
electrocyclization was not the end of the cascade. There was a consensus about the biosynthetic origin of 
1.69 and 1.70, thought to arise from spectinabilin after a double olefin isomerization and electrocyclic 
cascade (Scheme 1.18), which was proven by Baldwin’s later work.[54] Trauner and Hertweck studied the 
metabolic profile of Streptomices orinoci, a bacteria known to produce spectinabilin under various growth 
conditions.[55] As expected, the bicyclo[4.2.0]octadienes were only produced under light exposure, which 
was necessary for the double olefin isomerization, but more interestingly, a new natural product named 
orinocin was found (Scheme 1.18). Orinocin was only produced in the presence of light and was detected 
together with isolated fractions of 1.69 and 1.70, which suggested that 1.118 could originate from the 
SNF4435 natural products. This was proven by submitting SNF4435 C and D to fermentation conditions (28 
ºC, sunlight), under which 1.69 and 1.70 underwent a photochemical retro-[2+2] cycloaddition, releasing 
orinocin and mesitylene, the latter of which has been catalogued as a natural product. This process of 
extrusion of internal ketide units from a polyene backbone has been named “polyene splicing” by Trauner 
and Hertweck.[55] 
16 
 
 
Scheme 1.18. Biosynthetic origin of SNF4435 C and D as proven by Baldwin and further conversion into 
orinocin as proven by Trauner and Hertweck. 
 
Baldwin and Moses later presented a unified synthesis of spectinabilin and SNF4435 C and D along with the 
related natural products aureothin and aureothamine.[54,56] 
 
Scheme 1.19. Collective total synthesis of racemic SNF4435 C and D, spectinabilin, aureothin and 
aureothamine by Moses and Baldwin. 
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Their synthesis started with pyrone 1.120, obtained from pyrone 1.119 in 3 steps. The aldehyde could be 
converted into alkenyl boronic ester 1.123 via a formal [3+2] cycloaddition with 1.121 under Tsuji−Trost 
conditions in the presence of an indium salt to promote 1,2-addition[57] followed by cross-metathesis with 
pinacol boronate 1.122 giving pyrone 1.123 as a mixture of E/Z isomers. Suzuki coupling of 1.123 with vinyl 
dibromide 1.124 in the presence of thalium ethoxide followed by Negishi coupling to install the olefinic 
methyl group yielded racemic aureothin (1.125), which was converted into aureothamine (1.126) by 
reduction of the nitro group with Zn/ammonium chloride. 
Spectinabilin (1.128) was synthesized in a similar fashion as aureothin via Suzuki coupling of dibromotriene 
1.127 with boronate 1.123 followed by Negishi coupling to install the olefinic methyl group. Treatment of 
spectinabilin with palladium(II) at 70 ºC for 24 hours in the dark caused isomerization of the E,E,E,Z-tetraene 
to the required E,Z,Z,Z configuration, triggering the 8π/6π electrocyclization as previously seen. Racemic 
SNF4435 C and D were obtained together with isomers 1.130 and 1.131, presumably consequence of the 
isomerization of 1.128 to the E,Z,Z,E tetraene. The yield of the final step was therefore quite modest. 
 
1.2.3 Elysiapyrones 
In 2005, Trauner published 3 papers on the synthesis of natural products originating from 8π/6π 
electrocyclizations.[33,52,58] Elysiapyrones are natural products isolated from the sea slug Elysia diomedea,[59] 
one of the few animals capable of retaining ingested chloroplasts in its own tissues to perform 
photosynthesis.[60] These natural products contain a rare bis-epoxide pattern in the 6 membered ring of the 
bicyclo[4.2.0]octane (Scheme 1.20). 
 
Scheme 1.20. Total synthesis of racemic elysiapyrones A and B by Trauner. 
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The synthesis started with dienal 1.132, which was elongated by addition of ketoester 1.133 followed by 
DMP oxidation to yield tricarbonyl 1.134. This species underwent a Dieckmann-type condensation upon 
heating in the presence of base and was later methylated with methyl fluorosulfonate affording 1,4-pyrone 
1.135. Synthesis of the stannane 1.137, partner for the Stille coupling, was initiated by a Stork−Zhao[61] 
olefination of tiglic aldehyde with ylide 1.136 followed by lithiation/stannylation. Submission of vinyl iodide 
1.135 and stannane 1.137 to Baldwin’s Stille 8π/6π electrocyclization conditions yielded a mixture of endo 
and exo isomers (1.140 and 1.141) which could be separated by column chromatography. The lower yield 
of the 1.141 is probably a consequence of the torsional strain between the pyrone and the β-methyl groups 
in the transition state of the 6π electrocyclization. 
Now the core structure was set for the introduction of the bis-epoxide groups. This was accomplished by 
the Diels−Alder reaction of 1.140 and 1.141 with singlet oxygen generated upon light irradiation in the 
presence of a photosensitizer delivering endo-peroxides 1.142 and 1.143. These adducts were isomerized 
using the Noyori protocol with RuCl2(PPh)3 yielding elysiapyrones A and B in good yield.[62] 
 
1.2.4 Ocellapyrones 
Ocellapyrones A and B were isolated from Placobranchus ocellatus, a mollusc found in shallow waters.[63] 
Ocellapyrone A, whose structure was corrected simultaneously by Baldwin and Trauner,[32,33] is an ethylated 
derivative of elysiapyrone A precursor 1.140 (Scheme 1.20) and ocellapyrone B the ethyl derivative of 
endoperoxide 1.142, precursor of elysiapyrone A (Scheme 1.20). Trauner theorized that the ocellapyrones, 
photodeoxytridachione and 9,10-deoxytridachione could originate from the same tetraene precursor 
(Scheme 1.5). Since the biogenesis had been already established for photodeoxytridachione and 9,10-
deoxytridachione,[31,32] the synthesis of 1.147 and 1.148 demonstrated the versatility of the tetraene 
scaffold. 
The synthesis followed the same pathway as for elysiapyrones and can be seen in Scheme 1.22. 
 
Scheme 1.22. Total synthesis of ocellapyrones A and B by Trauner. 
 
1.2.5 Shimalactones A and B 
The shimalactones were isolated from the marine fungus Emericella variecolor.[64,65] They contain a unique 
oxabicyclo[2.2.1]heptane moiety linked to a bicyclo[4.2.0]octadiene core by a trisubstituted ethylene linker. 
Trauner proposed an interesting biosynthesis for these natural products in which the polyene chain of 1.149 
(Scheme 1.23) would undergo oxidation to epoxide 1.150 followed by protonation yielding 
undecapentaheptenyl cation 1.151. This species can now be intercepted by the enol present in the adjacent 
lactone, forming the bicyclic structure 1.152. Finally, E/Z isomerization of the two central double bonds 
would trigger the 8π/6π electrocyclization.[66] 
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Scheme 1.23. Biosynthesis of shimalactones A and B as proposed by Trauner. 
 
The bicyclic ketolactone moiety was prepared starting from oxazolidinone 1.155, which was converted into 
diene 1.157 upon asymmetric anti-aldol reaction with aldehyde 1.156 followed by esterification of the 
secondary alcohol and a Stille coupling to introduce the terminal olefin. Then, a Dieckmann condensation 
of 1.157 afforded ketolactone 1.158, which upon treatment with CSA at 150 ºC cyclized to give the desired 
oxabicyclo[2.2.1]heptane 1.159, which subsequently yielded vinyl iodide 1.160 in 6 further steps. 
 
Scheme 1.24. Total synthesis shimalactones A and B by Trauner. 
 
Stannane 1.163 was obtained from aldehyde 1.161 upon reaction with 2-butenyl methyl zinc in the 
presence of asymmetric ligand 1.162 followed by halogen-metal exchange. Finally, a Liebeskind-type Stille 
coupling between vinyl iodide 1.160 and stannane 1.163 at room temperature yielded both shimalactones 
in 66% overall yield. Interestingly, when the same reaction conditions were applied to polyene 1.164, the 
equivalent Z,E,Z,Z,E isomer, the cascade did not take place even under forcing conditions and only 1.164 
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could be isolated. Presumably, the bulk of the bicyclic substituent which would be positioned in endo in the 
transition state does not allow for the 8π electrocyclization to occur. 
1.2.6 Kingianins 
Once again, Parker and Moses worked in parallel on the same natural product and this time also Sherburn 
pursued the synthesis of Kingianin A (1.175). This natural product was found as a racemate in the bark of 
Endiandra kingiana, a tree collected in the rainforest of Malaysia.[67] The fact that Kingianin A is found as a 
racemic mixture again suggests that no enzymes take part in the 8π/6π cascade. 
The first synthetic approach was published by Moses, who tested the biosynthetic proposal suggested by 
Litaudon and co-workers, featuring an endo-Diels−Alder dimerization after the 8π/6π 
electrocyclization.[67,68] This hypothesis was rather controversial, since a spontaneous intermolecular 
Diels−Alder reaction of unactivated dienes seemed unlikely without the assistance of enzymes.  
Thus, Moses synthesized prekingianins 1.168 and 1.169 starting from catechol acetal 1.165, which was 
transformed into vinyl bromide 1.166 in four steps. The stannane partner for the Stille coupling was 
prepared by DIBAL reduction of ester 1.166 followed by treatment with acetone cyanohydrin, delivering 
vinyl stannane 1.167. Stille coupling of 1.167 and 1.166 yielded the expected bicyclooctanes 1.168 and 
1.169, which were partially hydrolyzed to the respective amides and N-alkylated by reductive amidation 
affording 1.170 and 1.171. All attempts to thermally induce the Diels−Alder dimerization of 1.170 and 1.171 
failed, even at 195 ºC or using Grieco’s conditions in a 5M LiClO4 ethereal solution. 
 
Scheme 1.25. Moses’ studies towards the synthesis of kingianin A. 
 
In parallel to this work, new kingianins were isolated[69] and tested for inhibition of Bcl-xL, an anti-apoptotic 
protein implicated in tumour growth, showing modest binding affinity (Scheme 1.26). All the kingianins 
isolated from Endiandra kingiana (A-N) share common patterns, since they derive from an endo-Diels−Alder 
reaction taking place on the less hindered convex face of both diene and dienophile (“open book effect”) 
(1.175TS, Scheme 1.27). This arrangement leads to a transition state stabilized through secondary orbital 
interactions and avoids steric clashes between the cyclobutane ring of the dienophile and the hexadiene 
ring of the diene (Scheme 1.27). 
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Scheme 1.26. Structure of kingianins A, D, E and K. Kingianin A is the homodimer of one enantiomer of pre-
kingianin A. Kingianin D is the heterodimer of both enantiomers of pre-kingianin A. 
 
Moreover, of the two possible arrangements fulfilling the previous conditions, only the olefin closest to the 
exo-substituent engages as a dienophile in the [4+2] cycloaddition.  
 
Scheme 1.27. Three possible regiosomers for the endo-[4+2] cycloaddition. Top. Favoured arrangement 
leading to kingianin A: reaction from both convex faces of diene and dienophile; dienophile olefin proximal 
to the exo-substituent. Middle. Unfavoured arrangement: dienophile olefin proximal to the endo-
substituent. Bottom. Unfavoured arrangement: approach from the concave face of the dienophile, clash 
between the cyclobutane ring and the diene. 
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Therefore, the cyclohexene bridge formed upon the [4+2] cycloaddition is always located on the same face 
as the closest substituent on the cyclobutane ring of the former dienophile (marked in blue on Schemes 
1.26 and 1.27). 
Parker deduced that if the thermal Diels−Alder was not taking place and was not the result of enzymatic 
participation, the dimerization could occur via a radical cation Diels−Alder reaction (RCDA), maybe 
photoinduced in nature. Putting all this into context, kingianin A (homoenantiomeric, 1.175) and kingianin 
D (heteroenantiomeric, 1.176) would be obtained from racemic pre-kingianin A (1.174) by means of a RCDA 
reaction, whose stereochemistry would be defined by an endo transition state stabilized by secondary 
orbital interactions. The regiochemistry would in turn be dictated by the “open book effect” (i.e. reaction 
on both convex faces of diene and dienophile) and by the substituents at the cyclobutane ring of the 
dienophile. Given the difficulties experienced by Litaudon in separating kingianins A and D during the 
isolation process,[69] Parker opted to perform an intramolecular RCDA approach binding two molecules of 
1.174 by a tether, reasoning that only the homoenantiomeric C2 symmetric dimer could adopt the 
conformation required for the endo transition state (1.188, Scheme 1.28). The disposition of the ester 
substituents in the heteroenantiomeric dimer would keep the diene and dienophile too far from each other 
to engage in the same reaction. Thus, this dimer was expected to remain unreacted and would be easily 
separated from the Diels−Alder product and recycled (1.189, Scheme 1.28). 
 
Scheme 1.28. Total synthesis of kingianin A by Parker. 
 
Parker’s synthesis began with trans hydroboration of enyne 1.181 under rhodium catalysis yielding Z-vinyl 
boronate 1.182 (Scheme 1.28). Suzuki coupling of 1.182 with vinyl iodide 1.183 followed by heating at 100 
ºC for several hours and TBAF deprotection delivered two diastereomeric analogues of pre-kingianin A, 
1.184 and 1.185, which were separated using Nicolaou’s iodoetherification (Scheme 1.8).[40] The high yield 
of the Suzuki coupling is notable, and avoided the use of highly toxic organotins. Upon separation of the 
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reacted tricycle 1.186, 1.184 was treated with adipoyl dichloride and DMAP yielding the expected 1:1 
mixture of dimeric esters 1.188 and 1.189.  
As it was expected, only the homoenantiomeric dimer underwent the endo-Diels−Alder reaction upon 
treatment with Weitz’ aminium salt (1.190). However, the heteroenantiomeric substrate 1.189 underwent 
an exo-Diels−Alder reaction, affording 1.192 in a slightly higher yield than the desired product 1.191. 
Presumably, the presence of the tether induced a prearrangement favourable for this type of Diels−Alder. 
Upon isolation by column chromatography, the desired product 1.191 was converted into Kingianin A in 5 
steps. In subsequent work, Kingianin A was prepared by the same means and in similar yields without the 
use of a tether, together with other members of the kingianin family.[70] 
Moses, inspired by Nigenda et al., who performed an exhaustive study on the radical cation Diels−Alder 
reaction of cyclohexadiene, [71] later published on how the [4+2] cycloaddition could be performed by means 
of an electrochemically induced RCDA on pre-kingianin A. The reaction was triggered by electron transfer 
using a reticulated vitreous carbon electrode in a 0.4 M solution of n-Bu4NBF4.[72] The yield was however 
rather low (Scheme 1.29). 
 
Scheme 1.29. Formal synthesis of kinginain A by Moses. 
 
Michael S. Sherburn presented in a series of two articles the total synthesis of kingianin A by using a 
combination of the strategies developed by Nicolaou, featuring the semi-hydrogenation of polyynes, and 
Parker’s intermolecular RCDA for the dimerization of pre-kingianins.[73,74] The synthesis featured an 
unprecedented semi-reduction of a tetrayne to an all-Z tetraene. 
The starting point for the synthesis was a Negishi coupling between benzyl bromide 1.193 and alkynylzinc 
1.194 affording TMS benzyl diyne 1.195, which was then converted into tetrayne 1.197 by the first reported 
unsymmetric Mori−Hiyama coupling[75] (Scheme 1.30). In previous syntheses,[40,76] Lindlar reduction was 
ineffective due to the low reactivity of the catalyst, so after an extensive screening campaign, Rieke zinc in 
ethanol proved to be the best choice for semi-reduction of tetrayne 1.197. The obtained tetraene 1.198 
was immediately submitted to cyclization conditions (PhMe, 100 ºC) followed by TBAF deprotection, 
delivering bicyclo[4.2.0]octadienes 1.199 and 1.200. These were separated and submitted to a sequence of 
oxidation to carboxylic acid under Stark’s conditions,[77] radical cation Diels−Alder reaction induced by 
Ledwith−Weitz’s salt (1.190) and amidation to give Kingianins A, D and F.   
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Scheme 1.30. Total synthesis of kingianins A, D and F by Sherburn. 
 
1.2.7 Unified Synthesis of Kingianins and Endiandric Acids 
Finally, Sherburn developed a unified synthesis of endiandric acid A, kingianic acid E and kingianins A, D and 
F, achieving the highest step efficiency to date for these natural products.[74] The synthesis relied on the 
preparation of the versatile tetrayne intermediate 1.206, which diverges into three different routes upon 
coupling with three different alkyl bromides (Scheme 1.31). 
The preparation of the key building block 1.206 started with homopropargylic alcohol 1.204, which was 
transformed into tetrayne 1.205 in 3 steps and deprotected by treatment with potassium carbonate in 
methanol to yield 1.206, which was immediately submitted to three different reaction sequences. 
For kingianic acid E, metalation of 1.206 with tert-butylmagnesium bromide was followed by alkylation with 
vinyl bromide 1.202 under copper catalysis. The resulting tetrayne 1.213 was submitted to reduction on 
Rieke zinc at 0 ºC and subsequent thermal treatment at 150 ºC, which triggered the 8π/6π/Diels−Alder 
cascade yielding alcohol 1.208. This alcohol was oxidized with TPAP/NMO·H2O under Stark’s conditions[77] 
to yield racemic kingianic acid E. 
Endiandric acid A was synthesized in a similar manner as 1.209 by copper catalysed alkylation of 1.206 with 
allyl bromide 1.203, semi-reduction on Rieke Zinc and 8π/6π/Diels−Alder cascade sequence, delivering 
tetracycle 1.211. Exhaustive oxidation of the primary alcohol of 1.211 afforded endiandric acid A in 9 total 
steps from commercial precursors. 
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Scheme 1.31. Unified total synthesis of endiandric acids and kingianins by Sherburn. 
 
Tetrayne 1.206 failed to provide propargyl catechol 1.212 upon reaction with benzyl bromide 1.193 under 
the previous copper catalysed conditions. Therefore, 1.212 was accessed through Negishi cross-coupling 
and was further elaborated in 6 steps following the sequence shown in Scheme 1.30. 
With this, Sherburn presented an elegant and step-economic synthesis of kingianins A, D and F, kingianic 
acid E and endiandric acid A with an approach that combines Nicolaou’s alkyne reduction strategy,[40–43] 
extending it to more advanced tetrayne intermediates, and the intermolecular radical cation Diels−Alder 
reaction developed by Parker.[70] The low yields of the electrocyclization cascades are the major drawback 
of this otherwise brilliant work. 
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Scheme 1.32. Use of photoredox catalysis in the RCDA of 1.214 compared to the Ledwitz−Weiz salt 
procedure. 
 
Lastly, a new method for the generation of the radical cation intermediate was applied to 
bicyclo[4.2.0]octadiene 1.214. Photoredox catalysis under Yoon’s conditions[78] yielded tetracycle 1.208 in 
slightly higher yields than Parker’s, who generated the radical cation with Ledwith-Weitz salt.[70]  
 
1.2.8 Hypnophilin, Coriolin and Ceratopicanol 
Although they cannot be considered members of the Cyclooctratriene-Derived NP family given their 
sesquiterpene nature, the total synthesis of these natural products presented by Paquette features a rare 
8π electrocyclization/transannular aldol cascade. 
In 2002, Paquette et al. exploited the applications of his previously developed squarate ester cascade[79–81] 
for the step-economic total synthesis of hypnophilin, coriolin and ceratopicanol.[82,83] These compounds 
possess antibiotic and antitumor activity.[84–86] 
 
Scheme 1.33. Squarate ester cascade developed by Paquette giving access to triquinane 1.221. 
 
The substrate for the cascade is obtained through selective 1,2-addition of a pair of alkenyl anions to 
squarate ester 1.215 resulting in syn or anti addition. The resulting anti cyclobutene undergoes a 4π 
conrotatory ring opening followed by an 8π electrocyclization leading to cyclooctatriene 1.219. In the case 
of the syn product, the retro 4π electrocyclization is outcompeted by a faster oxy-Cope rearrangement, 
which directly delivers the same cyclooctatriene 1.219. Elimination of the β-acetal leads to intermediate 
1.220, which upon ring closing aldol reaction yields linear triquinane 1.221. 
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This cascade was used for the synthesis of hypnophilin, coriolin and ceratopicanol (Scheme 1.34). For 
ceratopicanol, isolated from the fungus Ceratocystis piceae,[87] squarate ester 1.215 was treated with 
alkenyllithium 1.222 followed by isopropenyllithium, yielding triquinane 1.223 in 44% yield. Further 
elaboration of 1.223 afforded α-β unsaturated ketone 1.224 in 3 steps. Exhaustive reduction of 1.224 in 3 
further steps delivered ceratopicanol (1.225). 
 
Scheme 1.34. Total synthesis of racemic ceratopicanol, hypnophilin and coriolin by Paquette. 
 
The cascade reaction shown in Scheme 1.33 delivered triquinane 1.221, bearing an enol-ether handle. 
Hydrolysis of this ether with diluted aqueous sulfuric acid followed by chlorination of the tertiary hydroxylic 
carbon and Birch reductive cleavage of the resulting chloride led to alcohol 1.226 in good yield (Scheme 
1.34). Further elaboration of 1.226 into 1.227 was accomplished in 5 steps after which one-pot epoxidation 
and MOM deprotection with basic hydrogen peroxide afforded hypnophilin (1.230). Intermediate 1.227 was 
also used for the synthesis of coriolin by means of a KOt-Bu-induced double bond migration followed by 
monoepoxidation, -elimination and bisepoxidation. 
Starting from simple building blocks, this stereoselective cascade, featuring a non-isolable cyclooctatriene 
intermediate, delivered a tricyclic system bearing 4 stereocentres, which gave access to three different 
racemic natural products in few synthetic steps: 7 for ceratopicanol (vs 7 for Prof. Michel Chanon[88]), 10 for 
hypnophilin, shortening the previous shortest 14-step racemic synthesis by Curran[89] and 13 for coriolin, 
again shortening previous syntheses of 16-21 steps.[89–92] 
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2. Project Background 
2.1 Isolation and Structure of (−)-PF-1018 
 
In 1993, Koyama and co-workers, from the Meiji Seika Kaisha Pharmaceutical Research Center in Japan, 
performed a screening program in the search for novel insecticides of microbial origin. In this context, a 
fungal strain found in a soil sample from Ohmachi city, identified as Humicola sp. PF1018, produced a new 
polyketide which they called (−)-PF-1018 (2.1).[93]  
 
Scheme 2.1. Different projections of (−)-PF-1018. 
 
The structure of (−)-PF-1018 features two distinguishable parts. First, a tricyclic 8-6-5 ring system bearing 
six contiguous stereocentres, two of which are quaternary, and three trisubstituted double bonds 
containing methyl groups. This congested core is connected by an ethylene linker to a proline-derived 
tetramic acid bearing an additional stereocentre (Scheme 2.1).  
1H and 13C CDCl3 NMR spectra of 2.1 showed a main set of signals accompanied by minor peaks, which upon 
the addition of water, coalesced into a single set of broad peaks. It was therefore concluded that PF-1018 
existed as two interconverting isomeric forms, as it is known for other acyl tetramic acids.[94,95] 2D NMR 
studies provided the structure of 2.1, which was later verified by X-ray analysis (Figure 2.1). The absolute 
configuration was confirmed by degradation with sodium hypochlorite followed by HCl, which afforded L-
proline. 
 
 
Figure 2.1. Crystal structure of (−)-PF-1018 
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2.2 Proposed Biosynthesis of (−)-PF-1018 
 
As a polyketide, 2.1 originates from the assembly line within the polyketide synthase (PKS).[96,97] However, 
given the presence of a non-ribosomally-derived tetramic acid moiety, it is most likely that a hybrid of a PKS 
and a non-ribosomal peptide synthase (NRPS) is responsible for the biosynthesis of (−)-PF-1018.[98–102]  
 
Scheme 2.2. Proposed biosynthesis of (−)-PF-1018. 
 
Thus, the biosynthesis would start with a keto synthase domain (KS)-bound acetyl-CoA (2.2) which 
undergoes a Claisen condensation with a proximal methyl malonyl-CoA unit linked to the acetyl carrier 
protein (ACP) domain (2.3). Then KS-bound cysteinyl residue 2.5 binds covalently to the extended chain 2.4 
forming complex 2.6, which yields alkene 2.7 under the action of the ketorreductase (KR) and the 
dehydratase (DH) domains. Repetition of these Claisen condensation/decarboxylation/migration steps with 
a new methylmalonyl unit leads to diene 2.8. The incorporation of three more units of methylmalonyl-CoA 
and 2 of acetyl CoA yields polyene 2.9. We propose that the tricyclic core of 2.1 could be obtained from 2.9 
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in a similar fashion as the natural products shown in Chapter 1.2, but with a key difference: After the 8π 
electrocyclization, the resulting cyclooctatriene 2.10, unlike for all the other cyclooctatriene-derived natural 
products, is intercepted by a dienophile engaging in a [4+2] cycloaddition instead of undergoing a 6π 
electrocyclization. This reactivity leads to tricyclic intermediate 2.11. We think that this sequence takes 
place early in the biosynthesis given the spontaneous nature of the 8π/6π electrocyclization, but a latter 
cascade reaction cannot be ruled out.[103,104] To the best of our knowledge, this is an unprecedented reaction 
sequence, and consequently so is the structure of 2.1. Given the fact that unlike the endiandric acids or the 
kingianins, PF-1018 has been isolated as a single enantiomer, it seems that the diastereo- and 
enantioselectivity of these steps could derive from the chiral environment within the enzyme.  
After the pericyclic cascade, the chain is extended again with two units of acetyl-CoA leading to intermediate 
2.12. The transfer of proline takes place from the thiolation domain of the non-ribosomal peptide synthase 
(NRPS) 2.14 and the tetramic acid is formed upon Dieckmann condensation releasing 2.1 from the hybrid 
complex. 
 
2.3 Biological Activity of (−)-PF-1018 
 
As it has been mentioned in Chapter 2.1, PF-1018 was found in a screening campaign for new insecticides. 
2.1 was tested against critical pests including Thrips palmi Kany, Tetranychus cinnabarinus Boisd., Plutella 
xylostella L. and Musca domestica.[105] Exposure of these insects to aqueous solutions of 2.1 at different 
concentrations led to high levels of mortality, especially for the diamondback moth (Table 2.1).[93,105] The 
mode of action has not been studied and is therefore unknown. 
 
Table 2.1. Biological activity of 2.1 on critical pests. Test periods of 48 hours. 
 
Of all the pests tested, the most problematic is Plutella xylostella or diamondback moth. This lepidoptera is 
a major destructive pest affecting the Brassicaceus vegetables (includes cabbage, brussels sprouts, 
cauliflower, broccoli, etc.) showing high adaptability to different environments, a fast reproductive cycle 
and high mutability, which results in quick development of insecticide resistance.[106–108] More specifically, 
the diamondback moth has developed resistance to virtually all insecticides, being the only species showing 
resistance against Bt toxin.[109] Moreover, Plutella xylostella has spread to the whole world affecting 
dramatically to the yields of Brassicaeus crops, lowering crop yields by nearly 70%.[108,110–112] Fighting this 
plague has an estimated cost of US$ 5 billion per year,[113] therefore the development of new insecticides is 
essential to keep the damage under control. 
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2.4 Previous Efforts Towards (−)-PF-1018 
 
Initial studies at the Trauner group aimed for a straightforward synthesis of (−)-PF-1018 following the 
tandem Stille coupling/8π electrocyclization strategy analogous to the synthesis of ocellapyrones and 
elysiapyrones, which have been highlighted in Chapters 1.2.3 and 1.2.4. In this case, however, the desired 
reactivity involved intercepting the cyclooctatriene intermediate with an intramolecular dienophile 
inducing a Diels−Alder reaction. For this purpose, stannane 2.15 and vinyl iodide 2.16 were prepared 
(Scheme 2.3). Not surprisingly, the 8π/6π electrocyclization reaction took place instead. Trying to reverse 
the 6π electrocyclization by heating over 150 ºC led to thermal retro-[2+2] cycloaddition, releasing triene 
2.21 and mesitylene in a new case of “polyene splicing”, which was previously observed in the orinocin 
cascade (Scheme 1.18). 
 
Scheme 2.3. Initial studies in the Trauner group towards (−)-PF-1018. 
 
A new asymmetric approach started with aldehyde 2.23 (Scheme 2.4). Two stereogenic centres were 
introduced by means of an Evans aldol reaction in a “bioinspired” dehydration strategy in order to control 
the stereoelectronics of the polyene system.  
 
Scheme 2.4. Previous efforts towards (−)-PF-1018. 
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The resulting alcohol 2.25 was transformed in 4 steps into vinyl iodide 2.26, which would serve as the 
reaction partner for the Stille coupling. The reaction cascade with stannane 2.15 gave 2.27 as the only 
isolable product in 32% yield.[114] Interestingly, the same reaction with the unprotected alcohol did not 
deliver the desired product, suggesting that the OTBS and the β-methyl group impart a torsional strain 
which avoids the 6π electrocyclization (see Figure 1.1 for the 6π transition state structure). 
Further elaboration of cascade product 2.27 yielded alcohol 2.28 in 3 steps. A set of elimination conditions 
including Burgess and Chugaev was tried on 2.28, but failed to afford the desired product 2.30 either by lack 
of reactivity or decomposition. Hoping that an anti-elimination would solve this problem, the configuration 
of the free alcohol was inverted by the formation of a chloromethyl sulfonate derivative followed by 
treatment with CsOAc, affording an acetate with net inversion of configuration. Methanolysis upon 
treatment with sodium methoxide in methanol yielded alcohol 2.29. Unfortunately, all attempts for 
elimination failed again, frustrating this approach towards PF-1018. 
 
2.5 Project Outline 
 
The structure of (−)-PF-1018 is not only aesthetically attractive given the complexity of its tricyclic core, but 
also entails a challenge for synthetic chemists, since the ubiquitous 8π/6π cascade must intercepted at the 
cyclooctatriene intermediate with an intramolecular dienophile. This is a unique case in the Cyclooctatriene-
Derived natural product family described in Chapter 1, and the synthesis of 2.1 will add new significant 
insights on how these secondary metabolites arise from cyclooctatrienes and what is the reason behind the 
fact that some are isolated as racemates or as single enantiomers. 
 
Scheme 2.5. Examples of tetramic acid natural products with relevant bioactivity. 
 
Regarding the applications of synthetic 2.1 given its bioactivity, maybe the heavy economic losses in 
agriculture caused by the diamondback moth could justify the use of complex synthetic molecules such as 
(−)-PF-1018. Moreover, other natural products bearing tetramic acids have proven to entail a very broad 
range of interesting biological activities such as antibiotic[115], antifungal[116], cytotoxic[117], antimoebal[98] and 
antiviral.[118–120] For example, vermisporin, produced by the fungus Ophiobolus vermisporis exhibits activity 
against Bacteroides spp, Clostridium perfringens (90% inhibition at 0.25-2 µg/mL), and Staphylococos aureus 
(90% inhibition at 0.15-0.5 µg/mL)[121] pyreudione C shows antimoebal activity (IC50 1 µg/mL)[98] and eliamid 
cytostatic activity against human lymphoma cell line U-937 (IC50 0.5 ng/mL).[122] Hence, it is likely that 2.1  
would also display potent bioactivity against some of these targets, which could be identified by means of 
a screening process. The material for this screening could be obtained through the total synthesis of (−)-PF-
1018. 
In our initial retrosynthesis, we envisioned that 2.1 could be obtained via Horner−Wasworth−Emmons 
reaction between aldehyde 2.35 and phosphonate ester 2.34 (Scheme 2.6). 2.34 could be accessed from L-
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proline and diethyl phosphonacetic acid. Tricycle 2.35 could in turn be obtained from ketone 2.36 by 
olefination and double bond migration. Consequently, ketone 2.36 could be derived from diol 2.37 upon 
deprotection, oxidation and deoxygenation at C2. Diol 2.37 would in turn arise from the previously 
described Stille/8π/[4+2] cascade of stannane 2.15 and vinyl iodide 2.38. By exchanging the methyl group 
at C3 (compound 2.26, Scheme 2.4) by a protected alcohol (compound 2.38, Scheme 2.6) we expected to 
overcome the elimination problem described above. Triene 2.38 would be synthesized in an analogous 
manner as 2.26 via Evans aldol reaction of conjugated aldehyde 2.23 (Scheme 2.4), itself arising from vinyl 
iodide 2.39. Stannane 2.15 could be accessed from angelic aldehyde by means of a Stork−Zhao olefination. 
 
Scheme 2.6. Initial retrosynthetic analysis of (−)-PF-1018. 
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3. Results and Discussion 
3.1 Evans Aldol Approach 
 
This approach aimed for the asymmetric installation of the syn-diol via Evans aldol reaction of aldehyde 3.4 
with oxazolidinones 3.8 and 3.9 (Scheme 3.1), chosen for their different bulk and stability towards 
deprotection. As it has been mentioned Chapter 2.4, it seemed that the substituent size at C2 and C3 
strongly influence the outcome of the cascade reaction. 
Thus, the preparation of aldehyde 3.4 started with propargyl alcohol, which underwent a carbocupration 
followed by iodine quench to deliver Z-vinyl iodide 3.1.[123,124] Oxidation of the alcohol with manganese 
dioxide led to an unstable conjugated aldehyde which was immediately submitted to a 
Horner−Wasworth−Emmons reaction with diethyl phosphonate 3.2, leading to conjugated ester 3.3. 
Aldehyde 3.4 was obtained by DIBAL reduction of 3.3 followed by allylic oxidation. 
 
Scheme 3.1. Attempts for the preparation of syn-diols 3.10 and 3.11. 
 
Oxazolidinones 3.8 and 3.9 were synthesized by reaction of protected α-hydroxy acids 3.5 and 3.6 with PivCl 
in the presence of a base and Evans auxiliary 3.7. The Evans aldol reaction of aldehyde 3.4 and 
oxazolidinones 3.8 and 3.9 was initially performed using the same reaction conditions developed in previous 
work.[114] However, Evans glycolate aldol couplings with conjugated aldehydes are rare, and the reported 
yields are usually markedly lower than for non-conjugated or non-oxidized systems, occasionally displaying 
lower stereoselectivity.[125–128] Thus, these reaction conditions using dibutylboron triflate and triethylamine 
yielded only traces of 3.10 (Method A, Table 3.1, Entries 1, 2 and 7). The same reaction under Paterson’s 
conditions (Method B, Entries 3-6 and 8) with different sources of dibutylboron triflate also failed to deliver 
the desired product.[129] We confirmed the validity of this method by testing it with the same substrate used 
by Paterson, noticing that freshly distilled dibutylboron triflate was required for the reaction to succeed 
(Table 3.2, Entry 3). An attempt lacking boron chelation also failed to provide the desired product (Table 
3.1, Method C, Entry 9).[130,131] 
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Scheme 3.2 and Table 3.1. Conditions screened for the Evans aldol reaction of aldehyde 3.4. 
 
 
Scheme 3.3 and Table 3.2. Reproduction of Paterson’s Evans aldol reaction with different dibutylboron 
triflate sources. 
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3.2 Brown Allylation Approach 
 
Although many variations could still be applied to the Evans aldol reaction, we thought of a more 
straightforward approach towards 1,3-diol 3.17 which involved a cross-metathesis of triene 3.18 with 
methyl acrylate. In turn, 3.18 could be accessed from aldehyde 3.4 via Brown allylation with MOM protected 
allyl alcohol. This strategy would afford the desired triene 3.17 in three steps including alcohol protection, 
versus 4-5 steps for the Evans aldol route (Scheme 3.4).[132] 
 
Scheme 3.4. New strategy towards 3.17 featuring a Brown allylation/cross-metathesis strategy. 
 
In the Brown allylation, the allyllithium species 3.20 generated by treatment of allyl alcohol 3.19 with sec-
buthyllithium reacts with diisopinocampheylborane and boron trifluoride etherate to deliver allylboron 
intermediate 3.21, whose Z-configuration is maintained at low temperature through boron-oxygen 
coordination (Scheme 3.5). This configuration will dictate the diastereoselectivity of the reaction upon 
addition of aldehyde 3.4, yielding syn-diol 3.22 via transition state 3.22 TSB. The isomer of α-pinene 
employed is responsible for the enantioselectivity result of the steric repulsion between the methyl groups 
from pinene and the terminal allyl hydrogens (3.22TSA, Scheme 3.5).[132] 
 
Scheme 3.5. Brown allylation mechanism. 
 
Thus, the following conditions for Brown allylation were screened (Table 3.3). 
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Scheme 3.6 and Table 3.3. Conditions screened for Brown allylation of 3.4. 
 
We first used the reaction conditions by Crimmins et al., who reported an excellent yield in the reaction of 
a conjugated aldehyde in the synthesis of Sorangicin A.[133] In our hands this method delivered the desired 
product in moderate yield (55%) and low diastereoselectivity (6:1 d.r.) for this kind of reaction (Table 3.3, 
Entry 1). Intrigued by the large excess of borane used by Crimmins, we decided to use less equivalents. This 
led to a slightly higher yield (57 %) but a decrease in stereoselectivity (5:1 d.r., Entry 2). Since the 
temperature is a key factor to control the stereoselectivity in the Brown allylation,[132,134] we decided to 
lower it to −78 ºC while diminishing the equivalents of allyl borane (Entry 3). These changes led to a much 
higher diastereomeric rate (>20:1) and excellent enantioselectivity (92% e.e.). Finally, upon further 
modifications in concentration, reagent ratio and workup procedure, we obtained diol 3.22 in decent yield 
(60%) and excellent diastereo- and enantioselectivity (>20:1 d.r. and 94% e.e., Entry 4). The enantiomeric 
excess was calculated by Mosher ester analysis.[135] 
Further chain elongation could be achieved by cross-metathesis of the terminal alkene of 3.22. Both 
metathesis partners are considered type II olefins, therefore they are not expected to homodimerize at a 
significant rate.[136] Thus, the reaction was initially set with the second-generation Grubbs catalyst and an 
excess of methyl acrylate in refluxing toluene with phenol as a stabilizer,[137–139] and stirred for 45 minutes. 
The desired product 3.23 was obtained, although conversion was not complete (Table 3.4, Entries 1 and 2). 
We run again the reaction under the same conditions and then added more equivalents of catalyst and 
acrylate while extending the reaction time, but this did not lead to any relevant improvement (Entry 3). 
Thus, we exchanged the catalyst with the more stable second-generation Hoveyda-Grubbs and further 
extended the reaction time while decreasing the temperature. Unfortunately, these changes only led to 
lower starting material recovery or increased decomposition when the temperature was kept at 110 ºC 
(Entries 4-5). Further improvement was observed when the reaction scale was increased from 100 to 700 
mg and the temperature decreased to 80 ºC (Entry 6). At this point it seemed clear that the catalyst turnover 
was low, and that the high temperatures were leading to decomposition. Therefore, addition of 10 mol% of 
the catalyst with a syringe pump over 19 hours to a refluxing toluene solution of 3.22 and methyl acrylate 
allowed for isolation of triene 3.23 in a 50% yield and no starting material recovery (Entry 7). When the 
addition was performed over 8 hours and at lower temperature (80 ºC) the yields decreased again (Entry 8). 
Finally, given the inconvenience of injecting the material over so many hours, a solution of the catalyst was 
prepared, loaded into a syringe and connected to the system doing periodic injections of 1% after each 
hour (Entries 9-17). The best reaction conditions involved the sequential addition of the catalyst solution 
over 12 hours to the reaction mixture at 50 ºC, leading to a 66% yield (Entry 17). 
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Scheme 3.7 and Table 3.4. Reaction conditions screened for the cross-metathesis reaction. 
 
With vinyl iodide 3.23 in hand, the stannane partner was synthesized via Stork−Zhao olefination.[58,61] This 
one-pot procedure started with phosphonium salt 3.24 (Scheme 3.8, A), which was deprotonated with n-
BuLi and trapped with iodine giving alkyl iodide 3.25. This intermediate was subsequently deprotonated 
with a milder base and condensed with angelic aldehyde (3.14). The resulting vinyl iodide was then 
submitted to a lithium/halogen exchange with n-BuLi and transmetalated with trimethyltin chloride, 
affording the unstable stannane 3.16. 
As it has been mentioned in Chapters 2.4 and 3.1.1, the substitution pattern and stereochemistry of the 
hydroxy substituents in triene 3.23 proved to be essential for outcome of the cascade reaction, probably as 
a result of the existing steric strain between the OTBS and the β-methyl group, which disfavours the 6π 
electrocyclization. To further explore this effect, a series of silyl ethers was used to protect the free alcohol 
of triene 3.23 (Scheme 3.8, B).  
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Scheme 3.8. Synthesis of tricycles 3.31-3.34. 
 
Now the stage was set for the key step, a one-pot Liebeskind-type Stille coupling followed by an 8π 
electrocyclization and a Diels−Alder reaction.[140,141] The Liebeskind-type reaction takes advantage of the 
“copper effect”, which increases the reaction speed upon transmetalation from stannane 3.16 to copper 
and then to palladium. Copper also sequesters the free triphenylphosphine ligands which cause 
autoretardation and could also catalyse the cross-coupling by itself (Scheme 3.9).[53,142–144] 
 
Scheme 3.9. Proposed mechanism for the Liebeskind-type Stille coupling.[143,144] 
 
Thus, in parallel experiments performed in the dark to avoid undesired photochemical pathways (Scheme 
1.5), stannane 3.16 and the different vinyl iodides 3.27-3.30 were heated in DMF together with Pd(PPh3)4 
and copper thiophene carboxylate. Under these conditions, the desired tricyclic product could be cleanly 
isolated for R = TBS (3.31) and TES (3.32) in 42 and 32% yield respectively (Scheme 3.8, B). The reactions 
with TIPS and TBDPS were more sluggish and 3.33 and 3.34 were obtained in lower purity and yield 
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(calculated by NMR). No other products could be isolated. Although computational studies later predicted 
that bulkier substituents at C2 would inhibit the 6π electrocyclization while promoting the Diels−Alder 
reaction (Chapter 3.3), in our hands the introduction of TIPS and TBDPS silyl ethers led to decreased yields. 
These reactions were performed once, in parallel with the TBS and TES experiments and under optimized 
conditions. The fact that these were one-time reactions could explain the divergent results, but given our 
broad experience with this particular reaction, we think that other options should be considered: the 
introduction of these groups could have promoted unexplored reaction pathways, or, the presumably 
higher activation energies required for the 8π electrocyclization in the presence of bulkier substituents may 
demand longer reaction times or higher temperatures. 
Taking a closer look to the cascade reaction, many potential products could arise from tetraene 3.35. 
Discarding the photochemical pathway, polyene 3.35 could undergo a 6π disrotatory electrocyclization 
yielding cyclohexadienes 3.36 and 3.38 depending on the reaction torquoselectivity (Scheme 3.10). 
Moreover, it would be theoretically possible for both to engage in a [4+2] cycloaddition affording tricycles 
3.37 and 3.39.  
Given the lower activation energy required for 8π electrocyclizations (in unsubstituted octatetraene 18 
kcal/mol less than for the corresponding 6π), this is expected to be the major reaction pathway.[27] 
Depending on the torquoselectivity, the conrotatory electrocyclization could lead to cyclooctatrienes 3.40 
and 3.41, each of which exists as a mixture of two conformers that interconvert by ring flip with an activation 
energy of 4-7 kcal/mol.[39] These cyclooctatrienes would afford bicyclo[4.2.0]octadienes 3.42 to 3.45 upon 
6π electrocyclization, which in turn could undergo a retro-[2+2] cycloaddition extruding mesitylene and 
triene 3.47, as earlier described for Orinocin (Scheme 1.18).[55] For endo bicycles 3.42 and 3.45, a Diels−Alder 
reaction analogous to the one yielding endiandric acid C could take place affording tetracycles 3.46 and 
3.48. 
Finally, the desired product 3.31 is obtained from 3.40 by the reaction sequence comprising a conrotatory 
counterclockwise 8π electrocyclization followed by a [4+2] cycloaddition with the appropriate 
regioselectivity. If the other possible diene in cyclooctatriene precursor 3.40 would engage in the 
Diels−Alder reaction, tricycle 3.49 would be obtained instead. Evidently, the homologous compounds 3.50 
and 3.51 would arise from the same process, starting with cyclooctatriene 3.41, itself originating from 
clockwise 8π electrocyclization of tetraene 3.35. 
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Scheme 3.10. Potential products that could arise from cascade reaction 3.35 → 3.31. 
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Scheme 3.11. Possible reaction pathways followed by 3.40 and 3.52 including transition states. 
 
As it can be deduced from the experimental results, the right arrangement of substituents at C2 and C3 
positions allowed for remarkable stereoselectivity, and consequently, a reaction which could yield at least 
14 different products delivered the desired tricycle in 42% yield. The explanation for this phenomenon can 
be attributed to the steric strain between the side chain, increased by the presence of the OTBS group, and 
the β-methyl group present in transition states 3.43TS and 3.42TS, of which the latter is presumably higher 
in energy given the endo position of the alkyl chain (Scheme 3.11). Computational calculations in this regard 
can be seen in Chapter 3.3. This strain is not present (or is greatly minimized) in the transition states of the 
analogous tetraene (3.54TS and 3.55TS), explaining why in previous work only the 6π products, 
bicyclo[4,2,0]octadienes 3.54 and 3.55 were isolated under similar reaction conditions. Moreover, attempts 
to thermally reverse this reaction only led to retro-[2+2] cycloaddition (Scheme 3.11). 
With the core structure in hand, we aimed to install the olefinic methyl group in the cyclopentane ring. We 
envisioned that α-hydroxyketone 3.57 (Scheme 3.12) obtained from tricycle 3.31 by MOM deprotection, 
oxidation and TBS deprotection could be deoxygenated with SmI2 yielding ketone 3.58.[145,146] This versatile 
intermediate could potentially deliver cyclopentene 3.59 by 3 different approaches based on intermediates 
3.60 to 3.62. The first strategy would involve olefination of the ketone yielding exo-methylene 3.60, which 
could be isomerized to the desired intermediate 3.59.[147–150] Another option would be the synthesis of an 
enol sulfonate (3.61a, b or c) which could engage in a cross-coupling reaction to install the methyl 
group.[151,152] Finally, methylation of ketone 3.59 with a Grignard or an equivalent reagent would lead to 
tertiary alcohol 3.62, which upon elimination would afford 3.59.[153,154] 
2 
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Scheme 3.12. Envisioned routes towards intermediate 3.59. 
 
For this purpose, we first proceeded to deprotect the MOM group of intermediate 3.31. After trying 
different methods including the use of B-Bromo catecholborane, (Table 3.13, Entries 1-2),[155,156] zinc 
bromide (Entries 3-4)[157–159] and TES triflate and base (Entries 5, 7-8)[160] at different temperatures, either 
no conversion or decomposition was observed (Table 3.5, Entries 1-5). We then tried Fujioka’s conditions, 
which consisted in the treatment of the acetal with TESOTf and 2,6-lutidine at 0 ºC, forming a lutidinium salt 
intermediate which could be hydrolysed in situ yielding the desired alcohol.[161] For our hindered substrate, 
3.31, no conversion was observed under the mentioned conditions. This prompted us to apply more forcing 
conditions, switching the solvent to chloroform and heating up to reflux. After 5 hours the expected 
lutidinium salt 3.63 was observed by proton NMR, and further hydrolysis was achieved by keeping the 
sample in a biphasic mixture of chloroform and water at 65 ºC for 48 h, obtaining alcohol 3.64 in 81% yield. 
In another publication by Fujioka,[162] the problem of lutidinium salt hydrolysis was addressed by the use of 
bipyridine, which yielded labile bipyridinium salts. However, when we applied this method, only 
decomposition was observed (Entries 7-8).[162] 
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Scheme 3.13 and Table 3.5. Conditions screened for the deprotection of MOM alcohol 3.31. 
 
Alcohol 3.64 was oxidized with DMP yielding protected α-hydroxy ketone 3.65, which we were unable to 
deprotect by treatment with various fluoride sources including TBAF, TASF, HF/Pyridine and BF3 due to 
decomposition (Scheme 3.13).[163–166] An attempt to directly deoxygenate silyl ether 3.65 with SmI2 based 
on literature precedents also failed.[145,167] Thinking that the ester group could be playing a role in the 
decomposition of 3.65, we opted to reduce it and protect the resulting alcohol. This was accomplished by 
treatment of 3.64 with DIBAL followed by primary alcohol protection with TBDPSCl and oxidation with DMP, 
which smoothly delivered ketone 3.67. We attempted the SmI2 mediated α-hydroxy ketone deoxygenation 
on 3.67,[163–166] but again no conversion was observed. Wittig olefination of 3.67 to obtain exo-methylene 
3.69 and alkylation attempts with different organometallic reagents including methyl magnesium bromide, 
methyllithium, lithium trimethyl magnesiate and methyl titanium trichloride aiming to deliver tertiary 
alcohol 3.70 were also unsuccessful,[153,168–173] presumably due to the steric hindrance around the carbonyl 
group. 
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Scheme 3.14. Attempts to synthesize advanced intermediates 3.58 and 3.68 to 3.70. 
 
Since the deoxygenation attempts on α-hydroxy ketones 3.65 and 3.67 were unsuccessful, we decided to 
first deprotect the TBS silyl ether and submit the resulting alcohol to deoxygenation with Nugent’s reagent 
using Barrero’s conditions (Scheme 3.15).[174] Unfortunately, when applied to alcohol 3.71 or silyl ether 3.31, 
no conversion was observed. This prompted us to redesign our retrosynthesis for the last time (Scheme 
3.16). 
 
Scheme 3.15 and Table 3.6. Attempts to deoxygenate intermediates 3.31 and 3.71 with Nugent’s reagent. 
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Scheme 3.16. Definitive retrosynthesis of (−)-PF-1018. 
 
We envisioned a new way of obtaining tricycle 3.75 from diol 3.31. The olefinic methyl group of 3.75 could 
be installed by means of Negishi coupling on an enol triflate derived from ketone 3.58. 3.58 could in turn 
be obtained from 3.31 upon TBS deprotection, Barton−McCombie deoxygenation and oxidation of the 
alcohol at C3. This strategy together with the Brown allylation route towards 3.31 and the final HWE 
reaction define the retrosynthetic analysis that delivered (−)-PF-1018 (Scheme 3.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
3.3 Bioinspired Synthesis of (−)-PF-1018 
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3.4 Unpublished Results 
 
The side reactions identified within the Barton−McCombie deoxygenation of methyl xanthate 3.76 are 
disclosed in Scheme 3.17.  
Pathway A leading to desired product 3.72. 
The stannyl radical derived from tributyltin hydride (TBHT) attacks the thiocarbonyl sulfur atom reversibly, 
originating xanthate-centred radical 3.77, which undergoes homolytic cleavage of the adjacent C-O bond 
leading to the alkyl radical 3.78. An extra equivalent of TBHT quenches radical 3.78 by hydrogen atom 
abstraction yielding the desired product 3.72.[175,176] 
Pathway B leading to tetracycle 3.79. 
Following the exact same route until intermediate 3.78, the alkyl radical is not quenched by tin hydride and 
a 4-exo-trig radical cyclization takes place leading to tetracycle 3.79. This pathway is inhibited by high 
loadings of TBTH, which would trap the alkyl radical before it undergoes cyclization to 3.79. 
Pathway C leading to methyl ether 3.84. 
A different reaction course competes with the homolytic fragmentation of intermediate 3.77. This radical 
can be quenched by TBTH generating intermediate 3.80, which can be attacked again at the less hindered 
sulfur atom by a stannyl radical leading to mixed acetal 3.82. Repetition of this process leads to methyl ether 
3.84.[177] Obviously, the greater the excess of the hydride source, the faster these reactions will occur and 
the higher the yields of 3.84. 
 
Scheme 3.17. Mechanism of the Barton−McCombie reaction of xanthate 3.76 leading to 3 different 
products. 
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Hence, trying to inhibit pathway B by tuning the stoichiometry of TBHT will promote pathway C and vice 
versa. We therefore thought of two other methods to direct the reactivity of the Barton−McCombie 
reaction towards the desired product. The first consisted in the use of different hydride sources with a 
reductive potential capable of quenching radical 3.78 without encouraging pathway C.[178] The other method 
involved the employment of different xanthates more prone to undergo fragmentation in order to favour 
pathway A.[179] 
 
Scheme 3.18. Preparation of different xanthates from alcohol 3.71. 
 
We therefore pursued the synthesis of xanthates 3.85 to 3.87 and succeeded in the isolation of ethyl 
xanthate 3.85 and benzyl xanthate 3.86. We did not observe any conversion towards neopentyl xanthate 
3.87 and could not surpass the 10% yield in the synthesis of the imidazole derivative 3.88. With these 
increasingly hindered xanthates we hoped to obtain intermediate radical species more prone to undergo 
fragmentation as a consequence of a greater release of steric strain between the xanthate and alkyl 
moieties, as compared to methyl xanthate 3.76.[179,180] Moreover, xanthate centred radical species such as 
3.87 (Scheme 3.19), would more reluctant than 3.77 to be overreduced, since the environment around the 
radical is more congested. 
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Scheme 3.19. Comparison between the kinetics of xanthates 3.76 and 3.86 in the Barton−McCombie 
deoxygenation. 
 
As it can be seen in Scheme 3.19, the first step consisting in addition of the stannyl radical to methyl 
xanthate 3.76 is fast and reversible. Once radical 3.77 is generated, the faster pathway C (if run in neat 
TBTH, see Table 3.7) leads to methyl ether 3.84, and paths A and B, initiated by fragmentation are slightly 
slower in delivering radical 3.78.[179,180] If xanthate 3.86 is submitted to the same process, the first addition 
of the radical will presumably be slowed down by the increased steric bulk around the sulfur atom, but this 
will still be the fastest step. The quench of radical intermediate 3.90 follows the same logic, occurring at a 
slower rate than for the methyl xanthate 3.77. Finally, 3.90 will undergo fragmentation to deliver radical 
3.78 at a faster rate than 3.77 given the greater steric strain between the alkyl and xanthate moieties. 
The empirical proof for these claims can be seen in Table 3.7. While working with methyl xanthate 3.76, we 
obtained a more favourable ratio of deoxygenated product 3.72 + tetracycle 3.79, both arising from initial 
fragmentation, when the reaction was run with 1.5 equivalents of TBTH than when we used 50 (Entries 1 
and 3). In the latter case the ratio of 3.84 increased almost fivefold. A larger scale attempt (400 mg of 3.76 
versus 25 mg) followed this trend delivering large amounts of 3.79 (Entry 2). 
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Scheme 3.20 and Table 3.7. Conditions screened for the deoxygenation of 3.76. 
 
We also run the reaction with different hydride sources aiming for a faster quenching of radical 3.78 or a 
slowest overreduction of radical 3.77. For the latter option, use of the milder reductant triethyl silane led 
to no observable reaction after 10 hours (in agreement with its hydrogen-atom abstraction rate constant, 
3 orders of magnitude smaller than for TBHT)[178,181] and for tris(trimethylsilyl)silane, the reaction took 6 
hours to reach completion, giving a mixture where none of the expected products could be identified 
(Entries 4 and 5).[178,182] 
When using ethyl xanthate 3.85, we observed the expected lower ratio of methyl ether 3.84 compared to 
the sum of 3.72 and 3.79. Moreover, the yield of 3.72 increased to 50% (Entries 7 and 9). Using triphenyltin 
hydride as a more efficient hydrogen-atom donor did not lead to the expected increase in the yield of 3.72, 
delivering instead 3.84 as the major product. The result was comparable to that of TBHT (Entries 7-8). 
Finally, we carried out the reaction in the presence of phenylselenol expecting that its electrophilic radical 
nature would induce an increase in reaction speed and an adjustment in product distribution,[183,184] but it 
did not induce any significant change in the product ratio (Entries 10 and 11).  
For benzyl radical 3.86, the differences in yield were more marked. If run in neat TBTH, the amount of 
overreduced product 3.84 dropped, and only traces of tetracycle 3.79 were found (Entries 12-15). 
Moreover, the yields for 3.72 increased up to 76% (Entry 15). 
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Scheme 3.21 and Table 3.8. Fragmentation of cyclobutene ring in tetracycle 3.91. 
 
As soon as we saw the crystal structure of 30 (see Chapter 3.3, Figure 1), we noticed that the hydrogen in 
the γ position relative to the carbonyl group was in an almost perfect antiperiplanar conformation with 
respect to the cyclobutane ring (see 3.91, Scheme 3.21). We thought that we could use this in our advantage 
to recycle tetracycle 3.79 by means of a fragmentation reaction.[185] Since esters react with Tf2O to yield 
unstable acyl triflates[186] we reacted instead alcohol derivative 3.91 with triflic anhydride in the presence 
of 2,6-di-tert-butyl-4-methylpyridine (DTMP) to provide enol triflate 3.92, an intermediate that could be 
used to install the olefinic methyl group (Table 3.8).[187] When the reaction was run at room temperature 
the desired product 3.92 was obtained in 12% yield together with the same amount of exo-methylene 
product 3.93, which results from elimination at the easily accessible methyl group (Entry 1). When the 
reaction temperature was lowered to 0 ºC the yield improved to 24%, and the 3.92/3.93 ratio increased 
threefold (Entry 2). When performed at lower temperatures the reaction worked smoothly affording the 
desired product with increased yields and higher regioselectivity (Entries 3-4). 
The last step of the synthesis was the Horner−Wasworth−Emmons reaction between phosphonate 3.74 and 
aldehyde 3.75 (Scheme 3.22). Given the high value of 3.75, we decided to first run the reaction with simpler 
aliphatic aldehydes to find the most suitable reaction conditions. To the dianion of 3.74 generated by 
treatment with different tert-butoxide salts was added the corresponding aldehyde leading to the isolation 
of the different condensation products. 
We first performed the reaction with isobutyraldehyde (3.97) using potassium, sodium and lithium tert-
butoxide salts. Among these, the best yield was achieved with the latter. In addition, two different workups 
in combination with flash chromatography or HPLC were tested. The first method involved quenching with 
a saturated NH4Cl solution followed by extraction (Table 3.9, Entry 1). In the second procedure, after 
quenching the reaction all solvents were evaporated under reduced pressure and the remaining residue 
was suspended in acetone, filtered and submitted to purification (no ext., Entries 2-3). The second method 
in combination with lithium tert-butoxide and HPLC purification gave 3.94 in excellent yield (97%, Entry 3). 
We confirmed the better performance of the lithium salt in the reaction with cyclohexanecarboxaldehyde 
(3.98), which delivered 3.95 in 75% yield, in contrast to the modest 52% for potassium tert-butoxyde 
(Entries 4 and 5). The reaction with octanal (3.99) was completely unsuccessful upon extractive workup, but 
again the  combination of lithium tert-butoxide with the alternative workup and HPLC purification delivered 
the natural product pyreudione C (3.96) in 71% yield (Entries 6 and 7).[98] 
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For aldehyde 3.75, potassium tert-butoxide afforded the product in low yields and the combination of 
extractive workup with HPLC purification failed to provide (−)-PF-1018 (Entries 8-9). By using LiOt-Bu as base 
and after HPLC purification (−)-PF-1018 was obtained in 30% yield (Entry 10). Finally, we added additional 
equivalents of phosphonate 3.74 and LiOt-Bu and performed the extractive workup followed by flash 
chromatography. These conditions allowed for the isolation of (−)-PF-1018 in 47% yield (Entry 11). We 
assign the low yields to the unstable nature of aldehyde 3.75, which decomposed slowly at room 
temperature. Not surprisingly, the reaction times varied notably depending on the starting aldehyde. The 
bulkier aldehyde 3.75, required 26 hours to reach full conversion whereas with octanal the reaction was 
finished after 2.5 hours. 
 
Scheme 3.22 and Table 3.9. Reaction conditions screened for the HWE leading to (−)-PF-1018. 
 
 
 
 
 
 
 
 
58 
 
4. Summary and Outlook 
 
The first total synthesis of (−)-PF-1018 was achieved using a biomimetic approach. The key step of the 
synthesis comprises an unprecedented Stille/8π electrocyclization/Diels−Alder cascade which is an 
exception to the ubiquitous 8π/6π electrocyclization sequence which gives rise to all the other members of 
the Cyclooctatriene-Derived NP family, such as endiandric acids and the elysiapyrones. The regio- and 
diastereoselectivity of the key step was dictated by two protected hydroxy groups (4.2, Scheme 4.1), which 
promoted the 8π/Diels−Alder pathway and inhibited the 6π electrocyclization delivering the desired 
product in satisfactory yield. The synthesis of cascade precursor 4.2 was accomplished by means of a Brown 
allylation/cross-metathesis approach, which delivered the desired product with excellent enantiopurity and 
shortened a previous route by two steps. 
The tricyclic core 4.7 obtained in the key step was deoxygenated by means of a highly optimized 
Barton−McCombie reaction using an uncommon benzyl xanthate (4.10). This reaction also gave variable 
amounts of a 4-exo-trig radical cyclization product (4.12) which could be recycled upon ring opening by 
means of a regioselective fragmentation triggered by triflic anhydride. Both routes reconverged into alcohol 
4.13, which was condensed with phosphonate ester 4.14 giving (−)-PF-1018. This phosphonate was also 
used to synthesize the natural product pyreudione C. 
 
Scheme 4.1. Summarized synthesis of (−)-PF-1018. 
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With this synthesis we have shown how the introduction of substituents with a defined stereochemistry 
can modulate the reactivity of cyclooctatriene intermediates, proving that their chemistry goes beyond the 
classic 8π/6π electrocyclization cascade. Moreover, given the interesting bioactivities displayed by other 
natural products bearing tetramic acids, our synthesis can be used to access (−)-PF-1018 to test its biological 
activity against new targets. 
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PHOTOSWITCHABLE GABAA RECEPTOR 
POTENTIATORS 
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5. Introduction 
5.1 GABAA Receptors 
 
GABA receptors (GABARs) are transmembrane protein assemblies that respond to gamma-aminobutyric 
acid or GABA. Once GABARs are activated, a sequence of events induces certain ions to flow through ion 
channels following concentration gradient and causing a repolarization of the membrane.[188] 
Gamma aminobutyric acid is the most common inhibitory neurotransmitter found in the central nervous 
system (CNS) of mammals and is released by GABAergic neurons. GABA’s main function is to keep the 
neuron’s potential at or below the resting level (about −70 mV), increasing the firing threshold and 
therefore reducing the chance of initiation of an action potential (AP).[188] GABA also influences brain 
development by regulating neuron proliferation and growth.[189–191]  
The system formed by GABA and GABARs, together with other inhibitors of the nervous response, such as 
glycine receptors (GlyR),[192] act as a counterpart for the distinct excitatory systems of the CNS, the most 
prevalent of which in mammals are glutamate receptors (GluRs).[193] The balance between the excitatory 
and inhibitory neurotransmission generated by these mechanisms allows for the correct performance of 
the CNS. Decreased GABAR activity causes imbalances which provoke increased anxiety, fear, insomnia or 
seizures and disorders such as autism, epilepsy or depression.[194–196] 
GABA receptors can be classified into two types, GABAA and GABAB.[197] The latter are metabotropic 
receptors mainly located at extrasynaptic sites which induce slow membrane polarization by efflux of 
potassium ions. GABAB receptors display a less marked effect on the inhibition of the AP and will not be 
further discussed here.[197] 
 
Figure 5.1. Left. Schematic representation of a GABAAR subunit comprising the N-terminal extracellular 
domain (NTED) with the cys-loop structure, 4 transmembrane domains (TM) connected by the corresponding 
amino acid chains, the TM3-4 binding domain where gephyrin binds and the C-terminal extracellular domain. 
Right. Schematic representation of a 2α2β1γ GABAAR assembly. The approximate binding sites of GABA, BZs 
and neurosteroids are indicated. 
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GABAARs are typically located in neuronal tissues but are also present in other organs. They belong to the 
Cys-loop super-family of the ligand-gated ion channels (LGIC), which also includes the nicotinic acetylcholine 
receptors, glycine receptors (GlyRs) and 5-HT3 receptors.[198]  All members of the family are formed by 
pentamers of analogous subunits, which contain an N-terminal extracellular domain (NTED) featuring a 
conserved 15-residue chain with a disulfide bridge forming the cysteine loop, 4 transmembrane (TM) 
domains, an intracellular TM3-4 binding domain, and an extracellular C-terminal domain (CTED). Five of 
these units assemble together to form a central ion channel. GABAAR and GlyR ion channels are anion 
selective due to the presence of several cationic residues on the pore surface.[192] 
GABAARs are ionotropic receptors ubiquitous in CNS neurons which are activated by GABA and its isosteres 
(Figure 5.1). The binding of two molecules of GABA induces pore opening causing a flow of chloride anions 
into the cell making its potential more negative (polarization). As members of the Cys-loop superfamily, 
GABAARs are pentamers formed by limited combinations of 8 different subunit types with different variants: 
six types of α subunit, three of β, γ, and ρ and one known variant of δ, ε, π, and Θ subunits.[199] The sequence 
homology within one subtype is about 70%, whereas between classes it is only 30%.[200] The majority of the 
GABAAR subtypes contain two α, two β and one γ unit, being α1β2γ2 the most abundant and predominant 
in the mammalian brain, whereas the ρ containing subtypes are pseudo-homopentameric and prominently 
found in the retina.[201] The specific configuration of the GABAARs determines their channel and gating 
profile, pharmacokinetic properties as well as cell location and presence in different CNS regions. Table 5.1 
shows the relative abundance and pharmacological roles of the different α subunits.[202] 
 
Table 5.1. Location and function of the different GABAAR α subunits.[202] + indicates that the minority of the 
receptors are located at the specified location. ++ indicates that the majority of receptors are located at the 
specified location. – indicates no presence of receptors at the specified location. α4 is mostly extrasynaptic 
and present together with δ subunits. α6, not shown here is mostly located at the cerebellum. 
 
The majority of GABAARs cluster at the synaptic cleft of postsynaptic neurons anchored by proteins as 
gephyrin.[203] Gephyrin interacts with the loops of the TM3-4 intracellular binding chain, preferentially of 
GABAR subtypes containing α1-3, β2-3 and γ2 subunits[204,205] (Figure 5.1). The high local concentration of 
GABA at the synaptic cleft leads to fast receptor binding and chloride channel opening, mediating phasic 
inhibition that occurs within a few milliseconds. Other GABAARs are located at the extrasynaptic membrane 
causing tonic inhibition, which is constant (lasting for minutes or hours) and weaker given the low 
concentration of GABA in the extracellular medium.[202,206] 
The affinity for GABA depends on the receptor subtypes. Generally, those responsible for keeping a tonic 
current and located outside of the synaptic cleft display much higher affinities given the lower concentration 
of GABA outside of the synapses. Thus, GABAARs expressed in Xenopus oocytes containing α4β1δ α4β3δ 
subunits are activated by nanomolar concentrations of GABA, whereas α4β2δ is only activated at 
micromolar concentrations.[207] 
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5.2 The GABA Binding Site, GABAAR Agonists and                          
….…Antagonists  
 
The GABA binding site is located at the ECD of the α/β subunit interface, and a large number of amino acids 
are implicated in its binding.[208] The exact location was corroborated by the works of Zhu and Aricescu, who 
unravel the structure of the α1β2γ2 and α1β3γ2 GABAAR complexes by means of high-resolution cryo-
electron microscopy (cryo-EM)[208,209] (Figure 5.2). Thus, in subtypes containing two α, two β and one γ units 
two binding sites for GABA exist, but the asymmetry of the heteropentameric complex given by the 
presence of the γ unit results in a three-fold higher affinity of GABA for one of the pockets. This affinity is 
reversed for the conformationally restricted analogues muscimol and tetrahydroisoxazolo-pyridinol 
(THIP).[210] When one GABA molecule binds to the receptor channel, opening occurs just to a small extent. 
When a second unit binds the open probability increases by more than 60-fold and chloride ions rush into 
the postsynaptic neuron.[210] The conformational change responsible for the channel opening induces 
closing of a large region of the receptor at the α/β interface trapping the agonists inside the binding 
pockets[208,209,211] (Figure 5.2). 
 
Figure 5.2. Left. Structure of a desensitized α1β3γ2 subtype GABAAR bound to two units of GABA and 
alprazolam by Aricescu.[209] Binding sites for GABA can be found at the α/β interfaces and alprazolam at the 
α/γ interface. Comparison with the right structure highlights the free pore structure and the tight 
conformation of the β loops around the GABA neurotransmitters. Right. Structure of a  picrotoxin-blocked 
α1β3γ2 subtype GABAAR by Aricescu.[209] It can be observed how the red β loops are in an opened 
conformation in contrast with the left structure and how the constriction of the central TM2 units close the 
pore around picrotoxin. . Images from PDB database created with PyMOL.[212,213] 
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5.2.1 GABAA Receptor Agonists 
GABA is the main endogenous agonist of GABAARs, although several molecules can replicate or antagonize 
its function by binding to the same or different pockets. Most GABAAR agonists are derived from GABA by 
restricting different conformations by means of ring incorporation (Scheme 5.1).   
5.2.1.1 Muscimol 
Muscimol, a constituent of the Amanita muscaria mushroom, is a potent agonist of the GABAAR and partial 
agonist of the ρ receptor subtype.[214] Its binding affinity and potency are higher for extrasynaptic receptors 
bearing α4β3δ subunits, on which it  acts as a superagonist at high concentrations by reducing receptor 
desensitisation.[215] These and other properties make muscimol a hypnotic, depressant and inhibitor of 
memory retention by action on CNS GABAARs and an alleviator of airway constriction by action on peripheral 
GABAA receptors.[216,217] Muscimol has been used to study the pharmacology of GABAARs and as a lead 
compound for the development of related substances showing increased GABAAR affinity. Derivatives of 
muscimol such as THIP, THPO, nipecotic acid, isoguvacine or tiagabine, act as true inhibitors of GABA uptake 
and display anticonvulsant effects. Among these, tiagabine is an approved drug under the commercial name 
of Gabitril (Scheme 5.1).[214,215] 
 
Scheme 5.1. Structure of gamma-aminobutyric acid and related agonists. 
 
5.2.1.2 THIP 
The GABA agonist THIP (tetrahydroisoxazolo-pyridinol, also known as gaboxadol) is a restricted analogue of 
muscimol which exhibits higher selectivity for certain GABAAR subtypes. Similar to muscimol, 5.3 binds 
preferentially and with high affinity to extrasyaptic GABAARs (eGABAARs) bearing α4δ subunits, with channel 
activation taking place at nanomolar concentrations whereas lack of the δ subunit causes a marked 
decrease in activity.[218] THIP also acts as a superagonist on the GABAAR α4β3δ subtype but in a different 
way than muscimol; instead of reducing desensitisation, 5.3 increases the duration and frequency of 
channel openings.[215] Unlike GABA or muscimol, THIP also works as an antagonist for GABAA ρ subtypes.[214] 
Given the unique performance of THIP at the molecular level it is not surprising that 5.3 also displays 
interesting pharmacological effects acting as a potent analgesic and hypnotic by mediating tonic inhibition 
at extrasynaptic sites, differently from other hypnotic drugs such as zolpidem and zaleplon which induce 
synaptic phasic inhibition. It was therefore considered as a candidate for the treatment of Huntington’s 
disease, Alzheimer’s disease and for the treatment of insomnia, but the studies were cancelled due to safety 
and efficacy concerns.[219,220] 
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5.2.2 GABAA Receptor antagonists 
Unlike for GABAAR agonists, the activity of most antagonists is independent of the receptor-subunit 
composition and hence the potencies displayed on different subtypes are often very similar. 
5.2.2.1 Bicuculline, RU5135 and TPMPA 
Bicuculline’s convulsant properties were first described in the 1960’s.[221] Problems in reproducing the 
results revealed that bicuculline (5.10) is converted into the almost inactive bicucine (5.11) at physiological 
pH and that bicuculline can be recovered upon acidic treatment of 5.11.[222,223] This problem could be 
overcome by using quaternary ammonium salts of 5.10, but these exhibit off-target effects and do not cross 
the blood-brain barrier as easily as bicuculline, thus requiring injection.[224] 5.10 is a potent competitive 
antagonist of all kinds of GABAARs with the exception of α6 subtypes (displaying milder effects) and ρ 
subtypes, which remain unaffected. Bicuculline prevents the open state by stabilizing β subunit rotation 
(Figure 5.2, right), encouraging the closed conformation of the GABAAR. Moreover, it has been found that 
5.10 can also act as an allosteric inhibitor.[225] Gabazine, also a competitive GABAAR antagonists displays 
very similar properties.[226] 
RU5135 is a steroid derivative. This competitive GABAAR antagonist is 500 times more potent than 
bicuculline but is not as specific and affects glycine receptors.[225] 
Substitution of the acid group of GABAAR agonist isoguvacine by a methylphosphinic acid yields TPMPA 
(tetrahydropyridinyl methylphosphinic acid), which acts as a potent and selective ρ subtype GABAAR 
competitive antagonist, and only as a weak antagonist for other GABAAR subtypes. It shows 8-fold increased 
selectivity for human ρ1 over ρ2 GABAA subtype receptors. This selectivity for ρ subunits involves the lack 
of convulsant properties and makes of TPMPA a candidate in the treatment of myopia.[227] 
 
 
Scheme 5.2. Structures of GABAAR antagonists. 
 
5.2.2.2 Picrotoxin 
Picrotoxin was the first non-competitive antagonist of GABAARs discovered. It was isolated from the fruit of 
Anamirta cocculus and can be accessed by total synthesis.[228,229] Picrotoxin is a 1:1 mixture of picrotoxinin 
(5.8) and picrotin (5.9) of which 5.8 is the more active species. Picrotoxin shows convulsant properties 
derived from induced stabilization of the closed form of the GABAAR and other Cys-loop superfamily 
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members, such as GlyRs and 5-HT3 receptors, which occurs even in the presence of GABA.[209,230] The exact 
mechanism has been described by Ariescu by means of cryo-EM, showing how picrotoxin binds to the 
opened channel and subsequently stabilizes the closed state, explaining the previously observed properties 
as channel blocker and allosteric antagonist.[209] 
 
5.3 Elucidation of GABAA Receptor Binding Sites 
 
Multiple binding sites are present at GABAAR constructs as a result of the complexity of its assembly formed 
by limited combinations of 19 different subunits, the most ubiquitous of which comprises two α1, two β2 
and one γ2 subunits (simply named α1β2γ2).[197]  
Until recently, the architecture and binding sites within GABAARs had been mostly studied by means of 
radioligand binding, photolabeling, mutagenesis and homology models based on other members of the LGIC 
superfamily, as for example the Torpedo marmorata nicotinic acetylcholine receptor (nAChR), unveiled in 
2005 by Unwin et al. or the high resolution structure of Erwinia chrisanthemi’s ligand-gated ion 
channel.[231,232] However, in the past few years major achievements on the knowledge of GABAAR structures 
and binding sites have been made. In 2014 the structure of a homopentameric β3 GABAAR was solved by 
Miller and Aricescu.[233] In 2017 Duncan, Laverty and others presented the structure of a GABAAR α1 subunit 
chimera with NTED and TM3-4 binding region of a prokaryotic LGIC, helping to identify the binding sites of 
some neurosteroids.[234] In 2018, a cryo-EM structure of the α1β2γ2 GABAAR-Fab complex, the most 
predominant form in the human adult brain, was published, including bound flumazenil and GABA.[208] In 
2019, Ariescu presented several cryo-EM structures of α1β3γ2 GABAAR bound to GABA, alprazolam, 
diazepam and picrotoxin, describing binding modes and mechanistic effects of these ligands (Figures 5.2 
and 5.4).[209] The binding site of flumazenil at the α/γ interface was precisely defined giving a very high level 
of detail allowing for identification of binding poses and interactions. 
 
5.4 GABAAR Allosteric Modulators 
5.4.1 Neurosteroids 
In addition to GABA, other endogenous ligands such as neurosteroids can bind to GABAARs. Neurosteroids 
are synthesized within the CNS by glial cells and neurons from cholesterol, but can also be exogenously 
administered.[235] Their main target are GABAARs, where they most often act as positive allosteric 
modulators (PAMs) influencing mood and behaviour through anxiolytic, analgesic, anticonvulsant, sedative, 
hypnotic and anaesthetic effects. Several binding sites have been identified but many of them do not exert 
allosteric effects.[236] In this regard, binding sites at the / interface on the inner edge of the TMD bind 
tetrahydrodeoxycorticosterone and similar steroids (with higher affinity for 3 and 1 subunits) inducing 
positive allosteric modulation (Figure 1). Another allosteric binding site is present at the  subunit TMD, 
where pregnelonone sulfate binds with high affinity acting as a negative allosteric modulator (NAM).[234] 
67 
 
 
Scheme 5.3. Structures of neurosteroids acting as PAM (5.15) and NAM (5.16) on GABAARs. 
 
5.4.2 Anaesthetics 
The clinical effect of anaesthetics involves a temporary loss of awareness or sensation. GABAA receptors are 
an important target for anaesthetic drugs, which entail substances such as barbiturates, propofol, 
etomidate or ketamine. Despite the fact that some of these drugs do not bind to the same binding site, the 
main pockets are thought to be close to each other at the TM2 of β subunits.[237] 
5.4.2.1 Propofol 
Propofol (5.17) is used for fast-acting general anaesthesia. 5.17 binds to the TMD2 of β subunits close to 
the etomidate binding pocket.[238,239] However, its affinity for GABAARs is affected by changes at α, γ and δ 
subunits, suggesting that it binds to other sites depending on the receptor subtype. Propofol acts as a PAM 
at low concentrations and as a GABA agonist at high concentrations. The alcohol group is critical for its 
activity.[240] 
 
5.4.2.2 Etomidate 
Etomidate is used as a short-acting anaesthetic, sharing most of its properties with propofol. It is sensitive 
to β2 and β3 and insensitive to the β1 subunit. The binding site is located at TM2, probably overlapping with 
the volatile anaesthetic binding site.[241] Mutation of key residues at β2 and β3 subunits supressed its 
binding, with similar effects on propofol. These results suggested that they either share the same binding 
pocket or bind to proximal sites.[242] 
5.4.2.3 Barbiturates 
Barbiturates display anticonvulsant, anxiolytic, sedative and hypnotic effects, with a relatively narrow 
therapeutic window and high death risk in case of overdose. They also cause addiction, deep sedation and 
depression of the CNS activity including respiratory function. For these reasons they have been substituted 
by the safer benzodiazepines and Z-drugs. The barbiturates are still used for general anesthesia (thiopental) 
and the treatment of epilepsy (phenobarbital, primidone).[243,244] Their structure features a pyrimidinetrione 
core with different substitution patterns at the sp3 carbon (Scheme 5.4). 
 
 
 
Scheme 5.4. Anaesthetic compounds active on GABAARs. 
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Although barbiturates bind to GABAARs with lower affinity than other allosteric modulators, they act as 
potent GABAAR PAMs and enhance the binding affinity of the receptor to benzodiazepines while inhibiting  
the binding of some NAMs.[206] 
 
Barbiturates act in three different ways depending on concentration. At low micromolar levels they act as 
PAMs. Above 50 µM they behave as agonists, causing channel opening without need for GABA. When bound 
to 6 subtype receptors the barbiturates cannot be displaced by competitive antagonists and cause more 
intense responses than GABA.[206] At high mM range, they block GABA induced current.[245] This behaviour 
can be explained by the presence of different binding sites with different pharmacological effects, two of 
which have been identified at the α/β and the γ/β interfaces in the TMD.[246] Point mutations at β1 subunits 
blocked the allosteric function without affecting the agonistic or inhibitory effects of pentobarbital, 
supporting that these distinct action modes are mediated by different binding sites.[247] The selectivity of 
barbiturates for different GABAAR subtypes is rather low, but this is partially compensated by the variable 
potencies displayed on different receptor types.[245] 
 
5.4.3 Ethanol 
Ethanol acts as a PAM of tonic currents associated to extrasynaptic GABAAR bearing δ subunits.[248] It has 
been reported that the potentiating effect of ethanol in tonic currents takes place at or below 30 mM 
concentration, and near to 10 mM for the more sensitive α4/6β3δ GABAAR subtype, although these 
experiments could not be reproduced.[206] The ethanol binding site is thought to overlap with the secondary 
imidazobenzodiazepine Ro15-4513 (Scheme 5.5) binding site at the α4,6+/β3- interface, which is analogous 
to the classical α/γ benzodiazepine binding site. This is in agreement with the fact that Ro15-4513 acts as 
an alcohol competitive antagonist in rats.[206] Moreover, the fact that flumazenil does not display these 
effects suggest that ethanol binds close to the azido-site of Ro15-4513’s binding pocket.[248] Rats treated 
with ethanol show dramatic δ subtype GABAAR downregulation.[188] It has been speculated that many of the 
effects induced by ethanol on GABAAR currents may be caused by its ability to increase neurosteroid levels, 
which favour GABAAR responses.[199] This is supported by the fact that these effects are inhibited by blockers 
of steroid synthesis.[249] 
 
5.4.4 Benzodiazepines 
5.4.4.1 General Aspects 
Benzodiazepines (BZs) have been used for treatment of anxiety, panic attacks, epilepsy, muscle relaxation 
and sleep disorders for more than 50 years.[250] Almost all clinically used benzodiazepines target GABAAR 
subtypes with low selectivity,[251] causing several side effects such as sleepiness, anterograde memory loss 
and ataxia, in addition to tolerance and physical and psychological dependence.[251,252] 
BZs can act as positive allosteric modulators (PAMs, or potentiators), negative allosteric modulators (NAMs) 
or “benzodiazepine site antagonists”. The classical BZ drugs (like diazepam, flunitrazepam or lorazepam) 
and most commercial drugs of this type are potentiators that increase the response generated by the 
GABAAR at a given GABA concentration. Hence, when BZs bind to the benzodiazepine binding site they 
induce conformational changes on the GABAAR increasing its affinity for GABA. This is followed by pore 
opening at lower neurotransmitter concentrations without increasing the maximal current.[253] These 
effects seem to be reciprocal, since GABA and its agonists stimulate BZ binding and inhibit binding of inverse 
agonists at benzodiazepine binding site.[206] 
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Figure 5.3. Left. Graphical representation of firing potential in neurons. Below time 0 the neuron is at resting 
state with an approx. potential of −70 mV. When the glutamate receptors (glu) are activated, a flow of Na+ 
ions from the extracellular medium enters the cell and partially depolarizes the membrane. When a 
threshold of about −55 mV is reached, additional sodium channels open starting an action potential which 
fully depolarizes the membrane. This is followed by a refractory period when the opening of GABAAR 
channels causes hyperpolarization of the membrane at about −75 mV. The hyperpolarization inhibits a new 
AP since the triggering threshold is harder to reach. Right. The same process in the presence of 
benzodiazepines. The higher affinity of GABAARs for GABA induced by BZs causes a more marked 
hyperpolarization, which in this case reaches −80 mV. The −55 mV threshold is now further from the current 
membrane potential than in the absence of benzodiazepines. 
 
NAMs display the opposite effect, lowering the affinity of GABAARs for GABA, so that higher concentrations 
of the neurotransmitter are needed to induce channel opening.[254] Examples of these type of BZs are 
Sarmazenil or Ro15-4513 (Scheme 5.5). The “benzodiazepine site antagonists” used as benzodiazepine 
antidotes (flumazenil), displace ligands bound to the BZ binding site and recover the native activity of the 
GABAAR.[255] 
5.4.4.2 Benzodiazepine Binding Sites 
The BZ binding site is located at the α/γ interface of the ECD and is chemically very similar to the GABA 
binding site, found at the α/β junction. This explains why BZDs act as agonists at high concentrations 
although with low efficacy.[256]  
Depending on the binding affinity of the BZ dictated by the different α subunits, the receptors can be 
classified as diazepam-sensitive (containing α1,2,3,5 subunits) or diazepam-insensitive (containing α4 or α6 
subunits).[257] Diazepam is considered a “classical benzodiazepine”, meaning that it comprises a 5-phenyl-
1,4-benzodiazepine structure, the same as flunitrazepam or lorazepam.[258] The diazepam-sensitive group 
can be further subdivided in 2 groups: type I BZ receptors, containing α1βxγ2 subunits, which bind 
preferentially PAM benzodiazepines, and type II BZ receptors, containing α2,3,5βxγ2 subunits and showing 
10-fold decreased affinity for BZ PAMs.[206] 
A specific histidine residue, H101 at the α1 subunit, with homologous residues in α2,3 and 5 is key for the 
high affinity of the receptor for BZs. When H101 is replaced by arginine the sensitivity for benzodiazepines 
decreases dramatically, explaining why classical BZs do not show any significant binding to α4,6 containing 
receptors, which lack this residue. The cryo-EM structure of diazepam-bound α1β3γ2 GABAAR confirmed 
these results.[209,259,260] 
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Scheme 5.5. Structures of benzodiazepines and BZ type drug basmisanil. 
 
In the early 2000’s, punctual mutations in key residues at the BZ binding sites proved that the sedative, 
anterograde amnesic and partly anticonvulsant effects of BZs could be attributed to α1 (type I BZ receptors) 
and that α2 and α3 (type II BZ receptors) were anxiolytic and myorelaxant (Table 5.1).[261,262] This can explain 
why classical benzodiazepines, which exhibit high affinities for α1-3 GABAAR subtypes, are effective in 
treating symptoms like muscle spasms, insomnia, anxiety or convulsions, and also why they incur in 
prevalent side effects owed their low selectivity.[251] 
Effects of BZDs on memory are also attributed to the activity on tonic receptors bearing α5 subunits (type 
II BZ receptors) mainly found at the hippocampus. This is based on the observation that deletion of this 
subunit in rats caused improved spatial learning.[263] New drugs based on the BZ scaffold are being 
developed in an effort to achieve higher selectivity for these receptor subtypes. For example, basmisanil 
(Scheme 5.5) has being designed trying to address disorders derived of schizophrenia or Down 
syndrome.[264,265] 
As mentioned before, GABAARs containing α4 and α6 subunits do not bind classical BZs, but they do bind 
BZ inverse agonists such as Ro15-4513 and flumazenil.[266] For these GABAAR types lacking the α/γ2 binding 
site (also called benzodiazepine Site 1), the presence of other binding pockets could be exploited. Indeed, 
recent studies revealed the existence of new binding sites displaying low to moderate sensitivity for BZs, 
namely BZ binding Sites 2 and 3. Site 2 binds through the same protein loops as Site 1 but in the non-γ-
adjacent α subunit at the interface with the β subunit, similar to the GABA binding site[267,268] and 
independent of the presence of γ or δ subunits.[254] Site 3 appears to be located in the TMD, probably being 
the same as for general anaesthetics.[269] 
Given the high similarities between type I and type II BZ receptors and the great abundance of high-affinity 
GABAAR subtypes containing γ2 subunits, which represent 75-90% of the GABAARs,[270] the design of BZs 
displaying selective GABAAR binding entails a major challenge. Alternative strategies include the design of 
ligands capable of exerting different degrees of potentiation on different receptor subtypes despite of 
binding non-selectively.[271] Another option would involve targeting the additional BZ binding sites, although 
the affinity for those is notably lower.[267] Finally, the use of photoswitchable benzodiazepine ligands could 
render the drug active only in specific areas of the brain at a given time, thus minimizing the side effects 
caused by BZ promiscuity. 
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5.4.4.3 Benzodiazepine Binding Modes 
Benzodiazepines exist as an equilibrium of two conformers, P and M, in which the diazepine ring can flip to 
either face of the plane of the benzene ring (Scheme 5.6, left). When no substituents are present at C3, the 
interconversion of both forms occurs fast at room temperature yielding a racemic mixture with a calculated 
energy barrier of 12.3 kcal/mol for N-unsubstituted benzodiazepines.[272] When substituents other than H 
are present at C3, the conformation with the bulkiest substituent at a pseudo-equatorial position is 
favoured (R3 for P and R2 for M conformation, Scheme 5.6, left). Binding studies with 3-methyl-
flunitrazepam (5.32), showed that the (S)-enantiomer, stabilized in M conformation, binds to GABAARs with 
200 times more affinity than the (R)-isomer, most stable at the P conformation.[273] Further studies 
confirmed this binding preference with ethyl and iso-propyl C3 substituted BZs.[274] The energy barrier for 
ring flip can be increased upon introduction of bulky substituents at the amide nitrogen.[272]  Hence, by 
introducing a tert-butyl substituent at R1, Gilman and co-workers at Hoffmann-LaRoche could separate M 
and P isomers, confirming that the M conformers bind preferentially independently of the substitution 
pattern at C3.[272] 
 
Scheme 5.6. Left. P and M atropisomers of a classical benzodiazepine. Right. Chiral benzodiazepines which 
confirmed the preference of the M-conformer for GABAAR binding. The tert-butyl group increases the energy 
barrier needed to interconvert both enantiomers allowing for individual testing of each atropisomer. 
 
Years later, docking studies on species similar to M-5.32 performed by Ernst, Sigel and others identified 
different BZ binding modes.[275] Three different BZ types were examined, all of them as C3-Me enantiomeric 
pairs leading to two possible binding modes named BM I and BM II (5.34-5.36, Scheme 5.7, A). The docking 
studies predicted that for all BZ types BM I was compatible with both (R) and (S) enantiomers, whereas BM 
II could only accommodate the (S) enantiomer given the steric clash caused by the C3-Me group of the (R) 
isomer with the receptor (Table 5.2). Hence, a similar affinity for GABAARs would be expected for both 
enantiomers of a BZ type if these would bind using BM I, whereas if using BM II, the (S) enantiomer would 
display a higher affinity for the receptor (Table 5.2). Indeed, when radioligand displacement experiments 
were performed on α5β2γ2 GABAAR subtypes, only diazepam and triazolam derivatives 5.34 and 5.35 
showed marked binding differences for (R) and (S) forms (>300 and >125 fold respectively), whereas (R) and 
(S) imidazobenzodiazepines 5.36 displayed similar affinities (Scheme 5.7, A; Table 5.2). The results strongly 
suggested that these BZs bind in different binding modes.[276] 
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Scheme 5.7 and Table 5.2. A. Studies on BZ binding modes by Sigel and Ernst. (S) enantiomers of 
benzodiazepines 5.34 and 5.35 bind with much higher affinity to α5β2γ2 GABAARs than (R) enantiomers, as 
predicted by BM II. Both enantiomers of imidazobenzodiazepine 5.36 bind with similar affinity to α5β2γ2 
GABAARs as predicted by BM I. B. Two of the several ligands found in a virtual screening campaign using the 
docking parameters of BM II. 5.37 comprises a Z-drug structure and displayed a GABAAR affinity comparable 
to that of diazepam. 
 
These results were in good agreement with previous studies based on radioligand displacement and 
covalent binding experiments that pointed flumazenil as a candidate for BM I and diazepam for BM II. [277,278] 
A virtual screening for new high-affinity binding partners based on BM II delivered 30 candidates with 
affinities below 20 µM, of which 5.37 equalled diazepam.[277,278] 5.37 was later used by us as a lead 
compound for the development of photoswitchable Z-drugs (see Chapter 6.2). 
Binding mode I was later confirmed by Zhu, who resolved the cryo-EM structure of α1β3γ2 GABAAR subtype 
bound to flumazenil (Figure 5.4, Right).[208] Zhu argued that diazepam and other classical benzodiazepines 
would bind at the same pocket sharing the pose of flumazenil, claim which was contradicted by Sigel, who 
replied that diazepam would most likely bind using BM II.[279] Sigel’s prediction was confirmed in 2019 by 
Aricescu, who published the structure of α1β3γ2 GABAAR bound to diazepam in a strikingly similar pose as 
the one calculated by Sigel and Ernst (Figure 5.4, Left).[276] 
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Figure 5.4. Left. Cryo-EM structure of α1β3γ2 GABAAR BZ binding pocket by Aricescu[209] with the cyan and 
yellow chains respectively representing α1 and γ2 subunits and bound diazepam displaying BM II. Note the 
M conformation of the diazepine ring and the interactions between the chloride atom and the residues Asn60 
and αHis 102, π stacking between the pendant phenyl ring and Tyr210 and Phe100, and hydrogen bonding 
between the amide carbonyl and Ser205. Right. Cryo-EM structure of the same binding pocket by Zhu,[208] 
with bound flumazenil in BM I. It can be observed how flumazenil is located deeper and higher in the pocket 
than diazepam and how the ligand is anchored by interaction of the chloride atom with His102 and the ester 
carbonyl with Thr 142. Images from PDB database created with PyMOL.[212,213] 
 
5.4.5 Z-Drugs 
The binding sites of Z-drugs as well as their pharmacological performance are very similar to that of BZs, 
although their binding mode is still unknown. The structure of these compounds features an electron-
deficient 6-5 fused ring system bearing at least two nitrogen atoms with different substitution patterns at 
C3 (Zolpidem numbering, Scheme 5.8). Most Z-drugs exhibit higher affinity for the α1 receptor subtype, 
with some activity at α2 and α3 and very low affinity for α5 subunits.[280] Hence, the effects of the majority 
of Z-drugs is related with sedation but not as much with anxiety, minimizing day drowsiness[281] and 
respiratory depression.[280] Moreover they display lower affinities for GABAARs, resulting into faster onset 
and clearance, with half-lives below 4 hours in most of cases, thus minimizing residual sedation.[281,282]  
 
Scheme 5.8. Structure of selected Z-drugs. Zopiclone, zolpidem and zaleplon are commercially available for 
the treatment of insomnia. L838,417 is only used for research purposes. It binds to α1,2,3 and 5 with Ki 
values of 0.67 to 2.25 nm. It is a non-sedative anxiolytic, anticonceptive and anti-inflammatory drug.[199] 
 
With this, Z-drugs display slightly more benign side effects than BZs and a better pharmacological profile 
when used to treat sleep disorders. Finally, Z-drugs generally show milder withdrawal symptoms and lower 
tolerance according to studies performed on zopiclone, which proved to cause less receptor adaptation. 
Other drugs as zaleplon did not exhibit abuse potential on clinical studies.[283] 
His102 His102 
Thr142 
Asn60 
Ser205 
Phe100 
Tyr210 
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5.5 Photopharmacology 
 
The field of photopharmacology aims to control biological function through the use of molecular tools 
sensitive to light, which is the unique stimulus capable of inducing controlled release or activation of a drug 
at the desired site with extremely high resolution and without inherent toxicity.  As such, the development 
of photopharmacology is expected to overcome one of the major weaknesses of current pharmacology, 
which is the lack of control on the local action of the drug. Most current drug treatments involve the uptake 
of a substance followed by its distribution throughout the body causing several undesired interactions with 
multiple biological processes. Hence, each single drug exhibits a list of potentially serious side effects 
provoked by the perturbation of undesired targets in the patient’s body. Off-target effects strongly 
influence the process of drug development and are the main factors to negatively influence the therapeutic 
window and the risk-benefit ratio. Examples of drugs with a narrow therapeutic window are the 
barbiturates, which if taken in excess can affect the respiratory function leading to death.[284] The 
suppression or drastic minimization of side effects by precisely controlling the activity of a drug in space and 
time would imply a huge improvement in the patient’s life quality and bring out a medical revolution second 
only in significance to the discovery of antibiotics. Photopharmacology could in fact also help in fighting 
antibiotic resistance, given the possibility of deactivating the drug after interacting with its target.[285] It is 
hard to overstate how improvements in this field could boost the treatment of cancer or cognitive diseases, 
a fact which makes each attempt at advancing photopharmacology an exciting endeavour.  
It can be considered that photopharmacology was born in 1969 with the work of Erlanger and colleagues, 
who were able to optically control the nicotinic acetylcholine receptors (nAChRs) of the electric cells 
(electroplax) of the Electrophorus electricus, or electric eel by using azobenzene based photoswitches.[286,287] 
This was followed by a long period with few publications until over the last 15 years a series of articles 
described the optical control of several biological processes, including ion channels, G-protein-coupled 
receptors, lipids, enzymes and others.[288–290] 
There are different ways photopharmacology can precisely deliver a drug (Figure 5.5). First, it is possible to 
apply a photochromic ligand (PL) in an inactive form, followed by activation (irreversible or reversible) at 
the site of interest by a light-triggered structural change (Figure 5.5, A). 
Another approach is known as photo-uncaging (Figure 5.5, B).[291] This consist in the application of a caged 
ligand, which is a biologically inactive pharmacophore formed by the drug covalently bound to a photolabile 
protecting group. Upon irradiation, the bond is broken in an irreversible process and the ligand is released 
at the desired site. 
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Figure 5.5. Four types of light-controlled drug delivery. A) Photoswitchable ligand, (PL). The initial form of 
the ligand does not bind the target, light irradiation induces a structural change in the ligand which allows 
binding to the receptor. This process can be either reversible or irreversible. B) Photo-uncaging. The drug is 
bound to a photochemically labile counterpart forming an inactive complex. Upon irradiation both parts 
split, releasing the active ligand in an irreversible process. C) Photoswitchable orthogonal remotely tethered 
ligand (PORTL). The same concept as for A regarding the structural change of the ligand, which in this is case 
is bound to the target by a long linker. This results in constant ligand concentration and fast binding. D) 
Photoswitchable tethered ligand (PTL). Light irradiation induces a conformational change in the short tether 
that links the ligand to the receptor allowing for binding or pulling the ligand out of the pocket. 
 
A third way known as PORTL (photoswitchable orthogonal remotely tethered ligand) involves tethering of 
the ligand to the wild type or engineered receptor with a long linker via any of the available tag techniques 
(SNAP, Halo, CLIP…).[292] Then, as for the free photoswitchable ligand (case A), light irradiation at the site of 
interest yields the active drug, which then binds to the target in a reversible manner. This approach keeps 
the concentration around the target constantly high, resulting in rapid binding (Figure 5.5, C).[292] 
The last modality, which also involves tethered pharmacology, is known as PTL, photoswitchable tethered 
ligand. In this approach the linker itself contains the photoswitch. Thus, upon irradiation, the right 
configuration of the linker allows for the ligand to reach into the binding site in a reversible fashion.[292] 
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5.6 Photoswitchable Ligands 
 
The basis of photopharmacology resides in the molecules that interact with light in a controlled manner, 
the photochromic ligands (PLs) or photoswitches. These entities undergo structural changes upon 
irradiation with light, triggering the desired biological response. The changes are based upon two principles: 
1) Photoinduced ring closing/opening reactions 2) Photoinduced cis/trans isomerizations. 
5.6.1 Photoswitches Displaying Ring Opening/Closing Interconversion 
5.6.1.1 Diarylethenes 
Diarylethenes (Scheme 5.9) are switched from the hexatriene opened state 5.43a into a closed 
cyclohexadiene configuration 5.43b by a photochemical 6π electrocyclization with UV wavelengths strongly 
dependent on the substitution pattern, and can be re-opened by irradiation at >450 nm.[293] These 
compounds are very resistant to fatigue, can undergo up to 104 switching cycles and cannot be switched 
thermally. 
5.6.1.2 Thiophenefulgides 
Similarly to the diarylethenes, the thiophenefulgides (Scheme 5.9, 5.44) also undergo photochemical 6π 
electrocyclization to yield a tricyclic closed form. Simple substitution patterns strongly influence the 
absorption spectra, switching wavelengths and thermal reversibility.[288] 
5.6.1.3 Spiropyranes 
Spiropyranes can be switched from their low polarity spiro-indoline (spiropyran) form 5.45a, configured in 
two perpendicular planes, into planar zwitterion 5.45b (merocyanine) upon irradiation with 360 nm 
light.[288] Switching back can in turn be achieved thermally or with visible light above 460 nm. The switching 
wavelengths are strongly influenced by the pH value. Other stimuli capable of isomerizing spiropyranes are 
solvents, metal ions, acids and bases, redox potential and mechanical force.[294] Spiropyranes have been 
incorporated into oligonucleotides and proteins, changing their polarity and conformations.[288,295] 
 
 
Scheme 5.9. Different types of photochromic ligands undergoing reversible ring opening reactions. 
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5.6.2 Photoswithces Displaying cis/trans Isomerization 
5.6.2.1 Hemithioindigos 
The cis→trans (or E→Z) isomerization of hemithioindigos is achieved upon irradiation at 400 nm and the 
trans→cis at 480 nm. The switching changes not only the geometry of the molecule but also its dipolar 
moment (Scheme 5.10, 5.46). The thermal isomerization of the metastable trans-form takes place more 
slowly than for regular azobenzenes.[296] As a drawback, the quantum yield of the trans to cis isomerization 
is very low, φ=0.05.[296] 
5.6.2.2 Acylhydrazones 
Acylhydrazones (Scheme 5.10, 5.47) are the most versatile class of cis/trans photoswitches. They allow for 
functionalization at four different positions, permitting the tuning of several properties such as thermal 
stability, photostationary state (equilibrium composition during irradiation) or absorption spectrum.[297] 
Moreover, their synthesis is simple and often high yielding. As a drawback, the maximum absorption 
wavelength (λmax) for these photochromic ligands most often lies around 320 nm.[297] 
5.6.2.3 Stilbenes 
Stilbenes are the simplest class of cis/trans photoswitches. Unlike for azobenzenes, the trans-isomer is 
metastable, with an energy barrier of 40 kcal/mol. The trans→cis isomerization of stilbene occurs at about 
310 nm for unsubstituted stilbene.[288] The major disadvantage of these PLs is the lability of the cis-form, 
which tends to undergo irreversible 6π electrocyclizations.[298] 
 
Scheme 5.10. Different types of photochromic ligands undergoing reversible cis/trans isomerization. 
 
5.6.2.4 Azobenzenes 
Azobenzenes have been known for more than 150 years and have the honour of being among the founders 
of the modern chemical industry.  These compounds revolutionized the dye production thanks to their high 
affinity for different fabrics, their broad range of colours −easily tuned with simple structural modifications− 
and their simple chemistry, derived from inexpensive aniline.[299] Industries like Bayer or BASF (Badische 
Anilin & Soda Fabrik) owe their initial success to azobenzenes, which are still the most common base of 
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modern dyes.[300] In the field of photopharmacology, azobenzenes are the most widely used PLs given their 
relatively low size and molecular weight, simple synthesis, wide versatility towards functionalization, fast 
switching and favourable extinction coefficients and quantum yields. Azobenzenes usually show λmax = 340-
360 nm (trans→cis), with optimal switching at about 20 nm above the absorption maximum, and can be 
easily switched back upon irradiation at >440 nm. Photostationary states usually contain 50-90% of the cis-
isomer, which is about 10 kcal/mol higher in energy than the trans-form. On the other hand, obtaining the 
pure trans-form is generally possible through the thermal relaxation of the cis-isomer, which occurs with 
half-lives (t1/2) varying from milliseconds to years depending on the substituent pattern. 
 
Scheme 5.11. A) Azologization (AZ inside of the arrows) motifs. B) Proposed new type of azosteres resulting 
from breaking planar rings. C) Two proposed bioactive molecules and azobenzene analogues which would 
arise upon application of the azologization principle depicted in B. 
 
The incorporation of azobenzenes to the pharmacophore can be addressed by two different strategies. First, 
common patterns present in the original drug can be identified as potential analogues to the structure of 
azobenzene. These moieties known as “azosteres” can be stilbenes, diphenylethanes, benzyl phenyl 
(thio)ethers or amines, phenyl-benzamides and related compounds, where heterocycles can also be present 
(Figure 5.11, A).[301] The consideration of these groups as equivalent to the N=N moiety should be taken with 
care, since key interactions with the target protein may be established by the linkers, especially if they are 
amines or amides.[301] Additional azosteres could comprise some bicyclic systems such as naphthalene, 
indole or quinoline (5.55-5.57, Scheme 5.11), which would match the geometry of trans-azobenzenes. Upon 
azologization, the ring fragments excluded from the azo-linker would remain as ortho substituents in the 
azobenzene (R group, Scheme 5.11, 5.57). This kind of azologization has not yet been explored but could 
greatly increase the number of molecules available to turn into photoswitches. Two proposed examples for 
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this approach are flavopiridol, a CDK9 inhibitor tested for treatment of acute myeloid leukemia[302] which 
would yield azobenzene 5.59 or indazole 5.60, a CDK2 inhibitor developed by Pfizer[303] which would render 
azobenzene 5.61.  
A successful example of classical azologization can be seen in Scheme 5.12, where azobenzene 5.63 was 
developed based on the structure of combretastatin A4, a potent inhibitor of tubulin polymerization, 
enabling optical control of cell division among other tubulin-dependent processes.[304]  
 
Scheme 5.12. Examples of successful azologization and azo-extension strategies on bioactive molecules. 
Azologization of combretastatin A4 (5.62) allowed for optical control of tubulin polymerization.[304] Azo-
extension of capsazepine yielded a molecule whose inhibitory activity on TRPV1 (transient receptor potential 
vanilloid 1)  could be regulated by light irradiation.[305] 
 
A second approach for the introduction of azobenzene is the strategy known as “azo-extension”, which 
consists in the addition of an azobenzene group to the pre-existing drug structure. A successful azo-
extension approach was performed on the structure of capsazepine (5.64, Scheme 5.12). This molecule is 
an antagonist of the transient receptor potential vanilloid 1 (TRPV1), an ion channel involved in pain and 
temperature sensation. The azo-extension strategy led to azobenzene 5.65, which acted as a 
photoswitchable antagonist of the TRPV1 channels.[305] The azo-extension alternative involves a greater 
change in ligand shape, and requires empty regions in the binding pockets which can allocate the azo group.  
This fertile azobenzene chemistry has been applied to several biological targets such as lipids, enzymes, 
GPCRs and LGICs, by means of tethered or untethered photopharmacology, allowing for optical control of 
processes like ion transport, cell adhesion and communication, metabolism or immunobiology.[288–290,306] 
5.6.2.5 Diazocines 
Diazocines[307,308] are 8-membered heterocycles which result from the closure of an azobenzene by an 
ethylene or equivalent bridge (Scheme 5.13). Diazocines present some advantages compared to 
azobenzenes: they display a red-shifted absorption spectrum, with absorption maxima at about 400 nm for 
the cis-form and 490 nm for the trans-form, generally with less overlap than azobenzenes. This allows for 
the exclusion of UV radiation, harmful for living organisms.[308] Moreover, opposite to azobenzenes, cis-
diazocines are thermodynamically stable isomers, resembling azobenzene’s cis-configuration. This implies 
that many of the previously designed azobenzenes active in trans-state, which had to be deactivated with 
light irradiation, now can be turned into the corresponding diazocines and be activated in situ, a much more 
convenient scenario.[309] Diazocines have already been successfully used for the control of Shaker K+, GIRK 
and glutamate channels among others.[310,311] 
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Scheme 5.13. Diazocines derived from analogous azobenzenes used for the control of Glutamate receptors 
(5.66) and GIRK channels (5.67).[310–313] 
 
5.7 Selected Examples of Photocontrolled LGICs 
5.7.1 Photoregulation of Acetylcholine Receptors 
In 1969, Erlanger and co-workers inaugurated the field of photopharmacology by treating the electricity 
producing cells (electroplax) of electric eel (Electrophorus electricus) with a solution of azobenzene-
derivatives of nAChR agonists. nAChRs, or nicotinic acetylcholine receptors, are ionotropic receptors that 
respond to acetylcholine, allowing sodium ions to rush into the cell propagating action potentials. The 
azobenzenes used were azo-extended versions of carbamylcholine (5.68) and PTA, named azo-CarCh (5.69) 
and azo-PTA (5.70, Scheme 5.14).[286] Once azo-CarCh was added to the nicotinic acetylcholine receptors in 
the presence of 5.68, the cell membrane repolarized (i.e. more negative potential inside the cell), meaning 
trans-5.69 displaced the native ligand and acted as a weaker agonist, discouraging channel opening and 
inhibiting the flow of sodium ions into the cell. When the same solution was irradiated with UV light (320 
nm), inducing trans→cis isomerization of 5.69, the repolarization further increased, since cis-5.69 displayed 
a lower affinity for the receptor. This process could be reversed upon irradiation at 420 nm, thus leading to 
the first reported optical control of nAChR. The results obtained with PTA and 5.70 followed the same trend. 
Two years later, the first example of a photoswitchable tethered ligand (PTL) was presented by the same 
group.[287] Bis-Q (5.71) and QBr (5.72) proved to be potent agonists of nAChRs in their trans-form causing 
rapid depolarization whereas the cis-compound could be considered inactive. When electroplax cells were 
treated with pre-irradiated 5.71 (330 nm), a slight depolarization was observed given the presence of 
residual trans-5.71. When the mixture was illuminated with a photoflood lamp inducing cis/trans 
isomerization, strong depolarization occurred. Binding of 5.72 to cysteine residues yielded the first reported 
PTL, which gave similar results as the free ligands.[287] 
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Scheme 5.14. Structures of azobenzene photoswitches used by Erlanger for the optical control of 
nAChRs.[286,287] 
 
5.7.2 Photocontrolled AMPA Receptors 
AMPA receptors are ligand-gated ion channels sensitive to glutamate which are specifically activated by 
AMPA (2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid). Once the agonist binds, the channel 
opens and allows sodium ions to flow into the cell mediating synaptic transmission.[314] MPQX (5.75), a 
potent and selective AMPA receptor antagonist was derivatized to gain optical control over these receptors 
giving rise to azobenzenes 5.76-5.78.[315] The design of these photoswitchable ligands was based on the 
following premises: The morpholino group was dispensable for the antagonistic activity, given its absence 
in potent antagonists such as 5.74 (Scheme 5.15). Moreover, LU115455 proved that bulky groups at the 6-
position of the quinoxaline-dione were well tolerated. Thus, azo-extension was performed at the mentioned 
position leading to ShuBQX-1 to ShuBQX-3. Among these, ShuBQX-3 (5.78) displayed superior properties as 
a photochromic ligand, since in the trans-form and in the presence of glutamate (300 µM) it acted as a 
GluA1 (an AMPA receptor subtype) antagonist with an IC50 of 3.1 µM.[315] Moreover, in the cis-form 5.78 
displayed a much weaker antagonist character, allowing for reactivation of the GluA1 currents.[315] Thus, 
ShuBQX-3 was the first photoswitchable AMPA receptor antagonist. 
 
Scheme 5.15. Structures of AMPA and antagonists used for the control of AMPA receptors. 
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5.7.3 Azo-propofol 
In 2012, Sigel, Trauner and co-workers synthesized and studied a series of azo-extended propofol analogues 
(Scheme 5.16) aiming for the photocontrol of GABAA receptors.[316] Extension at the 4 position was 
performed based on the previous knowledge that relatively large groups were well tolerated (5.79, Scheme 
5.16).[317]  Of all the synthesized analogues, AP2 (5.80) proved to be the best-suited photoswitch. Inclusion 
of the amino group red shifted the maximum absorption of the trans-form to 400 nm and induced very fast 
thermal relaxation. Moreover, 5.80 exhibited higher affinity than propofol for the α1β2γ2 GABAAR receptor 
subtype, albeit inducing half as much potentiation. When applied to HEK cells in patch-clamping 
experiments, trans-AP2 induced increased currents, which dramatically decreased when irradiated with 
390-450 nm light. This indicated that the cis-isomer was inactive. In vivo experiments with Xenopus tadpoles 
in a 1.0 µM solution of 5.80 showed deep anaesthesia in the dark and under green light. When the 
wavelength was switched to 360-370 nm, the specimens woke up and moved. Immediately after removing 
the light source the movement stopped again, due to the thermal relaxation of the cis-inactive form. 
 
Scheme 5.16. Structures of GABAAR positive allosteric modulator propofol and derivatives thereof. 
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6. Project Background and Aims 
 
As discussed in Chapter 5.4.4, benzodiazepines (BZs) and other GABAAR positive allosteric modulators 
(PAMs) generally lack specificity for different receptor subtypes, causing side effects that affect memory, 
wakefulness, movement and attention. The later development of Z-drugs, which share binding sites with 
BZs, slightly improved this situation, mostly because of their faster clearance. Further, the number of SAR 
studies on these drugs is strikingly scarce considering their extended use and economic impact.[318–320] 
Moreover, it has been only very recently that the BZ binding site has been elucidated, allowing for a deeper 
understanding of the binding mode of these drugs.[208,209] 
Therefore, the introduction of a photoswitchable benzodiazepine or Z-drug as a research tool could provide 
further insights into how these drugs bind to their target: influence of substituents, switching between 
binding modes, increase in subtype selectivity, secondary binding pockets, etc. It could be expected, for 
example, that a cis-state drug would more effectively bind to a specific receptor subtype, or that an in situ 
light-induced conformational change would provoke the exchange between binding modes within the 
binding pocket, or that the cis-form could bind with higher affinity to any of the secondary binding pockets 
allowing for better understanding of these new sites. All the potential knowledge that could arise from the 
transformation of a benzodiazepine into a photoswitchable ligand could help in the further development of 
these drugs by means of rational design. 
These photochromic ligands could also be used to better understand the function of different GABAARs by 
selectively potentiating particular receptor subtypes, or receptor clusters within certain brain regions. In a 
longer timeframe, maybe photoswitchable benzodiazepines or Z-drugs could be the ultimate solution to 
the undesired side effects of sleeping drugs, including tolerance and addiction, since the PLs would not 
remain in the body in their active form.  
 
6.1 Synthesis of a Photoswitchable Benzodiazepine 
6.1.1 Previous Work 
A previous collaboration with the Sigel group pursued the development of a photoswitchable 
benzodiazepine. Matthias Schönberger, a former Trauner group member synthesized 6 different 
azobenzodiazepines using the scaffold of clonazepam (Scheme 6.1). The azo-extension was performed at 
the amide nitrogen. 
 
Scheme 6.1. Azo-extension approaches towards a photoswitchable BZ by Trauner and Sigel. Compounds 6.2 
to 6.7 displayed low affinity for the GABAAR with only slight differences in cis and trans potentiation. 
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Unfortunately, the potentiation induced by these compounds was low compared to clonazepam (max. 154% 
potentiation at 10 µM), suggesting that the extension negatively affected the receptor binding and 
modulation. Moreover, the difference in current potentiation induced by the cis and trans-forms was 29% 
in the best case, reason why they were not further investigated. 
Gorostiza and co-workers recently published their own work on an azobenzodiazepine (Scheme 6.2). Their 
azo-extension approach was accomplished by reduction of the nitro group of nitrazepam followed by 
Baeyer−Mills coupling with aniline 6.11. The presence of the sulfonate group aimed to increase 
solubility.[321] Interestingly, 6.9 did not behave as a PAM but as an inhibitor of the GABAAR currents. 6.9 
displayed an IC50 of 67 µM for the GABAA α1β2γ2 receptor subtype and showed certain affinity for the 
GABAA ρ2 subtype (IC50 = 128 µM) and for glycine channels. It was found that 6.9 works as a channel blocker 
which binds at the lowest end of the TM2 when the pore is opened. The trans-isomer blocked the flow of 
chloride ions more effectively since this conformation allowed the sulfonate group to reach deeper into the 
pore, stablishing hydrogen bonds with four serine residues. 
 
Scheme 6.2. Photoswitchable BZ synthesized by Gorostiza et al. based on the structure of nitrazepam. 6.9 
did not bind to the BZ binding site and acted as a channel blocker.[321] 
 
6.1.2 Project Outline 
We aimed to modify the structure of an unsubstituted classical benzodiazepine, leaving aside imidazo- and 
triazolo-BZs to obtain a simple lead compound. However, we presume that the chemistry described here 
would be compatible with a wide variety of substitution patterns and benzodiazepine subtypes. 
We decided to perform the azo-extension at the ortho-position of the pendant benzene ring of 6.12 
(Scheme 6.3) for the following reasons:  
1. The presence of substituents at this position induces a ring twist out of the benzodiazepine ring 
plane which results in increased affinity for the receptor.[318] This twisted conformation was 
corroborated by a cryo-EM structure showing interactions of the pendant phenyl ring with Tyr210 
and Phe100 residues (Figure 5.4, Left).[209] 
2. Electron-withdrawing groups at this position increase bioactivity (known for F and Cl).[318] 
3. Substitution of the pendant phenyl ring by naphtalene is well tolerated.[318,322] 
4. Presence of a large hydrophobic pocket proximal to the non-fused phenyl ring that could 
accommodate the azobenzene moiety (both in predicted binding models and cryo-EM structure, 
Figure 6.1).[209,276] 
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Figure 6.1. Cryo-EM structure of diazepam bound to GABAAR by Aricescu et al.[209] The large hydrophobic 
pocket present behind the ligand could allocate the azobenzene moiety. Images from PDB database created 
with PyMOL.[212,213] 
 
Our first retrosynthesis disconnected the imine of 6.13 at the C=N bond, which can be formed by means of 
Sternbach cyclization of intermediate 6.14. This amide can be synthesized from aniline 6.15 via amidation 
with chloroacetyl chloride followed by Delepine reaction.  6.15 could in turn be obtained from the oxidative 
coupling of 2-nitrotoluene and azobenzene. 
 
Scheme 6.3. Azo-extension of BZ 6.12 and first retrosynthetic analysis of the targeted photoswitchable 
benzodiazepine 6.13. 
 
6.1.3 Results and Discussion 
We initially aimed to synthesize benzophenones 6.23 to 6.25 using a method by Wu, which consisted in the 
one-pot reaction of the corresponding toluene derivative with azobenzene in the presence of palladium 
acetate and an excess of tert-butyl hydroperoxide (TBHP) at 80 ºC.[323] Under these conditions toluene 
(present in large excess) undergoes a series of benzylic oxidations promoted by palladium acetate and TBHP, 
which generate acyl radical 6.19. In parallel to this process, ortho-directed metalation of azobenzene takes 
place and the resulting palladium complex 6.20 incorporates acyl radical 6.19 and undergoes reductive 
elimination yielding the desired benzophenone 6.22. 
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Scheme 6.4. Top. Reaction mechanism for the synthesis of azobenzophenone 6.22 by Wu reproduced by 
us.[323] Bottom. Attempts to synthesize azobenzophenones 6.23-6.25 using the method described above. 
 
Although we could reproduce this reaction to obtain the known compound 6.22, when we applied the same 
reaction conditions to deliver amino or nitro derivatives 6.23 to 6.25, only complex product mixtures were 
obtained. In the case of aminobenzophenones 6.24 and 6.25 this could be due to the palladation of the 
starting toluidines leading to symmetrical benzophenones among other products.[324] For the case of 
nitrotoluene, presumably the system was too electron deficient to stabilize the benzyl radical 
intermediates, frustrating the generation of the corresponding acyl radical. 
Given the difficulty of quickly accessing benzophenones 6.23 to 6.25 by means of Wu’s procedure, we 
changed our strategy to obtain benzophenone 6.15. We envisioned that this could be accomplished by the 
addition of Grignard reagent 6.26 to 2-nitrobenzaldehyde followed by alcohol oxidation and nitro group 
reduction followed by Baeyer−Mills coupling (Scheme 6.5).  
 
Scheme 6.5.  Second-generation retrosynthesis towards photoswitchable BZ 6.13. 
 
We proceeded to synthesize starting benzhydrol 6.27 using a method by Knochel, which consisted of metal-
halogen exchange of 2-iodonitrobenzene to give a Grignard intermediate which would be trapped with 2-
nitrobenzaldehyde (Scheme 6.6).[325] We started with a 0.12 M solution of 2-iodonitrobenzene obtaining 
the desired product in 12% yield and recovering unreacted 2-iodonitrobenzene (Table 6.1, Entry 1). We 
reasoned that the metal-halogen exchange had not been completed and therefore repeated the reaction 
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allowing the iodide and the phenylmagnesium bromide to react for a longer time period. This delivered 6.27 
in 18% yield, which was still unsatisfactory (Entry 2). Addition of 0.4 more equivalents of the Grignard 
reagent together with a longer reaction time lifted the yield to 21% (Entry 3). We then opted to increase 
the speed of the first step by increasing the concentration of the reagents (Entries 4-5). This modification 
was crucial and delivered the desired product 6.27 in 87% yield. 
 
Scheme 6.6 and Table 6.1. Conditions screened for the synthesis of benzhydrol 6.27. 
In 1964, Dickinson described the transformation of 2-nitrobenzhydrol into 2-nitrosobenzophenone by 
reaction of the former with tosyl chloride in pyridine at low temperature.[326] The reaction mechanism is 
exemplified for substrate 6.27 in Scheme 6.7. The formation of adduct 6.28 is followed by an intramolecular 
SN displacement of the tosylate by the proximal nitro group. The subsequent heterocyclic intermediate 6.29 
collapses into nitrosobenzophenone 6.30 upon deprotonation by pyridine resulting in the formal 
disproportionation of 6.27. The key nitroso intermediate 6.30 could be used to access azobenzophenone 
6.23 (Scheme 6.8). 
 
Scheme 6.7.  Reaction mechanism for the disproportionation of benzhydrol 6.27 into nitrosobenzophenone 
6.30. 
 
Although Dickinson’s method[326] was described only for mono-nitrobenzophenones, we were confident 
that the presence of an additional nitro group at the ortho-position would not be detrimental.  Even though 
we could never isolate the nitroso intermediate, since it quickly decomposed at room temperature, we 
successfully ran the subsequent Baeyer−Mills reaction using the reaction crude. The azo-coupling delivered 
azobenzophenone 6.23 in good yield for this kind of transformation (Scheme 6.8). A crystal structure of 6.23 
was obtained, showing a twisted conformation for the benzophenone rings and an almost planar 
conformation for the azobenzene moiety (Figure 6.2). 
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Scheme 6.8. Synthesis of azobenzophenone 6.23 from intermediate 6.27. 
 
We reasoned that this two-step procedure could be also triggered by acetic acid and aniline in a one-pot 
procedure, but no product was observed under these conditions.[327] However, when tosyl chloride was 
added to the mixture, traces of 6.23 where found. 
With the desired azobenzene 6.23 in hand, we proceeded to reduce the nitro group which would allow for 
installation of the amide needed for the subsequent Sternbach cyclization. The reduction of nitro groups in 
the presence of azobenzenes can be easily accomplished by treatment with sodium sulfide in refluxing 
ethanol.[328] In the case of nitrobenzophenone 6.23 however, these reaction conditions did not translate 
into any conversion (Scheme 6.9). Therefore, we exchanged the solvent for the less volatile dioxane, which 
also displayed better solubility, and allowed the mixture to react at 130 ºC under microwave irradiation. 
Unfortunately, only traces of the desired product were obtained together with the major product, indazole 
6.33, which resulted from the condensation of the azobenzene nitrogen with the carbonyl group. This 
reaction had been previously reported under different reaction conditions.[329] We attempted an oxidative 
opening of 6.33 with Jones’ reagent, but it failed to provide the desired product.[330]  
Figure 6.2. X-ray structure of azobenzophenone 6.23. 
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Scheme 6.9. Attempts to synthesize azobenzodiazepine 6.13 from azobenzophenone 6.23. 
 
Moreover, attempts to avoid indazol formation by protecting the carbonyl group of intermediate 6.23 as an 
acetal,[331] an hydroxylamine[332] or an imine[333] were met with failure (Scheme 6.23). 
Since the reduction of 6.23 to azobenzene 6.15 seemed unfeasible, we decided to change the order of 
events and first reduce both nitro groups prior to the Baeyer−Mills coupling with nitrosobenzene. This was 
accomplished by alcohol oxidation of dinitrobenzhydrol 6.27 with manganese dioxide followed by 
exhaustive nitro group reduction under hydrogen atmosphere catalyzed by palladium on charcoal (Scheme 
6.10). The resulting diamine 6.37 was submitted to Baeyer−Mills conditions yielding azobenzophenone 6.15 
in good yield, which was subsequently acylated by treatment with chloroacetylchloride delivering 
chloroacetamido intermediate 6.38. Finally, 6.13 was obtained via Delépine reaction of 6.38 with urotropine 
and ammonium chloride in refluxing ethanol, yielding amine 6.14, which underwent an in situ Sternbach 
cyclization.[334] 
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Scheme 6.10. Synthesis of photoswitchable benzodiazepine 6.13 from benzhydrol 6.23. 
 
We analysed the UV/Vis behaviour of the previously unreported azobenzophenone 6.15 (Figure 6.4). A 50 
µM DMSO solution of 6.15 was irradiated for 10 minutes at various wavelengths with the help of a 
monochromator and the resulting absorption spectra were measured. The absorption spectra of the trans-
form (blue) and the cis-form (orange) can be clearly distinguished in Figure 6.3, with absorption maxima at 
328 nm and 389 nm, and an isosbestic point at 378 nm. The best wavelength to induce trans→cis 
isomerization was found at 340 nm. 
The UV/Vis absorption spectra of azobenzodiazepine 6.13 are shown below (Figure 6.4, left). A 50 µM 
solution of 6.13 in (20% v/v) DMSO/PBS mixture was irradiated at various wavelengths for 10 minutes with 
the help of a monochromator before the absorption spectra were measured. The maximum absorption was 
found at 327 nm. Switching between cis- and trans-forms is most effectively induced upon irradiation at 
Figure 6.3. UV/Vis absorption spectrum of 6.15 in DMSO in the dark and upon light irradiation at the 
specified wavelengths. 
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360 nm. The apparent weak switching between cis- and trans-isomers is owed to the fast thermal relaxation 
of 6.13, with a cis half-life of 2.6 s (Figure 6.4, right). 
 
 
Figure 6.4. Left. UV/Vis absorption spectra of 6.13 in 20% DMSO/PBS buffer obtained in the dark and upon 
irradiation at the specified wavelengths. Right. Thermal relaxation of 50 µM 6.13 in 20% DMSO/PBS buffer 
recorded at 327 nm from which cis t1/2 = 2.6 s was determined. 
 
 
 
Figure 6.5. Left. UV/Vis absorption spectra of 50 µM 6.13 in 20% DMSO/PBS buffer obtained in the dark and 
upon irradiation with HP-LEDs at the specified wavelengths for the given time periods. Note that there is 
almost no difference between the absorption spectrum after irradiation for 10 or 60 s, indicating that the 
photostationary state is quickly reached. Right. Photoswitching of 6.13 repeated over several cycles. The 
white columns represent no irradiation (dark, relaxation), and the purple columns irradiation with a 365 nm 
HP-LED inducing cis-isomerization. 
Preliminary one pulse 1H NMR experiments in CDCl3 performed after 5 minutes of irradiation at 365 nm with 
HP-LED showed a cis/trans ratio of 33%. (See chapter 8.8.5). The fast thermal relaxation did not allow for 
precise calculation of the photostationary state (PSS). 
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We were able to obtain a crystal structure of azobenzodiazepine 6.13 (Figure 6.6). The X-ray structure shows 
how the trans-azobenzene moiety is oriented towards the benzodiazepine core, itself arranged in P 
conformation. As it has been discussed in Chapter 5.4.4.3, this conformation is not compatible with GABAA 
receptor binding. Therefore, if this arrangement is maintained in solution, 6.13 would be expected to be 
trans-inactive.  
 
6.2 Synthesis of GABAAR Light-Controlled Z-Drug                                                
……Allosteric Modulators 
6.2.1 Project Outline 
As it has been discussed in Chapter 5.4.5, Z-drugs share a fused 6/5 heterocyclic aromatic scaffold bearing 
a variable number of nitrogen atoms and their binding mode to GABAARs is not known. In addition, in 
Chapter 5.4.4.3 it was explained that Sigel, Ernst and others used a combination of covalent binding 
experiments and docking studies to define BZ binding modes I and II, which were later used in a virtual 
screening campaign to find new high affinity ligands for the GABAAR.[277] The highest affinity was displayed 
by compound 6.39 (Ki = 11 nM), comparable to that of diazepam.[318] 
Given the high affinity displayed by 6.39 for the α1β2γ2 GABAAR subtype and the presence of an “azostere” 
in its structure, we decided to pursue the azologization depicted in Scheme 6.11, which resulted in GABAAR 
Light-controlled Z-drug Allosteric modulator-1 (GALiZA-1, 6.40). This azobenzene could be obtained by 
means of nucleophilic aromatic substitution of 6.41 with 3-chlorophenylhydrazine followed by hydrazine 
reduction. Triazolopyridazine 6.41 could in turn be obtained by condensation of nicotinic hydrazide and 2,6-
dichloropyridazine (Scheme 6.11). 
 
Scheme 6.11. Proposed azologoziation of 6.39 and retrosynthesis of GALiZA-1. 
Figure 6.6. X-ray structure of azobenzodiazepine 6.13. 
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6.2.2 Results and Discussion 
The synthesis started with nicotinamide, which was treated with hydrazine monohydrate in refluxing 
ethanol to yield nicotinic hydrazide.[335] The condensation of nicotinic hydrazide and 2,6-dichloropyridazine 
was attempted by following the method by Hernández et al., which consisted in the treatment of 2,6-
dichloropyridazine derivatives with different aromatic hydrazides in a PTSA/Et3N buffered dioxane solution 
at high temperatures.[336] When we applied these reaction conditions to our system, no conversion was 
observed (Entry 1, Table 6.2). Heating at 135 ºC led to some decomposition without any trace of product 
(Entry 2). We considered that the presence of water could be detrimental given the highly electrophilic 
nature of 2,6-dichloropyridazine, so we used anhydrous sulfonic acid instead of PTSA monohydrate under 
the same conditions, but again, the reaction failed to deliver the desired product (Entries 3 and 4). Since the 
exact role of the acid and the base was not clear, we decided to separately run the reaction under either 
basic or acidic conditions, but this only led to decomposition (Entries 5 and 6). Finally, the reaction was run 
in n-butanol, under microwave irradiation and in the absence of additives allowing for isolation of the 
desired product 6.41 in 86% yield (Entries 7 and 8). 
 
Scheme 6.12 and Table 6.2. Conditions screened for the synthesis of intermediate 6.41. 
 
With triazolopyridazine 6.41 in hand, we proceeded to introduce the 3-chlorophenylhydrazine at C5 via 
SNAr. This reaction was unproductive when performed in refluxing toluene, and yielded only traces of 
hydrazine 6.43 when run at low temperature using n-BuLi as a base. The major product was instead N,N-
disubstituted hydrazine 6.42, and although we identified the desired product in the crude mixture, we were 
not able isolate it. Moreover, traces of the final product 6.40 were also found in the crude mixture, 
suggesting that hydrazine 6.43 could spontaneously oxidize to the desired azobenzene when exposed to 
air. 
We therefore repeated the reaction and submitted the crude to different oxidation conditions reported to 
yield azobenzenes from N,N’-diaryl hydrazines.[337] The first approach consisted in bubbling oxygen through 
an ethanolic solution of the reaction crude containing 6.42 and 6.43. However, after 2 hours no conversion 
was observed (Table 6.2, Entry 1). Stirring the mixture in EtOH under open air in the presence of excess 
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FeCl3 over 96 hours led to the same result (Entry 2). In 2016, Hashidoko published an article on the 
dehydrogenation of a series of aromatic hydrazines mediated by potassium tert-butoxide in liquid ammonia 
at room temperature.[337] The reaction conditions described consisted in mixing liquid ammonia with the 
corresponding hydrazine, air and potassium tert-butoxide in a sealed tube, allowing the mixture to warm to 
room temperature and let react for a few minutes. Concerned about the handling of pressurized ammonia, 
we modified the reaction conditions letting the reaction stir at either −75 ºC or −60 ºC in an opened system 
for one hour and then allowed the solvent to evaporate slowly. Unfortunately, no product was found (Table 
6.2, Entries 3 and 4). When the reaction mixture was stirred in the same manner at −33 ºC for 30 minutes 
followed by rapid ammonia evaporation, 6.40 was found in the reaction crude and could be isolated by 
HPLC in 5% yield (Entry 5). 
 
 
Scheme 6.13 and Table 6.2. Attempts to synthesize 6.40 from 6.41 and conditions screened. 
 
We discarded the hydrazine method since it could not deliver substantial amounts of azobenzene 6.40 and 
opted to step back and introduce an amino group at the C2 position of 6.41, which would allow for a 
subsequent Baeyer−Mills reaction. Since we only obtained traces of the desired amine 6.46 upon reaction 
of heteroaryl chloride 6.41 with ethanolic ammonia (Scheme 6.14) we decided to install the amine by SNAr 
with benzylamine followed by deprotection with sulfuric acid. This strategy allowed us to obtain amine 6.46 
in good yield, although the yield for the benzyl deprotection decreased dramatically when scaling up the 
reaction from 15 mg to 100 mg of benzylamine 6.45. In parallel to this synthetic work we prepared unstable 
hydrazine 6.44 by reacting heteroaryl chloride 6.41 with hydrazine in toluene at 70 ºC. The resulting product 
was immediately treated with a mixture of magnesium and titanium tetrachloride which induced radical 
cleavage of the terminal amine leading to the desired product 6.46 in low yield. [338] 
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Scheme 6.14. Synthesis of amine 6.46 from intermediate 6.41. 
 
Now that we had established an efficient route to amine 6.46, Baeyer−Mills coupling was performed with 
3-chloronitrosobenzene under acidic and basic conditions, of which only the latter allowed us to obtain 
trace amounts of the desired product 6.40 (Scheme 6.15). We tried to transfer the nitroso functionality to 
the triazolopyridazine by treating heterocyclic amine 6.46 with Oxone in a biphasic system, but no product 
was obtained. Finally, since the Baeyer−Mills approach was unsatisfactory, we synthesized the diazonium 
salt of 6.46 by treatment with sodium nitrite in the presence of sulfuric acid and sodium tetrafluoroborate. 
However, we could not isolate or transform this salt with any substrate given the immediate conversion of 
6.47 into heteroaryl chloride 6.41, presumably upon uncatalyzed Sandmeyer reaction of the very reactive 
diazonium salt with trace amounts of chloride ions present in sulfuric acid. 
 
Scheme 6.15. Attempts to synthesize azobenzene 6.40 from amine 6.46. 
 
Given the unsatisfactory results, we decided to change the order of events and first perform an 
unprecedented Baeyer−Mills reaction with nitrosopyridazine 6.50, which would yield azobenzene 6.49, and 
condense the latter with 3-chlorophenylhydrazine to obtain GALiZA-1 (Scheme 6.16). 
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Scheme 6.16. New strategy followed for the synthesis GALiZA-1 starting from nitrosopyridazine 6.50. 
 
Hence, following a procedure by Yamamoto,[339] 2,6-dichloropyridazine was reacted with hydroxylamine in 
the presence of triethylamine in refluxing ethanol to yield hydroxylamine 6.51 (Scheme 6.17). 6.51 was 
subsequently oxidized with manganese dioxide at low temperature yielding unstable nitrosopyridazine 
6.50, which was immediately submitted to a Baeyer−Mills coupling with 3-chloroaniline, affording the 
desired azopyridazine 6.49. Despite the low yield of the azo-coupling, given the low cost of the starting 
materials and the simplicity of the procedures, hundreds of milligrams of 6.49 could be easily obtained using 
this route. Finally, condensation of pyridazine 6.49 with nicotinic hydrazide under the previously examined 
conditions delivered GALiZA-1 in excellent yield (Scheme 6.17). 
 
Scheme 6.17. Synthesis of GALiZA-1. 
 
Given the unprecedented structure of 6.49, we decided to record its UV/Vis absorption profile. Thus, a 50 
µM DMSO solution of 6.49 was irradiated for ten minutes at different wavelengths with help of a 
monochromator before the absorption spectra were measured (Figure 6.8). The spectra of 6.49 show a 
maximum absorption peak at 312 nm together with a small local maximum for the cis-form at 429 nm. 
These peaks are slightly blue-shifted compared to the homologous azobenzene (330 and 435 nm, solvent 
not reported)[340] The spectrum corresponding to the trans-form shows the highest absorption upon 
irradiation at 600 nm (top blue line), and the cis-enriched form the lowest (green line, 360 nm). The most 
efficient wavelength to induce cis isomerization was found at 360 nm whereas for trans-6.49 was at 420 nm 
(Figure 6.8). 
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Figure 6.8. UV/Vis absorption spectra of a 50 µM solution of 6.49 in DMSO. Each measurement was recorded 
after 10 minutes of irradiation at the specified wavelength. 
 
The UV/Vis data of GALiZA-1 was also collected, this time from a 50 µM solution in 20% DMSO in PBS buffer. 
The spectra show clear switching and reveal 3 isosbestic points at 400, 279 and 263 nm, with maximum 
absorption at 312 nm and a cis local maximum at 438 nm. The best wavelength for trans to cis switching 
was 360 nm and from cis to trans 440 nm. 
 
Figure 6.9. Left. UV/Vis absorption spectra of GALiZA-1 in 20% DMSO/PBS buffer upon irradiation at the 
specified wavelengths for 10 minutes with help of a monochromator. Right. Crystal structure of GALiZA-1. 
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The crystal structure of GALiZA-1 revealed its high planarity, with a slightly twisted pyridine ring. The 
switching was repeated over several cycles without any significant loss in absorbance (Figure 6.10, left). The 
cis-form was allowed to thermally relax over several hours, allowing for the calculation of cis-6.40 half-life, 
t1/2 = 40 minutes. 
Figure 6.10. Left. Switching of a 50 µM solution of 6.40 in 20% DMSO/PBS buffer induced by HP-LED at 365 
nm (trans to cis, pink columns) and at 460 nm (cis to trans, blue columns). Right. Thermal relaxation of 6.40 
recorded at 323 nm from which a t1/2 of 40 minutes was determined. 
 
Preliminary 1H NMR measurements in CDCl3 were performed after irradiation at 365 nm for 5 minutes 
showing a cis/trans ratio of 25/75. 
Given the successful synthesis of GALiZA-1, we decided to use this efficient route to obtain new derivatives 
with varying solubilities, steric bulk and maximum absorption wavelengths. Hence, we aimed to synthesize 
analogues GALiZA-2 to GALiZA-5 (Scheme 6.18). 
 
Scheme 6.18. Structure of GALiZA-2 to 5. 
 
The synthesis of GALiZA-2 was accomplished in the same way as GALiZA-1 and in higher yield (Scheme 6.19). 
Introduction of the 6-membered heterocyclic moieties was accomplished via Buchwald−Hartwig amination 
with variable amounts of catalyst and temperatures (Scheme 6.19).[341] The UV/Vis data for these 
compounds can be seen in Figures 6.11 to 6.19, together with the description. 
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Scheme 6.19 and Table 6.3. Synthesis of GALiZA-2-5. 
 
 
Figure 6.11. UV/Vis absorption spectra of a 50 µM solution of 6.56 in DMSO upon 10 minutes of irradiation 
at the specified wavelengths with help of a monochromator. The maximum absorbance was found at 313 
nm with a local maximum for the cis-form at 438 nm and no clear isosbestic points. The best trans→cis 
isomerization wavelength was found at 360 nm whereas for cis→trans was 400 or 420 nm.  
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Figure 6.12. UV/Vis absorption spectra of a 50 µM solution of 6.52 in 20% DMSO/PBS upon 10 minutes of 
irradiation at the specified wavelengths with help of a monochromator. The absorption maximum was found 
at 314 nm and 3 isosbestic points were found at 277, 266 and 401 nm. The best trans→cis isomerization 
wavelength was 340 nm whereas for cis→trans was 440 nm.  
 
 
Figure 6.13. Left. Switching of a 50 µM solution of 6.52 in 20% DMSO/PBS buffer induced by HP-LED. Starting 
in the dark (grey column) the solution was irradiated at 365 nm (trans to cis isomerization, purple columns) 
and then at 460 nm (cis to trans isomerization, blue columns). Right. Thermal relaxation of 6.52 recorded at 
323 nm with a t1/2 of 40 minutes. 
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Figure 6.14. UV/Vis absorption spectra of a 50 µM solution of 6.53 in 20% DMSO/PBS buffer upon 10 minutes 
of irradiation at the specified wavelengths with help of a monochromator. The absorption maximum was 
found at 324 nm and no isosbestic points were found. The best trans→cis isomerization wavelength was 340 
nm whereas for cis→trans was 460 nm.  
 
 
Figure 6.15. Left. Switching of a 50 µM solution of 6.53 in 20% DMSO/PBS buffer induced by HP-LED upon 
irradiation at 365 nm (trans to cis isomerization, purple columns) and at 460 nm (cis to trans isomerization, 
blue columns). Preliminary 1H NMR measurements in CDCl3 were performed after irradiation at 365 nm for 
5 minutes showing a cis/trans ratio of 17/83. Right. Thermal relaxation of 6.53 recorded at 323 nm with a 
t1/2 of 22 minutes. The fluctuation of data points could be consequence of the relatively small changes in 
absorption upon switching. 
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Figure 6.16. UV/Vis absorption spectra of a 50 µM solution of 6.54 in 20% DMSO/PBS buffer upon 10 minutes 
of irradiation at the specified wavelengths with help of a monochromator. The absorption maximum was 
found at 322 nm with no isosbestic points. The best trans→cis isomerization wavelength was found at 340 
nm whereas for cis→trans at 440 nm.  
 
 
 
 
 
 
 
 
Figure 6.17. Left. Switching of a 50 µM solution of 6.54 in 20% DMSO/PBS buffer induced by HP-LED at 365 
nm (trans to cis, purple columns) and at 460 nm (cis to trans, blue columns). Preliminary 1H NMR 
measurements in CDCl3 were performed after irradiation at 365 nm for 5 minutes showing a cis/trans ratio 
of 13/87.  Right. Thermal relaxation of 6.54 recorded at 323 nm with a t1/2 of 120 minutes. 
 
 
* 
*Irradiated for 15 min 
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Figure 6.18. UV/Vis absorption spectra of a 50 µM solution of 6.55 in 20% DMSO/PBS buffer upon 10 minutes 
of irradiation at the specified wavelengths with help of a monochromator. The absorption maximum was 
found at 322 nm with no isosbestic points. The best trans→cis isomerization wavelength was 340 nm 
whereas for cis→trans was 440 nm.  
 
 
 
 
 
 
 
 
 
Figure 6.19. Left. Switching of a 50 µM solution of 6.55 in 20% DMSO/PBS buffer induced by HP-LED at 365 
nm (trans to cis, purple columns) and at 460 nm (cis to trans, blue columns). Preliminary 1H NMR 
measurements in DMSO-d6 were performed after irradiation at 365 nm for 5 minutes showing a cis/trans 
ratio of 17/83.  Right. Thermal relaxation of 6.54 recorded at 323 nm with a t1/2 of 59 minutes. 
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7. Summary and Outlook 
 
In the second part of the thesis we described the rational design and synthesis of a photoswitchable 
benzodiazepine bearing an azobenzene moiety. The design was based on four premises depicted in Scheme 
7.1. Azobenzodiazepine 7.1 was synthesized in 6 steps from commercially available precursors and based 
on the unusual strategy of introducing the azobenzene moiety in initial stages, giving rise to rare 
azobenzophenone intermediates. Given the simplicity, low cost and robustness of this method, we presume 
that several other benzodiazepine derivatives could be synthesized along this route. 
We have also acquired data on the UV/Vis properties of 7.1, which presents an absorption maximum at 327 
nm and half-life of 2.6 s for the cis-form. 7.1 has been isolated with high purity and is ready for biological 
testing, which will be performed in collaboration with Prof. Francisco Ciruela from University of Barcelona. 
We hope that this or other analogues will prove to be a useful tool to gain better understanding on BZ 
binding and GABAA receptors. 
 
Scheme 7.1. Summarized synthesis of photoswitchable benzodiazepine 7.1 and premises which guided its 
design. 
 
The synthesis of a small family of photoswitchable Z-drug derivatives based on the lead compound by Sigel 
was also described. These compounds entail a triazolo[4,3-b]pyridazine core, whose azologization led to an 
unprecedented class of heterocyclic azobenzenes. Again, an unusual strategy based on the early 
introduction of the azobenzene group allowed us to synthesize not only the desired GABAAR light-controlled 
Z-drug Allosteric modulators (GALiZA) but also previously unreported pyridazine azobenzenes. The synthetic 
route developed delivered the final products in 4-5 linear steps from inexpensive starting materials. We are 
again confident that this route could tolerate several modifications on the substitution pattern of any of the 
aromatic moieties.  
 
Scheme 7.1. Summarized synthesis of photoswitchable Z-drugs. 
105 
 
The spectral properties of GALiZA 1-5 have also been defined, with λmax ≈ 324 nm, and cis thermal 
relaxation half-lives between 22-120 minutes. Preliminary 1H NMR measurements showed 
photostationary states with low content of cis-isomer. These results could be improved by changing the 
solvent and diluting the samples. We hope that these compounds will provide new insights in the 
binding modes of Z-drugs upon testing on GABAARs by Ciruela’s group. 
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EXPERIMENTAL PART 
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8. Experimental section 
8.1 General Experimental Details 
 
Unless otherwise stated, reactions were carried out under nitrogen atmosphere utilizing standard Schlenk-
technique using oven-dried glassware and stir bars (160 ºC) or heat gun-dried (>550 ºC) while under vacuum 
glassware and stir bars.  Heating over room temperature was achieved with aluminium heating blocks or oil 
baths.  Low temperature reactions were performed with acetone/dry ice baths (–78 ºC, –50 ºC, –30 ºC) or 
ice baths (0 ºC). Dry solvents were used from the following sources: tetrahydrofuran (THF), dichloromethane 
(DCM), benzene, hexane and diethyl ether (Et2O) were Fisher certified ACS reagents dried and degassed 
with an Innovative Technology PS-MD-6 solvent system. Chloroform (CHCl3), toluene (PhMe), pyridine, ethyl 
acetate, dioxane and N,N-dimethylformamide (DMF) were purchased as extra dry and stabilized from Acros 
Organics. Ethanol was purchased from Decon Labs with USP certified quality. n-Butanol 99% pure was 
purchased from Oakwood chemicals. Methanol >99.8% purity was acquired from VWR chemicals. The last 
three alcohols were independently stored in amber flasks under 3Å molsieves and septum. 
n-Buthyllithium and s-Buthyllithium were purchased from Acros Organics and titrated using N-
benzylbenzamide. All reagents used were purchased from commercial vendors and directly used unless 
otherwise stated.  
Reactions were monitored by thin layer chromatography (TLC) on glass plates precoated with silica gel (0.25 
mm, 60Å pore size, F254) from MilliporeSigma and visualized under UV light (254 nm) or stained with ceric 
ammonium molybdate. Flash column chromatography was performed either by hand or on Teledyne ISCO 
Combiflash Rf+ system with manually packed Universal RediSep cartridges using Geduran® Si 60 silicagel 
(40-60 µm particle size) from MilliporeSigma or when specifically stated with spherical 20-40 µm particle 
size silica from RediSep Rf. HPLC purifications were performed on an Agilent 1260 Infininty Prep Pump 
system with 1260 Infinity II Diode Array Detector WR connected to a Gemini 5 µm, C18, 110Å  
semipreparative column. 
Microwave reactions were run in a Biotage Initiator+ with original equipment. 
1H and 13C spectra were measured with a Bruker Avance III HD 400 MHz spectrometer equipped with a 
CryoProbeTM operating at 400 MHz for 1H and 100 MHz for 13C spectra.  Signals were calibrated from 
residual protium in NMR solvents (CHCl3: δ 7.26; DMSO-d6: δ 2.50) for 1H and solvent resonance (CDCl3: δ 
77.00; DMSO-d6: δ 39.53) for 13C. NMR data are reported as: chemical shift (δ ppm), multiplicity expressed 
as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, coupling constant (Hz), and 
integration. 13C NMR shifts expressed with the exact same number are distinguishable as two peaks on the 
correspondent spectrum.  All raw FID files were processed and the spectra analyzed using the program 
Mnova 11.0.3 from Mestrelab Research S. L. 
High-resolution mass spectra (HRMS) were recorded on an Agilent Technologies 6224 time-of-flight (TOF) 
spectrometer with either atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) 
sources. Infrared (IR) spectra were recorded on a ThermoScientific Nicolet-6700 Fourier Transform Infrared 
Spectrometer (FTIR) and reported as frequency of absorption (cm–1) with intensity of absorption (s = strong, 
m = medium, w = weak, br = broad). Optical rotations were measured on a Jasco P-2000 polarimeter using 
a 100 mm path-length Jasco CG3-100/10 Cylindrical Glass Cell at the Sodium D-line (589 nm) at the given 
temperature in (ºC) and concentration expressed in g/100 mL. Melting points were measured on a Stanford 
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Research Systems OptiMelt MPA100 automated melting point system in open glass capillaries and are 
uncorrected. 
The single-crystal X-ray analyses published here were performed by Dr. Peter Mayer (compound 18) in the 
Analytic Department of the Faculty for Chemistry and Pharmacy of the Ludwig-Maximilians Universität 
Munich, and by Dr. Hu (rest of compounds) at the Department of Chemistry of New York University, with 
support from the X-ray facility from the Materials Research Science and Engineering Center (MRSEC) 
program of the National Science Foundation (NSF) under Award Numbers DMR-0820341 and DMR-
1420073.
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8.2 Supporting Information for Chapter 3.1 
8.2.1 Experimental Procedures for Chapter 3.1 
 
 
 
Vinyl iodide 3.1 was synthesized following the procedure by Hiroya et al.[123] 
Propargyl alcohol (2.20 mL, 37.5 mmol, 1.00 equiv.) was added to a suspension of copper iodide (713 mg, 
3.75 mmol, 0.10 equiv.) in anhydrous THF (83 mL) at 0 ºC and stirred for 1 hour. Then a solution of MeMgBr 
(3.0 M in Et2O, 25 mL, 2.00 equiv.) was added to the reaction mixture over 10 minutes and the stirring was 
continued for 90 minutes at the same temperature. A solution of I2 (14.4 g) in anhydrous Et2O (83 mL) was 
added to the reaction mixture over 10 min then stirred at room temperature for 90 min. 
The reaction mixture was treated with a saturated aqueous NH4Cl (71 mL) solution and subsequently 
quenched with sat. Na2S2O3 (30 mL). The aqueous layer was extracted three times with Et2O. The combined 
organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated under reduced 
pressure yielding a yellow oil. 
The residue was purified by flash column chromatography on silica gel (EtOAc/Hexanes, 33%) yielded 
alcohol 3.1 as a yellow oil (5.76 g, 29.3 mmol, 76% yield). 
1H NMR (400 MHz, CDCl3) δ 5.98 (s, 1H), 4.25 (s, 2H), 1.98 (s, 3H) 
HRMS (+APCI): calc. for C4H6I [M−OH]+   180.9509, found 180.9509 
 
 
 
Aldehyde S3.1 was synthesized following the procedure by Baldwin and Moses.[342] 
Alcohol 3.1 (5.67 g, 28.6 mmol, 1.00 equiv.) was dissolved in DCM (250 mL) and MnO2 (49.74 g, 0.573 mol, 
20.0 equiv.) was added in portions. The mixture was stirred at room temperature for 24 hours before it was 
filtered through a pad of Celite. The the solvent was evaporated at 28 ºC and 350 mbar yielding a yellow 
liquid (5.60 g, 28.6 mmol, quant. yield) which was immediately used for the next step. 
1H NMR (400 MHz, CDCl3) δ 5.98 (s, 1H), 4.25 (s, 2H), 1.98 (s, 3H) 
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Conjugated ester 3.3 was synthesized following the procedure by Parker et al.[51]  
To a solution of triethyl 2-phosphonopropionate (9.20 ml, 42.9 mmol, 1.5 equiv.) in dry hexane (77 mL) at 
room temperature was added a suspension of lithium tert-butoxyde (3.43 g, 42.9 mmol, 1.5 equiv.) in 
hexane (32 mL) which had been previously stirred for 10 minutes and sonicated for 2 minutes. The reaction 
mixture was stirred for 30 minutes after which aldehyde S3.1 (5.60 g, 28.6 mmol, 1 equiv.) in hexane (30 
mL) was added over 10 minutes via syringe. The reaction mixture was stirred for 1 hour.  
Water was then added, the phases were separated and the organic phase was washed with water (4 x 100 
mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure giving pure ester 3.3 an orange 
oil (7.94 g, 28.4 mmol, 99% yield), which was used for the next step without further purification. 
1H NMR (400 MHz, CDCl3) δ7.09 (s, 1H), 6.25 (br s, 1H), 4.24 (q, J = 7.1 Hz, 1H), 2.02 (s, 3H), 1.91 (s, 3H), 1.33 
(t, J = 7.1 Hz, 1H) 
HRMS (+APCI): calc. for C9H14IO2 [M+H]+ 281.0033 found 281.0031 
 
 
 
 
Allyl alcohol S3.2 was synthesized following the procedure by Trauner et al.[58] 
To a solution of 3.3 (13.5 g, 48.2 mmol, 1 equiv.) in DCM (400 mL) −78 °C was added dropwise a solution of 
DIBAL (1.2 M in PhMe, 101 mL, 2.52 equiv.). 
After 45 minutes the reaction mixture was quenched with a half-saturated aqueous solution of Rochelle's 
salt (1065 mL), diluted with DCM (500 mL) and stirred vigorously for 30 min. The phases were separated 
and the aqueous phase was extracted with DCM (2 x 300 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure yielding a yellow oil, 10.9 g. 
Purification by flash column chromatography on silica gel (20% EtOAc in hexanes) delivered S3.2 (10.2 g, 
42.8 mmol, 89% yield) as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ6.05 (s, 1H), 5.95 (br s, 1H), 4.10 (s, 2H), 2.01 (s, 3H), 1.73 (s, 3H) 
HRMS (+ESI): calc. for C14H23I2O2 [2M+H]+ 476.9779 found 476.9782 
 
 
Aldehyde 3.4 was synthesized following the procedure by Trauner et al.[343] 
To a solution of alcohol S3.2 (2.45 g, 10.3 mmol, 1.00 equiv.) in Et2O (69 mL) was added Na2CO3 (14.5 g, 137 
mmol, 13.3 equiv.) followed by MnO2 (12.2 g, 139 mmol, 13.6 equiv). The suspension was stirred in the dark 
for 18 hours. 
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The reaction mixture was diluted with Et2O (75 mL), filtered through a pad of Celite and the solvent was 
evaporated under reduced pressure yielding a yellow oil (2.10 g, 8.90 mmol, 86% yield) which was directly 
used for the next step without further purification given its instability. 
1H NMR (400 MHz, CDCl3) δ9.56 (s, 1H), 6.93 (s, 1H), 6.50 (s, 1H), 2.17 (s, 3H), 1.90 (s, 3H) 
HRMS (+APCI): calc. for C7H10IO [M+H]+ 236.9771 found 236.9774 
 
 
 
α-hydroxy acid 3.6 was synthesized following the procedure by Hongwu et al.[344] 
α-hydroxy acid S3.3. 
To a stirred solution of glycolic acid (4,56 g, 60.0 mmol, 1 equiv.) in MeOH (90 mL) and H2O (9.0 mL) was 
added a 20% m/v solution of  Cs2CO3 in H2O until pH 7 was reached (about 15 mL), and then the solvent was 
removed under reduced pressure (1 h, 64 °C, 14 mbar). The gummy residue was redissolved in DMF (60 mL) 
and after few minutes a white precipitate appeared. Then benzyl bromide (7.54 mL, 63.1 mmol, 1.05 equiv.) 
was added. The reaction mixture was stirred for 24 h at room temperature.  
Brine was added to the solution, the phases were separated and the aqueous layer was extracted with 
EtOAc. The combined organic layers were washed with H2O and brine, dried over MgSO4 and 
concentrated under reduced pressure yielding a colourless liquid. 
The crude product was purified by flash column chromatography on silica gel (4:1 hexanes/EtOAc) to give 
product as a colourless oil (9.16 g, 55.1 mmol, 92% yield). 
1H NMR (400 MHz, CDCl3) δ 7.37 (m, 5 H), 5.23 (s, 2 H), 4.20 (d, J = 4.6 Hz, 1H), 2.49 (t, J = 5.0 Hz, 1H)  
HRMS (+APCI): calc. for C9H10NaO3 [M+H]+  189.0522 found 189.0538 
 
 
MOM protected glycolate S3.4. 
Benzyl glycolate S3.3 (5.66 mL, 39.9 mmol, 1.00 equiv.) was dissolved in THF (35 mL) at room temperature 
and DIPEA (8.27 mL, 47.8 mmol, 1.20 equiv.) was added followed by MOMBr (7.48 mL, 59.8 mmol, 1.5 
equiv.), resulting in fuming and exotherm. After stirring at room temperature for 3.5 hours the mixture was 
heated to reflux for 24 hours. 
45 mL of an ice-cold aqueous saturated solution of K2CO3 was added to the reaction mixture, which upon 
phase separation was extracted with EtOAc (3x45 mL). The combined extracts were washed with brine, 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to give a brown gum which 
was purified by flash column chromatography on silica gel (EtOAc/Hexanes, gradient, 0 to 10%) yielding S3.4 
as a yellow liquid (7.25 g, 34.5 mmol, 86% yield). 
1H NMR (400 MHz, CDCl3) δ 7.36 (m, 5 H), 5.20 (s, 2 H), 4.71 (s, 2H), 4.21 (s, 2H), 3.39 (s, 3H)  
HRMS (+ESI): calc. for C11H15O4 [M+H]+  211.0965 found 211.0951 
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α-hydroxy acid 3.6. 
Ester S3.4 (5.3 g, 25.2 mmol, 1 equiv.) was dissolved in EtOAc (65 mL). The flask was evacuated and flushed 
with N2 three times. Pd(OH)2 (582 mg) was added to the solution and the flask was evacuated and flushed 
with H2 (balloon pressure) three times. The suspension was stirred at room temperature for 2 hours, after 
which the mixture was filtered through a pad of Celite. The filtrate was evaporated under reduced pressure 
to give a yellow liquid which was purified by flash column chromatography on silica gel (EtOAc/hexanes, 
gradient, 0 to 60%) to deliver 3.6 as a yellow liquid, (2.43 g, 20.2 mmol, 80% yield). 
1H NMR (400 MHz, CDCl3) δ 8.89 (br s, 1 H), 4.72 (s, 2H), 4.22 (s, 2H), 3.40 (s, 3H)  
HRMS (+ESI): calc. for C4H9O4 [M+H]+  121.0495  found 121.0484 
 
 
Glycolic acid 3.5 was synthesized following a procedure by Solladié et al.[345] 
To a suspension of NaH (60 wt% in mineral oil, 1.50 g, 37.5 mmol, 2.5 equiv.) in THF (75 mL) was carefully 
added bromoacetic acid (2.08 g, 15.0 mmol, 1 equiv.) and the mixture was stirred at room temperature until 
the H2 evolution had ceased. After cooling to 0 °C, a solution of PMBOH (7.10 mL, 58.0 mmol, 1.05 equiv.) 
in THF (150 mL) was carefully added via cannula. The mixture was allowed to warm to room temperature 
and stirred for an additional 1 h at this temperature before adding Bu4NBr (1.00 g, 3.00 mmol, 5.2 mol%) 
and heating the suspension to reflux for 4 h.  
The reaction was cooled to 0 °C and EtOH (20 mL) was carefully added. The white precipitate was filtered 
off and dissolved in H2O (50 mL). This solution was acidified with aqueous HCl (2N, 20 mL) to pH 1 
precipitating a colourless solid. The aqueous phase was extracted with Et2O (3 x 50 mL) and the combined 
organic layers were dried over MgSO4. Evaporation of the solvent under reduced pressure yielded pure 3.5 
(2.70 g, 13.8 mmol, 92% yield) as a slightly yellow solid. Was used for the next step without need for further 
purification. 
1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.58 (s, 2H), 4.11 (s, 2H), 3.81 
(s, 3H)  
HRMS (+ESI): calc. for C10H12NaO4 [M+Na]+  219.0628 found 219.0627 
 
 
Oxazolidinones 3.8 and 3.9 were synthesized following the procedure by Askin et al.[346] 
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Oxazolidinone 3.9. 
To a solution of 3.6 (84 mg, 0.700 mmol, 1.00 equiv.) in THF (2.5 mL) at −78 °C was added triethylamine 
(122 µL, 0.875 mmol, 1.25 equiv.) followed by pivaloyl chloride (95 µL, 0.77 mmol, 1.1 equiv.). The resultant 
thick white precipitate was stirred 1 h at rt, then recooled to −78 °C. Meanwhile, a separate solution of 
oxazolidinone 3.7 (123 mg, 0.700 mmol, 1.00 equiv.) in THF (2.0 mL) at −78 °C was prepared. To this solution 
was added n-butyllithium (2.43 M in hexane, 0.331 mL, 0.805 mmol, 1.15 equiv.) and the resulting mixture 
was stirred for 25 min at the same temperature. The resulting orange solution was added by syringe (1 mL 
THF rinse) to the mixed anhydride solution. After being stirred for 20 min at −78 °C, the mixture was allowed 
to warm to rt and was stirred 2 h before being quenched. 
A saturated aqueous NH4Cl was added. The bulk of the THF was removed under reduced pressure and the 
residue was poured onto DCM. After mixing, the layers were separated and the aqueous layer was extracted 
with DCM. The combined DCM layers were washed with saturated aqueous NaHCO3 and brine, dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. A yellow gum, 220 mg was obtained 
and purified by flash column chromatography on silica gel (EtOAc/hexanes, gradient, 0 to 50%) delivering 
3.9 as a colourless oil (127 mg, 0.455 mmol, 65% yield). 
1H NMR (400 MHz, CDCl3) δ 7.38-7.16 (m, 5H), 4.77 (s, 4H), 4.73-4.65 (m, 1H), 4.33-4.20 (m, 2H), 3.43 (s, 
3H), 3.32 (d, J = 13.4 Hz, 1H), 2.82 (dd, J = 13.4, 9.5 Hz, 1H)  
HRMS (+APCI): calc. for C13H14NO4 [M-OMe]+  248.0917 found 248.0913 
[𝜶]𝑫
𝟐𝟒 -81.8º (c 0.93, CHCl3) 
 
 
Oxazolidinone 3.8. 
The same procedure as for 3.9 was followed: 3.5 (4.67 g, 23.8 mmol, 1.00 equiv.), Et3N (4.14 mL, 29.8 mmol, 
1.25 equiv.), PivCl (3.22 mL, 26.2 mmol, 1.10 equiv.), 3.7 (4.22 g, 23.8 mmol, 1.00 equiv.), n-BuLi (2.33 M in 
hexane, 11.2 mL, 26.2 mmol, 1.10 equiv.). Purification by flash column chromatography on silica gel 
(EtOAc/hexanes, gradient, 0 to 30%) delivered 3.8 as a white solid (6.20 g, 17.4 mmol, 73% yield). 
1H NMR (400 MHz, CDCl3) δ 7.37-7.26 (m, 5H), 7.20 (d, J = 7.0 Hz, 2H), 4.73-4.60 (m, 5H), 4.31-4.20 (m, 2H), 
3.81 (s, 3H), 3.43 (s, 3H), 3.33 (d, J = 13.4 Hz, 3.1 Hz, 1H), 2.81 (dd, J = 13.4, 9.5 Hz, 1H)  
HRMS (+ESI): calc. for C20H21NNaO5 [M+Na]+  378.1312 found 378.1294 
[𝜶]𝑫
𝟐𝟒 +57.2º (c 0.4, CHCl3) 
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Oxazolidinone 3.13 was synthesized following the method by Paterson et al.[129] 
Et3N (52.2 µL, 0.376 mmol, 1.3 equiv.) was added to a solution of 3.8 (103 mg, 0.289 mmol, 1.00 equiv.) in 
PhMe (0.38 mL) and cooled to −50 °C prior to the careful addition of freshly distilled Bu2BOTf (87.1 µL, 0.318 
mmol, 1.1 equiv.) via syringe. The resulting yellow solution was stirred at −50 °C for 1.5 h, during which time 
a light precipitate formed. Aldehyde 3.12 (104 mg, 0.532 mmol, 1.84 equiv.) in PhMe (0.38 mL) was added 
to the mixture via syringe and the system allowed to warm to −30 °C and stirred for a further 1.5 h. 
The solution was quenched by the addition of MeOH (0.24 mL), pH7 phosphate buffer (0.240 mL) and 30% 
v/v H2O2 (0.24 mL) and stirred vigorously for 1 h at rt before separation of the organic phase and extraction 
of the aqueous layer (3 × 0.5 mL Et2O). The combined organic phases were dried over MgSO4 
and concentrated under reduced pressure yielding the crude material a brown oil, 265 mg, which was 
purified by flash column chromatography on silica gel (EtOAc/hexanes, gradient, 0 to 40%) delivering 3.13 
as a yellow oil (87.0 mg, 0.158 mmol, 55% yield). 
1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 5H), 7.23-7.17 (d, J = 7.0 Hz, 2H), 6.90 (d, J = 8.7 Hz, 1H), 6.31 (dq, 
J = 8.9, 1.5 Hz, 1H), 5.18 (d, J = 4.2 Hz, 1H), 4.70-4.52 (m, 4H), 4.26 (dd, J = 8.6, 2.7 Hz, 1H), 4.19 (dd, J = 9.1, 
2.2 Hz, 1H), 3.77 (s, 3H), 3.15 (dd, J = 13.5, 3.4 Hz, 1H), 2.65 (dd, J = 13.4, 9.7 Hz, 1H), 2.41 (d, J = 1.5 Hz, 3H) 
 
8.3 Supporting Information for Chapter 3.2 
8.3.1 Experimental Procedures for Chapter 3.2 
 
 
Angelic aldehyde 3.14. 
 
Angelic alcohol (6.60 g, 76.6 mmol, 1.00 equiv.) was dissolved in THF (215 mL) and the flask was protected 
from light. Then MnO2 (151 g, 1.53 mmol, 20 equiv.) was added in 5 portions over 2 hours. The reaction 
mixture was stirred at rt for 22 h. 
The resulting suspension was filtered through celite and the solvent was removed under reduced pressure 
yielding pure angelic aldehyde as a yellow oil (6.50 g, 76.6 mmol, quant. Yield). 
1H NMR (400 MHz, CDCl3) (400 MHz, CDCl3) δ 10.19 (s, 1H), 6.60 (qq, J = 7.6, 1.4 Hz, 1H), 2.11 (dq, J = 7.6, 
1.4 Hz, 3H), 1.76 (p, J = 1.4 Hz, 3H). 
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Vinyl iodide 3.26.[114] 
To a suspension of ethyltriphenylphosphonium iodide (3.10 g, 7.40 mmol, 2.00 equiv) in THF (10 mL) was 
added n-BuLi (2.3 M in hexanes, 3.22 mL, 2.00 equiv.) at 0 °C. After 25 minutes, the red solution was slowly 
added to a vigorously stirred solution of I2 (1.88 g, 7.40 mmol, 2.00 equiv.) in THF (20 mL) at −78 °C. A viscous 
yellow-brownish suspension resulted after addition of about 50% of the material, which turned into an 
homogeneous yellow suspension upon addition of the majority of the ylide. After 30 minutes of stirring the 
mixture was warmed to −50 °C. Then NaHMDS (1.0 M in THF, 3.33 mL, 3.33 mmol, 0.90 equiv.) and KHMDS 
(11% in toluene, 7.00 mL, 3.33 mmol, 0.90 equiv.) were added giving a red suspension which was stirred at 
−50 °C for 40 min. From this moment the reaction apparatus was kept in the dark. Angelic aldehyde (311 
mg, 3.70 mmol, 1.00 equiv) in THF (50 mL) was added to the mixture, which was warmed to rt and stirred 
for an additional 40 minutes.  
The reaction was quenched with sat NH4Cl (20.5 mL) and extracted with Et2O (2x26 mL). The organic layers 
were combined, washed with brine, dried over Na2SO4 and filtered. About 95 % of the solvent was 
evaporated at 50 mbar at 28 °C and the residue was submitted to flash column chromatography over Basic 
Alumina (Brockman I) eluting with pure pentane. Vinyl iodide 3.26 was obtained as a colourless oil (312 mg, 
1.40 mmol, 38% yield). Given its instability, 3.26 was directly submitted to the next step. 
1H NMR (400 MHz, CDCl3) δ 6.11 (s, 1H), 5.40 (q, J = 6.8 Hz, 1H), 2.57 (d, J = 1.1 Hz, 3H), 1.76 (s, 3H), 1.58  
(d, J = 6.8 Hz, 3H) 
 
 
Vinyl stannane 3.16.[114] 
Reaction performed in the dark. To a solution of vinyl iodide 3.26 (1.92 g, 7.78 mmol, 1 equiv.) in Et2O (55 
mL) at −78 °C was added n-BuLi (2.49 M in hexanes, 2.60 mL, 1.04 equiv.) dropwise over 10 minutes. The 
resulting solution was stirred 5 additional minutes after which a solution of Me3SnCl (1.0 M in hexane, 8.80 
mL, 8.80 mmol, 1.13 equiv.) was slowly added. The reaction mixture was stirred at −78 °C for 1.5 hours, 
after which it was quenched by addition of water (80 mL). After warming to room temperature, the mixture 
was extracted with Et2O (2 x 50 mL). The organic layers were combined, dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure at 30 ºC. The remaining liquid contained stannane 3.16 
(1.92 g, 7.41 mmol, 95% yield) was kept in benzene (20 mL) at −20 ºC, being stable for several weeks. 
1H NMR (400 MHz, CDCl3) δ 6.54 (s, 1H), 5.27 (qt, J = 6.7, 1.4 Hz, 1H), 2.00 (d, J = 1.7 Hz, 3H), 1.73 (s, 3H), 
1.59  (d, J = 6.8 Hz, 3H), 0.13 (s, 9H) 
HRMS (+ESI): calc. for C9H17Sn [M-Me]+  245.0352 found 245.0357 
 
 
 
116 
 
 
 
 
Silyl ether 3.27. 
See Silyl ether 14 in Chapter 8.3. 
 
Silyl ether 3.28. 
To vinyl iodide 3.23 (250 mg, 0.631 mmol, 1.00 equiv.) in dry DCM (6.3 mL) was added 2,6-lutidine (0.21 mL, 
1.8 mmol, 2.9 equiv.). The solution was cooled down to 0 ºC and TESOTf (0.18 ml, 0.85 mmol, 1.3 equiv.) 
was added dropwise. The reaction mixture was allowed to warm up to room temperature and was stirred 
for 1.5 h. 
An aqueous saturated NaHCO3 solution was added and the layers were separated. The aqueous phase was 
extracted three times with DCM and the organic layers were combined, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude material (yellow oil, 365 mg) was purified by flash column 
chromatography on silica gel (EtOAc/hexanes, gradient, 0 to 10%) affording silyl ether 3.28 as a yellow oil 
(245 mg, 0.48 mmol, 76% yield). 
1H NMR (400 MHz, CDCl3) δ 6.89 (dd, J = 15.9, 5.8 Hz, 1H), 6.06 (d, J = 15.0 Hz, 2H), 5.85 (s, 1H), 4.74 (d, J = 
6.7 Hz, 1H), 4.65 (d, J = 6.8 Hz, 1H), 4.25 (t, J = 6.4 Hz, 1H), 4.10 (d, J = 6.8 Hz, 1H), 3.71 (s, 3H), 3.38 (s, 3H), 
1.92 (s, 3H), 1.67 (s, 3H), 0.96 (t, J = 8.0 Hz, 9H), 0.63 (q, J = 8.0 Hz, 6H) 
13C NMR (101 MHz, CDCl3) δ 166.52, 145.25, 144.29, 138.20, 129.82, 122.12, 95.78, 80.22, 78.28, 55.76, 
51.56, 24.45, 14.18, 6.85, 4.84 
IR (ATR): 2952 (m), 2912 (m), 2877 (m), 1728 (s), 1437 (m), 1436 (w), 1306 (w), 1275 (m), 1236 (w), 1167 
(m), 1152 (m), 1098 (s), 1032 (s), 741 (m) 
HRMS (+APCI): calc. for C20H36IO5Si [M+Na]+  511.1371, found 511.1387 
[𝜶]𝑫
𝟐𝟒 +1.2º (c 0.36, CHCl3) 
RF = 0.62 (20% EtOAc in hexanes) 
 
Silyl ether 3.29. 
3.23 (42.0 mg, 0.106 mmol, 1.00 equiv.) was dissolved in chloroform (1.0 mL) and 2,6-lutidine (31.0 µL, 
0.265 mmol, 2.50 equiv.) and imidazole (14.8 mg, 0.217 mmol, 2.05 equiv.) were added followed by TBDPSCl 
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(41.0 µL, 0.159 mmol, 1.50 equiv.). The mixture was stirred under reflux for 24 hours before it was cooled 
down to room temperature. Then lutidine (31.0 µL, 0.265 mmol, 2.50 equiv.) and TBDPSCl (41.0 µL, 0.159 
mmol, 1.50 equiv.) were added and the reflux was restarted and held for 48 hours. The solution was cooled 
down to room temperature and stirred for 1.5 hours after which an aqueous saturated solution of sodium 
bicarbonate was added. The layers were separated and the aqueous phase was extracted three times with 
DCM. The combined organic layers were combined, dried over anhydrous MgSO4 and concentrated under 
reduced pressure yielding a yellow oil, 142 mg.  Purification by flash column chromatography on silica gel 
(AcOEt/Hexanes, gradient, 0 to 10%) led to the obtention of 3.29 as a yellow oil (48.0 mg, 75.6 µmol, 70% 
yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.70 (dd, J = 21.7, 7.9 Hz, 4H), 7.45–7.36 (m, 6H), 6.95 (dd, J = 15.8, 5.7 
Hz, 1H), 6.02 (d, J = 16.1 Hz, 1H), 5.98 (s, 1H), 5.78 (s, 1H), 4.47–4.42 (m, 2H), 4.27 (d, J = 6.0 Hz, 1H), 4.16 (t, 
J = 5.9 Hz, 1H), 3.71 (s, 3H), 3.20 (s, 3H), 1.76 (s, 3H), 1.59 (s, 3H), 1.11 (s, 9H) 
13C NMR (101 MHz, CDCl3) δ 166.48, 145.09, 144.43, 137.35, 136.04, 135.98, 133.60, 133.35, 130.03, 129.78, 
129.69, 127.61, 127.52, 122.32, 95.63, 79.29, 78.92, 55.74, 51.51, 27.10, 24.41, 19.35, 15.42 
IR (ATR): 2931 (w), 2857 (w), 1724 (s), 1661 (w), 1427 (m), 1271 (m), 1167 (m), 1151 (m), 1104 (s), 1127 (s), 
919 (m), 821 (m), 739 (m) 
HRMS (+ESI): calc. for C30H39IO5NaSi [M+Na]+   657.1504, found 657.1528 
[𝜶]𝑫
𝟐𝟒 = +6.95 (c 2.90, CHCl3) 
RF = 0.88 (20% AcOEt in hexane) 
 
Silyl ether 3.30. 
The same procedure as for 3.28 was followed. 3.23 (250 mg, 0.63 mmol, 1.00 equiv.), lutidine (0.18 mL, 1.58 
mmol, 2.50 equiv.), TIPSOTf (0.25 mL, 0.95 mmol, 1.30 equiv.). Stirred for 20 hours. Purification by flash 
column chromatography on silica gel (EtOAc/hexanes, gradient, 0 to 10%) yielded 3.30 as a yellow oil, (298 
mg, 0.539 mmol, 80% yield). 
1H NMR (400 MHz, Chloroform-d) δ 6.95 (dd, J = 15.7, 4.6 Hz, 1H), 6.09–5.85 (m, 3H), 4.72 (d, J = 6.6 Hz, 1H), 
4.65 (d, J = 6.9 Hz, 1H), 4.33–4.28 (m, 2H), 3.71 (s, 3H), 3.38 (s, 3H), 1.92 (s, 3H), 1.69 (s, 3H), 1.15–1.07 (m, 
3H), 1.08 (t, J = 6.0 Hz, 18H) 
13C NMR (101 MHz, CDCl3) δ 166.55, 145.28, 144.30, 138.19, 129.84, 122.10, 95.76, 79.67, 78.93, 55.81, 
51.53, 24.53, 18.11, 18.09, 14.85, 12.46 
IR (ATR): 2944(m), 2866 (m), 1726 (s), 1463 (w), 1435 (m), 1271 (m), 1151 (m), 1098 (s), 1028 (s), 919 (m), 
882 (s), 771 (m) 
HRMS (+ESI): calc. for C23H41IO5NaSi [M+Na]+  575.1660, found 575.1677 
[𝜶]𝑫
𝟐𝟒 = +2.8 (c 3.83, CHCl3) 
RF = 0.70 (20% EtOAc in hexanes) 
118 
 
 
 
 
 
 
 
TBS cascade product 3.31. 
See cascade product 18 in Chapter 3.3. 
 
 
 
TES cascade product 3.32. 
The same procedure as for 18 (Chapter 3.3) was followed: 
3.28 (102 mg, 0.200 mmol, 1.00 equiv), Pd(PPh3)4 (23.0 mg, 0.020 mmol, 0.10 equiv.), CuTC (42.0 mg, 0.220 
mmol, 2.20 equiv.), 3.16 (72.4 mg, 0.280 mmol, 1.4 equiv.). The crude material was purified by flash column 
chromatography on silica gel, (EtOAc/Hex, gradient, 0 to 3%) providing tricycle 3.32 as a white solid (31.0 
mg, 64.8 µmol, 32% yield). 
1H NMR (400 MHz, CDCl3) δ 5.33 (s, 1H), 4.99 (s, 1H), 4.62 (s, 2H), 3.87 (br s, 2H), 3.59 (s, 3H), 3.25 (s, 3H), 
2.86 (q, J = 7.6 Hz, 1H), 2.70 (s, 1H), 2.65 (d, J = 11.3 Hz, 1H), 2.32 (dt, J = 10.1, 2.3 Hz, 1H), 1.85 (s, 3H), 1.81 
(d, J = 1.8 Hz, 3H), 1.20 (s, 3H), 1.12 (s, 3H), 1.05 (d, J = 7.4 Hz, 3H), 0.96 (t, J = 7.9 Hz, 9H), 0.62 (q, J = 8.0 Hz, 
6H) 
13C NMR (101 MHz, CDCl3) δ 175.46, 140.81, 138.03, 132.98, 124.98, 97.84, 93.47, 87.74, 55.34, 54.09, 
51.29, 50.92, 44.37, 40.51, 34.50, 29.40, 29.05, 24.95, 24.13, 15.67, 6.95, 5.08 
IR (ATR): 2926 (s), 2854 (m), 1734 (s), 1463 (m), 1380 (w), 1251 (m), 1196 (m), 1107 (m), 1039 (s), 874 (m), 
836 (s), 1032 (s), 776 (m) 
HRMS (+APCI): calc. for C27H47O5Si [M+H]+   479.3187, found 479.3183 
RF = 0.45 (10% EtOAc in hexanes) 
 
 
 
 
 
TBDPS cascade product 3.33. 
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The same procedure as for 18 (Chapter 3.3) was followed: 
3.29 (117 mg, 0.200 mmol, 1.00 equiv), Pd(PPh3)4 (23.0 mg, 0.020 mmol, 0.10 equiv.), CuTC (42.0 mg, 0.220 
mmol, 2.20 equiv.), 3.16 (72.4 mg, 0.280 mmol, 1.4 equiv.). The crude material was purified by flash column 
chromatography on silica gel, (EtOAc/Hex, gradient, 0 to 3%) providing tricycle 3.33 as a white solid (27.7 
mg, 46.0 µmol, 23% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.79 (d, J = 7.2 Hz, 2H), 7.60 (d, J = 7.4 Hz, 2H), 7.41–7.33 (m, 6H), 5.30 
(s, 1H), 5.09 (s, 1H), 3.98 (d, J = 7.4 Hz, 1H), 3.94 (dd, J = 8.3, 5.6 Hz, 1H), 3.79 (d, J = 8.5 Hz, 1H), 3.67 (d, J = 
7.3 Hz, 1H), 3.53 (s, 3H), 2.96 (s, 3H), 2.94 (q, J = 7.5 Hz, 1H), 2.64 (s, 1H), 2.47 (d, J = 11.2 Hz, 1H), 2.12 (dd, 
J = 11.5, 5.6 Hz, 1H), 2.08 (s, 3H), 1.76 (s, 3H), 1.23 (d, 7.5 Hz, 3H), 1.15 (s, 3H), 1.12 (s, 3H), 1.08 (s, 9H) 
HRMS (+APCI): calc. for C37H51O5Si [M+H]+   603.3500, found 603.3500 
RF = 0.63 (15% EtOAc in hexanes) 
 
 
 
 
TIPS cascade product 3.34 
The same procedure as for 18 (chapter 3.3) was followed: 
3.30 (111 mg, 0.200 mmol, 1.00 equiv.), Pd(PPh3)4 (23.0 mg, 0.020 mmol, 0.10 equiv.), CuTC (42.0 mg, 0.220 
mmol, 2.20 equiv.), 3.16 (72.4 mg, 0.280 mmol, 1.4 equiv.). The crude material was purified by flash column 
chromatography on silica gel, (EtOAc/Hex, gradient, 0 to 3%) providing tricycle 3.34 in about 80% purity as 
a colourless oil, (15.0 mg, 28.8 µmol, 14% yield). Yield calculated by NMR standard (trimethoxybenzene).  
1H NMR (400 MHz, Chloroform-d) δ 5.32 (s, 1H), 5.00 (s, 1H), 4.60 (s, 2H), 4.02 (d, J = 8.3 Hz, 1H), 3.93 (dd, 
J = 8.5, 5.5 Hz, 1H), 3.59 (s, 3H), 3.23 (s, 3H), 2.89 (q, J = 7.6 Hz, 1H), 2.70 (s, 1H), 2.66 (d, J = 11.3 Hz, 1H), 
2.34 (dd, J = 11.4, 5.4 Hz, 1H), 1.88 (s, 3H), 1.82 (s, 3H), 1.13–0.99 (m, 30H) 
HRMS (+APCI): calc. for C29H49O4Si [M-OMe]+   489.3395, found 489.3390 
RF = 0.55 (15% EtOAc in hexanes) 
 
 
Tricyclic alcohol 3.59. 
To a solution of acetal 3.31 (50.0 mg, 0.104 mmol, 1.00 equiv.) in dry chloroform (3.0 mL) were added 2,6-
lutidine (73 µL, 0.63 mmol, 6.0 equiv.) and TESOTf (89 µL, 0.42 mmol, 4.0 equiv.). After stirring under reflux 
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for 5 h the solution was allowed to cool down and water (2.0 mL), hexanes (1.5 mL) and chloroform (1.0 
mL) were added. The mixture was heated to 65 ºC and stirred vigorously for 72 h. 
The phases were separated and the aqueous layer was extracted three times with DCM. The organic layers 
were combined, dried over anhydrous MgSO4 and concentrated. The crude material was purified by flash 
column chromatography on silica gel (10% EtOAc/Hexanes) affording alcohol 3.59 (35.0 mg, 80.5 µmol, 77% 
yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 4.97 (s, 1H), 4.25 (br s, 1H), 3.77 (d, J = 8.2 Hz, 1H), 3.57 (s, 3H), 
2.87 (q, J = 7.5 Hz, 1H), 2.64 (d, J = 11.2 Hz, 1H), 2.50 (s, 1H), 2.25 (dd, J = 11.3, 6.1 Hz, 1H), 1.85 (s, 3H), 1.81 
(s, 3H), 1.65 (d, J = 4.1 Hz, 1H), 1.20 (s, 3H), 1.13 (s, 3H), 1.06 (d, J = 7.5 Hz, 3H), 0.93 (s, 9 H), 0.13 (d, J = 2.1 
Hz, 6H) 
13C NMR (100 MHz, CDCl3) δ 174.85, 141.23, 137.81, 132.63, 124.99, 89.95, 84.14, 56.49, 54.22, 51.09, 
50.74, 45.93, 40.53, 34.54, 29.41, 29.02, 26.02, 25.22, 24.14, 18.25, 15.81, -4.06, -4.41 
IR (ATR): 2956 (m), 2929 (m), 2855 (w), 2362 (w), 1719 (s), 1460 (w), 1435 (w), 1376 (w), 1250 (m), 1226 
(m), 1098 (m), 876 (s), 835 (s), 753 (s) 
HRMS (+ESI): calc. for C25H43O4Si [M+H]+   435.2925, found 435.2928 
[𝜶]𝑫
𝟐𝟓 +35.8º (c 0.66, CHCl3) 
RF = 0.39 (20% EtOAc in hexanes) 
 
 
 
Ketone 3.60. 
Alcohol 3.59 (20.0 mg, 46.0 µmol, 1.00 equiv.) was dissolved in DCM (0.55 mL) and NaHCO3 (11.6 mg, 0.138 
mmol, 3.00 equiv.) was added followed by 1 small drop of t-BuOH. Dess-Martin periodinane (29.3 mg, 69.0 
µmol, 1.5 equiv.) was added and the reaction mixture was stirred at room temperature for 60 min before 
additional NaHCO3 (4.0 mg, 47.6 µmol, 1.04 equiv.) followed by DMP (10.0 mg, 23.6 µmol, 0.513 equiv.) 
were added. The reaction mixture was stirred for 2 hours. 
A 1:1 solution of saturated aqueous Na2S2O3/NaHCO3 (1.5 mL each) was added and the result was vigorously 
stirred for 15 min, after which the mixture was diluted with water and DCM. The phases were separated, 
and the aqueous layer was extracted three times with DCM. The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure yielding a white solid, 20 mg. 
Purification by flash column chromatography on silica gel (Et2O/Hexanes, gradient, 0 to 15%) allowed for 
isolation of ketone 3.60 as a white solid (17.0 mg, 39.3 µmol, 85% yield). 
1H NMR (400 MHz, CDCl3) δ 5.36 (s, 1H), 4.85 (s, 1H), 4.03 (d, J = 2.2 Hz, 1H), 3.60 (s, 3H), 3.07 (s, 1H), 3.01 
(q, J = 7.3 Hz, 1H), 2.82 (d, J = 11.2 Hz, 1H), 2.72 (dd, J = 11.3, 2.2 Hz, 1H), 1.87 (d, J = 1.6 Hz, 3H), 1.69 (s, 
3H), 1.37 (s, 3H), 1.16 (s, 3H), 1.06 (d, J = 7.5 Hz, 3H), 0.95 (s, 9H), 0.19 (s, 3H), 0.07 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 212.65, 173.23, 138.93, 136.89, 136.56, 125.45, 86.17, 53.47, 51.53, 51.31, 
48.13, 44.11, 41.14, 34.05, 27.90, 27.78, 25.82, 24.51, 24.26, 18.47, 15.57, -4.34, -5.64. 
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IR (ATR): 2956 (s), 2928 (s), 2856 (m), 2361 (w), 1733 (s), 1461 (m), 1377 (w), 1252 (m), 1201 (s), 1174 (s), 
1139 (s), 1092 (w), 1053 (m), 1020 (w), 949 (w), 876 (s), 838 (s), 779 (m) 
HRMS (+ESI): calc. for C25H41O4Si [M+H]+   433.2769, found 433.2752 
[𝜶]𝑫
𝟐𝟒 +23.1º (c 0.08, CHCl3) 
RF = 0.62 (20% EtOAc in hexanes) 
 
 
 
 
 
 
 
Diol 3.61. 
To alcohol 3.59 (5.0 mg, 11 µmol, 1.00 equiv.) dissolved in DCM (0.22 mL) at −50 °C was added dropwise a 
solution of DIBAL (1.5 M in toluene, 24 µL, 46 µmol, 4.0 equiv.). The mixture was stirred at the same 
temperature for 4 hours before additional DIBAL (1.5 M in toluene, 20 µL, 38 µmol, 3.3 equiv.) was added. 
The mixture was then warmed to −30 ºC and stirred for 2 additional hours. 
The reaction was quenched with saturated aqueous Rochelle’s salt (0.40 mL), then warmed to room 
temperature and stirred for 30 min. The mixture was diluted with water/DCM and extracted three times 
with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure to afford 6.2 mg of a colourless oil, which was purified by flash column chromatography on silica 
gel (EtOAc/hexanes, 10%, then 20%, then 32%) delivering diol 3.61 as a colourless solid (2.8 mg, 6.9 µmol, 
60% yield). 
1H NMR (400 MHz, CDCl3) δ 5.42 (s, 1H), 4.94 (s, 1H), 4.28 (t, J = 7.2 Hz, 1H), 3.77 (d, J = 8.2 Hz, 1H), 3.65 (dd, 
J = 10.7, 3.9 Hz, 1H), 3.28 (t, J = 9.5 Hz, 1H), 2.81 (q, J = 7.2 Hz, 1H), 2.55 (d, J = 11.4 Hz, 1H), 2.21 (dd, J = 
11.4, 6.0 Hz, 1H), 1.95 (br s, 1H), 1.85 (s, 3H), 1.74 (s, 3H), 1.60 (dd, J = 8.3, 4.1 Hz, 2H), 1.19 (s, 3H), 1.12 (s, 
3H), 1.07 (d, J = 7.5 Hz, 3H), 0.94 (s, 9H), 0.14 (s, 6H) 
13C NMR (100 MHz, CDCl3) δ 139.12, 137.47, 133.99, 127.91, 90.11, 84.78, 63.64, 55.60, 51.90, 50.51, 
44.49, 39.77, 34.42, 29.44, 28.18, 26.04, 25.22, 24.03, 18.28, 15.88, -4.03, -4.49. 
IR (ATR): 3275 (m, br), 2955 (m), 2925 (s), 2854 (m), 1729 (w), 1461 (m), 1375 (w), 1251(m), 1130 (m), 
1105 (m), 1034 (m), 996 (m), 877 (s), 835 (s), 776 (s), 756 (s) 
HRMS (+APCI): calc. for C24H41O2Si [M–OH]+   389.2870, found 389.2864 
[𝜶]𝑫
𝟐𝟒 +6.9º (c 0.19, CHCl3) 
RF = 0.32 (40% EtOAc in hexanes) 
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TBDPS-protected alcohol S3.5. 
To a solution of diol 3.61 (2.0 mg, 4.9 µmol, 1.00 equiv.) in DCM (0.16 mL) was added imidazole (0.7 mg, 10 
µmol, 2 equiv.) followed by TBDPSCl (1.4 µL, 5.3 µmol, 1.1 equiv.). The resulting mixture was stirred at room 
temperature for 6 h after which water (20 µL) was added. The mixture was vigorously stirred for 5 min, after 
which the aqueous phase was separated and extracted three times with DCM. The organic layers were 
combined, dried over MgSO4 and concentrated under reduced pressure yielding a colourless oil. 
Purification by flash column chromatography on silica gel (EtOAc/Hexanes, 0%, then 2%, then 5%) yielded 
alcohol S3.5 (3.2 mg, 5.0 µmol, quantitative yield).  
1H NMR (400 MHz, CDCl3) δ 7.64 (ddd, J = 8.0, 5.4, 1.7 Hz, 4H), 7.43 – 7.35 (m, 6H), 5.23 (s, 1H), 4.89 (s, 1H), 
4.26 (dt, J = 8.1, 5.4 Hz, 1H), 3.76 (d, J = 8.1 Hz, 1H), 3.68 (dd, J = 9.9, 4.5 Hz, 1H), 3.16 (t, J = 9.8 Hz, 1H), 2.79 
(q, J = 7.3 Hz, 1H), 2.40 (d, J = 11.5 Hz, 1H), 2.30 (dd, J = 11.4, 5.7 Hz, 1H), 1.84 (s, 3H), 1.69 (dd, J = 9.6, 4.5 
Hz, 1H), 1.64 (d, J = 1.5 Hz, 3H), 1.55 (s, 3H), 1.42 (d, J = 5.1 Hz, 1H), 1.16 (s, 3H), 1.04 (s, 9H), 0.94 (s, 9H), 
0.93 (s, 3H), 0.16 (s, 3H), 0.14 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.94, 136.52, 135.64, 134.20, 129.52, 127.58, 90.23, 84.73, 63.79, 55.59, 
52.15, 50.31, 44.30, 39.75, 34.34, 29.42, 28.11, 26.99, 26.08, 25.17, 23.97, 19.22, 18.31, 15.92, -3.98, -4.60 
IR (ATR): 2957 (s), 2929 (s), 2856 (m), 2361 (w), 1471 (w), 1428 (w), 11253 (w), 1112 (s), 1060 (m), 878 
(m), 837 (m), 777 (w), 739 (w) 
HRMS (+APCI): calc. for C40H59O2Si2 [M–OH]+   627.4048, found 627.4031 
[𝜶]𝑫
𝟐𝟒 +13.41º (c 0.14, CHCl3) 
RF = 0.73 (40% EtOAc in hexanes) 
 
 
 
 
 
Ketone 3.62. 
Alcohol S3.5 (5.0 mg, 7.8 µmol, 1.00 equiv.) was dissolved in DCM (0.20 mL) and NaHCO3 (2.0 mg, 23 µmol, 
3.0 equiv.) was added followed by 1 small drop of t-BuOH. Dess−Martin periodinane (5.0 mg, 11.7 µmol, 
1.5 equiv.) was added and the reaction mixture was stirred at room temperature for 60 min before 
additional NaHCO3 (4.0 mg, 48 µmol, 6.0 equiv.) followed by DMP (10.0 mg, 23.6 µmol, 3.00 equiv.) were 
added. The reaction mixture was stirred for 2 hours. 
A 1:1 solution of saturated aqueous Na2S2O3/NaHCO3 (1.5 mL each) was added and the result was vigorously 
stirred for 15 min, after which the mixture was diluted with water and DCM. The phases were separated, 
and the aqueous layer was extracted three times with DCM. The organic layers were combined, dried over 
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Na2SO4 and concentrated under reduced pressure yielding pure ketone 3.62 a colourless oil (4.8 mg, 7.5 
µmol, 96% yield). 
1H NMR (400 MHz, CDCl3) δ 7.62 (td, J = 8.7, 1.6 Hz, 4H), 7.39 (dd, J = 11.1, 6.5 Hz, 6H), 5.25 (s, 1H), 4.81 (s, 1H), 3.97 
(d, J = 2.3 Hz, 1H), 3.71 (dd, J = 9.9, 4.8 Hz, 1H), 3.31 (t, J = 10.0 Hz, 1H), 2.93 (q, J = 7.4 Hz, 1H), 2.76 (d, J = 11.3 Hz, 1H), 
2.46 (d, J = 11.3 Hz, 1H), 2.42 (dd, J = 10.0, 4.8 Hz, 1H), 1.70 (d, J = 1.4 Hz, 3H), 1.67 (s, 3H), 1.31 (s, 3H), 1.02 (s, 9H), 
0.96 (s, 9H), 0.90 (s, 3H), 0.23 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 214.24, 138.07, 136.83, 135.69, 135.56, 135.42, 134.18, 133.68, 129.60, 129.48, 127.75, 
127.61, 86.29, 62.60, 51.86, 50.33, 47.66, 41.78, 40.05, 33.95, 31.94, 29.71, 26.90, 25.88, 24.44, 24.11, 22.71, 19.24, 
18.52, 15.68, 14.14, 1.03, -4.22, -5.66 
IR (ATR): 2958 (w), 2920 (s), 2850 (m), 2360 (s), 2341 (s), 1463 (w), 1261 (w), 1053 (m), 1034 (m), 1018 
(w), 803 (w) 
HRMS: No mass peak found 
RF = 0.56 (5% Et2O in hexanes) 
 
8.4 Supporting Information for Chapter 3.3 
8.4.1 Experimental Procedures for Chapter 3.3 
 
 
 
 
 
 
 
 
Vinyl iodide 13. 
To a solution of allyl methoxymethyl ether (1.30 g, 12.7 mmol, 2.26 equiv.) in dry THF (12 mL) at −78 °C was 
added s-butyllithium (1.4 M in cyclohexane, 8.53 mL, 11.9 mmol, 2.12 equiv.) over 20 min. The reaction 
mixture was stirred at −78 °C for 30 min after which a solution of (+)-B-methoxydiisopinocampheylborane 
(3.74 g, 11.8 mmol, 2.10 equiv.) in dry diethyl ether (22 mL) was added over 20 min. The reaction was further 
stirred at −78 °C for 1 h before boron trifluoride diethyl etherate (1.61 mL, 12.7 mmol, 2.26 equiv.) was 
added dropwise, followed by immediate addition of a solution of aldehyde 11 (1.33 g, 5.63 mmol, 1.00 
equiv.) in dry THF (30 mL) in the dark and in contact with the flask’s inner wall to ensure pre-cooling. The 
reaction mixture was stirred for an additional 3 h at −78 °C, then slowly warmed to room temperature and 
stirred overnight. 
The solvent was exchanged to diethyl ether (45 mL) and an aqueous solution of NaOH (2.5 M, 8 mL) was 
added followed by careful addition of H2O2 in water (30% w/w, 23 mL) causing intense gas evolution. The 
mixture was stirred under reflux for 3 h or until no more gas evolution was observed at room temperature. 
The layers were separated, and the aqueous phase was extracted three times with diethyl ether. The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
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The crude residue was purified by flash column chromatography on silica gel, (EtOAc/Hex, gradient, 0 to 
12%) yielding 13 as a colourless oil (1.14 g, 3.37 mmol, 60% yield, d.r.>20:1, 96% ee, Mosher’s ester analysis, 
see below). 
1H NMR (400 MHz, CDCl3) δ 6.05 (s, 1H), 5.94 (s, 1H), 5.74 (ddd, J = 17.5, 10.3, 7.3 Hz, 1H), 5.36–5.26 (m, 
2H), 4.76 (d, J = 6.7 Hz, 1H), 4.64 (d, J = 6.7 Hz, 1H), 4.07 (t, J = 7.4 Hz, 1H), 4.01 (dd, J = 7.5, 2.1 Hz, 1H), 3.43 
(s, 3H), 2.90 (d, J = 2.4 Hz, 1H), 1.97 (s, 3H), 1.71 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 144.4, 137.2, 134.3, 130.5, 119.4, 94.5, 80.1, 79.4, 77.30, 55.9, 24.6, 14.1 
IR (ATR): 3465 (br), 2924 (s), 2851 (m), 2363 (w), 1261 (w), 1151 (m), 1081 (m), 1031 (s), 922 (m), 768 (w) 
HRMS (+ESI): calc. for C12H19INaO3 [M+Na]+  361.0271 found 361.0275 
[𝜶]𝑫
𝟐𝟑 +70.6º (c 0.67, CHCl3) 
RF = 0.42 (25% EtOAc in hexanes) 
 
 
Procedure for Mosher’s ester analysis 
 
 
 
 
Mosher’s ester S1. 
To a solution of triene 13, (5.0 mg, 15 µmol, 1.0 equiv.) and DMAP (6.4 mg, 52 µmol. 3.5 equiv.) in pyridine 
(0.50 mL) was added (R)-(−)-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (Mosher’s acyl chloride, 
2.8 µL, 15 µmol, 1.0 equiv.). The reaction mixture was stirred for 1.5 h. 
The solvent was evaporated and the residue was filtered through a pad of silica eluting with 30% 
EtOAc/hexanes affording ester S1 as a colourless oil (6.6 mg, 12 µmol, 80% yield, d.r. 1:0.02). 
(S)-diastereomer: 
1H NMR (400 MHz, CDCl3) δ 7.61–7.55 (m, 2H), 7.43–7.34 (m, 3H), 6.08 (br, 1H), 5.96 (s, 1H), 5.69 (ddd, J = 
18.0, 10.3, 7.8 Hz, 1H), 5.41–5.31 (m, 3H), 4.69 (d, J = 6.7 Hz, 1H), 4.57 (d, J = 6.7 Hz, 1H), 4.27 (t, J = 8.2 Hz, 
1H), 3.59–3.57 (br, 3H), 3.29 (s, 3H), 1.89 (s, 3H), 1.56 (d, J = 1.3 Hz, 3H) 
(R)-diastereomer: 
1H NMR (400 MHz, CDCl3) δ 7.59–7.50 (m, 2H), 7.42–7.34 (m, 3H), 6.10 (app quintet, J = 1.5 Hz, 1H), 6.03 
(br, 1H), 5.66 (ddd, J = 17.2, 10.3, 7.7 Hz, 1H), 5.45 (d, J = 8.7 Hz, 1H), 5.37–5.27 (m, 2H), 4.50 (d, J = 6.8 Hz, 
1H), 4.37 (d, J = 6.8 Hz, 1H), 4.22 (t, J = 8.1 Hz, 1H), 3.58 (d, J = 1.4 Hz, 3H), 3.10 (s, 3H), 1.90 (dd, J = 1.5, 0.7 
Hz, 3H), 1.69 (d, J = 1.3 Hz, 3H) 
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Conjugated ester S2. 
A Schlenk tube was charged with vinyl iodide 13 (1.00 g, 2.96 mmol, 1.00 equiv.), methyl acrylate (0.80 mL, 
8.9 mmol, 3.0 equiv.) and dry degassed toluene (freeze-pump-thaw, 3x10 min, 5.0 mL). A solution of 2nd 
generation Hoveyda–Grubbs catalyst (186 mg, 0.300 mmol, 0.10 equiv.) in dry degassed toluene (freeze-
pump-thaw, 3x10 min, 6.6 mL) was loaded in a syringe. 0.55 mL of the solution were added in one portion 
every hour while the reaction mixture was stirred at 50 ºC. After the addition was complete the suspension 
was stirred for an additional 12 h at the same temperature. 
The solvents were evaporated at 28 ºC and the crude product was submitted to flash column 
chromatography on silica gel (EtOAc/Hex, gradient, 0 to 30%) affording ester S2 (776 mg, 1.96 mmol, 66% 
yield) as yellow oil. 
1H NMR (400 MHz, CDCl3) δ 6.87 (dd, J = 15.8, 6.4 Hz, 1H), 6.10–6.04 (m, 2H), 5.91 (s, 1H), 4.70 (s, 2H), 4.24 
(ddd, J = 7.4, 6.4, 1.3 Hz, 1H), 4.03 (dd, J = 7.4, 2.7 Hz, 1H), 3.72 (s, 3H), 3.43 (s, 3H), 2.96–2.94 (m, 1H), 1.94 
(d, J = 1.3 Hz, 3H), 1.71 (d, J = 1.3 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 166.2, 144.2, 144.0, 136.2, 131.0, 123.4, 95.5, 78.9, 78.5, 77.4, 56.1, 51.7, 24.6, 
14.0 
IR (ATR): 3560 (br), 2950 (m), 1721 (s), 1660 (w), 1436 (m), 1277 (s), 1150 (m), 1023 (s), 916 (s), 730 (s) 
HRMS (+APCI): calc. for C14H20IO4 [M−OH]+   379.0401, found 379.0434 
[𝜶]𝑫
𝟐𝟑 +56.9º (c 0.93, CHCl3) 
RF = 0.16 (20% EtOAc in hexanes) 
 
 
 
 
 
 
Silyl ether 14. 
To vinyl iodide S2 (1.04 g, 2.63 mmol, 1.00 equiv.) in dry DCM (22 mL) was added 2,6-lutidine (0.76 mL, 6.6 
mmol, 2.5 equiv.). The solution was cooled down to 0 ºC and TBSOTf (0.91 ml, 3.9 mmol, 1.5 equiv.) was 
added dropwise. The reaction mixture was allowed to warm up to room temperature and was stirred for 
1.5 h. 
An aqueous saturated NaHCO3 solution was added and the layers were separated. The aqueous phase was 
extracted three times with DCM and the organic layers were combined, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude material (yellow oil, 1.50 g) was purified by flash column 
chromatography on silica gel (EtOAc/hexanes, gradient, 0 to 15%) affording silyl ether 14 as a yellow oil 
(1.20 g, 2.35 mmol, 89% yield). 
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1H NMR (400 MHz, CDCl3) δ 6.88 (dd, J = 15.7, 6.0 Hz, 1H), 6.09–6.03 (m, 2H), 5.82 (br s, 1H), 4.75 (d, J = 6.7 
Hz, 1H), 4.65 (d, J = 6.7 Hz, 1H), 4.23 (ddd, J = 7.3, 6.0, 1.5 Hz, 1H), 4.08 (dd, J = 6.9, 0.9 Hz, 1H), 3.71 (s, 3H), 
3.37 (s, 3H), 1.91 (dd, J = 1.5, 0.7 Hz, 3H), 1.66 (d, J = 1.3 Hz, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 166.5, 145.2, 144.3, 138.0, 130.0, 122.1, 96.0, 80.4, 78.5, 77.1, 55.8, 51.5, 25.8, 
24.4, 18.2, 14.2, −4.6, −4.9 
IR (ATR):  2951 (m), 2928 (m), 2888 (w), 2856 (m), 2361 (w), 1726 (s), 1661 (w), 1435 (m), 1251 (m), 1152 
(m), 1092 (s), 1028 (s), 912 (m), 872 (m), 837 (s), 775 (s) 
HRMS (+APCI): calc. for C18H30IO3Si [M−OMOM]+   449.1003, found 449.1009 
[𝜶]𝑫
𝟐𝟑 +1.5º (c 1.07, CHCl3) 
RF = 0.58 (20% EtOAc in hexanes) 
 
 
 
 
 
 
 
 
 
Cascade product 18. 
Pd(PPh3)4 (25.8 mg, 22.3 µmol, 0.100 equiv.) and copper(I) thiophene-2-carboxylate (CuTC, 46.8 mg, 0.246 
mmol, 1.10 equiv.) were charged into a dried flask under N2 that was wrapped in aluminum foil to shield it 
from light. A solution of vinyl stannane 15 (81.0 mg, 0.313 mmol, 1.40 equiv.) in benzene (1.2 mL) and vinyl 
iodide 14 (114 mg, 0.223 mmol, 1.00 equiv.) were combined and concentrated (rotary evaporator bath 
temperature 30 °C, pressure 35 mbar, darkness) to azeotropically remove traces of water. The 
iodide/stannane mixture was redissolved in dry DMF (2.2 mL) and added to the Pd/Cu solid mixture avoiding 
light. The result was immediately heated to 65 °C (external aluminium block temperature) and stirred for 
50 min. The temperature was then increased to 125 °C and the mixture further stirred in the dark for 20 h. 
After cooling, the solvent was evaporated at 60 ºC and 10 mbar. The resulting black gum was dissolved in a 
small amount of DCM and loaded on a pad of silica pre-equilibrated with hexanes. The DCM was evaporated 
under a flow of nitrogen and the remaining residue was eluted with 7:3 hexanes/Et2O (4x3.8 mL) yielding 
95 mg of a slightly yellow which was purified by flash column chromatography on silica gel, (EtOAc/Hex, 
gradient, 0 to 3%) providing tricycle 18 as a white crystalline solid (45.0 mg, 94.0 µmol, 42% yield). The same 
procedure performed on 831 mg of vinyl iodide 14 afforded 18 (309 mg, 0.645 mmol, 40% yield). 
1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 5.00 (s, 1H), 4.63–4.57 (m, 2H), 3.93–3.84 (m, 2H), 3.59 (s, 3H), 3.25 
(s, 3H), 2.88 (q, J = 7.6 Hz, 1H), 2.71 (s, 1H), 2.65 (d, J = 11.3 Hz, 1H), 2.32 (dd, J = 11.4, 4.9 Hz, 1H), 1.86 (s, 
3H), 1.82 (s, 3H), 1.19 (s, 3H), 1.12 (s, 3H), 1.07 (d, J = 7.5 Hz, 3H), 0.91 (s, 9H), 0.11 (s, 3H), 0.06 (s. 3H) 
13C NMR (100 MHz, CDCl3) δ 175.4, 140.6, 138.0, 133.1, 125.0, 97.8, 92.9, 87.8, 55.3, 55.2, 53.9, 51.2, 50.9, 
44.3, 40.5, 34.4, 29.3, 29.0, 26.0, 25.0, 24.2, 18.2, 15.8, –4.24, –4.39 
IR (ATR): 2929 (m), 2856 (w), 1731 (m), 1460 (m), 1252 (m), 1197 (m), 1173 (m), 1124 (s), 1109 (s), 1041 (s), 
876 (s), 837 (s), 774 (s) 
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HRMS (+APCI): calc. for C27H47O5Si [M+H]+   479.3187, found 479.3191 
[𝜶]𝑫
𝟐𝟑 +15.1º (c 2.33, CHCl3) 
RF = 0.29 (12% Et2O in hexanes), 0.36 (10% EtOAc in hexanes) 
Mp: 84-86 ºC 
 
Alcohol 19. 
To a solution of silyl ether 18 (120 mg, 0.251 mmol, 1.00 equiv.) in dry THF (4.0 mL) at room temperature 
were added 4Å molecular sieves followed by a solution of TBAF (1.0 M in THF, 0.45 mL, 0.45 mmol, 1.8 
equiv.). The mixture was stirred for 4 h at 45 ºC after which additional TBAF (1.0 M, 0.10 mL, 0.10 mmol, 0.4 
equiv.) was added, and the reaction was further stirred for 2 h. 
The mixture was filtered over a plug of silica gel, eluting with 3:1 hexanes/EtOAc. Alcohol 19 was obtained 
as a colourless oil (85.0 mg, 0.233 mmol, 93% yield) which solidified upon standing and could be used for 
the next step without further purification. 
1H NMR (400 MHz, CDCl3) δ 5.34 (d, J = 1.2 Hz 1H), 4.98 (s, 1H), 4.66 (q, J = 7.1 Hz, 2H), 3.98 (dd, J = 7.9, 6.2 
Hz, 1H), 3.79 (dd, J = 7.9, 1.5 Hz, 1H), 3.58 (s, 3H), 3.40 (s, 3H), 2.88 (q, J = 7.3 Hz, 1H), 2.69 (d, J = 11.3 Hz, 
1H), 2.50 (s, 1H), 2.41 (dd, J = 11.3, 6.1 Hz, 1H), 1.88 (s, 3H), 1.82 (d, J = 1.5 Hz, 3H), 1.28 (s, 3H), 1.13 (s, 3H), 
1.10 (d, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 174.8, 141.5, 137.9, 132.7, 124.9, 97.9, 95.5, 87.4, 56.6, 55.6, 54.5, 51.4, 51.1, 
44.1, 40.6, 34.7, 29.7, 29.0, 25.1, 24.1, 15.7 
IR (ATR): 3473 (br), 2933 (m), 1731 (m), 1459 (m), 1376 (w), 1174 (m), 1148 (m), 1107 (s), 1039 (s), 912 (m) 
HRMS (+ESI): calc. for C21H33O5 [M+H]+   365.2323, found 365.2340 
[𝜶]𝑫
𝟐𝟑 +95.3º (c 1.73, CHCl3) 
RF = 0.20 (20% EtOAc in hexanes) 
 
 
Methyl xanthate 26. 
To alcohol 19 (130 mg, 0.357 mmol, 1.00 equiv.) dissolved in dry THF (6.0 mL) was added NaH (60% w/w in 
paraffin oil, 42.8 mg, 1.07 mmol, 3.00 equiv.) followed by CS2, (64 µL, 1.1 mmol, 3.0 equiv.). After vigorously 
stirring for 50 minutes, methyl iodide (68 µL, 1.1 mmol, 3.0 equiv.) was added and the mixture was stirred 
for an additional 20 h. 
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The reaction was quenched by the addition of aqueous saturated NH4Cl. The phases were separated and 
the aqueous layer was extracted three times with diethyl ether. The organic layers were combined, dried 
over Na2SO3, filtered and concentrated under reduced pressure. The crude material (168 mg) was purified 
by flash column chromatography on silica gel, (10% EtOAc/Hexanes). Methyl xanthate 26 was obtained as 
a dark yellow oil (145 mg, 0.319 mmol, 89% yield). 
1H NMR (400 MHz, CDCl3) δ 6.36 (d, J = 8.2 Hz, 1H), 5.39 (s, 1H), 5.12 (s, 1H), 4.56 (q, J = 6.9 Hz, 2H), 4.37 
(dd, J = 8.1, 6.0 Hz, 1H), 3.60 (s, 3H), 3.26 (s, 3H), 2.96 (q, J = 7.4 Hz, 1H), 2.90 (d, J = 11.3 Hz, 1H), 2.66 (s, 
1H), 2.62 (s, 3H), 2.51 (dd, J = 11.3, 5.8 Hz, 1H), 1.94 (s, 3H), 1.83 (s, 3H), 1.27 (s, 3H), 1.15 (s, 3H), 1.00 (d, J 
= 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 217.2, 174.7, 139.8, 137.2, 133.7, 125.7, 96.4, 94.6, 88.4, 57.1, 55.3, 54.0, 51.4, 
51.1, 44.4, 40.5, 34.8, 29.3, 29.0, 25.1, 24.1, 19.7, 15.6 
IR (ATR): 2919 (m), 2849 (w), 1731 (m), 1456 (m), 1380 (w), 1213 (s), 1106 (m), 1061 (s), 1036 (m), 914 (w), 
754 (m) 
HRMS (+ESI): calc. for C23H34O5S2Na [M+Na]+   477.1740, found 477.1762 
[𝜶]𝑫
𝟐𝟑 +63.1º (c 2.14, CHCl3) 
RF = 0.59 (20% EtOAc in hexanes) 
 
 
 
 
 
 
 
 
Ethyl xanthate 27. 
The same procedure as for methyl xanthate 26 (see above) was followed changing the reagent ratio: 19, 
(15.0 mg, 41.2 µmol, 1.00 equiv.), NaH, (60% w/w in paraffin oil, 6.6 mg, 0.16 mmol, 4.0 equiv.), CS2, (10 µL, 
0.16 mmol, 4.0 equiv.) and ethyl iodide, (20 µL, 0.25 mmol, 6.0 equiv.). The crude material (20 mg) was 
purified by flash column chromatography on silica gel (10% EtOAc/Hexanes) yielding xanthate 27 as a dark 
yellow oil (17.3 mg, 0.369 mmol, 90% yield). 
1H NMR (400 MHz, CDCl3) δ 6.36 (d, J = 8.2 Hz, 1H), 5.39 (s, 1H), 5.11 (s, 1H), 4.56 (q, J = 6.9 Hz, 2H), 4.36 
(dd, J = 8.3, 5.9 Hz, 1H), 3.60 (s, 3H), 3.26 (s, 3H), 3.20 (q, J = 7.4 Hz, 2H), 2.96 (q, J = 7.7 Hz, 1H), 2.90 (d, J = 
11.3 Hz, 1H), 2.66 (s, 1H), 2.51 (dd, J = 11.3, 5.8 Hz, 1H), 1.94 (s, 3H), 1.83 (s, 3H), 1.36 (t, J = 7.4 Hz, 3H), 1.26 
(s, 3H), 1.15 (s, 3H), 1.00 (d, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 216.2, 174.7, 139.9, 137.2, 133.7, 125.7, 96.4, 94.1, 88.4, 57.1, 55.3, 54.1, 51.4, 
51.1, 44.4, 40.5, 34.8, 31.0, 29.3, 29.0, 25.1, 24.1, 15.5, 13.0 
IR (ATR): 2923 (m), 2851 (w), 1732 (m), 1457 (m), 1379 (w), 1211 (s), 1172 (m), 1107 (m), 1065 (s), 1032 (s), 
915 (m) 
HRMS (+ESI): calc. for C24H36NaO5S2 [M+Na]+   491.1896, found 491.1909 
[𝜶]𝑫
𝟐𝟑 +53.0º (c 0.4, CHCl3) 
RF = 0.59 (20% EtOAc in hexanes) 
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Benzyl xanthate 20.  
The same procedure as for methyl xanthate 26 (see above) was followed changing the reagent ratio:  19 
(40.0 mg, 0.110 mmol, 1.00 equiv.), NaH (60% w/w in paraffin oil,17.6 mg, 0.439 mmol, 4.00 equiv.), CS2, 
(26 µL, 0.439 mmol, 4.00 equiv.) and freshly distilled BnBr, (65 µL, 0.549 mmol, 5.00 equiv.). 
The crude product (120 mg) was purified by flash column chromatography on silica gel, (Et2O/Hexanes, 
gradient, 0 to 10%) giving benzyl xanthate 20 as a yellow oil (45.0 mg, 84.8 µmol, 77 % yield). 
1H NMR (400 MHz, CDCl3) δ 7.39–7.27 (m, 5H), 6.36 (d, J = 8.2 Hz, 1H), 5.39 (s, 1H), 5.10 (s, 1H), 4.56 (dd, J 
= 9.6, 6.9, 2H), 4.46 (s, 2H), 4.36 (dd, J = 8.3, 5.9 Hz, 1H), 3.60 (s, 3H), 3.25 (s, 3H), 2.96 (q, J = 7.6 Hz, 1H), 
2.90 (d, J = 11.2 Hz, 1H), 2.66 (s, 1H), 2.51 (dd, J = 11.4, 5.8 Hz, 1H), 1.91 (s, 3H), 1.83 (s, 3H), 1.28 (s, 3H), 
1.15 (s, 3H), 1.00 (d, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 215.5, 174.7, 139.8, 137.2, 135.0, 133.7, 129.2, 128.6, 127.7, 125.7, 96.5, 94.6, 
88.5, 57.1, 55.3, 54.0, 51.4, 51.11, 44.4, 41.6, 40.5, 34.7, 29.3, 29.0, 25.1, 24.1, 15.6 
IR (ATR): 2924 (m), 2850 (w), 1730 (m), 1454 (m), 1380 (w), 1216 (s), 1107 (m), 1195 (m), 1058 (s), 1039 (s), 
914 (w) 
HRMS (+APCI): calc. for C27H33O3S2 [M−OMOM]+   469.1866, found 469.1882 
[𝜶]𝑫
𝟐𝟑 +53.4º (c 0.20, CHCl3) 
RF = 0.46 (15% EtOAc in hexanes) 
 
General procedure for Barton−McCombie Deoxygenation 
 
A vial was charged with the corresponding xanthate (45.0 µmol, 1.00 equiv.) and AIBN (1.9 mg, 9.7 µmol, 
0.25 equiv.). The vial was evacuated and flushed with nitrogen three times and tributyltin hydride (0.59 ml, 
2.2 mmol, 50 equiv., entries 2-3) or (0.47 ml, 2.8 mmol, 40 equiv., entry 4) was added. The mixture was 
stirred at 85 ºC for 1.5 to 4 h (monitored by 1H NMR). 
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The reaction mixture was then cooled down to room temperature and submitted to flash column 
chromatography on silica gel (Et2O/Hexanes, gradient, 0 to 12%). 
Results for entry 4 are shown below. 
 
 
         
Deoxygenated tricycle 21. 
Tricycle 21 was obtained together with methyl ether 28 as a white solid, 14 mg. NMR shows a 21 to 28 molar 
ratio of 1:0.15 (12.0 mg, 34.4 µmol, 76% yield). Elution at 6% Et2O in hexanes. 
An additional run using benzyl xanthate 20 (92 mg) allowed for isolation of fractions with clean tricycle 21 
after a second separation on spherical 20-40 µm particle size silica. 
1H NMR (400 MHz, CDCl3) δ 5.31 (s, 1H), 5.01 (s, 1H), 4.61–4.56 (m, 2H), 4.05–3.96 (m, 1H), 3.58 (s, 3H), 3.29 
(s, 2H), 2.82 (q, J = 7.0, 1H), 2.79 (d, J = 11.9, 1H), 2.59 (s, 1H), 2.57 (dd, J = 11.7, 4.9 Hz, 1H), 2.20 (dd, J = 
13.7, 7.7 Hz, 1H), 1.83 (d, J = 1.3 Hz, 3H), 1.71 (s, 3H), 1.42 (dd, J = 13.7, 9 Hz, 1H), 1.41 (d, J = 13.5 Hz, 1H), 
1.12 (s, 3H), 1.10 (s, 3H), 0.90 (d, J = 7.3 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 174.9, 139.4, 138.3, 134.2, 124.3, 96.4, 88.2, 56.7, 56.4, 55.3, 55.0, 51.0, 50.0, 
42.6, 40.8, 34.8, 30.7, 28.7, 25.4, 24.1, 14.7 
IR (ATR): 2929 (s), 2851 (w), 1734 (s), 1461 (m), 1442 (m), 1378 (w), 1244 (w), 1195 (m), 1152 (s), 1102 (s), 
1043 (s), 915 (w) 
HRMS (+APCI): calc. for C21H33O4 [M+H]+   349.2373, found 349.2372 
[𝜶]𝑫
𝟐𝟑 +26.0º (c 0.25, CHCl3) 
RF = 0.28 (20% Et2O in hexanes) 
 
 
 
 
 
Methyl ether 28. 
Methyl ether 28 was obtained together with tricycle 21 as a white solid, 14 mg. NMR shows a 21 to 28 molar 
ratio of 1:0.15 (2.0 mg, 5.3 µmol, 12% yield). Elution at 6% Et2O in hexanes. 
An additional run using benzyl xanthate 20 (92 mg) allowed for isolation of fractions with clean 28 after a 
second separation on spherical 20-40 µm particle size silica. 
1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 5.00 (s, 1H), 4.67 (dd, J = 18.1, 6.8 Hz, 2H), 4.06–4.01 (m, 1H), 3.59 
(s, 3H), 3.52 (d, J = 7.9 Hz, 1H), 3.48 (s, 3H), 3.29 (s, 3H), 2.85 (q, J = 7.4 Hz, 1H), 2.71 (d, J = 11.3 Hz, 1H), 2.66 
(s, 1H), 2.36 (dd, J = 11.3, 5.6 Hz, 1H), 1.82 (s, 3H), 1.81 (s, 3H),  1.27 (s, 3H), 1.12 (s, 3H), 1.04 (d, J = 7.4 Hz, 
3H) 
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13C NMR (100 MHz, CDCl3) δ 175.3, 140.8, 137.8, 132.8, 125.1, 96.7, 96.6, 91.5, 60.0, 55.7, 55.4, 54.6, 51.5, 
51.0, 44.8, 40.5, 34.7, 29.9, 29.0, 24.9, 24.2, 15.6 
IR (ATR): 2930 (s), 2851 (w), 2362 (w), 2337 (w), 1733 (s), 1460 (m), 1376 (w), 1198 (w), 1174 (m), 1124 (m), 
1107 (s), 1142 (s), 977 (w), 917 (w) 
HRMS (+APCI): calc. for C22H35O5 [M+H]+   379.2479, found 379.2474 
[𝜶]𝑫
𝟐𝟑 +33.7º (c 0.33, CHCl3) 
RF = 0.27 (20% Et2O in hexanes) 
 
 
 
 
Tetracycle 29. 
Tetracycle 29 was obtained as a colourless oil (1.0 mg, 2.9 µmol, 6% yield). Elution at 5.5% Et2O in hexanes. 
1H NMR (400 MHz, CDCl3) δ 5.33 (s, 1H), 4.62 (q, J = 6.7 Hz, 2H), 3.74 (s, 1H), 3.59 (s, 3H), 3.34 (s, 3H), 2.86 
(d, J = 9.3 Hz, 1H), 2.68 (d, J = 9.3 Hz, 1H), 2.21 (d, J = 8.9 Hz, 2H), 2.01 (q, J = 7.5 Hz, 1H), 1.60 (s, 3H), 1.20 
(d, J = 14.7 Hz, 1H), 1.13 (s, 3H), 1.13 (d, J = 14.8 Hz, 1H), 1.01 (s, 3H), 0.95 (d, J = 7.6 Hz, 3H), 0.87 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 206.9, 175.3, 138.0, 125.7, 94.6, 87.6, 58.5, 55.5, 53.3, 51.7, 51.1, 50.9, 46.9, 
38.18, 37.5, 30.9, 30.4, 26.5, 24.2, 23.5, 13.9 
IR (ATR): 2956 (s), 2924 (s), 1739 (s), 1457 (m), 1374 (m), 1206 (w), 1150 (s), 1097 (m), 1038 (s), 922 (w) 
HRMS (+APCI): calc. for C21H33O4 [M+H]+   349.2373, found 349.2373 
[𝜶]𝑫
𝟐𝟑 +37.1º (c 0.20, CHCl3) 
RF = 0.36 (20% Et2O in hexanes) 
 
 
Tricyclic alcohol S4. 
To a solution of acetal 21 (28.0 mg, 80.3 µmol, 1.00 equiv.) in dry chloroform (0.62 mL) were added 2,6-
lutidine (56 µL, 0.48 mmol, 6.0 equiv.) and TESOTf (68 µL, 0.32 mmol, 4.0 equiv.). After stirring under reflux 
for 4 h, the solution was allowed to cool down and water (0.67 mL) was added. The mixture was heated to 
65 ºC and stirred vigorously for 24 h. 
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The phases were separated and the aqueous layer was extracted three times with DCM. The organic layers 
were combined, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography on silica gel (35% EtOAc/Hexanes) affording alcohol 
S4 (20.0 mg, 65.8 µmol, 82% yield) as a white fluffy solid. 
1H NMR (400 MHz, CDCl3) δ 5.32 (s, 1H), 5.01 (s, 1H), 4.27 (ddd, J = 8.2, 5.1 Hz, 1H), 3.59 (s, 3H), 2.84 (d, J = 
11.4 Hz, 1H), 2.82 (q, J = 7.3 Hz, 1H), 2.56 (s, 1H), 2.47 (dd, J = 11.5, 4.9 Hz, 1H), 2.23 (dd, J = 13.6, 7.6 Hz, 
1H), 1.83 (d, J = 1.5 Hz, 3H), 1.71 (s, 3H), 1.37 (ddd, J = 13.6, 8.8, 1.1 Hz, 1H), 1.14 (s, 3H), 1.12 (s, 3H), 0.92 
(d, J = 7.4 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 174.7, 139.6, 138.3, 134.0, 124.3, 81.7, 57.3, 56.6, 55.2, 52.7, 51.1, 45.2, 40.8, 
34.8, 30.8, 28.7, 25.5, 24.0, 14.7 
IR (ATR): 3517 (m), 2923 (s), 2851 (w), 1709 (s), 1437 (m), 1373 w), 1355 (w), 1238 (w), 1201 (m), 1178 (m), 
1021 (w) 
HRMS (+APCI): calc. for C19H27O2 [M−OH]+   287.2006, found 287.2003 
[𝜶]𝑫
𝟐𝟑 +28.0º (c 1.00, CHCl3) 
Mp: 158-160 ºC 
RF = 0.20 (30% EtOAc in hexanes) 
 
Procedure for Mosher’s ester analysis 
 
 
 
 
 
Mosher’s ester S5. 
To a solution of tricycle S4, (3.5 mg, 12 µmol, 1.0 equiv) and DMAP (4.9 mg, 40 µmol. 3.5 equiv.) in pyridine 
(0.40 mL) was added (R)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (Mosher’s acyl chloride, 
3.0 µL, 12 µmol, 1.0 equiv.). The reaction mixture was stirred for 1.5 h. 
The solvent was evaporated, and the residue was filtered through a pad of silica eluting with 30% 
EtOAc/Hexanes. Ester S5 was obtained as a colourless oil (4.9 mg, 9.4 µmol, 82% yield, d.r. 1:0.02). 
1H NMR (400 MHz, CDCl3) δ 7.52–7.44 (m, 2H), 7.42–7.34 (m, 3H), 5.42 (td, J = 8.4, 4.9 Hz, 1H), 5.36 (s, 1H), 
5.15 (s, 1H), 3.58 (s, 3H), 3.55 (d, J = 0.8 Hz, 3H), 2.89 (q, J = 7.3 Hz, 1H), 2.85 (s, 1H), 2.79 (d, J = 11.6 Hz, 1H), 
2.53 (dd, J = 11.6, 4.8 Hz, 1H), 2.33 (dd, J = 13.8, 7.9 Hz, 1H), 1.82–1.77 (m, 6H), 1.56 (ddd, J = 13.8, 8.8, 1.0 
Hz, 1H), 1.15 (d, J = 2.7 Hz, 6H), 0.94 (d, J = 7.4 Hz, 3H) 
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Tetracyclic alcohol S7. 
The same procedure as for alcohol S4 was followed (see above). 29 (16.2 mg, 46.2 µmol, 1.00 equiv.), TESOTf 
(40 µL, 0.19 mmol, 4.0 equiv.), 2,6-lutidine (32 µL, 0.28 mmol, 6.0 equiv.). Alcohol S7 was obtained as a 
white solid (14.1 mg, 46.3 µmol, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 3.93 (s, 1H), 3.59 (s, 3H), 2.77 (s, 2H), 2.24 (s, 1H), 2.12 (s, 1H), 2.02 
(q, J = 7.6 Hz, 1H), 1.62 (s, 3H), 1.25 (br s, 1H), 1.20 (s, 3H), 1.17 (q, J = 14.7 Hz, 2H), 1.02 (s, 3H), 0.96 (d, J = 
7.6 Hz, 3H), 0.88 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 175.2, 137.9, 125.8, 83.5, 61.5, 55.2, 54.0, 53.2, 51.6, 51.1, 47.0, 38.1, 37.7, 
37.4, 30.4, 26.5, 24.9, 23.5, 13.8 
IR (ATR): 3418 (w, br), 2959 (s), 2922 (s), 2873 (m), 2358 (w), 1724 (s), 1457 (m), 1434 (m), 1374 (m), 1206 
(m), 1158 (m), 1025 (m) 
HRMS (+APCI): calc. for C19H29O3 [M+H]+   305.2111, found 305.2108 
[𝜶]𝑫
𝟐𝟑 +19.1º (c 0.42, CHCl3) 
Mp: 103-104 ºC 
RF = 0.29 (30% EtOAc in hexanes) 
 
 
Tetracyclic diol S8. 
To alcohol S7 (49.2 mg, 0.162 mmol, 1.00 equiv.) dissolved in DCM (2.7 mL) at −78 °C was added dropwise 
a solution of DIBAL (1.5 M in toluene, 0.43 mL, 0.65 mmol, 4.0 equiv.). The mixture was warmed to −50 ºC 
and stirred at the same temperature for 2.5 h.  
The reaction was quenched with saturated aqueous Rochelle’s salt (1.5 mL), then warmed to room 
temperature and stirred for 30 min. The mixture was diluted with water/diethyl ether and extracted three 
times with diethyl ether. The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure to afford pure diol S8 (44.8 mg, 0.162 mmol, quantitative yield) as a white fluffy 
solid. It was used for the next step without further purification. 
1H NMR (400 MHz, CDCl3) δ 5.42 (s, 1H), 3.95 (s, 1H), 3.68 (dt, J = 9.8, 4.6 Hz, 1H), 3.47–3.38 (m, 1H), 2.74 
(d, J = 9.3 Hz, 1H), 2.68 (d, J = 9.3 Hz, 1H), 2.13 (s, 1H), 1.93 (q, J = 7.5 Hz, 1H), 1.56 (s, 3H), 1.45 (br s, 1H), 
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1.33 (dd, J = 7.1, 3.9 Hz, 2H), 1.20 (s, 3H), 1.14 (d, J = 2.2 Hz, 2H), 1.01 (s, 3H), 0.97 (d, J = 7.6 Hz, 3H), 0.88 
(s, 3H) 
13C NMR (100 MHz, CDCl3) δ 137.8, 128.6, 84.3, 65.0, 61.0, 53.1, 53.0, 52.7, 52.3, 47.6, 37.5, 37.4, 37.3, 29.6, 
26.5, 24.9, 23.4, 13.9 
IR (ATR): 3263 (m, br), 2957 (m), 2922 (s), 2868 (m), 1724 (w), 1453 (m), 1371 (w), 1022 (s), 981 (w), 814 (w) 
HRMS (+APCI): calc. for C18H29O2 [M+H]+   277.2162, found 277.2167 
[𝜶]𝑫
𝟐𝟑 −14.1º (c 1.00, CHCl3) 
RF = 0.10 (40% EtOAc in hexanes) 
 
 
 
TBDPS-protected alcohol S9. 
To a solution of diol S8 (45.0 mg, 0.163 mmol, 1.00 equiv.) in DCM (3.3 mL) was added imidazole (22.7 mg, 
0.334 mmol, 2.05 equiv.) followed by TBDPSCl (63 µL, 0.24 mmol, 1.5 equiv.). The resulting mixture was 
stirred at room temperature for 20 min after which an aqueous saturated NaHCO3 solution (4.0 mL) was 
added. The mixture was vigorously stirred for 5 min, after which the aqueous phase was separated and 
extracted three times with DCM. The organic layers were combined, dried over MgSO4 and concentrated 
under reduced pressure yielding a colourless oil, 113 mg. 
Purification by flash column chromatography on silica gel (EtOAc/Hexanes, gradient, 0 to 20%) yielded 95 
mg of a colourless oil containing alcohol S9 (62.4 mg, 0.121 mmol, 74% yield). Despite our efforts, separation 
of product from TBDPSOH was not possible by either flash chromatography or HPLC.  
1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 6.9 Hz, 4H), 7.47–7.34 (m, 6H), 5.21 (s, 1H), 3.87 (s, 1H), 3.73 (dd, J 
= 10.0, 4.2 Hz, 1H), 3.29 (t, J = 9.8 Hz, 1H), 2.80 (d, J = 9.3 Hz, 1H), 2.47 (d, J = 9.3 Hz, 1H), 1.89 (q, J = 7.6 Hz, 
1H), 1.43 (s, 3H), 1.37 (dd, J = 9.7, 4.3 Hz, 1H),1.16 (s, 3H), 1.10–1.00 (m, 12H), 0.93 (d, J = 7.6 Hz, 3H), 0.85 
(s, 3H), 0.78 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 136.8, 135.7, 134.9, 134.2, 134.1, 129.5, 128.2, 127.6, 127.6, 84.5, 65.5, 61.0, 
52.9, 52.7, 52.5, 52.2, 47.5, 37.4, 37.2, 29.5, 27.0, 26.6, 24.9, 23.3, 19.3, 13.9 
IR (ATR): 3392 (w, br), 2958 (m), 2928 (m), 2857 (m), 2361 (s), 2340 (m), 1472 (w), 1428 (m), 1111 (s), 1061 
(m), 822 (m), 739 (m) 
HRMS (+ESI): calc. for C34H47O2Si [M+H]+   515.3340, found 515.3360 
[𝜶]𝑫
𝟐𝟑 +6.9º (c 1.00, CHCl3) 
RF = 0.29 (10% Et2O in hexanes) 
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Tricyclic ketone 22. 
Alcohol S4 (38.0 mg, 0.125 mmol, 1.00 equiv.) was dissolved in DCM (2.6 mL) and NaHCO3 (52.4 mg, 0.624 
mmol, 5.00 equiv.) was added followed by 1 small drop of t-BuOH. Dess Martin periodinane (132 mg, 0.312 
mmol, 2.50 equiv.) was added and the reaction mixture was stirred at room temperature for 90 min. 
A 1:1 solution of saturated aqueous Na2S2O3/NaHCO3 (3.5 mL each) was added and the result was vigorously 
stirred for 15 min, after which the mixture was diluted with water and DCM. The phases were separated, 
and the aqueous layer was extracted three times with DCM. The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure yielding a slightly yellow solid, 51 mg. 
Purification by flash column chromatography on silica gel (Et2O/Hexanes, gradient, 0 to 20%) allowed for 
isolation of ketone 22 as a white crystalline solid (37.8 mg, 0.125 mmol, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 5.37 (s, 1H), 4.92 (s, 1H), 3.60 (s, 3H), 3.07 (s, 1H), 3.04 (q, J = 7.3 Hz, 1H), 2.97 
(d, J = 11.8 Hz, 1H), 2.82 (d, J = 11.8 Hz, 1H), 2.36 (d, J = 17.2 Hz, 1H), 2.08 (dd, J = 17.2, 0.9 Hz, 1H), 1.88 (d, 
J = 1.5 Hz, 3H), 1.58 (s, 3H), 1.26 (s, 3H), 1.17 (s, 3H), 0.91 (d, J = 7.4 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 216.4, 173.1, 137.7, 137.5, 124.9, 55.8, 52.7, 51.3, 50.0, 49.3, 48.0, 41.6, 34.4, 
28.9, 27.7, 24.7, 24.2, 14.6 
IR (ATR): 2923 (m), 2851 (w), 1733 (s), 1459 (m), 1234 (m), 1174 (m), 1019 (w) 
HRMS (+APCI): calc. for C19H27O3 [M+H]+   303.1955, found 303.1955 
[𝜶]𝑫
𝟐𝟑 +97.3º (c 0.53, CHCl3) 
Mp: 110-112 ºC 
RF = 0.40 (20% EtOAc in hexanes) 
 
Tetracyclic ketone 30. 
The same procedure as for ketone 22 (see above) was followed: S7 (11.9 mg, 39.1 µmol, 1.00 equiv), NaHCO3 
(16.4 mg, 0.195 mmol, 5.00 equiv.), Dess Martin periodinane (41.4 mg, 98.5 µmol, 2.50 equiv.). Ketone 30 
was obtained as a white crystalline solid (11.8 mg, 39.0 µmol, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 5.40 (s, 1H), 3.61 (s, 3H), 3.03 (dd, J = 10.1, 2.0 Hz, 1H), 2.80 (d, J = 10.1 Hz, 1H), 
2.44 (s, 1H), 2.41 (s, 1H), 2.39 (q, J = 7.5 Hz, 1H), 1.65 (s, 3H), 1.39 (d, J = 15.3 Hz, 1H), 1.27 (d, J = 16.0 Hz, 
1H), 1.12 (s, 6H), 1.02 (d, J = 7.5 Hz, 3H), 0.96 (s, 3H) 
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13C NMR (100 MHz, CDCl3) δ 173.8, 137.6, 125.7, 62.2, 53.7, 53.1, 51.6, 51.5, 50.2, 40.6, 39.9, 38.7, 37.7, 
30.2, 26.0, 23.9, 23.3, 14.0 
IR (ATR): 2960 (m), 2923 (m), 2851 (m), 2357 (W), 1743 (m), 1454 (w), 1376 (w), 1106 (s), 814 (m) 
HRMS (+APCI): calc. for C19H27O3 [M+H]+   303.1955, found 303.1947 
[𝜶]𝑫
𝟐𝟑 +76.7º (c 0.3, CHCl3) 
RF = (20% Et2O in hexanes) 
Mp: 147-150 ºC 
 
 
Tetracyclic ketone 32. 
The same procedure as for ketone 22 (see above) was followed. S9 (81.1 mg, 0.158 mmol, 1.00 equiv.), 
NaHCO3 (66.2 mg, 0.788 mmol, 5.00 equiv.), Dess Martin periodinane (167 mg, 0.393 mmol, 2.50 equiv.). 
Purification by flash column chromatography on silica gel (Et2O/Hexanes, gradient, 0 to 30%) yielded ketone 
32 as a colourless oil (81.0 mg, 0.158 mmol, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 7.66 (td, J = 7.5, 1.8 Hz, 4H), 7.44–7.35 (m, 6H), 5.29 (s, 1H), 3.74 (dd, J = 9.9, 
4.7 Hz, 1H), 3.35 (t, J = 9.8 Hz, 1H), 3.16 (dd, J = 10.2, 2.1 Hz, 1H), 2.45 (d, J = 10.2 Hz, 1H), 2.40 (br s, 1H), 
2.26 (q, J = 7.5 Hz, 1H), 1.68 (dd, J = 9.8, 4.7 Hz, 1H), 1.48 (d, J = 1.5 Hz, 3H), 1.25 (d, J = 14.6 Hz, 1H), 1.19 (d, 
J = 14.3 Hz, 1H), 1.07 (s, 12H), 0.99 (d, J = 7.6 Hz, 3H), 0.94 (s, 3H), 0.82 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 175.2, 136.1, 135.8, 135.6, 134.0, 133.8, 129.5, 129.5, 128.1, 127.6, 127.6, 64.0, 
62.1, 52.3, 52.2, 50.8, 49.8, 40.4, 39.2, 37.7, 37.7, 29.1, 27.0, 26.1, 23.9, 23.1, 19.2, 14.1 
IR (ATR): 2957 (m), 2928 (s), 2856 (m), 2360 (m), 2340 (w), 1724 (s), 1455 (m), 1428 (w), 1112 (s), 1087 (s), 
823 (w) 
HRMS (+APCI): calc. for C34H45O2Si [M+H]+   513.3183, found 513.3179 
[𝜶]𝑫
𝟐𝟑 +47.6º (c 0.6, CHCl3) 
RF = 0.36 (20% Et2O in hexanes) 
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Enol triflate S10. 
A flame-dried vial charged with ketone 22 (15.0 mg, 49.6 µmol, 1.00 equiv.) and dry THF (1.4 mL) was cooled 
to −78 ºC. To the stirred mixture was added a solution of KHMDS (1.2 M in toluene, 46 µL, 55 µmol, 1.1 
equiv.) in a dropwise manner. The reaction was stirred at the same temperature for 35 min after which a 
solution of Comins' reagent (25.3 mg, 64.5 µmol, 1.3 equiv.) in THF (0.40 mL) was added dropwise.  
After stirring for 60 min at −78 ºC, diethyl ether (0.7 mL) was added to the reaction mixture followed by an 
aqueous saturated solution of NH4Cl (1.2 mL). Upon warming to room temperature, the mixture was 
extracted three times with diethyl ether and the combined extracts were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure yielding a yellow oil, 48 mg. 
Purification by flash column chromatography on silica gel, (EtOAc/Hexanes, 0%, then 4%) afforded enol 
triflate S10 as a colourless oil (12.0 mg, 39.7 µmol, 80% yield). 
1H NMR (400 MHz, CDCl3) δ 5.38 (s, 2H), 5.06 (s, 1H), 3.61 (s, 3H), 3.19 (d, J = 9.8 Hz, 1H), 2.97 (q, J = 7.3 Hz, 
1H), 2.81 (d, J = 9.8 Hz, 1H), 2.63 (s, 1H), 1.83 (s, 3H), 1.47 (s, 3H), 1.31 (s, 3H), 1.12 (s, 3H), 0.94 (d, J = 7.5 
Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 173.9, 149.5, 138.7, 137.1, 132.1, 125.5, 120.0, 118.4 (q, J = 320.2 Hz), 57.3, 
52.2, 51.5, 51.4, 46.4, 40.4, 37.3, 29.0, 27.5, 24.9, 24.1, 15.0 
IR (ATR): 2925 (m), 2361 (m), 2340 (m), 1736 (m), 1423 (m), 1214 (s), 1142 (m), 827 (w) 
HRMS (+APCI): calc. for C20H26F3O5S [M+H]+   435.1448, found 435.1453 
[𝜶]𝑫
𝟐𝟑 +17.1º (c 0.5, CHCl3) 
RF = 0.59 (10% Et2O in hexanes) 
 
Enol triflate 33. 
To ketone 32 (18.5 mg, 36.1 µmol, 1.00 equiv.) and 2.6-di-tertbutyl-4-methylpyridine (14.8 mg, 72.2 µmol, 
2.0 equiv.) dissolved in DCM (0.95 mL) at −78 ºC was added Tf2O (11.5 µL, 68.5 µmol, 1.90 equiv.) and the 
mixture was stirred at −78º C for 45 min, then warmed to −30 ºC and stirred for 1 h. 
A saturated aqueous solution of NaHCO3 was added and the cold solution was warmed to room 
temperature. The phases were separated, and the aqueous phase was extracted twice with diethyl ether. 
The organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. 
Crude product was a yellow oil, 39 mg. 
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Purification by flash column chromatography on silica gel (EtOAc/Hexanes, 0%, then 0.5%) allowed for 
isolation of enol triflate 33 as a colourless oil, (16.0 mg, 24.8 µmol, 69% yield). 
1H NMR (400 MHz, CDCl3) δ 7.63 (ddd, J = 9.4, 7.8, 1.7 Hz, 4H), 7.40 (dd, J = 11.0, 7.0 Hz, 6H), 5.33 (d, J = 1.9 
Hz, 1H), 5.27 (s, 1H), 4.99 (s, 1H), 3.66 (dd, J = 9.9, 4.6 Hz, 1H), 3.34 (d, J = 10.1 Hz, 1H), 3.19 (t, J = 9.9 Hz, 
1H), 2.89 (q, J = 7.6 Hz, 1H), 2.55 (d, J = 10.1 Hz, 1H), 1.90 (dd, J = 10.1, 4.6 Hz, 1H), 1.67 (d, J = 1.7 Hz, 3H), 
1.45 (s, 3H), 1.28 (s, 3H), 1.04 (s, 9H), 0.92 (d, J = 7.7 Hz, 3H), 0.91 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 151.4, 136.8, 135.9, 135.6, 135.6, 133.9, 133.5, 129.6, 129.5, 127.9, 127.6, 
116.6, 62.9, 56.6, 51.6, 49.0, 44.4, 39.6, 37.4, 34.7, 31.6, 26.8, 22.7, 19.1, 15.0, 14.1, 11.4 
IR (ATR): 2956 (m), 2930 (m), 2856 (m), 2359 (w), 1565 (w), 1640 (s), 1423 (m), 1249 (w), 1432 (m), 1212 
(s), 1143 (m), 1112 (m), 835 (m) 
HRMS (+ESI): calc. for C35H44F3O4SSi [M+H]+   645.2676, found 645.2670 
[𝜶]𝑫
𝟐𝟑 +8.6º (c 0.47, CHCl3) 
RF = 0.70 (5% Et2O in hexanes) 
 
 
Triene ester S11. 
To a solution of triflate S10 (4.0 mg, 8.3 µmol, 1.0 equiv.) in THF (0.35 mL) at 0 ºC was added Pd(PPh3)4 (1.9 
mg, 1.7 µmol, 0.20 equiv.) and the mixture was stirred for 30 min at the same temperature. Then, a solution 
of dimethylzinc (1.2 M in toluene, 17.3 μL, 20.7 µmol, 2.50 equiv.) was added at 0 ºC, and the reaction was 
stirred at room temperature for 20 h. 
The reaction mixture was quenched with water (0.8 mL) and extracted four times with diethyl ether. The 
combined extracts were dried over MgSO4 yielding a brown residue, 5 mg, which was purified by flash 
column chromatography on silica gel (Et2O/Hexanes, 0%, then 0.5%, then 1% then 2%) affording triene S11 
as a slightly yellow solid (2.0 mg, 6.7 µmol, 80% yield). 
1H NMR (400 MHz, CDCl3) δ 5.35 (s, 1H), 5.04 (s, 1H), 4.91 (s, 1H), 3.59 (s, 3H), 2.86 (q, J = 7.4 Hz, 1H), 2.80 
(d, J = 9.6 Hz, 1H), 2.69 (d, J = 9.6 Hz, 1H), 2.44 (s, 1H), 1.82 (d, J = 1.5 Hz, 3H), 1.70 (s, 3H), 1.42 (s, 3H), 1.22 
(s, 3H), 1.08 (s, 3H), 0.91 (d, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 175.3, 141.0, 139.4, 139.0, 131.6, 129.0, 124.6, 60.8, 55.7, 53.2, 52.1, 51.0, 
40.4, 37.3, 29.7, 29.1, 27.8, 24.9, 24.2, 15.3, 14.6 
IR (ATR): 2961 (m), 2926 (s), 2854 (m), 2361 (s), 2340 (m), 1738 (s), 1434 (m), 1375 (w), 1170 (m), 1147 (s), 
1015 (w), 841 (m) 
HRMS (+APCI): calc. for C20H29O2 [M+H]+   301.2162, found 301.2168 
[𝜶]𝑫
𝟐𝟑 +40.4º (c 0.2, CHCl3) 
RF = 0.53 (10% Et2O in hexanes) 
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Triene TBDPS-alcohol S12. 
Tricycle S12 was synthesized following the same procedure as for triene S11 (see above). 33 (15.0 mg, 20.9 
µmol, 1.00 equiv.), Pd(PPh3)4 (4.8 mg, 4.2 µmol, 0.20 equiv.), dimethylzinc (1.2 M in toluene, 47 μL, 57 µmol, 
2.5 equiv). Purification by flash column chromatography on silica gel (Et2O/Hexanes, 0%, then 1%) afforded 
tricycle S12 as a colourless oil, (6.0 mg, 12 µmol, 56% yield). 
1H NMR (400 MHz, CDCl3) δ 7.70–7.60 (m, 4H), 7.44–7.34 (m, 6H), 5.20 (s, 1H), 4.99 (s, 1H), 4.84 (s, 1H), 3.69 
(dd, J = 9.7, 4.5 Hz, 1H), 3.21 (t, J = 9.8 Hz, 1H), 3.01 (d, J = 9.8 Hz, 1H), 2.77 (q, J = 7.6 Hz, 1H), 2.49 (d, J = 9.9 
Hz, 1H), 1.74 (s, 3H), 1.71 (dd, J = 10.2, 4.4 Hz, 1H), 1.66 (s, 3H), 1.40 (s, 3H), 1.20 (s, 3H), 1.05 (s, 9H), 0.92–
0.87 (m, 6H) 
13C NMR (100 MHz, CDCl3) δ 143.2, 138.1, 137.4, 135.6, 134.1, 133.2, 129.5, 127.6, 127.1, 126.8, 64.1, 59.8, 
55.3, 50.3, 49.5, 39.8, 37.4, 28.4, 27.6, 26.9, 24.8, 24.1, 19.2, 15.3, 14.8 
IR (ATR): 2958 (m), 2927 (m), 2855 (m), 1428 (w), 1105 (s), 1055 (m), 821 (m), 777 (s), 757 (m) 
[𝜶]𝑫
𝟐𝟑 +12.0º (c 0.25, CHCl3) 
HRMS (+ESI): calc. for C35H46OSi [M+H]+   511.3391, found 511.3395 
RF = 0.26 (1% Et2O in hexanes) 
 
 
 
Triene alcohol 23. 
Ester S11 (5.0 mg, 16.6 µmol, 1.00 equiv.) was dissolved in DCM (0.80 mL) and cooled to −78 °C. A solution 
of DIBAL (1.2M in toluene, 55 µL, 66 µmol 4.0 equiv.) was added dropwise and the resulting mixture was 
stirred for 1.5 h. 
The reaction was quenched with a saturated aqueous solution of Rochelle’s salt (0.5 mL), then warmed to 
room temperature and stirred for 30 min. The mixture was diluted with water/DCM and extracted three 
times with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. Purification by flash column chromatography on silica gel (5% EtOAc/Hexanes) afforded 
alcohol 23 (4.0 mg, 15 µmol, 88% yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 5.45 (s, 1H), 5.00 (s, 1H), 4.87 (s, 1H), 3.62–349 (m, 2H), 2.84–274 (m, 1H), 2.64 
(d, J = 9.7 Hz, 1H), 1.75 (s, 3H), 1.70 (s, 3H), 1.44 (br s, 1H), 1.40 (s, 3H), 1.25 (br s, 1H),  1.21 (s, 3H), 1.12 (s, 
3H), 0.90 (d, J = 7.5 Hz, 3H) 
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13C NMR (100 MHz, CDCl3) δ 142.5, 140.1, 137.6, 132.8, 127.7, 127.5, 65.4, 60.0, 55.7, 51.4, 49.8, 39.7, 37.2, 
28.5, 27.7, 24.9, 24.1, 15.3, 14.6 
IR (ATR): 3286 (m, br), 2958 (s), 2919 (s), 2850 (m), 1728 (w, br), 1657 (w), 1455 (m), 1441 (m), 1033 (s), 
1005 (s), 840 (s) 
HRMS (+APCI): calc. for C19H29O [M+H]+   273.2213, found 273.2219 
[𝜶]𝑫
𝟐𝟑 +8.5º (c 0.30, CHCl3) 
RF = 0.35 (10% Et2O in hexanes) 
 
 
Triene alcohol 23. 
To a solution of silyl ether S12 (10.0 mg, 19.6 µmol, 1.00 equiv.) in dry THF (0.76 mL) were added 4 Å 
molecular sieves followed by a solution of TBAF (1 M in THF, 35 µL, 35 µmol 1.8 equiv.). The mixture was 
stirred at room temperature for 3 h, after which additional TBAF (1 M, 10 µL, 10 µmol 0.50 equiv.) was 
added, and the reaction was further stirred for 1 h.  
The mixture was filtered through a pad of silica, eluting with 25% EtOAc in hexanes. A colourless oil, 9 mg, 
was obtained and submitted to flash column chromatography on silica gel (EtOAc/Hexanes, 2%, then 3% 
then 3.75%) affording alcohol 23 as a colourless gum (4.5 mg, 16.5 µmol, 85% yield). 
 
 
 
 
L-Proline was acylated following the procedure by Budiša et al. [347] 
N-acetyl-L-proline (13). 
L-Proline (500 mg, 4.34 mmol, 1.00 equiv.) was stirred in DCM (9.0 mL) and acetic anhydride (0.41 mL, 4.3 
mmol, 1.0 equiv.) until a clear solution was obtained (30 min). DCM was removed under reduced pressure 
and the residue was dissolved in water (4.5 mL) and freeze-dried. The resulting solid contained approx. 1/10 
of unreacted proline, therefore it was dissolved in water (5.6 mL) and filtered through a short ion-exchange 
column (Dowex® 50WX8, 50-100 mesh). Acidic fractions were collected and freeze-dried to give N-acetyl-L-
proline (S13) as a white solid (620 mg, 3.95 mmol, 91% yield). 
1H NMR (400 MHz, CDCl3) δ 4.60 (dd, J = 8.0, 2.5 Hz, 1H), 3.59 (ddd, J = 10.6, 7.4, 3.4 Hz, 1H), 3.52–3.43 (m, 
1H), 2.56–2.48 (m, 1H), 2.17 (s, 3H), 2.13–1.90 (m, 3H) 
13C NMR (100 MHz, CDCl3) δ 173.4, 171.2, 60.2, 48.8, 27.1, 24.8, 22.1 
HRMS (+ESI): calc. for C7H12NO3 [M+H]+   158.0812, found 158.0815 
[𝜶]𝑫
𝟐𝟕 –177.0º (c 0.51, CHCl3) 
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Weinreb amide 24 was synthesized following the procedure by Stallforth et al.[98] 
Weinreb amide 24. 
N-acetyl proline (S13) (1.11 g, 7.09 mmol, 1.00 equiv.) was dissolved in DCM (20.6 mL) and cooled down to 
0 ºC. To the solution was added EDC (1.60 g, 8.36 mmol, 1.18 equiv.) followed by DIPEA (2.40 mL, 13.9 mmol, 
1.96 equiv.). The mixture was stirred for 15 min at 0 ºC and then N,O-dimethylhydroxylamine hydrochloride 
(691 mg, 7.09 mmol, 1.00 equiv.) was added. The resulting mixture was further stirred for 1 h at 0 ºC and 
another 2 h at room temperature. 
Water was added, the aqueous phase was extracted with DCM and the combined organic layers were dried 
over sodium Na2SO3. The solvent was evaporated, and the crude product purified by flash column 
chromatography on silica gel (5% MeOH/DCM) affording amide 24 as a slightly yellow oil (857 mg, 4.28 
mmol, 60% yield). 
1H NMR (400 MHz, CDCl3) δ 4.96–4.86 (m, 1H), 3.83 (s, 3H), 3.70 (ddd, J = 9.9, 7.4, 4.9 Hz, 1H), 3.52 (dt, J = 
9.7, 7.0 Hz, 1H), 3.20 (s, 3H), 2.21–2.11 (m, 2H), 2.09 (s, 3H), 2.02–1.86 (m, 2H) 
13C NMR (100 MHz, CDCl3) δ 172.5, 169.3, 61.2, 58.3, 56.1, 48.0, 29.1, 24.7, 22.3 
HRMS (+ESI): calc. for C9H17N2O3 [M+H]+   201.1234, found 201.1237 
[𝜶]𝑫
𝟐𝟕 –22.0º (c 0.43, CHCl3) 
 
 
S14 was synthesized following the procedure by Stallforth et al.[98] 
Pyrrolizidine dione S14. 
A solution of LiHMDS (1 M in THF, 3.60 mmol, 3.60 mL, 2.00 equiv.) diluted in dry THF (17.7 mL) at –78 ºC 
was added over 0.5 h to a solution of S14 (360 mg, 1.80 mmol) in THF (21 mL). 
After 2 h the reaction was allowed to warm to –30 ºC and acidified with 1M HCl. The aqueous phase was 
extracted with DCM, dried over Na2SO4 and concentrated under reduced pressure. A slightly yellow gum 
230 mg containing S14 was obtained. 
Due to thermal instability it was directly used for the next step. 
1H NMR (400 MHz, CDCl3) δ 4.31–4.23 (m, 1H), 3.88 (dt, J = 11.6, 7.9 Hz, 1H), 3.45 (dd, J = 21.6, 2.0, Hz, 1H), 
3.31–3.22 (m, 1H), 3.10 (dd, J = 21.6, 1.5 Hz, 1H), 2.20–2.05 (m, 3H), 1.72–1.62 (m, 1H) 
IR (ATR): 2890 (w), 2579 (br), 1765 (m), 1688 (s), 1586 (s), 1369 (s), 1308 (s), 1258 (m), 1222 (m), 1074 (w), 
809 (m), 750 (s) 
[𝜶]𝑫
𝟐𝟒 –61.3º (c 0.1, CHCl3) 
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The synthesis of phosphonate ester 25 was accomplished by a modification of the procedure by Yoshii et 
al.[348] 
Phosphonate ester 25. 
To a solution of pyrrolizidinedione S14 (230 mg, 1.65 mmol, 1.00 equiv.), DMAP (263 mg, 2.15 mmol, 1.30 
equiv.) and DCC (375 mg, 1.82 equiv.) in DCM (11.3 mL) at room temperature was added dropwise diethyl 
phosphonacetic acid (292 µL, 1.82 mmol, 1.10 equiv). The reaction mixture was stirred at room temperature 
for 18 h. 
The suspension was filtered, and the solvents evaporated to yield a brown gum which was purified by flash 
column chromatography on silica gel (MeOH/DCM, gradient, 0 to 6%). The obtained fractions were washed 
with a saturated aqueous solution of NH4Cl followed by a 1M aqueous solution of HCl. Phosphonate ester 
25 was obtained as an orange gum (300 mg, 0.946 mmol, 53% yield from 24), which turned solid upon 
standing for 2 days. 
1H NMR spectrum showed broaden peaks, most likely caused by an increased isomer exchange rate in the 
presence of residual water. By using chloroform stored over 4Å mol. sieves, both isomers could be 
distinguished. 
1H NMR (400 MHz, CDCl3, * denotes minor isomer) δ 4.17 (app quintet, J = 7.2 Hz,  4H+4H*), 3.99 (dd, J = 
10.4 Hz, 6.7 1H), 3.89 (dd, J = 23.0 Hz, 13.6, 1H*), 3.78–3.67 (m, 1H+1H*), 3.61 (d, J = 23.4 Hz, 1H*), 3.57 (d, 
J = 23.8 Hz, 1H), 3.51 (d, J = 23.4, 1H), 3.48 (d, J = 23.1, 1H*), 3.29 (ddd, J = 11.9, 9.0, 3.8 Hz, 1H), 3.21 (ddd, 
J = 8.4, 4.4, 3.7 Hz, 1H*), 2.25–2.02 (m, 3H+3H*), 1.60–1.47 (m, 1H+1H*), 1.32 (t, J = 7.1 Hz, 6H+6H*) 
13C NMR (100 MHz, CDCl3) δ 194.2, 177.7 (d, J = 9.4 Hz), 176.0, 104.1 (d, J = 6.6 Hz), 69.0, 62.8 (d, J = 6.2 Hz), 
62.8 (d, J = 6.1 Hz), 42.8, 31.6 (d, J = 130.3 Hz), 26.6 (d, J = 20.7 Hz), 16.2 (d, J = 6.4 Hz) 
IR (ATR): 3399 (w, br), 2977 (w), 2926 (w), 1672 (m), 1609 (s), 1544 (m), 1441 (s), 1231 (s), 1033 (s), 968 (s), 
753 (m) 
HRMS (+APCI): calc. for C13H21NO6P [M+H]+   318.1101, found 318.1099 
[𝜶]𝑫
𝟐𝟑 –19.5º (c 0.53, CHCl3) 
 
 
Tricyclic aldehyde S15. 
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To alcohol 23 (4.0 mg, 15 µmol, 1.0 equiv.) dissolved in DCM (1.6 mL) were added NaHCO3 (6.2 mg, 73 µmol, 
5.0 equiv.), 1 small drop of t-BuOH and Dess Martin periodinane (15.6 mg, 37.0 µmol, 2.50 equiv.). The 
mixture was stirred for 60 min at room temperature. 
A 1:1 mixture of saturated aqueous Na2S2O3/NaHCO3 (0.5 mL each) was added. The resulting mixture was 
stirred for 20 min at room temperature, the layers were separated and the aqueous phase was extracted 
three times with DCM. 3.2 mg of a colourless oil containing aldehyde S15 were obtained. Given its instability 
it was immediately used for the next step. 
1H NMR (400 MHz, CDCl3) δ 9.49 (d, J = 4.5 Hz, 1H), 5.49 (s, 1H), 5.07 (s, 1H), 4.88 (s, 1H), 2.89–2.81 (m, 2H), 
2.69 (d, J = 9.6 Hz, 1H), 2.22–2.17 (m, 1H), 1.80 (d, J = 1.5 Hz, 3H), 1.68 (s, 3H), 1.44 (d, J = 0.7 Hz, 3H), 1.23 
(s, 3H), 1.18 (s, 3H), 0.92 (d, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 205.4, 140.2, 140.1, 139.7, 131.0, 129.1, 126.4, 61.0, 60.8, 55.5, 49.2, 39.6, 
37.1, 28.4, 27.7, 24.8, 24.2, 15.3, 14.4 
IR (ATR): 2957 (m), 2922 (s), 2851 (m), 2366 (w), 1719 (m), 1457 (w), 1019 (w) 
HRMS (+APCI): calc. for C19H27O [M+H]+   271.2056, found 271.2058 
[𝜶]𝑫
𝟐𝟑 +10.6º (c 0.26, CHCl3) 
RF = 0.68 (10% Et2O in hexanes) 
 
(–)-PF-1018.  
To phosphonate 25 (9.4 mg, 30 µmol, 2.5 equiv.) dissolved in THF (0.50 mL) at 0 ºC was added LiOt-Bu (4.7 
mg, 59 µmol, 5.0 equiv.). The reaction was stirred at 0 ºC for 30 min after which a solution of aldehyde S15 
(3.2 mg, 12 µmol, 1.0 equiv.) in THF (0.16 mL) was added dropwise. The reaction mixture was allowed to 
warm to room temperature and stirred for 26 h. 
To the resulting suspension was added an aqueous saturated solution of NH4Cl followed by DCM. The phases 
were separated, and the aqueous layer was extracted five times with DCM. The organic layers were 
combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting yellow gum, 
5.2 mg, was submitted to flash column chromatography on spherical 20-40 µm particle size, 60Å pore size 
silica (MeOH/DCM, 0.1%, then 0.2% then 0.5%). (−)-PF-1018 was obtained as a slightly yellow solid, (2.4 mg, 
5.5 µmol, 47% yield from alcohol 23). 1H NMR shows two isomers in ratio 4:1. 
1H NMR (400 MHz, CDCl3, * denotes minor isomer) δ 13.72 (br, 1H+1H*) 7.12 (d, J = 15.7 Hz, 1H*), 7.04 (dd, 
J = 15.6, 10.1 Hz,1H*), 7.01–6.98 (m, 2H), 5.37 (s, 1H+1H*) 5.03 (s, 1H+1H*), 4.91 (s, 1H+1H*), 4.05 (dd, J = 
9.9, 6.9 Hz, 1H*), 3.96 (dd, J = 10.0, 6.9 Hz, 1H), 3.78 (ddd, J = 11.6, 7.9, 7.9, 1H*) 3.76 (ddd, J = 11.4, 7.9, 7.9 
1H), 3.27 (ddd, J = 11.2, 9.2, 3.8 Hz, 1H), 3.24-3.18 (m, 1H*),  2.83 (q, J = 7.3 Hz, 1H+1H*),  2.63 (d, J = 9.7 
Hz, 1H+1H*), 2.51 (d, J = 9.6 Hz, 1H+1H*), 2.43 (d, J = 10.0 Hz, 1H*), 2.43–2.38 (m, 1H) 2.00–2.23 (m, 3H + 
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3H*) 1.82 (br, s, 3H+3H*), 1.73 (br, s, 3H+3H*), 1.48-1.67 (m, 1H + 1H*), 1.43 (br, s, 3H+3H*) 1.22 (br, s, 
3H+3H*), 0.95 (br, s, 3H+3H*), 0.92 (d, J = 7.5 Hz, 3H+3H*) 
13C NMR (100 MHz, CDCl3, * denotes minor isomer) δ 203.8, 195.0, 177.6, 175.7*, 174.3, 155.7*, 154.7, 
140.7, 140.7*, 139.5*, 139.4, 139.0, 139.0*, 132.1, 132.0*, 128.6, 126.4, 120.1, 119.6*, 103.7*, 101.3, 68.7, 
66.4*, 60.8*, 60.8, 55.3, 55.3*, 54.3, 54.2*, 53.5*, 53.3, 43.3*, 43.1, 41.1, 37.4, 29.8 (q), 29.7* (q), 27.7, 
27.1*, 27.0*, 26.9, 24.8, 24.7*, 24.2, 15.3, 14.6, 14.6* 
IR (ATR): 2959 (m), 2922 (s), 2852 (m), 1706 (m), 1640 (s), 1578 (s), 1432 (m) 
HRMS (+APCI): calc. for C28H36NO3 [M+H]+ 434.2690, found 434.2686 
[𝜶]𝑫
𝟐𝟑 −76.6º (c 0.04, CHCl3) 
RF = 0.30 (4% MeOH in DCM) 
 
 
 
 
 
Pyreudione C. 
To a solution of phosphonate 25 (12.4 mg, 39.0 µmol, 1.50 equiv.) in THF (0.9 mL) at 0 ºC was added LiOt-
Bu (6.2 mg, 78 µmol, 3.0 equiv.). The orange suspension was stirred at 0 ºC for 30 min after which octanal 
(4.0 µL, 26 µmol, 1.0 equiv.) in THF (0.18 mL) was added dropwise. The reaction was stirred at room 
temperature for 2.5 h. 
A saturated aqueous solution of NH4Cl (0.5 mL) was added and all solvents were evaporated under reduced 
pressure. To the remaining residue was added acetone (1.0 mL) and the resulting suspension was stirred 
for 20 min at room temperature. The mixture was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure and submitted to HPLC purification (H2O/ACN, gradient, 66 to 100%) 
yielding pyreudione C (5.4 mg, 18 µmol, 71% yield) as yellow oil, 1H NMR shows two isomers in ratio 1:0.22. 
1H NMR (400 MHz, CDCl3, * denotes minor isomer) δ 7.25–7.07 (m, 2H+2H*), 4.06 (dd, J = 9.9, 6.8 Hz, 1H*), 
3.96 (dd, J = 10.1, 6.8 Hz, 1H), 3.75 (dt, J = 11.3, 8.2 Hz, 1H+1H*), 3.27 (ddd, J = 11.9, 8.8, 4.0 Hz, 1H), 3.22 
(ddd, 11.7, 8.6, 4.0 Hz, 1H*), 2.32 (app. q, J = 7.1 Hz, 2H+2H*), 2.24–2.00 (m, 3H+3H*), 1.60–1.44 (m, 
3H+3H*), 1.37–1.19 (m, 8H+8H*), 0.88 (t, J = 6.7 Hz, 3H+3H*) 
13C NMR (100 MHz, CDCl3, * denotes minor isomer) δ 203.9*, 195.1, 177.5, 175.6*, 174.3, 170.7*, 152.1*, 
151.2, 121.3, 120.8*, 103.6*, 101.2, 68.7, 66.4*, 43.4*, 43.1, 33.5*, 33.3, 31.7, 29.7*, 29.2, 29.0, 28.2, 28.1*, 
27.1*, 27.0*, 26.9, 26.8, 22.6, 14.1 
IR (ATR): 2925 (m), 2854 (w), 1704 (m), 1641 (s), 1575 (s), 1425 (m), 1532 (m), 1352 (m), 1242 (m), 1036 (w), 
982 (w), 944 (w), 881 (w), 771 (w) 
HRMS (+ESI): calc. for C17H26NO3 [M+H]+ 292.1907, found 292.1910 
[𝜶]𝑫
𝟐𝟕 −24.2º (c 0.33, CHCl3); [𝜶]𝑫
𝟐𝟒 –29.6º (c 0.42, MeOH) 
RF = 0.21 (1% MeOH in DCM) 
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8.4.2 Comparison of Natural and Synthetic (−)-PF-1018 and Pyreudione C 
 
NMR signals from natural PF-1018.[93] 
 
 
Proton Major Isomer Minor Isomer 
 Natural  Synthetic Natural Synthetic 
2 5.03 (br, s) 5.03 (br, s) 5.03 (br, s) 5.03 (br, s) 
3a 2.50 (br, d, 9.7) 2.51 (br, d, 9.6) 2.50 (br, d, 9.7) 2.51 (br, d, 9.6) 
4 2.41 (m) 2.38–2.43 (m) 2.43 (br, d, 10.1) 2.43 (br, d, 10.1) 
6 5.37 (br, s) 5.37 (br, s) 5.37 (br, s) 5.37 (br, s) 
7a 2.62 (d, 9.7) 2.63 (d, 9.7) 2.62 (d, 9.7) 2.63 (d, 9.7) 
8 4.91 (br, s) 4.91 (br, s) 4.91 (br, s) 4.91 (br, s) 
10 2.83 (br, q, 7.5) 2.83 (br, q, 7.3) 2.83 (br, q, 7.5) 2.83 (br, q, 7.3) 
11 1.22 (br, s) 1.22 (br, s) 1.22 (br, s) 1.22 (br, s) 
12 1.73 (br, s) 1.73 (br, s) 1.72 (br, s) 1.73 (br, s) 
13 0.95 (br, s) 0.95 (br, s) 0.95 (br, s) 0.95 (br, s) 
14 1.82 (br, d, 1.5) 1.82 (br, s) 1.83 (br, d, 1.5) 1.82 (br, s) 
15 1.43 (br, d, 0.8) 1.44 (br, s) 1.43 (br, d, 0.8) 1.44 (br, s) 
16 0.92 (d, 7.5) 0.92 (d, 7.5) 0.92 (d, 7.4) 0.92 (d, 7.5) 
17 7.01 (m) 7.01–6.98 (m) 7.04 (dd, 15.6, 10.1) 7.04 (dd, 15.6, 10.1) 
18 7.00 (m) 7.01–6.98 (m) 7.12 (d, 15.6) 7.12 (d, 15.7) 
19-OH 12.35 (br) 13.72 (br) 12.35 (br) 13.72 (br) 
5’ 
3.27(ddd, 11.5, 8.7, 3.8) 
3.75 (ddd, 11.5, 7.8, 7.8) 
3.27 (ddd, 11.2, 9.2, 3.8) 
3.76 (ddd, 11.4, 7.9, 7.9) 
3.22 (ddd, 11.5, 8.5, 4.1) 
3.79 (ddd, 11.5, 8.0, 8.0) 
3.24–3.18 (m) 
3.78 (ddd, 11.6, 7.9, 7.9) 
6’ 2.04–2.22 (m) 2.00–2.23 (m) 2.04–2.22 (m) 2.00–2.23 (m) 
7’ 
1.55 (dddd, 12.1, 10.3, 
10.3, 8.2) 
1.48–1.67 (m)  
1.55 (dddd, 12.1, 10.3, 
10.0, 8.2) 
1.48–1.67 (m)  
7’a 3.96 (dd, 10.3, 6.9) 3.96 (dd, 10.0, 6.9) 4.06 (dd, 10.0, 6.9) 4.05 (dd, 9.9, 6.9) 
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a Interchangeable according to the isolation paper   b Indistinguishable from noise 
 
NMR signals from natural PF-1018.[93] 
 
 
 
Carbon Major Isomer Minor Isomer 
 Natural Synthetic Natural Synthetic 
1 60.8 60.8 60.8 60.8 
2 128.6 128.6 128.6 128.6 
3 140.7 140.7 140.6 140.7 
3a 54.4 54.3 54.3 54.2 
4 53.3 53.3 53.5 53.5 
5 41.1 41.1 41.1 41.1 
6 126.4 126.4 126.4 126.4 
7 138.9 139.0 138.9 138.9 
7a 55.3 55.3 55.3 55.3 
8 132.1 132.1 132.0 132.0 
9 139.4 139.4 139.4 139.5 
10 37.4 37.4 37.4 37.4 
11 27.6 27.7 27.6 27.7 
12 14.6 14.6 14.6 14.6 
13 29.8 29.8 29.7 29.7 
14 24.1 24.2 24.1 24.2 
15 24.8 24.8 24.8 24.7 
16 15.3 15.3 15.3 15.3 
17 154.7 154.7 155.6 155.7 
18 120.1 120.1 119.6 119.6 
19 174.3 174.3 175.7 175.7 
2’ 101.3 101.3 103.7 103.7 
3’ 177.6 177.6 170.8 b 
5’ 43.1 43.1 43.3 43.3 
6’ 26.8a 26.9 27.1a 27.1 
7’ 26.8a 26.9 27.0a 27.0 
7’a 68.7 68.7 66.4 66.4 
1’ 195.0 195.0 203.7 203.8 
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*The 0.02 ppm deviation is owed to the different reference taken (Stallforth δ CHCl3 = 7.24, Trauner δ CHCl3 = 7.26) 
 
NMR signals from natural pyreudione C.[98] 
 
 
Proton Major Isomer Minor Isomer 
 Natural Synthetic Natural Synthetic 
5 
3.25 (ddd, 11.5, 8.9, 4.0) 
3.73 (dt, 11.5, 7.9) 
3.27 (ddd, 11.9, 8.8, 4.0) 
3.75 (dt, 11.3, 8.2) 
3.20 (ddd, 11.6, 8.8, 4.2) 
3.76 (dt, 11.4, 7.9) 
3.22 (ddd, 11.7, 8.6, 4.0) 
3.75 (dt, 11.3, 8.2) 
6 2.05 (m), 2.14 (m) 2.24–2.00 (m) 
1.60–1.44 (m) 
2.05 (m), 2.14 (m) 2.24–2.00 (m) 
1.60–1.44 (m) 7 1.52 (m), 2.14 (m) 1.52 (m), 2.14 (m) 
7a 3.94 (dd, 10.0, 6.9) 3.96 (dd, 10.1, 6.8) 4.04 (dd, 9.9, 7.0) 4.06 (dd, 9.9, 6.8) 
2’ 7.08 (dt, 15.7, 1.3) 
7.25–7.07 (m) 
7.19 
7.25–7.07 (m) 
3’ 7.18 (dt, 15.8, 7.0) 7.20 
4’ 2.30 (m) 2.32 (app q, 7.1) 2.30 (m) 2.32 (app q, 7.1) 
5’ 1.48 (m) 1.60–1.44 (m) 1.48 (m) 1.60–1.44 (m) 
6’ 1.30 (m) 
1.37–1.19 (m) 
1.30 (m) 
1.37–1.19 (m) 
7’ 1.27 (m) 1.27 (m) 
8’ 1.27 (m) 1.27 (m) 
9’ 1.27 (m) 1.27 (m) 
10’ 0.86 (t, 7.1) 0.88 (t, 6.7) 0.86 (t, 7.1) 0.88 (t, 6.7) 
Carbon Major Isomer Minor Isomer 
 Natural Synthetic Natural Synthetic 
1 195.1 195.1 203.8 203.9 
2 101.2 101.2 101.2 103.6 
3 177.5 177.5 170.7 170.7 
5 43.1 43.1 43.4 43.4 
6 26.9 26.9 27.1 27.1 
7 26.8 26.8 27.0 27.0 
7a 68.7 68.7 66.4 66.4 
1’ 174.3 174.3 175.6 175.6 
2’ 121.3 121.3 120.8 120.8 
3’ 151.1 151.2 152.1 152.1 
4’ 33.3 33.3 33.4 33.5 
5’ 28.2 28.2 28.1 28.1 
6’ 29.2 29.2 29.7 29.7 
7’ 29.0 29.0 29.0 29.0 
8’ 31.7 31.7 31.7 31.7 
9’ 22.6 22.6 22.6 22.6 
10’ 14.0 14.1 14.0 14.1 
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8.4.3 Potential Products from Cascade Reaction 16 to 18 
 
Figure S1. Potential products that could arise from cascade reaction 16 → 18. 
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8.4.4 Crystallographic Data 
8.4.4.1 Cascade Product 18 
 
 
 
net formula C27H46O5Si 
Mr/g mol−1 478.73 
crystal size/mm 0.090 × 0.060 × 0.050 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21 1' 
a/Å 9.6241(3) 
b/Å 12.7646(4) 
c/Å 11.3130(4) 
α/° 90 
β/° 95.6180(10) 
γ/° 90 
V/Å3 1383.10(8) 
Z 2 
calc. density/g cm−3 1.150 
μ/mm−1 0.117 
absorption correction Multi-Scan 
transmission factor range 0.8915–0.9705 
refls. measured 10273 
Rint 0.0272 
mean σ(I)/I 0.0561 
θ range 3.192–27.472 
observed refls. 5200 
x, y (weighting scheme) 0.0253, 0.4855 
hydrogen refinement constr 
  
  
  
  
  
  
  
  
  
  
Flack parameter 0.12(7) 
refls in refinement 6052 
parameters 310 
restraints 1 
R(Fobs) 0.0443 
Rw(F2) 0.0916 
S 1.055 
shift/errormax 0.001 
max electron density/e Å−3 0.296 
min electron density/e Å−3 −0.280 
150 
 
8.4.4.2 Tricycle 22 
 
 
 
 
 
 
Identification code 18dtr9h 
Chemical formula C19H26O3 
Formula weight 302.40 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.160 x 0.190 x 0.530 mm 
Crystal habit colorless rod 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 8.7775(10) Å 
 b = 7.8110(9) Å 
 c = 12.1927(14) Å 
 α = 90° 
 β = 99.3488(15)° 
 γ = 90° 
Volume 824.84(16) Å3 
Z 2 
Density (calculated) 1.218 g/cm3 
Absorption coefficient 0.081 mm-1 
F(000) 328 
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, Mo 
Theta range for data collection 1.69 to 28.28° 
Index ranges -11<=h<=11, -10<=k<=10, -16<=l<=16 
Reflections collected 11424 
Independent reflections 4102 [R(int) = 0.0245] 
Cov. of independent reflections 99.8% 
Absorption correction multi-scan 
Max. and min. transmission 0.7457 and 0.6166 
Structure solution technique direct methods 
Structure solution program SHELXT (Sheldrick 2015) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018/3 (Sheldrick, 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4102 / 1 / 205 
Goodness-of-fit on F2 1.061 
Final R indices 3765 data; I>2σ(I)   R1 = 0.0412, wR2 = 0.1026 
 all data                    R1 = 0.0456, wR2 = 0.1054 
Weighting scheme w=1/[σ2(Fo2)+(0.0698P)2+0.0163P] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.6(4) 
Largest diff. peak and hole 0.285 and -0.167 eÅ-3 
R.M.S. deviation from mean 0.046 eÅ-3 
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8.4.4.3 Tetracycle 30  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification code 18dtr10h 
Chemical formula C19H26O3 
Formula weight 302.40 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.160 x 0.540 x 0.560 mm 
Crystal habit colorless plate 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 8.7382(6) Å 
 b = 8.1682(6) Å 
 c = 11.6148(8) Å 
 α = 90° 
 β = 99.9432(10)° 
 γ = 90° 
Volume 816.56(10) Å3 
Z 2 
Density (calculated) 1.230 g/cm3 
Absorption coefficient 0.081 mm-1 
F(000) 328 
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, Mo 
Theta range for data collection 1.78 to 28.29° 
Index ranges -11<=h<=11, -10<=k<=10, -15<=l<=15 
Reflections collected 12719 
Independent reflections 4033 [R(int) = 0.0226] 
Cov. of independent reflections 100.0% 
Absorption correction multi-scan 
Max. and min. transmission 0.7457 and 0.6835 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014 (Sheldrick 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4033 / 1 / 205 
Goodness-of-fit on F2 1.037 
Final R indices 3883 data; I>2σ(I) R1 = 0.0366, wR2 = 0.0958 
 all data                  R1 = 0.0380, wR2 = 0.0971 
Weighting scheme w=1/[σ2(Fo2)+(0.0631P)2+0.0998P] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.4(3) 
Largest diff. peak and hole 0.259 and -0.183 eÅ-3 
R.M.S. deviation from mean 0.041 eÅ-3 
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8.4.5 Computational Studies 
Initial conformational searches were completed using the CREST conformer-rotamer ensemble sampling 
tool,[349,350] version 2.7.1 with xtb version 6.2 RC2 (SAW190805).[351–353] These inital conformer geometries 
were recalculated in Gaussian 16 Rev. A.03 (sse4)[354] with at the SMD(DMF)-ωB97X-D/6-311+G(d,p)[355–360] 
level of theory. This functional was chosen for its ability to reproduce CCSD geometries of asynchronous 
Diels–Alder reactions as well as its ability to accurately reproduce experimental reaction barriers.[361] 
Following Head-Gordon’s suggested basis set for energetics,[359] single point energies at the SMD(DMF)-
ωB97X-D/def2-QZVPP level of theory were computed.[362–364] Thermochemistry was calculated using the 
program GoodVibes version 3.0.1,[365] using quasiharmonic approximations to entropy[366] and enthalpy[367] 
and corrected for 398.15 K. All reported energies are quasiharmonic corrected. All reported structures are 
stationary points on the energy surface and characterized as transition states or minima by frequency 
calculations.  
 
Figure S2. Calculated TS-1 and TS-2 shown in two alternate angles. Hs on protecting groups are omitted 
for clarity. Silicon is shown in wheat colour. 
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Figure S3. Calculated cascade energy surface starting from 16 and leading to 18. 
 
Figure S4. Calculated cascade energy surface starting from 16-TMS and leading to 18-TMS. 
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Figure S5. (A) barriers for Diels–Alder and 6-  electrocyclization for OTBS, OTMS, and H substituent at the 
2 position. (B) biomimetic reaction model for competing Diels–Alder and 6-π electrocyclization. 
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Cartesian coordinates 
 
16-TBS.out 
ZPE                   0.686264 
DE                    0.728321 
DH                    0.729265 
DG                    0.610870 
E                 -1722.146990 
H                 -1721.417726 
G                 -1721.536120 
 
Cartesian coordinates 
 
C       -0.989261    0.190021   -2.866645 
C       -4.482147   -1.181718   -1.787092 
C       -2.225246   -0.629351   -2.649815 
C       -3.324300   -0.236090   -1.992309 
C       -3.953464    3.010275    0.078977 
C       -3.443521    1.151854   -1.486073 
C       -3.851648    1.549610   -0.273446 
C       -3.949182   -1.066574    2.586948 
C       -4.216451    0.623167    0.823026 
C       -3.380637   -0.173462    1.515643 
C       -1.942279   -0.155939    1.215940 
C       -0.994784   -2.059469    2.647323 
C       -0.934594   -0.910353    1.674514 
C        0.468027   -0.650650    1.151193 
C        0.994610   -1.843992    0.324550 
C        2.381614   -1.527291   -0.146525 
C        3.484866   -1.946533    0.467960 
C        4.841744   -1.492262    0.108111 
H       -0.440733   -0.154175   -3.747543 
H       -1.208591    1.253762   -2.995335 
H       -0.325942    0.088523   -2.001174 
H       -5.421386   -0.723361   -2.113981 
H       -4.333902   -2.105077   -2.351937 
H       -4.605233   -1.444529   -0.732622 
H       -2.192102   -1.656002   -3.010052 
H       -4.963113    3.255311    0.427523 
H       -3.267571    3.250252    0.899317 
H       -3.714134    3.650212   -0.773574 
H       -3.152132    1.934876   -2.185529 
H       -3.737262   -2.118603    2.374842 
H       -3.526519   -0.839248    3.569618 
H       -5.032499   -0.944222    2.648220 
H       -5.267490    0.635090    1.111602 
H       -1.650991    0.593136    0.487634 
H       -0.003976   -2.253565    3.067780 
H       -1.670539   -1.871979    3.478884 
H       -1.317299   -2.978595    2.148086 
H        2.445287   -0.855772   -0.996865 
H        3.441452   -2.605823    1.329018 
O        5.832210   -1.777081    0.747369 
O        4.872941   -0.715977   -0.981217 
C        6.149057   -0.181093   -1.345483 
H        5.971995    0.417018   -2.236792 
H        6.543047    0.446230   -0.544045 
H        6.855410   -0.983255   -1.565088 
H        1.001096   -2.727582    0.970415 
H        1.133559   -0.593270    2.027424 
O        0.573450    0.512612    0.371292 
O        0.147250   -2.052582   -0.793628 
C       -0.071770   -3.394009   -1.126978 
H       -0.470189   -3.379819   -2.147738 
H        0.858437   -3.970311   -1.089176 
O       -0.959931   -4.040378   -0.257947 
C       -2.293203   -3.563728   -0.368958 
H       -2.354047   -2.497275   -0.136834 
H       -2.680554   -3.734209   -1.381290 
H       -2.896057   -4.128588    0.342828 
Si        1.271162    1.936697    0.935135 
C        0.364395    2.484418    2.476616 
H       -0.695720    2.661035    2.271187 
H        0.434445    1.720141    3.258049 
H        0.795027    3.408247    2.876802 
C        3.077765    1.636662    1.324258 
H        3.195886    0.837932    2.063753 
H        3.640056    1.354859    0.429007 
H        3.531232    2.542556    1.740460 
C        1.059326    3.160364   -0.487565 
C        1.705829    4.501333   -0.107503 
H        2.781330    4.399081    0.072327 
H        1.575534    5.226067   -0.921509 
H        1.252879    4.932814    0.791642 
C        1.740596    2.610532   -1.750042 
H        2.817767    2.477925   -1.602712 
H        1.321728    1.646237   -2.050039 
H        1.605599    3.309439   -2.585896 
C       -0.437640    3.375179   -0.756995 
H       -0.949761    2.433784   -0.971058 
H       -0.936217    3.840965    0.099033 
H       -0.577660    4.037853   -1.621285 
 
16-TMS.out 
ZPE                   0.600600 
DE                    0.638975 
DH                    0.639919 
DG                    0.528669 
E                 -1604.208888 
H                 -1603.568969 
G                 -1603.680219 
 
Cartesian coordinates 
 
C       -0.840755   -0.327794    2.943558 
C       -4.156793    1.369473    1.768905 
C       -1.976304    0.607418    2.663217 
C       -3.117432    0.305909    2.028301 
C       -4.149145   -2.963822    0.164642 
C       -3.405171   -1.086040    1.606919 
C       -3.882539   -1.504266    0.426020 
C       -3.743141    0.945973   -2.579361 
C       -4.166373   -0.611588   -0.721588 
C       -3.263429    0.069617   -1.452961 
C       -1.837516   -0.057077   -1.130553 
C       -0.660626    1.542118   -2.751159 
C       -0.746470    0.520461   -1.649168 
C        0.608478    0.151875   -1.064242 
C        1.302232    1.363957   -0.408834 
C        2.655417    0.944008    0.082069 
C        3.781812    1.137331   -0.599753 
C        5.094603    0.606192   -0.184353 
H       -0.342893   -0.065533    3.881667 
H       -1.161932   -1.370612    3.005253 
8.4.5.1 Cartesian Coordinates of Calculated Structures 
Energies reported below are at the B97X-D/6-311+G(d,p) level of theory. Frequencies for transition states given as F. 
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H       -0.102755   -0.257304    2.137104 
H       -5.141064    1.044586    2.122359 
H       -3.895718    2.298379    2.281424 
H       -4.256968    1.586946    0.702119 
H       -1.823058    1.644170    2.958490 
H       -5.175877   -3.114861   -0.186854 
H       -3.486080   -3.333498   -0.626105 
H       -3.995581   -3.570526    1.060097 
H       -3.191904   -1.856210    2.347315 
H       -3.368505    0.601948   -3.547478 
H       -4.834341    0.949265   -2.621986 
H       -3.403269    1.977196   -2.445431 
H       -5.213988   -0.552719   -1.016683 
H       -1.636192   -0.742173   -0.315965 
H       -1.393276    1.377613   -3.537907 
H       -0.805081    2.552633   -2.354954 
H        0.330647    1.517653   -3.213669 
H        2.665910    0.402765    1.022595 
H        3.788890    1.668220   -1.546437 
O        6.097329    0.706967   -0.859235 
O        5.071957   -0.008224    1.003417 
C        6.305546   -0.582912    1.445839 
H        6.088960   -1.032983    2.412293 
H        6.646074   -1.345791    0.743801 
H        7.072411    0.185988    1.552678 
H        1.398162    2.151954   -1.162344 
H        1.257843   -0.135049   -1.907277 
O        0.540980   -0.874914   -0.111734 
O        0.523015    1.815081    0.688468 
C        0.427774    3.205619    0.817645 
H        0.081808    3.380694    1.842724 
H        1.397364    3.687651    0.655770 
O       -0.450123    3.787507   -0.105307 
C       -1.808323    3.442186    0.126826 
H       -1.957620    2.361686    0.063249 
H       -2.132703    3.794813    1.114273 
H       -2.401639    3.939391   -0.641212 
Si        0.903429   -2.488532   -0.402455 
C        2.761725   -2.663858   -0.516564 
H        3.159575   -2.062099   -1.340914 
H        3.247051   -2.331286    0.406381 
H        3.047881   -3.705910   -0.695568 
C        0.182883   -3.389109    1.060069 
H       -0.898383   -3.220096    1.111735 
H        0.354001   -4.467532    0.976732 
H        0.628875   -3.047323    1.998730 
C        0.093894   -3.031729   -1.997623 
H       -0.996619   -2.978569   -1.920390 
H        0.406581   -2.403647   -2.838352 
H        0.368058   -4.065368   -2.234876 
 
17-TBS.out 
ZPE                   0.689975 
DE                    0.730508 
DH                    0.731452 
DG                    0.616971 
E                 -1722.151182 
H                 -1721.419730 
G                 -1721.534211 
 
Cartesian coordinates 
 
C        1.611618   -3.174854   -0.393728 
C        1.822441   -1.285300   -2.677509 
C        2.358812   -1.853424   -0.163730 
C        2.754174   -1.216550   -1.493406 
C        6.364898   -1.174327   -1.030369 
C        3.979804   -0.702648   -1.668426 
C        5.027568   -0.600437   -0.644131 
C        4.057413    2.149054    1.475919 
C        4.837295   -0.008148    0.544024 
C        3.665662    0.763228    1.005840 
C        2.376669    0.406992    1.071896 
C        1.655456   -1.579140    2.241275 
C        1.643622   -0.901788    0.850025 
C        0.182392   -0.581450    0.328220 
C       -0.961541   -1.391704    0.972963 
C       -2.199000   -1.193091    0.144213 
C       -2.542669   -1.983567   -0.869965 
H        2.200615   -3.822202   -1.049540 
H        1.461191   -3.710307    0.545663 
H        0.634307   -3.038452   -0.863912 
H        0.905263   -0.711431   -2.520924 
H        1.517474   -2.313738   -2.890431 
H        2.308876   -0.884213   -3.569185 
H        3.298260   -2.117351    0.328638 
H        6.719160   -0.723120   -1.963787 
H        7.116964   -1.005256   -0.256641 
H        6.285931   -2.251956   -1.210353 
H        4.271279   -0.381538   -2.668555 
H        3.192732    2.712069    1.835473 
H        4.794711    2.093145    2.284893 
H        4.523618    2.715461    0.661747 
H        5.698386    0.055566    1.210443 
H        1.716870    1.164200    1.481904 
H        1.267848   -0.904584    3.005194 
H        1.062224   -2.495124    2.277445 
H        2.688176   -1.834153    2.497251 
H       -2.777114   -0.300635    0.360545 
H       -1.969523   -2.870417   -1.121793 
C       -3.654764   -1.683147   -1.787639 
H       -0.691665   -2.454247    0.978177 
H        0.157643   -0.869645   -0.724384 
O       -0.171637    0.774757    0.445711 
Si       -0.373617    1.923637   -0.755358 
C       -1.166314    3.354836    0.191232 
C       -0.192272    3.858625    1.267320 
H        0.074058    3.063221    1.970592 
H        0.733984    4.244850    0.829028 
H       -0.650821    4.674195    1.841882 
C       -1.499272    4.499822   -0.775888 
H       -0.603631    4.883115   -1.276840 
H       -2.208494    4.185071   -1.549035 
H       -1.955485    5.336688   -0.231305 
C       -2.454652    2.859016    0.866438 
H       -2.248898    2.035734    1.557493 
H       -2.922236    3.672975    1.435973 
H       -3.188673    2.507390    0.133153 
C        1.270637    2.407558   -1.506569 
H        1.953830    2.820672   -0.759285 
H        1.760014    1.543109   -1.966740 
H        1.119646    3.161095   -2.287467 
C       -1.496999    1.286661   -2.112413 
H       -1.141613    0.331182   -2.511760 
H       -2.523287    1.144255   -1.763380 
H       -1.513900    2.003688   -2.940414 
O       -1.155879   -0.934642    2.299437 
C       -1.851478   -1.818906    3.128943 
H       -1.476628   -2.841854    3.015149 
H       -1.681030   -1.458515    4.150047 
O       -3.224738   -1.882596    2.853254 
C       -3.909807   -0.676009    3.142626 
H       -3.791023   -0.403822    4.199335 
H       -3.551742    0.152160    2.521856 
H       -4.965606   -0.848626    2.933143 
O       -3.860989   -2.294334   -2.815314 
O       -4.411370   -0.652248   -1.388601 
C       -5.451962   -0.243242   -2.280386 
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H       -6.170230   -1.050499   -2.432634 
H       -5.936202    0.602595   -1.796896 
H       -5.034093    0.062464   -3.241290 
 
17-biomimetic.out 
ZPE                   0.435464 
DE                    0.459884 
DH                    0.460828 
DG                    0.382047 
E                  -929.329089 
H                  -928.868261 
G                  -928.947042 
 
Cartesian coordinates 
 
C       -2.909441    1.731959   -1.563751 
C       -0.356961    0.685935   -2.517482 
C       -2.243588    0.636939   -0.721111 
C       -1.174827   -0.091263   -1.517665 
C       -2.440038   -3.484931   -1.354368 
C       -1.023582   -1.419811   -1.431598 
C       -1.832320   -2.327266   -0.605998 
C       -0.807925   -1.989007    2.854076 
C       -2.026026   -2.180110    0.713203 
C       -1.364782   -1.252713    1.653216 
C       -1.203176    0.075096    1.585858 
C       -2.940743    1.754908    1.445692 
C       -1.742523    1.157091    0.667689 
C       -0.739119    2.287456    0.491293 
C        1.351051    3.570754    0.190291 
C        0.601475    2.277595    0.379603 
C        1.377335    1.040411    0.348333 
C        2.692506    0.959021    0.105449 
H       -3.797025    2.127029   -1.067120 
H       -2.235021    2.567624   -1.768914 
H       -3.231097    1.319310   -2.523699 
H       -0.971532    0.966938   -3.379300 
H        0.480439    0.087491   -2.882252 
H        0.035880    1.613185   -2.096056 
H       -3.018002   -0.096255   -0.477958 
H       -1.659895   -4.058980   -1.866296 
H       -2.984132   -4.157746   -0.688139 
H       -3.128148   -3.126862   -2.127776 
H       -0.310452   -1.903954   -2.098812 
H       -0.333505   -1.307649    3.563250 
H       -1.603374   -2.531966    3.376456 
H       -0.068187   -2.733785    2.540576 
H       -2.628878   -2.942132    1.207725 
H       -0.667676    0.513785    2.427425 
H       -2.634463    2.021306    2.461373 
H       -3.326655    2.658724    0.968649 
H       -3.748566    1.020884    1.513892 
H       -1.207482    3.268083    0.429787 
H        2.123695    3.696410    0.955268 
H        1.854785    3.590009   -0.782101 
H        0.675369    4.425816    0.241694 
H        0.844828    0.108345    0.498571 
H        3.317637    1.825255   -0.075656 
C        3.346173   -0.359560    0.055526 
O        2.810494   -1.429711    0.250119 
O        4.651272   -0.240749   -0.245320 
C        5.394625   -1.460195   -0.331410 
H        4.986268   -2.105357   -1.111281 
H        6.412094   -1.167635   -0.582482 
H        5.380269   -1.988043    0.623700 
 
17-TMS.out 
ZPE                   0.605684 
DE                    0.641969 
DH                    0.642913 
DG                    0.537815 
E                 -1604.214691 
H                 -1603.571778 
G                 -1603.676876 
 
Cartesian coordinates 
 
C       -1.086794    0.917664   -2.713454 
C       -1.497498   -1.941638   -2.052262 
C       -1.998001    0.587640   -1.522514 
C       -2.450451   -0.868968   -1.585878 
C       -6.040051   -0.315787   -1.818626 
C       -3.730583   -1.198494   -1.363497 
C       -4.800765   -0.275255   -0.964605 
C       -4.256688    0.395498    2.529476 
C       -4.712133    0.532311    0.102351 
C       -3.665725    0.557521    1.144254 
C       -2.340497    0.709050    1.025497 
C       -1.398657    2.604941   -0.130506 
C       -1.435188    1.058190   -0.139964 
C       -0.012039    0.406757    0.099570 
C        1.196384    1.283029   -0.298012 
C        2.413354    0.407875   -0.398394 
C        2.779518   -0.212355   -1.517708 
H       -1.592095    0.649003   -3.645454 
H       -0.864666    1.985633   -2.758346 
H       -0.138362    0.375327   -2.690902 
H       -0.639341   -2.061090   -1.385660 
H       -1.095314   -1.715790   -3.044083 
H       -2.006496   -2.906397   -2.105865 
H       -2.902857    1.184986   -1.659697 
H       -6.435380   -1.336243   -1.870432 
H       -6.822101    0.339213   -1.428559 
H       -5.811571   -0.012883   -2.846225 
H       -4.043878   -2.225413   -1.551513 
H       -3.490399    0.454283    3.305563 
H       -5.006146    1.170657    2.725603 
H       -4.768532   -0.569255    2.620951 
H       -5.583797    1.144774    0.335920 
H       -1.797298    0.716082    1.964425 
H       -1.087287    2.980815    0.845025 
H       -0.722787    3.023328   -0.878866 
H       -2.404793    2.980013   -0.339310 
H        2.957385    0.237938    0.525141 
H        2.238515   -0.071353   -2.448238 
C        3.871272   -1.198613   -1.584756 
H        0.998929    1.734628   -1.275500 
H        0.045566   -0.453445   -0.570269 
O        0.208320   -0.026441    1.425562 
Si        0.270523   -1.623627    1.944579 
C        0.791346   -1.501742    3.729643 
C       -1.401465   -2.449246    1.794394 
H       -2.150365   -1.963001    2.426373 
H       -1.768678   -2.433096    0.763809 
H       -1.321336   -3.496981    2.106304 
C        1.516918   -2.593673    0.939275 
H        1.280157   -2.576519   -0.129376 
H        2.533335   -2.210729    1.067011 
H        1.505704   -3.640344    1.263986 
O        1.383129    2.299973    0.671220 
C        1.998615    3.459597    0.186639 
H        1.529822    3.790785   -0.746305 
H        1.863611    4.211938    0.972182 
O        3.358191    3.294047   -0.110742 
C        4.163920    3.085485    1.036361 
H        4.071513    3.926154    1.735899 
H        3.896228    2.160256    1.556661 
H        5.196680    3.015676    0.694493 
158 
 
O        4.093173   -1.885626   -2.560025 
O        4.590292   -1.278703   -0.458055 
C        5.620122   -2.271069   -0.429949 
H        6.362818   -2.078890   -1.205923 
H        6.077561   -2.190952    0.553922 
H        5.196140   -3.267400   -0.566847 
H        0.066774   -0.922383    4.310447 
H        0.862302   -2.498172    4.178351 
H        1.768790   -1.018672    3.823500 
 
17-MOM.out 
ZPE                   0.498443 
DE                    0.526626 
DH                    0.527570 
DG                    0.438802 
E                 -1120.286954 
H                 -1119.759384 
G                 -1119.848151 
 
Cartesian coordinates 
 
C        1.368100   -2.211021    2.068964 
C        1.513923   -3.206262   -0.709384 
C        1.994389   -1.300150    1.004379 
C        2.407481   -2.094342   -0.223659 
C        5.997179   -1.506945   -0.188843 
C        3.599303   -1.901022   -0.807143 
C        4.617825   -0.932366   -0.381651 
C        3.531289    2.390069   -1.333298 
C        4.380195    0.374656   -0.188148 
C        3.174094    1.158824   -0.523398 
C        1.884516    0.950456   -0.218374 
C        0.857254    0.720845    1.992352 
C        1.148860   -0.030836    0.677219 
C       -0.183041   -0.427804   -0.017661 
C       -1.342611    0.566144    0.021500 
C       -2.578964   -0.091336   -0.524757 
C       -3.680125   -0.308736    0.189340 
H        2.016508   -3.074167    2.244108 
H        1.264475   -1.685171    3.019665 
H        0.383847   -2.592968    1.786434 
H        0.497393   -2.860134   -0.908746 
H        1.433885   -3.997722    0.042560 
H        1.910594   -3.650331   -1.624865 
H        2.914648   -0.907751    1.445611 
H        5.995235   -2.260567    0.606103 
H        6.331413   -2.011698   -1.101990 
H        6.726016   -0.734519    0.065699 
H        3.897690   -2.571768   -1.613017 
H        4.035150    2.113027   -2.265751 
H        2.647084    2.981896   -1.579923 
H        4.226529    3.027624   -0.775507 
H        5.233580    0.989443    0.099654 
H        1.198913    1.692197   -0.617494 
H        0.451884    1.715816    1.794642 
H        0.134530    0.185747    2.614652 
H        1.781407    0.844159    2.564786 
H       -2.540764   -0.400216   -1.567764 
H       -3.752733   -0.005154    1.228456 
C       -4.857252   -0.978482   -0.403465 
H       -1.529336    0.886622    1.050613 
H        0.011482   -0.681086   -1.064984 
O       -4.946069   -1.381090   -1.541697 
O       -5.847058   -1.088705    0.494730 
C       -7.050285   -1.718081    0.039777 
H       -6.850404   -2.742759   -0.277758 
H       -7.724292   -1.714463    0.893665 
H       -7.487164   -1.156316   -0.787493 
H       -0.567606   -1.333092    0.459340 
O       -1.036386    1.710428   -0.781902 
C       -1.830111    2.836571   -0.504947 
H       -1.699862    3.506247   -1.361763 
H       -2.883239    2.560833   -0.395630 
O       -1.472961    3.478087    0.687048 
C       -0.255243    4.199172    0.597555 
H       -0.086078    4.665971    1.568084 
H        0.590653    3.544333    0.365386 
H       -0.322297    4.980090   -0.170345 
 
17a-TBS.out 
ZPE                   0.690780 
DE                    0.730685 
DH                    0.731629 
DG                    0.619380 
E                 -1722.161976 
H                 -1721.430347 
G                 -1721.542596 
 
Cartesian coordinates 
 
C        0.988455   -2.515901    1.521120 
C       -1.736008   -1.802194    2.453516 
C       -0.130811   -2.417635    0.498644 
C       -1.592880   -2.360314    1.038789 
C       -3.828214   -5.283901   -0.235264 
C       -2.311313   -3.671260    0.920198 
C       -3.138765   -3.956729   -0.091239 
C       -3.283162   -0.676824   -2.128282 
C       -3.422312   -2.944092   -1.122677 
C       -2.891990   -1.713709   -1.117817 
C       -1.928561   -1.298730   -0.042458 
C       -0.066229   -1.429360   -1.892043 
C       -0.405094   -1.169122   -0.427109 
C        0.143536    0.195733    0.057565 
C        1.560004    0.547569   -0.439906 
C        2.638709   -0.433767   -0.092081 
C        3.399701   -1.053890   -0.990078 
C        4.478338   -2.000568   -0.644605 
H       -2.288989   -0.365126    0.390695 
H        1.956770   -2.695577    1.051577 
H        1.069846   -1.624732    2.148780 
H        0.786623   -3.365193    2.182699 
H       -1.349920   -2.501831    3.201722 
H       -1.204718   -0.852795    2.569228 
H       -2.793133   -1.620695    2.673086 
H       -0.054132   -3.282338   -0.168164 
H       -3.568942   -5.961237    0.581375 
H       -4.916433   -5.158343   -0.248182 
H       -3.553666   -5.762808   -1.181680 
H       -2.110269   -4.415542    1.689646 
H       -3.844006   -1.117453   -2.956116 
H       -3.912840    0.086597   -1.659121 
H       -2.410454   -0.154774   -2.527514 
H       -4.129767   -3.216822   -1.903292 
H       -0.261254   -0.554942   -2.518468 
H        0.985554   -1.700667   -2.005566 
H       -0.661116   -2.261011   -2.278885 
H        2.821455   -0.573513    0.967672 
H        3.249385   -0.911861   -2.055200 
H        0.173894    0.195722    1.154316 
H        1.510032    0.691720   -1.525608 
O        5.145662   -2.581099   -1.473954 
O        4.644085   -2.162268    0.672745 
C        5.662847   -3.082505    1.078804 
H        5.448365   -4.083108    0.700058 
H        6.640572   -2.755766    0.721013 
H        5.641910   -3.080649    2.166475 
O       -0.726544    1.217620   -0.394836 
159 
 
O        1.897112    1.780778    0.190873 
C        2.842020    2.524247   -0.524420 
H        2.399891    2.897778   -1.463426 
H        3.729538    1.915682   -0.762627 
O        3.189657    3.587896    0.312261 
C        3.966363    4.552043   -0.371241 
H        3.405965    4.993987   -1.205332 
H        4.214019    5.333341    0.346799 
H        4.895623    4.116345   -0.760047 
Si       -1.034951    2.701285    0.344804 
C       -2.897365    3.055275    0.150459 
C       -0.597434    2.596486    2.160932 
H       -0.867755    3.527670    2.669521 
H       -1.130126    1.778002    2.656370 
H        0.476264    2.438660    2.288060 
C       -0.101789    4.068930   -0.537057 
H        0.058578    3.801949   -1.586512 
H       -0.658696    5.010367   -0.517012 
H        0.873684    4.241053   -0.076955 
C       -3.219708    4.400504    0.825811 
H       -2.650094    5.231917    0.400023 
H       -4.284253    4.634246    0.694379 
H       -3.022238    4.373615    1.902572 
C       -3.761700    1.977282    0.818233 
H       -3.498685    1.835341    1.872041 
H       -4.820052    2.267897    0.779426 
H       -3.672699    1.012489    0.317153 
C       -3.253916    3.149150   -1.340729 
H       -3.008389    2.226874   -1.874893 
H       -4.329667    3.331541   -1.466065 
H       -2.722478    3.972258   -1.830362 
 
17a-TMS.out       
ZPE                   0.604816 
DE                    0.641030 
DH                    0.641975 
DG                    0.536792 
E                 -1604.229942 
H                 -1603.587967 
G                 -1603.693150 
 
Cartesian coordinates 
 
C        0.594756    2.261582    1.489349 
C        2.564870    0.291908    2.476927 
C        1.488299    1.564734    0.477081 
C        2.700869    0.748396    1.026125 
C        6.136441    1.868625   -0.429322 
C        4.012617    1.443570    0.812597 
C        4.841521    1.143632   -0.193924 
C        3.123252   -1.849020   -1.937040 
C        4.513077    0.050041   -1.125334 
C        3.392220   -0.678338   -1.040364 
C        2.372481   -0.389070    0.022562 
C        0.923169    0.693808   -1.887153 
C        1.041021    0.339660   -0.408390 
C       -0.168686   -0.488338    0.075945 
C       -1.557825   -0.035442   -0.407664 
C       -1.959502    1.368034   -0.074497 
C       -2.260613    2.286095   -0.989638 
C       -2.675253    3.666461   -0.670965 
H        2.149311   -1.332478    0.529405 
H       -0.135828    2.911254    1.004969 
H        0.057226    1.563356    2.136019 
H        1.214399    2.894530    2.133398 
H        2.651828    1.132409    3.172846 
H        1.602257   -0.198220    2.652467 
H        3.354960   -0.427951    2.714023 
H        1.872407    2.325325   -0.209774 
H        6.300031    2.649946    0.316096 
H        6.983507    1.174760   -0.394844 
H        6.146610    2.331112   -1.422506 
H        4.263826    2.243924    1.507492 
H        3.836648   -1.894816   -2.763409 
H        3.198098   -2.780486   -1.365321 
H        2.107840   -1.817687   -2.339904 
H        5.246387   -0.183193   -1.894752 
H        0.628684   -0.168507   -2.490955 
H        0.181459    1.482933   -2.035381 
H        1.877837    1.064750   -2.269618 
H       -2.048379    1.597131    0.981989 
H       -2.195477    2.069223   -2.050740 
H       -0.182238   -0.481999    1.172948 
H       -1.595168   -0.191510   -1.491758 
O       -2.935971    4.495558   -1.516488 
O       -2.729298    3.917351    0.641699 
C       -3.114948    5.242728    1.021479 
H       -2.408775    5.975109    0.627227 
H       -4.119242    5.468828    0.659580 
H       -3.097309    5.252210    2.109168 
O       -0.008254   -1.809069   -0.402676 
O       -2.486740   -0.907069    0.236012 
C       -3.602076   -1.194673   -0.557115 
H       -3.302582   -1.804332   -1.426834 
H       -4.083178   -0.269019   -0.915351 
O       -4.472240   -1.912276    0.267113 
C       -5.537837   -2.478509   -0.470521 
H       -5.167783   -3.195547   -1.214794 
H       -6.179469   -2.999233    0.239781 
H       -6.125594   -1.706694   -0.983636 
Si       -0.275722   -3.236693    0.438492 
C        1.232088   -4.300834    0.133422 
C       -0.448406   -2.878913    2.265126 
H       -0.560415   -3.818798    2.816698 
H        0.435226   -2.365281    2.658697 
H       -1.327310   -2.260594    2.467345 
C       -1.782132   -4.121236   -0.225514 
H       -1.775149   -4.138909   -1.320349 
H       -1.786646   -5.160590    0.121970 
H       -2.707432   -3.645493    0.108978 
H        1.389039   -4.469106   -0.936688 
H        2.136281   -3.838801    0.541518 
H        1.107821   -5.279219    0.610814 
 
17a-biomimetic.out 
ZPE                   0.435696 
DE                    0.459619 
DH                    0.460563 
DG                    0.383241 
E                  -929.344254 
H                  -928.883690 
G                  -928.961013 
 
Cartesian coordinates 
 
C        0.135353   -0.388993    2.235216 
C       -2.773943   -0.585569    2.560950 
C       -0.662127   -0.652441    0.968395 
C       -2.219343   -0.604404    1.138384 
C       -4.558411   -2.486835   -1.352145 
C       -2.936562   -1.678102    0.363648 
C       -3.800697   -1.413573   -0.623481 
C       -3.451734    2.408510   -1.108411 
C       -4.024890   -0.025301   -1.066405 
C       -3.298781    1.004407   -0.612529 
C       -2.230703    0.758721    0.408750 
C       -0.678008    0.027056   -1.527871 
C       -0.757727    0.526686   -0.079653 
160 
 
C        0.124076    1.736038    0.094518 
C        2.167585    3.135487    0.236806 
C        1.466735    1.812835    0.074508 
C        2.290674    0.619160   -0.097063 
C        3.629865    0.604105   -0.148857 
H       -2.233351    1.573092    1.142020 
H        1.209964   -0.399167    2.039727 
H       -0.109712    0.579149    2.680566 
H       -0.070831   -1.164600    2.978638 
H       -2.630730   -1.551647    3.056124 
H       -2.299828    0.187147    3.171714 
H       -3.848696   -0.378705    2.531810 
H       -0.310727   -1.580839    0.504925 
H       -4.325783   -3.479162   -0.959822 
H       -5.638550   -2.325534   -1.266988 
H       -4.319312   -2.472570   -2.421323 
H       -2.772116   -2.705059    0.686589 
H       -4.234220    2.491116   -1.866229 
H       -3.688285    3.088659   -0.282681 
H       -2.508680    2.760004   -1.544056 
H       -4.790759    0.141806   -1.820824 
H       -0.952371    0.822158   -2.227746 
H        0.337633   -0.294677   -1.769456 
H       -1.348042   -0.819124   -1.691624 
H       -0.415268    2.673135    0.228459 
H        2.827427    3.127519    1.110425 
H        2.790389    3.361899   -0.634627 
H        1.445790    3.944440    0.360133 
H        1.784568   -0.337052   -0.186020 
H        4.230737    1.502245   -0.070858 
C        4.349868   -0.669335   -0.313834 
O        3.845153   -1.767767   -0.408650 
O        5.678750   -0.471331   -0.346656 
C        6.489739   -1.640262   -0.499950 
H        6.259481   -2.148086   -1.438051 
H        7.518277   -1.285733   -0.508591 
H        6.335959   -2.326776    0.334358 
 
17'-TBS.out 
ZPE                   0.689667 
DE                    0.730075 
DH                    0.731020 
DG                    0.617626 
E                 -1722.152436 
H                 -1721.421417 
G                 -1721.534810 
 
Cartesian coordinates 
 
C        1.524096   -1.411696   -2.558022 
C        2.756948   -2.876649   -0.286563 
C        2.325537   -0.585812   -1.541492 
C        3.194334   -1.480709   -0.653838 
C        6.347974    0.156967   -1.372478 
C        4.430795   -1.088865   -0.316679 
C        5.044596    0.215025   -0.621919 
C        3.654731    2.243110    1.953768 
C        4.512935    1.377285   -0.219711 
C        3.331902    1.547088    0.652104 
C        2.079953    1.155383    0.395622 
C        1.414523    1.717436   -1.900757 
C        1.479481    0.568477   -0.868142 
H        2.202656   -2.053006   -3.127402 
H        1.012905   -0.761961   -3.272249 
H        0.773527   -2.057746   -2.096262 
H        2.371793   -3.424038   -1.150643 
H        3.600041   -3.439961    0.120173 
H        1.975216   -2.880284    0.476923 
H        3.056397   -0.031351   -2.134533 
H        6.201596   -0.282889   -2.365065 
H        7.065200   -0.482307   -0.845953 
H        6.790122    1.148457   -1.493387 
H        5.084226   -1.802072    0.186120 
H        4.355419    1.645144    2.548041 
H        2.756423    2.416760    2.550910 
H        4.139847    3.208601    1.770378 
H        5.068337    2.292060   -0.430713 
H        1.341089    1.380322    1.157179 
H        0.896977    2.582076   -1.486783 
H        0.890958    1.409194   -2.811884 
H        2.427606    2.025892   -2.171404 
C        0.002330    0.155737   -0.586774 
C       -0.203895   -0.989547    0.425706 
O       -0.737334    1.272329   -0.150873 
C       -1.603348   -1.521231    0.310718 
H        0.496921   -1.788275    0.182360 
O        0.034686   -0.505485    1.738741 
Si       -2.138029    1.965430   -0.751887 
C       -1.926521   -2.588777   -0.414843 
H       -2.376019   -0.955847    0.821756 
C        0.067256   -1.491916    2.732561 
C       -3.013022    2.646490    0.783239 
C       -1.718263    3.348512   -1.941287 
C       -3.200901    0.708394   -1.646062 
H       -1.172850   -3.173517   -0.933085 
C       -3.315483   -3.035450   -0.634615 
H        0.043868   -0.944580    3.681480 
H       -0.794572   -2.163883    2.660588 
O        1.197171   -2.314813    2.660333 
C       -2.147338    3.738275    1.429538 
C       -4.370464    3.242317    0.381079 
C       -3.234275    1.515371    1.798038 
H       -1.021738    4.067856   -1.501189 
H       -1.266835    2.955350   -2.857453 
H       -2.628802    3.888245   -2.223663 
H       -3.700310    0.017668   -0.962006 
H       -3.972585    1.235467   -2.217682 
H       -2.612942    0.117917   -2.356465 
O       -3.615300   -3.947223   -1.375708 
O       -4.216844   -2.327330    0.055747 
C        2.407677   -1.627331    2.941145 
H       -1.164183    3.352528    1.717850 
H       -1.992645    4.586841    0.755023 
H       -2.634731    4.121491    2.335698 
H       -4.261283    4.061512   -0.337672 
H       -5.028965    2.488897   -0.064618 
H       -4.882658    3.646121    1.264092 
H       -3.727058    1.906331    2.698020 
H       -3.875458    0.725026    1.391845 
H       -2.285880    1.060337    2.100115 
C       -5.591033   -2.671665   -0.146200 
H        3.217549   -2.350481    2.842056 
H        2.572411   -0.804535    2.239376 
H        2.398459   -1.232995    3.965395 
H       -5.778533   -3.702054    0.160073 
H       -6.159024   -1.985610    0.478548 
H       -5.868065   -2.543483   -1.193881 
H       -0.404205   -0.212366   -1.534340 
 
17'-TMS.out            
ZPE                   0.605174 
DE                    0.641625 
DH                    0.642569 
DG                    0.537132 
E                 -1604.217524 
H                 -1603.574955 
G                 -1603.680392 
 
161 
 
Cartesian coordinates 
 
C        0.950051   -0.223766   -2.775762 
C        2.111334   -2.572778   -1.397627 
C        1.893463    0.053154   -1.596195 
C        2.695555   -1.194500   -1.222276 
C        5.985466    0.296794   -1.544434 
C        3.987229   -1.084578   -0.881984 
C        4.737785    0.170987   -0.711719 
C        3.746113    1.156643    2.567252 
C        4.370627    1.122984    0.156814 
C        3.268086    1.045246    1.137845 
C        1.964746    0.898367    0.878965 
C        1.215520    2.369935   -0.936057 
C        1.221939    0.902290   -0.443529 
H        1.521560   -0.628345   -3.615723 
H        0.471183    0.696196   -3.119524 
H        0.162637   -0.943368   -2.538365 
H        1.667077   -2.701301   -2.388202 
H        2.889106   -3.330226   -1.276607 
H        1.335331   -2.792231   -0.661001 
H        2.651198    0.736333   -1.986554 
H        5.737943    0.301068   -2.611583 
H        6.646017   -0.560994   -1.376550 
H        6.537330    1.210346   -1.311855 
H        4.574422   -1.995750   -0.766095 
H        4.409216    0.320963    2.819194 
H        2.911196    1.159147    3.271874 
H        4.325366    2.075330    2.714476 
H        5.021478    1.991775    0.263652 
H        1.305590    0.880821    1.740101 
H        0.836481    3.037163   -0.162194 
H        0.593895    2.492919   -1.829204 
H        2.235234    2.679157   -1.179110 
C       -0.271690    0.525714   -0.206415 
C       -0.575584   -0.884527    0.330841 
O       -0.886769    1.468937    0.647137 
C       -2.062098   -1.108444    0.268879 
H       -0.077002   -1.607160   -0.317663 
O       -0.112929   -1.010056    1.665344 
Si       -2.204630    2.452523    0.306888 
C       -2.692878   -1.538793   -0.820995 
H       -2.623911   -0.832194    1.156028 
C       -0.156719   -2.312011    2.182718 
C       -1.696860    4.207884    0.694801 
C       -2.687777    2.280788   -1.492158 
H       -2.147642   -1.817451   -1.717557 
C       -4.160816   -1.608984   -0.947059 
H       -0.030084   -2.197727    3.265031 
H       -1.112295   -2.799587    1.962008 
O        0.830541   -3.150517    1.653403 
H       -1.288247    4.282933    1.707745 
H       -0.938827    4.570997   -0.005459 
H       -2.561499    4.877540    0.633022 
H       -3.033396    1.268171   -1.724281 
H       -3.508963    2.971413   -1.713554 
H       -1.857288    2.523954   -2.162500 
O       -4.729507   -1.934301   -1.967377 
O       -4.806946   -1.262286    0.172080 
C        2.144044   -2.773455    2.039004 
C       -6.236787   -1.256898    0.111353 
H        2.832411   -3.469658    1.559553 
H        2.378473   -1.755092    1.715602 
H        2.260486   -2.842508    3.128261 
H       -6.616120   -2.255454   -0.111141 
H       -6.569847   -0.940414    1.097572 
H       -6.585268   -0.553440   -0.646613 
H       -0.751591    0.559064   -1.188199 
C       -3.632046    1.956537    1.407685 
H       -3.315035    1.875403    2.452469 
H       -4.423647    2.712512    1.357295 
H       -4.065483    0.998625    1.104845 
 
18-TBS.out 
ZPE                   0.695861 
DE                    0.733707 
DH                    0.734651 
DG                    0.628868 
E                 -1722.201046 
H                 -1721.466394 
G                 -1721.572178 
 
Cartesian coordinates 
 
C       -1.213997   -3.560059    0.159319 
C       -0.565555   -2.529876   -2.395935 
C       -0.012162   -2.602954    0.137965 
C        0.448079   -2.313302   -1.294541 
C        4.101750   -1.549926   -1.712877 
C        1.654146   -1.854158   -1.654980 
C        2.841968   -1.327268   -0.863390 
C        2.592330   -2.169390    2.925118 
C        3.055941   -1.949672    0.495030 
C        2.333910   -1.609336    1.558328 
C        1.183126   -0.657789    1.389842 
C       -0.866664   -1.777026    2.376250 
C       -0.191015   -1.349620    1.068088 
C       -0.970114   -0.160743    0.449328 
C        0.043184    0.622547   -0.386468 
C        1.400363    0.447376    0.315268 
C        2.555097    0.205632   -0.670423 
C        3.793949    0.952355   -0.228597 
H       -1.400288   -3.925203    1.169679 
H       -2.129216   -3.094326   -0.208707 
H       -1.003856   -4.437602   -0.457293 
H       -0.872303   -3.576321   -2.478556 
H       -0.163510   -2.219527   -3.362632 
H       -1.465120   -1.943362   -2.187946 
H        0.801382   -3.159475    0.609369 
H        4.034122   -1.022025   -2.667540 
H        5.001186   -1.205238   -1.194829 
H        4.221889   -2.617915   -1.917451 
H        1.795708   -1.693833   -2.724250 
H        1.736208   -2.745508    3.289983 
H        3.469282   -2.821108    2.929281 
H        2.756933   -1.359677    3.644660 
H        3.870976   -2.663561    0.590482 
H        1.034368   -0.140968    2.342886 
H       -0.854865   -0.949268    3.091325 
H       -1.906590   -2.061716    2.216248 
H       -0.357977   -2.628730    2.835143 
H        1.634168    1.364101    0.850509 
H        2.285435    0.610083   -1.649682 
O        4.166526    1.097339    0.912185 
O        4.458834    1.464163   -1.276041 
C        5.680623    2.145025   -0.976750 
H        6.393351    1.464878   -0.506449 
H        6.068339    2.490116   -1.933051 
H        5.496759    2.994674   -0.317067 
H        0.061521    0.179758   -1.379928 
O       -0.351800    1.973286   -0.646484 
C       -0.163386    2.910159    0.354905 
H       -0.958457    3.660279    0.255978 
H       -0.217849    2.462624    1.360483 
O        1.095131    3.527137    0.176375 
C        1.439190    4.338639    1.280019 
H        2.400974    4.800681    1.056920 
H        0.695401    5.128732    1.448934 
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H        1.532973    3.742953    2.198489 
H       -1.288955    0.476059    1.288225 
O       -2.077570   -0.536168   -0.331792 
Si       -3.722288   -0.324549   -0.109492 
C       -4.470457   -1.394018   -1.445201 
H       -5.561653   -1.419828   -1.363859 
H       -4.214521   -1.022579   -2.442239 
H       -4.102827   -2.421664   -1.361256 
C       -4.252493   -0.910866    1.587597 
H       -4.127112   -1.993311    1.687512 
H       -3.680032   -0.424780    2.383079 
H       -5.310980   -0.679329    1.748555 
C       -4.237218    1.490210   -0.333252 
C       -3.802311    2.325724    0.880491 
H       -2.723035    2.278747    1.049689 
H       -4.064377    3.380963    0.726927 
H       -4.298428    1.993259    1.798093 
C       -5.768617    1.559588   -0.457043 
H       -6.089977    2.606167   -0.539395 
H       -6.128737    1.034579   -1.347622 
H       -6.274224    1.130165    0.414828 
C       -3.604058    2.067798   -1.606828 
H       -2.512845    2.073356   -1.541015 
H       -3.891747    1.496072   -2.496276 
H       -3.942076    3.101943   -1.758879 
 
18-TMS.out        
ZPE                   0.609918 
DE                    0.644122 
DH                    0.645067 
DG                    0.546177 
E                 -1604.266477 
H                 -1603.621411 
G                 -1603.720301 
 
Cartesian coordinates 
 
C       -2.205980   -3.091403    0.187824 
C       -1.286502   -2.331283   -2.375197 
C       -0.857122   -2.354839    0.182296 
C       -0.295576   -2.224280   -1.237643 
C        3.448074   -2.075688   -1.513847 
C        0.982411   -1.984975   -1.561537 
C        2.206619   -1.607194   -0.741050 
C        1.661214   -2.179795    3.066654 
C        2.260735   -2.175874    0.655934 
C        1.559796   -1.663372    1.662667 
C        0.586935   -0.551780    1.389199 
C       -1.666781   -1.268369    2.325132 
C       -0.866021   -1.038039    1.037736 
C       -1.412974    0.217536    0.322297 
C       -0.263708    0.779051   -0.511909 
C        1.019788    0.440990    0.267698 
C        2.162049   -0.039130   -0.642743 
C        3.486234    0.526521   -0.179510 
H       -2.489903   -3.368659    1.203539 
H       -3.010032   -2.489286   -0.238415 
H       -2.128674   -4.020834   -0.381814 
H       -1.757726   -3.316823   -2.425226 
H       -0.800899   -2.140844   -3.334484 
H       -2.085049   -1.596177   -2.236273 
H       -0.170047   -3.011636    0.721295 
H        3.505466   -1.601174   -2.496800 
H        4.369030   -1.847253   -0.969960 
H        3.403842   -3.159430   -1.656619 
H        1.189705   -1.909595   -2.629543 
H        0.705189   -2.584689    3.413307 
H        2.415224   -2.966213    3.148969 
H        1.927552   -1.368811    3.753562 
H        2.942705   -3.005658    0.827340 
H        0.484743    0.037154    2.305865 
H       -1.535097   -0.420715    3.003935 
H       -2.734010   -1.363665    2.116483 
H       -1.348578   -2.173772    2.848251 
H        1.370315    1.344062    0.762168 
H        2.002130    0.343334   -1.654454 
O        3.832577    0.676846    0.968859 
O        4.264917    0.865379   -1.218915 
C        5.568304    1.359495   -0.898059 
H        6.142870    0.604067   -0.358571 
H        6.043439    1.579735   -1.851875 
H        5.499348    2.266120   -0.294528 
H       -0.273874    0.278223   -1.477268 
O       -0.441545    2.154142   -0.864920 
C       -0.200470    3.106182    0.112123 
H       -0.884841    3.944676   -0.067724 
H       -0.373726    2.716412    1.127852 
O        1.136327    3.551380   -0.000702 
C        1.501491    4.378868    1.084003 
H        2.527546    4.705302    0.913880 
H        0.853902    5.263113    1.154332 
H        1.453440    3.832451    2.036073 
H       -1.640170    0.948061    1.114731 
O       -2.555751   -0.017025   -0.464111 
Si       -4.022532    0.776867   -0.309355 
C       -4.993827    0.213845   -1.796763 
H       -6.002618    0.639519   -1.791700 
H       -4.502330    0.518678   -2.725770 
H       -5.089057   -0.876764   -1.804290 
C       -4.866461    0.263485    1.279406 
H       -5.021657   -0.819414    1.315673 
H       -4.275412    0.553403    2.154103 
H       -5.845423    0.748497    1.363822 
C       -3.752499    2.626600   -0.292757 
H       -3.222477    2.958225   -1.189693 
H       -4.712779    3.151584   -0.242244 
H       -3.163207    2.927575    0.579623 
 
18-biomimetic.out 
ZPE                   0.440461 
DE                    0.462326 
DH                    0.463270 
DG                    0.392605 
E                  -929.375010 
H                  -928.911740 
G                  -928.982405 
 
Cartesian coordinates 
 
C        3.938487    0.037797   -0.889744 
C        2.381380   -2.125059   -1.828777 
C        2.426664    0.194518   -0.682586 
C        1.629880   -0.874373   -1.434082 
C       -1.874899    0.039772   -2.390388 
C        0.316615   -0.846299   -1.694243 
C       -0.800405    0.105243   -1.293674 
C        0.674716    3.382801    0.189650 
C       -0.382224    1.542264   -1.107105 
C        0.240021    1.962541   -0.010438 
C        0.612131    0.965601    1.047235 
C        3.083277    1.033575    1.650425 
C        2.021633    0.280717    0.837233 
C        1.771771   -1.089029    1.418353 
C       -0.095468   -2.642174    2.130728 
C        0.484678   -1.366898    1.611448 
C       -0.401853   -0.191694    1.253519 
C       -1.356878   -0.458721    0.065141 
H        4.470317    0.909211   -0.505537 
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H        4.344633   -0.848920   -0.394524 
H        4.172788   -0.034076   -1.954469 
H        3.199681   -1.920217   -2.524324 
H        1.714225   -2.852755   -2.294781 
H        2.827832   -2.593986   -0.944518 
H        2.165763    1.162866   -1.114904 
H       -2.273820   -0.972351   -2.495572 
H       -2.708068    0.716221   -2.178009 
H       -1.438924    0.338825   -3.348039 
H       -0.081807   -1.724331   -2.203687 
H        1.766483    3.446819    0.259888 
H        0.346156    4.024148   -0.631665 
H        0.274598    3.782309    1.127980 
H       -0.620710    2.237730   -1.908664 
H        0.685288    1.494582    2.001480 
H        2.737742    1.159851    2.680241 
H        4.029285    0.488028    1.684382 
H        3.279805    2.026865    1.235303 
H        2.584361   -1.785795    1.607398 
H       -0.685671   -2.458978    3.035454 
H       -0.772212   -3.095601    1.398451 
H        0.685366   -3.368673    2.366530 
H       -1.030223    0.046527    2.116878 
H       -1.485244   -1.534565   -0.072516 
C       -2.733469    0.099882    0.352413 
O       -2.975799    1.165604    0.868818 
O       -3.697715   -0.746789   -0.042641 
C       -5.044162   -0.288449    0.111572 
H       -5.211336    0.614159   -0.479323 
H       -5.674845   -1.096533   -0.253494 
H       -5.264714   -0.083968    1.160539 
 
18'.out 
ZPE                   0.695653 
DE                    0.733442 
DH                    0.734386 
DG                    0.629042 
E                 -1722.201106 
H                 -1721.466720 
G                 -1721.572064 
 
Cartesian coordinates 
 
C        1.345657   -3.607535    0.398089 
C        0.744383   -2.739398   -2.214834 
C        0.072521   -2.758438    0.288484 
C       -0.313174   -2.475709   -1.166599 
C       -3.861683   -1.471200   -1.841971 
C       -1.467026   -1.939073   -1.585752 
C       -2.687520   -1.396699   -0.850210 
C       -2.685725   -2.866068    2.755091 
C       -3.043040   -2.193392    0.380370 
C       -2.414986   -2.031616    1.540756 
C       -1.326472   -1.004409    1.636290 
C        0.961178   -1.663983    2.429537 
C        0.118857   -1.455277    1.166483 
C        0.641329   -0.219339    0.373968 
C       -0.264637    0.932832    0.784300 
C       -1.656002    0.295458    0.883311 
C       -2.361916    0.106094   -0.479955 
C       -3.626466    0.938059   -0.502797 
H        1.484585   -3.954291    1.422790 
H        2.245846   -3.062320    0.105437 
H        1.267983   -4.497546   -0.230232 
H        0.995513   -3.801308   -2.289744 
H        0.414467   -2.399545   -3.198325 
H        1.672942   -2.213586   -1.967594 
H       -0.722000   -3.376720    0.712116 
H       -3.668211   -0.867973   -2.732745 
H       -4.795227   -1.129502   -1.386247 
H       -4.005732   -2.507860   -2.159014 
H       -1.539867   -1.761887   -2.658823 
H       -1.780625   -3.410200    3.050110 
H       -3.483448   -3.591676    2.579759 
H       -2.964760   -2.235265    3.606158 
H       -3.815005   -2.951797    0.270003 
H       -1.224065   -0.730015    2.689788 
H        0.943210   -0.758930    3.042686 
H        2.003923   -1.881262    2.200102 
H        0.549002   -2.483713    3.026861 
H       -2.307606    0.895955    1.518223 
H       -1.727022    0.495020   -1.277493 
O       -4.467013    0.970398    0.366339 
O       -3.723626    1.656157   -1.630199 
C       -4.911847    2.440401   -1.779821 
H       -5.794532    1.798468   -1.787414 
H       -4.810284    2.949906   -2.735711 
H       -4.995745    3.169054   -0.971813 
O        2.009536    0.024706    0.588130 
Si        3.035328    0.902234   -0.408370 
C        2.348771    0.979729   -2.147672 
C        3.255289    2.621633    0.292295 
C        4.684711   -0.035687   -0.378937 
H        3.092736    1.413518   -2.824726 
H        2.087387   -0.012303   -2.528225 
H        1.452117    1.604509   -2.174927 
H        2.278219    3.088868    0.448368 
H        3.779231    2.593355    1.253543 
H        3.836826    3.252119   -0.388650 
C        5.045858   -0.410071    1.065634 
C        5.790932    0.855117   -0.964991 
C        4.574325   -1.316081   -1.218515 
H        4.290929   -1.068134    1.506715 
H        6.010118   -0.934948    1.092507 
H        5.135091    0.474271    1.706164 
H        6.741193    0.306193   -0.997990 
H        5.561402    1.173487   -1.988147 
H        5.950971    1.754448   -0.361634 
H        3.775232   -1.969704   -0.855214 
H        4.373686   -1.095561   -2.271996 
H        5.512821   -1.884252   -1.171979 
O       -0.137244    1.985283   -0.160084 
C       -0.757157    3.171566    0.197115 
H       -0.754668    3.809102   -0.695251 
H       -1.797180    3.009004    0.524880 
O       -0.033905    3.782058    1.240551 
C       -0.688439    4.936512    1.725130 
H       -0.066958    5.354176    2.517183 
H       -0.812025    5.688839    0.935014 
H       -1.676838    4.691919    2.136158 
H        0.034757    1.294708    1.774403 
H        0.468702   -0.377276   -0.694568 
 
18'-TMS.out             
ZPE                   0.610070 
DE                    0.644291 
DH                    0.645235 
DG                    0.546095 
E                 -1604.265283 
H                 -1603.620048 
G                 -1603.719188 
 
Cartesian coordinates 
 
C        1.656764   -3.707139    0.232921 
C        0.913299   -2.858501   -2.335989 
C        0.410355   -2.810601    0.209590 
C       -0.042780   -2.493275   -1.221719 
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C       -3.531912   -1.216660   -1.721813 
C       -1.171663   -1.865843   -1.579088 
C       -2.311238   -1.238739   -0.785130 
C       -2.244183   -2.756892    2.798190 
C       -2.665488   -2.025886    0.451468 
C       -1.972713   -1.926492    1.581191 
C       -0.812083   -0.978445    1.635468 
C        1.443624   -1.814691    2.332611 
C        0.574601   -1.527760    1.102922 
C        1.154908   -0.326717    0.300764 
C        0.353020    0.885993    0.748558 
C       -1.076689    0.351444    0.908673 
C       -1.859883    0.231620   -0.418919 
C       -3.061224    1.151970   -0.371391 
H        1.836717   -4.082744    1.240702 
H        2.558306   -3.182206   -0.094935 
H        1.517209   -4.579222   -0.409107 
H        1.036317   -3.941229   -2.432098 
H        0.561779   -2.473247   -3.294747 
H        1.908859   -2.444507   -2.148324 
H       -0.385258   -3.400555    0.672300 
H       -3.336332   -0.618211   -2.615282 
H       -4.416463   -0.814339   -1.220160 
H       -3.765209   -2.236470   -2.040382 
H       -1.289699   -1.688417   -2.648047 
H       -1.365101   -3.362608    3.047963 
H       -3.094756   -3.426570    2.651018 
H       -2.444335   -2.119925    3.666736 
H       -3.493346   -2.726695    0.368932 
H       -0.646015   -0.723564    2.685656 
H        1.506361   -0.921332    2.959779 
H        2.460857   -2.098025    2.066704 
H        0.996126   -2.615073    2.930944 
H       -1.649914    0.992342    1.578787 
H       -1.238658    0.583340   -1.244068 
O       -3.848503    1.239293    0.542707 
O       -3.170280    1.879043   -1.491914 
C       -4.310594    2.740099   -1.578506 
H       -5.232538    2.156989   -1.541991 
H       -4.225157    3.246852   -2.537422 
H       -4.305393    3.468288   -0.765848 
O        2.545276   -0.182648    0.462298 
Si        3.595283    0.553782   -0.619090 
C        2.831284    0.640553   -2.324104 
C        4.013299    2.267364   -0.004130 
H        3.550670    1.075148   -3.026993 
H        2.553586   -0.348569   -2.700753 
H        1.937759    1.270668   -2.316433 
H        3.102961    2.865482    0.100475 
H        4.506194    2.224123    0.972889 
H        4.690197    2.777330   -0.698598 
O        0.517335    1.926051   -0.203891 
C        0.027727    3.161513    0.187197 
H        0.015301    3.793919   -0.708731 
H       -0.993979    3.086884    0.593907 
O        0.876249    3.713462    1.167120 
C        0.357111    4.920109    1.687219 
H        1.069343    5.289183    2.425115 
H        0.235173    5.676465    0.900637 
H       -0.613609    4.759903    2.174910 
H        0.720726    1.223841    1.723995 
H        0.929324   -0.465482   -0.760684 
C        5.121564   -0.524184   -0.633904 
H        5.897264   -0.096046   -1.277979 
H        5.540689   -0.626778    0.372309 
H        4.886842   -1.526546   -1.006937 
 
TS-1.out 
ZPE                   0.686447 
DE                    0.727508 
DH                    0.728452 
DG                    0.611182 
E                 -1722.108355 
H                 -1721.379903 
G                 -1721.497172 
F                     -501.214 
 
Cartesian coordinates 
 
C        1.471133   -3.180691    1.247136 
C        0.488626   -2.752164    0.366650 
C        2.845344   -3.299358    0.964773 
C        3.710790   -2.705421    0.043241 
C        0.844717   -0.568643    0.511289 
C        1.352683   -0.399140   -0.770180 
C        2.613038   -0.714110   -1.297246 
C        3.578131   -1.637597   -0.881415 
H       -0.512612   -2.719192    0.787894 
C        0.494145   -3.076948   -1.099820 
H        1.491221   -3.064602   -1.537586 
H       -0.145016   -2.391693   -1.657835 
H        0.087746   -4.088363   -1.224480 
H        4.486378   -1.544999   -1.476124 
H        3.365408   -3.930890    1.684718 
H        0.653576    0.006579   -1.497433 
C        1.734332   -0.406375    1.715004 
H        2.674001   -0.944135    1.610078 
H        1.237191   -0.734269    2.629794 
H        1.965766    0.656378    1.833931 
C        1.058819   -3.514348    2.666425 
H        0.049920   -3.149975    2.874293 
H        1.739378   -3.082731    3.405145 
H        1.053340   -4.599848    2.818702 
C        5.125842   -3.279553    0.046277 
H        5.243719   -4.069750    0.789527 
H        5.871604   -2.505716    0.251900 
H        5.367316   -3.707902   -0.931960 
C        2.916244    0.015957   -2.599042 
H        2.268074   -0.353742   -3.401555 
H        3.950323   -0.129798   -2.916566 
H        2.734159    1.090455   -2.505046 
C       -0.591046   -0.093366    0.735508 
H       -0.993624   -0.613513    1.615191 
C       -0.710971    1.426651    1.060432 
H       -1.783509    1.642311    1.003243 
O       -1.361938   -0.334981   -0.411928 
O       -0.256866    1.664909    2.378518 
Si       -2.961654   -0.841445   -0.492323 
C       -4.019147    0.155899    0.685642 
H       -5.048813   -0.217082    0.669286 
H       -3.652757    0.065241    1.713734 
H       -4.040058    1.218099    0.426150 
C       -3.414556   -0.531177   -2.300350 
C       -2.458287   -1.310595   -3.215545 
H       -1.421594   -0.987935   -3.077713 
H       -2.503326   -2.389023   -3.030301 
H       -2.724315   -1.144185   -4.267578 
C       -4.857245   -0.992899   -2.555443 
H       -4.979507   -2.066082   -2.374780 
H       -5.574267   -0.460352   -1.921189 
H       -5.135639   -0.800958   -3.599584 
C       -3.295779    0.968844   -2.608747 
H       -3.533391    1.157781   -3.663642 
H       -3.986730    1.564820   -2.003495 
H       -2.281549    1.337427   -2.423902 
C       -3.093468   -2.650643   -0.038725 
H       -2.801605   -2.816361    1.003482 
H       -4.130375   -2.987232   -0.145188 
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H       -2.464507   -3.279026   -0.675437 
C       -1.005158    2.630770    3.073297 
H       -0.456504    2.801072    4.006055 
H       -1.086509    3.559043    2.499434 
O       -2.319458    2.225457    3.327946 
C       -2.409229    1.079496    4.157789 
H       -3.465951    0.925488    4.376085 
H       -2.011911    0.188818    3.659762 
H       -1.864761    1.233519    5.098130 
C       -0.013607    2.262108    0.037073 
H       -0.373635    2.143711   -0.981573 
C        1.005508    3.082703    0.276449 
H        1.406985    3.223782    1.273092 
C        1.663071    3.792763   -0.836721 
O        1.329506    3.756231   -2.000848 
O        2.719174    4.497818   -0.400348 
C        3.458076    5.212252   -1.396656 
H        4.264513    5.711156   -0.863401 
H        3.866978    4.523608   -2.138017 
H        2.822662    5.948329   -1.892004 
 
TS-1-TMS.out   
ZPE                   0.601357 
DE                    0.638495 
DH                    0.639439 
DG                    0.531575 
E                 -1604.172479 
H                 -1603.533040 
G                 -1603.640904 
F                     -500.847 
 
Cartesian coordinates 
 
C       -1.580302   -2.944468   -1.135382 
C       -0.795386   -2.676757   -0.023759 
C       -2.964488   -2.714956   -1.253746 
C       -3.870446   -1.850413   -0.636530 
C       -0.539907   -0.492925   -0.298638 
C       -1.326289   -0.090980    0.772393 
C       -2.721336   -0.048176    0.912633 
C       -3.733123   -0.757394    0.258158 
H        0.256378   -2.916210   -0.150570 
C       -1.269383   -2.853964    1.390570 
H       -2.300992   -2.537800    1.539996 
H       -0.629851   -2.311103    2.088693 
H       -1.207927   -3.920599    1.639536 
H       -4.716553   -0.397930    0.559068 
H       -3.410818   -3.276353   -2.074405 
H       -0.780074    0.206594    1.663815 
C       -0.987286   -0.241709   -1.714270 
H       -2.022192   -0.534454   -1.877845 
H       -0.352826   -0.761011   -2.434850 
H       -0.904621    0.829768   -1.920272 
C       -0.898114   -3.495079   -2.371319 
H        0.188406   -3.422600   -2.281652 
H       -1.204641   -2.969103   -3.279509 
H       -1.146664   -4.554180   -2.505518 
C       -5.327825   -2.077198   -1.032029 
H       -5.432100   -2.887235   -1.755524 
H       -5.769884   -1.175110   -1.465760 
H       -5.926746   -2.339288   -0.153786 
C       -3.179227    0.866010    2.041476 
H       -4.265883    0.962688    2.074082 
H       -2.748347    1.866648    1.941248 
H       -2.852061    0.468634    3.008665 
C        0.972670   -0.383778   -0.102176 
H        1.461176   -1.061914   -0.814671 
C        1.546348    1.030480   -0.422269 
H        2.567565    1.018989   -0.026716 
O        1.315040   -0.695394    1.226483 
O        1.590703    1.206067   -1.825470 
Si        2.662523   -1.578266    1.714079 
C        2.609128   -3.300494    0.989860 
H        1.741732   -3.862983    1.347942 
H        2.581059   -3.279944   -0.104545 
H        3.511040   -3.848159    1.285110 
C        4.228456   -0.726885    1.149091 
C        2.525190   -1.620939    3.569793 
H        1.590597   -2.099310    3.878935 
H        3.354645   -2.188036    4.004914 
H        2.548417   -0.611555    3.991527 
C        2.721787    1.905282   -2.280234 
H        2.544185    2.070116   -3.348577 
H        2.836992    2.859463   -1.756905 
O        3.917502    1.210271   -2.069549 
C        3.982657   -0.029330   -2.754865 
H        4.994160   -0.413735   -2.623711 
H        3.268033   -0.752536   -2.347771 
H        3.782710    0.103343   -3.825725 
C        0.787827    2.108911    0.280402 
H        0.769413    2.034061    1.364236 
C        0.128287    3.099280   -0.314089 
H        0.107725    3.209246   -1.391918 
C       -0.650416    4.060486    0.489296 
O       -0.720556    4.086261    1.698500 
O       -1.306799    4.925566   -0.300208 
H        4.283906   -0.670898    0.056980 
H        4.302987    0.290172    1.546417 
H        5.102712   -1.288653    1.496258 
C       -2.122043    5.896228    0.364791 
H       -1.514046    6.528107    1.014369 
H       -2.571914    6.493405   -0.425510 
H       -2.898797    5.405645    0.953854 
 
TS-2.out 
ZPE                   0.686227 
DE                    0.727420 
DH                    0.728365 
DG                    0.610361 
E                 -1722.105340 
H                 -1721.376976 
G                 -1721.494979 
F                     -502.648 
 
Cartesian coordinates 
 
C        0.876128   -3.323691   -0.507474 
C        0.454404   -2.740493    0.678102 
C        2.207302   -3.590395   -0.880630 
C        3.450263   -3.063608   -0.524708 
C        0.890882   -0.611710    0.203224 
C        1.958330   -0.461063    1.081329 
C        3.283760   -0.910561    0.993907 
C        3.857244   -1.954373    0.259001 
H       -0.620204   -2.608330    0.755236 
C        1.109103   -2.985544    2.007140 
H        2.195557   -3.035807    1.951840 
H        0.831097   -2.217780    2.733731 
H        0.748561   -3.946926    2.392797 
H        4.942043   -1.949970    0.362179 
H        2.272986   -4.310494   -1.696056 
H        1.730305    0.063187    2.005655 
C        1.113642   -0.612879   -1.286502 
H        1.952891   -1.241850   -1.574809 
H        0.220195   -0.935121   -1.820037 
H        1.346168    0.407657   -1.608389 
C       -0.173723   -3.677968   -1.540385 
H       -1.152623   -3.292360   -1.253310 
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H        0.073988   -3.282093   -2.529388 
H       -0.259570   -4.766472   -1.636150 
C        4.643817   -3.794734   -1.135001 
H        4.332770   -4.637376   -1.754401 
H        5.249449   -3.124489   -1.752634 
H        5.297048   -4.185740   -0.348329 
C        4.226632   -0.216585    1.968839 
H        5.271481   -0.350681    1.681743 
H        4.025876    0.855340    2.032675 
H        4.107458   -0.633948    2.975322 
C       -0.434676    0.004723    0.664807 
H       -0.659588   -0.377226    1.669672 
C       -0.417005    1.555201    0.820107 
O       -1.452667   -0.321744   -0.246537 
H       -1.466448    1.829715    0.973295 
O        0.325815    1.901540    1.973925 
C        0.057553    2.261951   -0.405693 
Si       -3.068534   -0.644574    0.088502 
C       -0.233596    2.950834    2.723964 
H       -0.495497    2.041986   -1.315406 
C        1.083688    3.107811   -0.448190 
C       -3.780605    0.640120    1.248488 
C       -3.881452   -0.583207   -1.616199 
C       -3.249296   -2.321046    0.898467 
H        0.521246    3.195351    3.479204 
H       -0.444488    3.820401    2.094017 
O       -1.451561    2.609087    3.320008 
H        1.663168    3.348687    0.435041 
C        1.486948    3.727293   -1.724154 
H       -4.816793    0.379917    1.490180 
H       -3.222980    0.676524    2.190328 
H       -3.777983    1.643900    0.814260 
C       -5.379401   -0.894864   -1.479051 
C       -3.703960    0.819150   -2.217450 
C       -3.227831   -1.616594   -2.545441 
H       -4.303176   -2.501970    1.136233 
H       -2.902496   -3.135565    0.256850 
H       -2.690025   -2.363706    1.839194 
C       -1.347362    1.552734    4.259891 
O        0.955399    3.553284   -2.798910 
O        2.551722    4.527586   -1.555102 
H       -5.550967   -1.896312   -1.070296 
H       -5.888343   -0.173958   -0.830207 
H       -5.864998   -0.852731   -2.462400 
H       -4.158880    0.862587   -3.215504 
H       -4.182884    1.589090   -1.603603 
H       -2.645968    1.080516   -2.320992 
H       -2.157922   -1.423859   -2.670516 
H       -3.343664   -2.637000   -2.165418 
H       -3.694978   -1.578562   -3.538211 
H       -2.321662    1.453881    4.738397 
H       -1.088029    0.605865    3.774748 
H       -0.591570    1.779688    5.022504 
C        3.046731    5.180255   -2.728893 
H        2.279239    5.822395   -3.164135 
H        3.892803    5.778848   -2.397983 
H        3.372101    4.446257   -3.468000 
 
TS-2-TMS.out 
ZPE                   0.601868 
DE                    0.638852 
DH                    0.639796 
DG                    0.532356 
E                 -1604.170494 
H                 -1603.530698 
G                 -1603.638138 
F                     -494.733 
 
Cartesian coordinates 
 
C       -3.098976   -0.829442   -1.080238 
C       -2.715101   -0.030021   -0.015117 
C       -3.305470   -2.221976   -1.053874 
C       -2.848853   -3.266874   -0.248724 
C       -0.526371   -0.498996   -0.011817 
C       -0.509727   -1.240852    1.163184 
C       -0.942845   -2.548047    1.429852 
C       -1.871931   -3.362885    0.774627 
H       -2.596107    1.020847   -0.268305 
C       -3.151923   -0.243180    1.404510 
H       -3.187665   -1.292787    1.693214 
H       -2.500624    0.290817    2.101991 
H       -4.161418    0.170418    1.518888 
H       -1.888591   -4.360385    1.212524 
H       -3.887480   -2.572083   -1.905601 
H       -0.125155   -0.721102    2.036765 
C       -0.297137   -1.164630   -1.342846 
H       -0.878884   -2.077938   -1.448454 
H       -0.527582   -0.493232   -2.169197 
H        0.759314   -1.442449   -1.420017 
C       -3.273717   -0.151684   -2.424690 
H       -2.572160    0.680064   -2.516825 
H       -3.100767   -0.836774   -3.257533 
H       -4.283941    0.260324   -2.529161 
C       -3.486332   -4.620968   -0.551518 
H       -4.222980   -4.554669   -1.353587 
H       -2.733976   -5.360898   -0.841201 
H       -3.996631   -5.010528    0.335206 
C       -0.392355   -3.112947    2.733090 
H       -0.551947   -4.190430    2.805748 
H        0.677881   -2.918620    2.837319 
H       -0.893865   -2.647551    3.589333 
C       -0.020022    0.939225    0.116574 
H       -0.549371    1.400846    0.955766 
C        1.493903    1.086506    0.471224 
O       -0.270364    1.647526   -1.073954 
H        1.717750    2.151520    0.324745 
O        1.739639    0.740172    1.820851 
C        2.377482    0.317845   -0.450394 
Si       -0.664538    3.285050   -1.166990 
C        1.957191    1.834599    2.675407 
H        2.232969    0.517606   -1.508689 
C        3.284938   -0.576396   -0.067396 
C        0.888652    4.281207   -1.467205 
C       -1.830178    3.445726   -2.612409 
C       -1.472723    3.810646    0.434514 
H        2.291846    1.399508    3.622915 
H        2.724619    2.497035    2.263238 
O        0.823530    2.631669    2.860087 
H        3.452472   -0.805330    0.977559 
C        4.079136   -1.308975   -1.071147 
H        0.635785    5.327986   -1.668500 
H        1.556292    4.261779   -0.599961 
H        1.441021    3.897727   -2.331078 
H       -0.763159    3.775097    1.267092 
H       -1.834320    4.840693    0.343501 
H       -2.329610    3.175982    0.684331 
C       -0.185476    2.021275    3.648563 
O        4.000538   -1.180951   -2.273420 
O        4.923771   -2.169492   -0.480407 
H        0.186627    1.807903    4.657919 
H       -1.013643    2.727269    3.711896 
H       -0.545903    1.090200    3.199071 
C        5.745694   -2.951394   -1.353260 
H        6.352553   -3.578006   -0.703019 
H        5.130041   -3.572535   -2.006061 
H        6.385556   -2.306767   -1.958212 
H       -2.799270    2.987035   -2.395443 
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H       -2.001525    4.502697   -2.842898 
H       -1.418679    2.970070   -3.508131 
 
TS-3.out 
ZPE                   0.690798 
DE                    0.729355 
DH                    0.730300 
DG                    0.623980 
E                 -1722.125332 
H                 -1721.395033 
G                 -1721.501352 
              F                     -450.791 
 
Cartesian coordinates 
 
C        1.009276   -2.910385    1.411527 
C        0.553899   -0.350810    2.669415 
C       -0.192499   -2.098040    0.910271 
C       -0.552191   -0.996359    1.876155 
C       -4.248678   -0.701467    2.369858 
C       -1.813971   -0.576457    2.063960 
C       -3.070807   -1.018068    1.478089 
C       -3.472920   -2.459590   -2.033619 
C       -3.343823   -1.774297    0.347289 
C       -2.674027   -1.897624   -0.880900 
C       -1.430861   -1.342667   -1.217365 
C        0.563857   -2.753255   -1.405880 
C       -0.064779   -1.620777   -0.573679 
C        0.728090   -0.322211   -0.841854 
C       -0.151327    0.886384   -0.534657 
C       -1.580602    0.644833   -0.985154 
C       -2.601841    1.130812   -0.166132 
C       -3.962562    1.138743   -0.617656 
H        1.100602   -3.849734    0.864831 
H        1.944437   -2.361455    1.306360 
H        0.872442   -3.164304    2.466051 
H        0.971969   -1.048959    3.402042 
H        0.190123    0.527558    3.206833 
H        1.373157   -0.053019    2.010016 
H       -1.041318   -2.789497    0.893057 
H       -4.313291    0.380803    2.518021 
H       -5.192969   -1.041054    1.942870 
H       -4.120959   -1.157429    3.357650 
H       -1.951937    0.208209    2.805774 
H       -2.993307   -3.362205   -2.427364 
H       -4.495708   -2.709061   -1.745646 
H       -3.517170   -1.729292   -2.846580 
H       -1.289974   -1.357764   -2.298869 
H        0.544764   -2.498267   -2.468914 
H        1.604209   -2.921563   -1.122777 
H        0.013655   -3.688888   -1.269175 
H       -1.747540    0.738294   -2.056085 
H       -2.387865    1.537599    0.811610 
H       -0.144450    1.074289    0.539565 
H        0.901678   -0.294991   -1.929179 
O       -4.373424    0.638685   -1.655772 
O       -4.802935    1.748819    0.264571 
C       -6.190885    1.655128   -0.032732 
H       -6.510473    0.611099   -0.080719 
H       -6.706118    2.160904    0.782791 
H       -6.427723    2.145155   -0.979931 
O        1.956703   -0.252615   -0.156020 
Si        3.468264   -0.022766   -0.853921 
C        3.843154   -1.444183   -2.013915 
C        3.525548    1.572564   -1.827088 
C        4.695096    0.013760    0.591766 
H        3.920605   -2.397137   -1.482414 
H        3.059387   -1.541691   -2.772038 
H        4.788932   -1.267776   -2.536840 
H        2.795388    1.551130   -2.640866 
H        3.297876    2.438801   -1.201692 
H        4.520199    1.708635   -2.265631 
C        4.453834    1.231916    1.495075 
C        6.115141    0.097863    0.005506 
C        4.578344   -1.258146    1.442956 
H        5.216116    1.268375    2.284445 
H        3.476612    1.180841    1.984545 
H        4.507191    2.174921    0.941098 
H        6.852273    0.138334    0.817487 
H        6.354502   -0.773765   -0.612422 
H        6.253638    0.994404   -0.608123 
H        3.615381   -1.302827    1.959135 
H        4.686585   -2.169595    0.845624 
H        5.364701   -1.270117    2.209126 
O        0.432760    2.000182   -1.200940 
C        0.009539    3.257050   -0.744600 
H        0.588473    3.977982   -1.334103 
H       -1.063619    3.403342   -0.904363 
O        0.212842    3.453359    0.627762 
C        1.567127    3.305203    1.019768 
H        1.912822    2.282416    0.854350 
H        2.215890    3.996206    0.465476 
H        1.619729    3.537015    2.083926 
H       -4.368974   -2.134151    0.310703 
 
TS-3-TMS.out 
ZPE                   0.605046 
DE                    0.639972 
DH                    0.640916 
DG                    0.541575 
E                 -1604.189391 
H                 -1603.548474 
G                 -1603.647815 
F                     -448.263 
 
Cartesian coordinates 
 
C        1.429985   -2.818008    1.662794 
C        0.835126   -0.258097    2.834156 
C        0.245325   -2.049378    1.057558 
C       -0.199451   -0.931766    1.970243 
C       -3.924604   -0.650591    2.194089 
C       -1.475317   -0.521659    2.059546 
C       -2.685306   -0.980470    1.395393 
C       -2.831855   -2.489936   -2.106792 
C       -2.875614   -1.759802    0.263193 
C       -2.120580   -1.901166   -0.911273 
C       -0.858444   -1.344323   -1.168523 
C        1.136725   -2.768636   -1.190278 
C        0.460504   -1.613616   -0.429571 
C        1.271330   -0.324920   -0.675218 
C        0.376817    0.887445   -0.443230 
C       -1.017890    0.640793   -0.989791 
C       -2.093572    1.144168   -0.252514 
C       -3.419241    1.142732   -0.796757 
H        1.597411   -3.757851    1.135577 
H        2.353514   -2.237695    1.632722 
H        1.212742   -3.069291    2.704423 
H        1.195302   -0.935187    3.615596 
H        0.422707    0.629461    3.318474 
H        1.704174    0.031466    2.237939 
H       -0.586455   -2.760513    1.005294 
H       -4.005898    0.434701    2.308579 
H       -4.834415   -1.008427    1.710947 
H       -3.863771   -1.079564    3.200133 
H       -1.670904    0.274566    2.775587 
H       -2.320862   -3.397334   -2.446491 
H       -3.871769   -2.739365   -1.888686 
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H       -2.819230   -1.776161   -2.935395 
H       -3.894063   -2.126476    0.162108 
H       -0.642203   -1.380840   -2.237014 
H        1.180097   -2.544414   -2.259534 
H        2.158393   -2.927825   -0.841977 
H        0.579476   -3.701032   -1.059374 
H       -1.109197    0.718155   -2.071119 
H       -1.948972    1.564600    0.732229 
H        0.308901    1.081741    0.627253 
H        1.521606   -0.317186   -1.747915 
O       -3.757870    0.623014   -1.851498 
O       -4.318548    1.768118    0.014333 
C       -5.683111    1.665155   -0.373618 
H       -5.996903    0.619501   -0.425046 
H       -6.252769    2.183012    0.396955 
H       -5.857219    2.138471   -1.342707 
O        2.441344   -0.240406    0.097821 
Si        4.018163   -0.055696   -0.442708 
C        4.147915    1.358959   -1.654877 
C        4.969844    0.287350    1.123684 
C        4.603309   -1.632844   -1.259443 
H        5.189091    1.486399   -1.972091 
H        3.544612    1.171454   -2.548036 
H        3.801267    2.293957   -1.207492 
H        4.816279   -0.513449    1.854166 
H        4.648283    1.229742    1.578851 
H        6.043817    0.358655    0.922384 
O        1.011512    1.997206   -1.069017 
C        0.629213    3.252025   -0.572700 
H        1.224049    3.973765   -1.144886 
H       -0.440554    3.433791   -0.719496 
O        0.847246    3.403007    0.803272 
C        2.200091    3.224339    1.189315 
H        2.270503    3.506336    2.240255 
H        2.509648    2.181895    1.074226 
H        2.866799    3.865383    0.598115 
H        4.007251   -1.865485   -2.147655 
H        5.646978   -1.529527   -1.576740 
H        4.541338   -2.483733   -0.573868 
 
TS-3-MOM.out 
ZPE                   0.499267 
DE                    0.525507 
DH                    0.526451 
DG                    0.445052 
E                 -1120.251677 
H                 -1119.725226 
G                 -1119.806625 
F                     -451.692 
 
Cartesian coordinates 
 
C        2.451797   -3.104992    1.003365 
C        2.245901   -0.580984    2.353742 
C        1.230993   -2.244765    0.650348 
C        1.030603   -1.143799    1.663171 
C       -2.571861   -0.609938    2.518109 
C       -0.173782   -0.642269    1.979443 
C       -1.509330   -0.976108    1.508949 
C       -2.322265   -2.219088   -2.006524 
C       -1.940182   -1.652076    0.379018 
C       -1.387089   -1.771853   -0.907694 
C       -0.133823   -1.302120   -1.326491 
C        1.707831   -2.867155   -1.749226 
C        1.255910   -1.723276   -0.820915 
C        2.151941   -0.502804   -1.074444 
C        1.415022    0.777143   -0.706977 
C       -0.071963    0.668635   -1.033577 
C       -0.973005    1.220158   -0.119527 
C       -2.362776    1.347461   -0.442018 
H        3.394501   -2.581181    0.820348 
H        2.422673   -3.385395    2.059162 
H        2.460621   -4.028454    0.423724 
H        3.019154   -0.296087    1.633596 
H        2.700822   -1.317583    3.023066 
H        1.987687    0.300290    2.943846 
H        0.355459   -2.900575    0.705637 
H       -2.569523    0.474240    2.669886 
H       -3.569942   -0.902972    2.190377 
H       -2.365797   -1.074408    3.488266 
H       -0.183516    0.131632    2.745044 
H       -1.953895   -3.140954   -2.469602 
H       -3.335589   -2.396616   -1.641875 
H       -2.370577   -1.455225   -2.787697 
H       -2.990746   -1.928978    0.419487 
H       -0.083002   -1.285360   -2.416023 
H        1.585034   -2.573744   -2.795104 
H        2.762409   -3.108995   -1.596678 
H        1.117578   -3.772526   -1.577018 
H       -0.320435    0.813283   -2.083369 
H       -0.643876    1.565488    0.850141 
H        1.513357    0.985021    0.359673 
H        2.361623   -0.454636   -2.148978 
O       -2.904668    0.917110   -1.451319 
O       -3.070708    1.985531    0.533410 
C       -4.483429    1.996189    0.369207 
H       -4.879040    0.978155    0.326907 
H       -4.882466    2.509945    1.242891 
H       -4.773982    2.530394   -0.538347 
H        3.115409   -0.574057   -0.563043 
O        2.035964    1.842644   -1.428903 
C        1.756231    3.127382   -0.937499 
H        2.271918    3.811411   -1.621468 
H        0.680760    3.329516   -0.930687 
O        2.183202    3.325694    0.382619 
C        3.580486    3.167659    0.555584 
H        3.887964    2.124980    0.421240 
H        3.813311    3.478846    1.574207 
H        4.138513    3.796310   -0.150325 
 
TS-4.out 
ZPE                   0.691282 
DE                    0.729582 
DH                    0.730527 
DG                    0.624997 
E                 -1722.095035 
H                 -1721.364508 
G                 -1721.470038 
F                     -587.374 
 
Cartesian coordinates 
 
C        4.587250   -2.473328   -0.341138 
H        5.318398   -1.659834   -0.383861 
H        4.583352   -2.979485   -1.308688 
H        4.943762   -3.186570    0.408973 
C        3.207260   -1.960573    0.017401 
C        2.181670   -2.205914   -0.882652 
C        3.180950   -0.994297    1.044946 
C        0.869475   -1.751701   -0.732267 
C        1.279866    0.417188   -0.754461 
C        2.560906    0.734040   -0.302190 
H        2.700988    1.395325    0.540149 
H        1.201653    0.294140   -1.825731 
C        3.679120    0.641389   -1.238890 
O        3.643119    0.111888   -2.332064 
O        4.804207    1.205938   -0.746502 
C        5.960450    1.126418   -1.579434 
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H        6.228726    0.085907   -1.774960 
H        5.793286    1.640587   -2.528110 
H        6.758603    1.618007   -1.026040 
C        0.004217   -1.801778   -1.977302 
H       -0.341806   -2.821240   -2.171975 
H       -0.876619   -1.167844   -1.874200 
H        0.576945   -1.477230   -2.848907 
C        0.214239   -2.109945    0.611408 
H        0.987235   -2.622612    1.187424 
C       -0.221421   -0.940892    1.527319 
C        0.963991   -0.421465    2.300038 
H        0.658628    0.113438    3.197427 
C        2.295314   -0.480920    2.125848 
H        4.205343   -0.765366    1.338499 
C        0.064420    1.080419   -0.111513 
H       -0.557274    1.463182   -0.925808 
C       -0.878394    0.224609    0.761146 
H       -1.257112    0.927353    1.513366 
C       -0.867884   -3.175144    0.366263 
H       -0.454782   -3.991357   -0.232656 
H       -1.201751   -3.606420    1.310946 
H       -1.734998   -2.766151   -0.150848 
C       -1.241661   -1.413673    2.581797 
H       -2.184395   -1.711841    2.120914 
H       -0.850181   -2.260098    3.153373 
H       -1.450845   -0.601412    3.284131 
C        3.142518    0.225164    3.171583 
H        2.534549    0.636824    3.978342 
H        3.879432   -0.456725    3.608336 
H        3.702687    1.048227    2.711876 
O        0.445862    2.183757    0.717393 
C        0.689688    3.373728    0.022966 
H        1.170307    4.041619    0.747128 
H        1.343859    3.212600   -0.839587 
O       -0.478089    3.958693   -0.488940 
C       -1.392378    4.352258    0.519894 
H       -2.212227    4.874039    0.025688 
H       -1.791380    3.487441    1.060505 
H       -0.914021    5.030433    1.238321 
O       -1.953328   -0.276938   -0.009049 
Si       -3.458524    0.450058   -0.163666 
C       -4.000902    1.109460    1.501906 
C       -3.371589    1.841464   -1.412230 
C       -4.607638   -0.925851   -0.770450 
H       -3.409369    1.979923    1.802161 
H       -5.049295    1.423155    1.459021 
H       -3.906445    0.347818    2.281633 
H       -3.126086    1.461432   -2.409150 
H       -4.330883    2.365674   -1.476570 
H       -2.608364    2.574880   -1.136063 
C       -4.019129   -1.593450   -2.022094 
C       -5.975534   -0.318313   -1.120859 
C       -4.791971   -1.980863    0.330314 
H       -3.059117   -2.072727   -1.811108 
H       -4.704481   -2.366511   -2.393801 
H       -3.864094   -0.874194   -2.833449 
H       -6.665604   -1.108304   -1.444014 
H       -6.433279    0.185524   -0.262499 
H       -5.901305    0.407590   -1.937148 
H       -3.839254   -2.432360    0.623339 
H       -5.252873   -1.554618    1.227495 
H       -5.446604   -2.787284   -0.025473 
H        2.484867   -2.580628   -1.857875 
 
TS-4-TMS.out   
ZPE                   0.605029 
DE                    0.639922 
DH                    0.640866 
DG                    0.540483 
E                 -1604.178638 
H                 -1603.537772 
G                 -1603.638154 
F                     -451.557 
 
Cartesian coordinates 
 
C       -1.115201   -1.749933    2.992983 
C       -0.202679    0.949518    3.114161 
C       -0.032680   -1.369387    1.971520 
C        0.604909   -0.047000    2.325326 
C        4.296856   -0.013369    1.736481 
C        1.873336    0.263258    2.014609 
C        2.918022   -0.497948    1.351750 
C        2.342361   -3.124877   -1.356400 
C        2.869572   -1.626394    0.549825 
C        1.889928   -2.105144   -0.338012 
C        0.603232   -1.584536   -0.529584 
C       -1.306838   -2.808435    0.364532 
C       -0.532192   -1.480273    0.493388 
C       -1.417881   -0.294673    0.016095 
C       -0.550084    0.837477   -0.580060 
C        0.771613    0.304301   -1.139218 
C        1.957044    0.976382   -0.840692 
C        3.158609    0.666518   -1.553695 
H       -1.385013   -2.802280    2.907830 
H       -2.026511   -1.156702    2.871702 
H       -0.745827   -1.594160    4.009050 
H       -0.338003    0.611999    4.147351 
H        0.292277    1.921173    3.132252 
H       -1.197202    1.088566    2.685792 
H        0.753451   -2.129213    2.047435 
H        4.422903    1.021518    1.402807 
H        5.086760   -0.612597    1.282058 
H        4.425074   -0.022261    2.824066 
H        2.219322    1.238784    2.350965 
H        1.787986   -4.061392   -1.229199 
H        3.409461   -3.342113   -1.283029 
H        2.138151   -2.757490   -2.366014 
H        3.843626   -2.083996    0.395633 
H        0.167735   -1.986369   -1.444631 
H       -1.527940   -3.028601   -0.678941 
H       -2.254570   -2.780515    0.903834 
H       -0.703099   -3.625789    0.770745 
H        0.702092   -0.053359   -2.163113 
H        2.000653    1.728979   -0.068997 
O        3.293208   -0.222460   -2.384695 
O        4.204440    1.464803   -1.188512 
C        5.473490    1.105894   -1.719638 
H        5.750737    0.092046   -1.419078 
H        6.184531    1.819468   -1.304867 
H        5.480805    1.168888   -2.810326 
O       -2.282224   -0.735649   -1.019390 
Si       -3.945544   -0.510153   -0.989280 
C       -4.705150   -1.549647    0.368315 
C       -4.326538    1.289634   -0.657492 
C       -4.529828   -1.054142   -2.672197 
H       -5.778786   -1.345473    0.446602 
H       -4.577168   -2.619295    0.177664 
H       -4.251776   -1.319143    1.338521 
H       -3.748079    1.956046   -1.303673 
H       -5.391251    1.487814   -0.823009 
H       -4.100861    1.548348    0.381008 
O       -0.354683    1.855496    0.383502 
C       -0.367179    3.157674   -0.122081 
H        0.141897    3.772700    0.629945 
H        0.154629    3.222140   -1.081323 
O       -1.663698    3.637262   -0.353296 
C       -2.401193    3.811390    0.843485 
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H       -3.397371    4.154469    0.564218 
H       -2.487249    2.873039    1.400771 
H       -1.925612    4.564313    1.485783 
H       -1.127753    1.250829   -1.412443 
H       -1.998277    0.113936    0.851896 
H       -4.249243   -2.093790   -2.867098 
H       -5.619991   -0.981188   -2.742509 
H       -4.098420   -0.430528   -3.461046 
 
TS-5.out 
ZPE                   0.687960 
DE                    0.728160 
DH                    0.729104 
DG                    0.615128 
E                 -1722.112161 
H                 -1721.383057 
  G                 -1721.497034 
  F                     -538.730 
 
Cartesian coordinates 
 
C        4.989179   -1.428178   -0.347412 
C        3.995440   -1.889077   -1.214156 
C        4.835893   -0.218967    0.351342 
C        3.787580    0.691301    0.157170 
H        5.754296    0.184079    0.774257 
C        2.457395    0.353222   -0.135732 
C        2.632451   -1.643702   -1.033876 
H        4.328458   -2.345730   -2.146528 
C        2.062185   -1.891379    0.369976 
C        1.549120   -0.501989    0.779734 
H        1.913894    1.153043   -0.635987 
H        2.926893   -2.075515    1.012769 
C        1.775959   -0.205048    2.262728 
H        1.423589    0.795489    2.523394 
H        2.841198   -0.274248    2.497857 
H        1.246364   -0.927252    2.890852 
C        1.186786   -3.138340    0.462639 
H        0.902887   -3.339017    1.499534 
H        1.754766   -4.003501    0.106442 
H        0.276747   -3.074169   -0.138195 
C        1.733120   -1.871475   -2.230365 
H        1.367780   -2.904312   -2.252800 
H        0.856648   -1.221763   -2.230109 
H        2.277997   -1.685646   -3.158564 
C        6.352591   -2.072505   -0.382543 
H        7.150970   -1.361974   -0.155655 
H        6.548006   -2.516886   -1.362737 
H        6.410204   -2.882479    0.352609 
C        4.165267    2.157714    0.087155 
H        5.246579    2.306486    0.120201 
H        3.792072    2.592362   -0.846004 
H        3.711706    2.728758    0.903773 
C        0.076819   -0.221819    0.379277 
H       -0.056506   -0.607074   -0.633847 
C       -0.995378   -0.930089    1.248017 
H       -0.619292   -1.914930    1.536677 
O       -0.173457    1.164315    0.394641 
O       -1.234440   -0.172367    2.421934 
Si       -1.071658    2.061856   -0.700857 
C       -2.909646    1.979190   -0.339023 
H       -3.405779    2.869810   -0.740546 
H       -3.382644    1.104206   -0.792014 
H       -3.097492    1.949098    0.738648 
C       -0.724064    1.424335   -2.426573 
H       -1.271691    2.014267   -3.168813 
H        0.341879    1.475228   -2.669574 
H       -1.048881    0.383592   -2.530356 
C       -0.470224    3.843398   -0.464291 
C        1.061162    3.898736   -0.518052 
H        1.452603    3.503715   -1.461949 
H        1.408185    4.936470   -0.424791 
H        1.505467    3.320511    0.295272 
C       -0.943881    4.371489    0.898611 
H       -0.570561    3.754268    1.722273 
H       -0.576431    5.394088    1.056161 
H       -2.036222    4.400191    0.967097 
C       -1.047966    4.728538   -1.579749 
H       -2.142909    4.706060   -1.600505 
H       -0.686651    4.423637   -2.567404 
H       -0.744715    5.772168   -1.425515 
C       -1.518529   -0.937218    3.558168 
H       -0.804758   -1.761673    3.663617 
H       -1.435611   -0.247851    4.405823 
O       -2.786723   -1.535537    3.529748 
C       -3.846995   -0.605803    3.673704 
H       -3.780088   -0.085253    4.637370 
H       -3.847000    0.138902    2.870359 
H       -4.778306   -1.170920    3.634983 
C       -2.272945   -1.131463    0.474619 
H       -3.177207   -0.731261    0.921642 
C       -2.363322   -1.740412   -0.706743 
H       -1.504087   -2.162115   -1.217366 
C       -3.661182   -1.831403   -1.399692 
O       -4.718010   -1.400285   -0.992988 
O       -3.530842   -2.455069   -2.581671 
C       -4.722746   -2.588766   -3.362982 
H       -4.423177   -3.111262   -4.268983 
H       -5.472559   -3.170258   -2.823990 
H       -5.130029   -1.607528   -3.612398 
 
TS-5-TMS.out 
ZPE                   0.601972 
DE                    0.638614 
DH                    0.639558 
DG                    0.531368 
E                 -1604.177340 
H                 -1603.537782 
G                 -1603.645973 
F                     -540.738 
 
Cartesian coordinates 
 
C       -4.957460    0.027121   -1.081900 
C       -3.983953   -0.601339   -1.865655 
C       -4.772905    0.208159    0.298436 
C       -3.698209   -0.312670    1.033348 
H       -5.678538    0.438968    0.856326 
C       -2.383625   -0.431392    0.568336 
C       -2.612812   -0.525626   -1.620968 
H       -4.343042   -1.300051   -2.622129 
C       -2.019113    0.863393   -1.349791 
C       -1.502669    0.749287    0.094181 
H       -1.820839   -1.195166    1.100953 
H       -2.870660    1.547056   -1.296068 
C       -1.765752    2.024540    0.897061 
H       -1.400918    1.932219    1.922089 
H       -2.839263    2.228768    0.923165 
H       -1.270313    2.883171    0.436452 
C       -1.125340    1.371421   -2.477581 
H       -1.691088    1.376890   -3.414362 
H       -0.238668    0.751111   -2.631616 
H       -0.800430    2.397685   -2.284368 
C       -1.736398   -1.557492   -2.296684 
H       -1.528344   -1.265720   -3.332561 
H       -0.773066   -1.680481   -1.800376 
H       -2.229790   -2.531477   -2.313502 
C       -6.335417    0.239135   -1.657971 
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H       -7.113962    0.194063   -0.892723 
H       -6.555103   -0.508571   -2.425635 
H       -6.399938    1.220299   -2.140524 
C       -4.017300   -0.964253    2.364287 
H       -5.085867   -0.941002    2.588613 
H       -3.701430   -2.013541    2.344906 
H       -3.478208   -0.485086    3.187648 
C       -0.023495    0.291452    0.221881 
H        0.125604   -0.509247   -0.508349 
C        1.065613    1.337517   -0.106931 
H        0.807425    1.831116   -1.046412 
O        0.225898   -0.194365    1.523377 
O        1.152326    2.305604    0.924544 
Si        0.854037   -1.683609    1.973873 
C       -0.180118   -2.235028    3.427729 
H        0.184695   -3.187470    3.826672 
H       -0.141931   -1.496791    4.235308 
H       -1.227947   -2.366050    3.139318 
C        2.641343   -1.503899    2.491820 
H        2.968400   -2.407806    3.018223 
H        3.306163   -1.357423    1.635118 
H        2.769603   -0.656982    3.173756 
C        0.711744   -2.890497    0.551121 
C        1.484374    3.589906    0.480172 
H        0.859489    3.881776   -0.370980 
H        1.303655    4.253015    1.333622 
O        2.808954    3.704196    0.034570 
C        3.762175    3.635986    1.081472 
H        3.605808    4.447438    1.803481 
H        3.717639    2.678539    1.610523 
H        4.747105    3.745508    0.627417 
C        2.384430    0.631353   -0.271686 
H        3.098543    0.744090    0.538648 
C        2.685175   -0.156199   -1.301617 
H        1.999986   -0.307728   -2.129742 
C        3.954831   -0.903960   -1.327058 
O        4.822803   -0.858994   -0.482504 
O        4.036896   -1.677812   -2.420647 
C        5.220889   -2.472703   -2.546611 
H        5.305714   -3.169090   -1.710636 
H        5.109716   -3.019894   -3.480252 
H        6.107376   -1.837611   -2.585790 
H        1.331972   -2.588264   -0.299025 
H        1.054696   -3.878881    0.876446 
H       -0.321833   -2.991138    0.205074 
 
TS-5-MOM.out 
ZPE                   0.495766 
DE                    0.523977 
DH                    0.524922 
DG                    0.434279 
E                 -1120.245916 
H                 -1119.720995 
G                 -1119.811638 
F                     -544.982 
 
Cartesian coordinates 
 
C        4.330226   -0.984500    0.828102 
C        4.216260   -0.592080   -0.508074 
C        3.379525   -0.594315    1.788490 
C        2.327213    0.298078    1.550765 
H        3.700794   -0.704672    2.822619 
C        1.617719    0.389964    0.345837 
C        3.001948   -0.390099   -1.169129 
H        5.138109   -0.292573   -1.008201 
C        1.933451   -1.486121   -1.039514 
C        0.813935   -0.767778   -0.282516 
H        1.147395    1.365007    0.202649 
H        2.345376   -2.233174   -0.355149 
C        0.154748   -1.675691    0.759171 
H       -0.535184   -1.126311    1.405492 
H        0.911595   -2.137092    1.399102 
H       -0.408641   -2.473946    0.263133 
C        1.584081   -2.202618   -2.338744 
H        0.823127   -2.966976   -2.153911 
H        2.466783   -2.702108   -2.749135 
H        1.198528   -1.522294   -3.102072 
C        3.039836    0.420535   -2.444962 
H        3.769746    1.229046   -2.367627 
H        3.321481   -0.211694   -3.294951 
H        2.071730    0.863437   -2.682867 
C        5.634664   -1.570356    1.309377 
H        5.843840   -1.313190    2.350499 
H        6.467986   -1.227260    0.689481 
H        5.610714   -2.662955    1.235787 
C        2.035272    1.343791    2.606613 
H        1.056921    1.176140    3.069929 
H        2.790992    1.365948    3.394649 
H        1.996128    2.335088    2.141314 
C       -0.261450   -0.183355   -1.215298 
H       -0.746994   -1.000823   -1.756806 
C       -1.323146    0.668934   -0.503840 
H       -0.981667    0.940699    0.499443 
C       -2.649198   -0.027833   -0.408312 
H       -3.104376   -0.313491   -1.353550 
C       -3.266304   -0.286337    0.742474 
H       -2.823637   -0.004676    1.692548 
C       -4.569646   -0.970883    0.857474 
O       -5.115798   -1.185488    1.918453 
O       -5.092252   -1.331269   -0.320321 
C       -6.359783   -1.995502   -0.276351 
H       -6.613868   -2.210032   -1.312125 
H       -6.287620   -2.923340    0.293345 
H       -7.116760   -1.348791    0.170257 
H        0.201427    0.461517   -1.964456 
O       -1.497136    1.873339   -1.264573 
C       -1.949685    2.963692   -0.503610 
H       -2.225436    3.733626   -1.232514 
H       -2.814294    2.692765    0.110520 
O       -0.980984    3.441391    0.388886 
C        0.139271    4.022946   -0.256183 
H        0.657611    3.301178   -0.895829 
H       -0.165946    4.882524   -0.866710 
H        0.819870    4.361793    0.524941 
 
TS-6.out 
ZPE                   0.434588 
DE                    0.457718 
DH                    0.458662 
DG                    0.385032 
E                  -929.290232 
H                  -928.831569 
G                 -928.905200 
F                     -443.945 
 
Cartesian coordinates 
 
C       -3.742929   -1.466312    0.195424 
C       -2.304947   -1.370549   -2.291800 
C       -2.270955   -1.043050    0.267898 
C       -1.533032   -1.385576   -1.000844 
C        1.906982   -2.685619   -0.356986 
C       -0.221571   -1.666104   -1.039549 
C        0.764877   -1.774388    0.024308 
C        0.750706    0.295715    3.226010 
C        0.773780   -1.288462    1.319966 
C        0.179582   -0.154114    1.902325 
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C       -0.705104    0.746618    1.292177 
C       -3.133132    0.913161    1.661021 
C       -2.069909    0.470393    0.636163 
C       -2.123960    1.390820   -0.555174 
C       -0.853154    2.892759   -2.114968 
C       -0.985419    1.952919   -0.953640 
C        0.262194    1.601434   -0.192825 
C        1.263150    0.876742   -0.849935 
H       -4.216614   -1.399707    1.175605 
H       -4.319070   -0.851296   -0.501463 
H       -3.817794   -2.506329   -0.132736 
H       -3.061789   -2.160712   -2.315315 
H       -1.641692   -1.507668   -3.147842 
H       -2.836613   -0.422087   -2.416775 
H       -1.815914   -1.608175    1.087408 
H        2.434443   -2.263249   -1.218295 
H        2.625202   -2.809278    0.454337 
H        1.534715   -3.671130   -0.656321 
H        0.190493   -1.905016   -2.018176 
H       -0.034782    0.347066    3.986974 
H        1.539478   -0.367785    3.584288 
H        1.172590    1.300369    3.122640 
H        1.559309   -1.720141    1.934623 
H       -0.818054    1.639139    1.907858 
H       -2.941667    1.941997    1.977387 
H       -4.137035    0.880570    1.232225 
H       -3.115606    0.272506    2.548186 
H       -3.071570    1.584577   -1.051303 
H       -0.387608    3.833588   -1.802650 
H       -0.209925    2.461036   -2.888617 
H       -1.826963    3.115688   -2.556946 
H        0.645443    2.382293    0.464059 
H        1.080188    0.389365   -1.796624 
C        2.569440    0.770640   -0.273816 
O        2.904496    1.183690    0.829309 
O        3.448457    0.113060   -1.085613 
C        4.722197   -0.171668   -0.520483 
H        4.623476   -0.784939    0.378825 
H        5.271451   -0.722676   -1.283009 
H        5.259526    0.745839   -0.269529 
 
TS-7.out 
ZPE                   0.433075 
DE                    0.457376 
DH                    0.458320 
DG                    0.379735 
E                  -929.285916 
H                  -928.827596 
G                 -928.906181 
F                     -527.558 
 
Cartesian coordinates 
 
C       -3.670133   -1.584158   -0.103696 
C       -3.673182   -0.445478   -0.917618 
C       -2.471560   -2.119537    0.397137 
C       -1.187429   -1.694950    0.022692 
H       -2.550580   -3.130148    0.793031 
C       -0.825606   -0.376262   -0.280431 
C       -2.740251    0.582735   -0.803337 
H       -4.357609   -0.446732   -1.766498 
C       -2.416982    1.101076    0.600832 
C       -0.917923    0.806997    0.715246 
H        0.026876   -0.308876   -0.956133 
H       -2.907971    0.421994    1.301926 
C       -0.545317    0.434107    2.161346 
H        0.498535    0.128750    2.258511 
H       -1.177989   -0.386617    2.510945 
H       -0.705900    1.295272    2.818435 
C       -2.929210    2.504312    0.906261 
H       -2.600330    2.816610    1.902418 
H       -4.023010    2.514090    0.895564 
H       -2.587057    3.253228    0.188466 
C       -2.591562    1.554201   -1.949409 
H       -3.373261    2.321426   -1.909919 
H       -1.629895    2.071990   -1.915815 
H       -2.668369    1.040162   -2.909507 
C       -4.926350   -2.412671    0.000305 
H       -4.710692   -3.469362    0.174377 
H       -5.526805   -2.323510   -0.909698 
H       -5.548583   -2.058636    0.829229 
C       -0.155596   -2.767434   -0.263762 
H       -0.556924   -3.773447   -0.123937 
H        0.183545   -2.681829   -1.302623 
H        0.731250   -2.652336    0.367777 
C       -0.044938    1.962790    0.265144 
H       -0.549218    2.920434    0.173636 
C        1.275362    1.975056    0.002976 
C        1.953668    3.250546   -0.425128 
H        2.764423    3.516599    0.260652 
H        2.396173    3.145804   -1.421107 
H        1.243572    4.078530   -0.453904 
C        2.105371    0.776595    0.117363 
H        1.639422   -0.138209    0.467322 
C        3.411807    0.707389   -0.173013 
H        3.983215    1.554696   -0.532616 
C        4.132365   -0.567870   -0.015314 
O        3.656752   -1.611582    0.377424 
O        5.421773   -0.440552   -0.371137 
C        6.227242   -1.618724   -0.266358 
H        5.841941   -2.406620   -0.915889 
H        7.224019   -1.323059   -0.586967 
H        6.254363   -1.975444    0.764614 
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8.5 Supporting Information for Chapter 3.4 
8.5.1 Experimental Procedures for Chapter 3.4 
 
Enol triflate 3.93. 
Synthetic procedure described for enol triflate 33 in Chapter 3.3. 
This reaction also gave small amounts of exo-methylene 3.93. Purification by flash column chromatography 
on silica gel (EtOAc/Hexanes, 0%, then 0.5%) allowed for isolation of enol triflate 3.93 as a colourless oil, 
(3.0 mg, 4.7 µmol, 13% yield). 
1H NMR (400 MHz, CDCl3) δ 7.60 (t, J = 8.5 Hz, 4H), 7.44–7.33 (m, 6H), 5.59 (s, 1H), 5.38 (s, 1H), 4.95 (s, 1H), 
4.56 (s, 1H), 3.69 (dd, J = 10.5, 3.8 Hz, 1H), 3.53 (dd, J = 10.4, 3.4 Hz, 1H), 2.99 (dd, J = 9.2, 3.5 Hz, 1H), 2.58 
(d, J = 9.1 Hz, 1H), 2.15 (q, J = 7.3 Hz, 1H), 2.03 (d, J = 13.0 Hz, 1H), 1.88 (d, J = 13.0 Hz, 1H), 1.79 (s, 3H), 1.71 
(q, J = 3.7 Hz, 1H), 1.30 (s, 3H), 1.06 (s, 3H), 1.05–0.99 (m, 12H) 
13C NMR (100 MHz, CDCl3) δ 152.88, 152.45, 135.70, 135.31, 133.67, 133.51, 131.16, 129.54, 127.54, 121.30, 
118.43, 66.55, 56.07, 53.18, 52.66, 45.79, 44.38, 42.43, 39.87, 28.90, 27.13, 26.80, 24.62, 19.28, 18.82 
HRMS (+ESI): calc. for C35H44F3O4SSi [M+H]+   645.2676, found 645.2668 
RF = 0.90 (5% Et2O in hexanes) 
 
 
 
 
 
Tetramic acid 3.94. 
To a solution of phosphonate 3.74 (8.24 mg, 26.0 µmol, 1.50 equiv.) in THF (0.6 mL) at 0 ºC was added LiOt-
Bu (4.2 mg, 52 µmol, 3.0 equiv.). The orange suspension was stirred at 0 ºC for 30 min after which 3.97 (1.6 
µL, 17 µmol, 1.0 equiv.) was added. The reaction was stirred at room temperature for 18 h. 
A saturated aqueous solution of NH4Cl (0.4 mL) was added and all solvents were evaporated under reduced 
pressure. To the remaining residue was added acetone (0.8 mL) and the resulting suspension was stirred 
for 20 min at room temperature. The mixture was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure and submitted to HPLC purification (H2O/ACN, gradient, 40 to 90%) 
yielding 3.94 (3.8 mg, 16.2 µmol, 97% yield) as yellow oil, 1H NMR shows two isomers in ratio 1:0.25. 
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1H NMR (400 MHz, CDCl3, * denotes minor isomer) δ 7.24–7.07 (m, 2H+2H*), 4.09 (dd, J = 9.9, 6.9 Hz, 1H*), 
3.99 (dd, J = 10.1, 6.9 Hz, 1H), 3.78 (dt, J = 11.4, 7.9 Hz, 1H+1H*), 3.30 (ddd, J = 11.8, 8.9, 4.0 Hz, 1H), 3.25 
(ddd, J = 11.9, 8.0, 4.0 Hz, 1H*), 2.62 (dq, J = 13.4, 6.6 Hz, 1H+1H*), 2.26 – 2.02 (m, 3H+3H*), 1.56 (dt, J = 
20.5, 10.1 Hz, 1H+1H*), 1.14 (d, J = 6.8 Hz, 6H+6H*) 
13C NMR (100 MHz, CDCl3, * denotes minor isomer) δ 202.4*, 195.1, 177.5, 176.0*, 174.7, 175.6*, 174.3, 
170.7*, 157.7*, 156.8, 118.7, 118.3*, 101.4, 68.8, 66.4*, 43.4*, 43.1, 32.2*, 32.0, 27.2*, 27.1*, 26.9, 26.8, 
21.3, 21.2*  
IR (ATR): 3350 (br w), 2962 (m), 2927 (m), 1700 (s), 1640 (s), 1582 (s), 1363 (m), 1244 (m), 1191 (m), 1025(w), 
911 (s), 729 (s) 
HRMS (+ESI): calc. for C13H17NNaO3 [M+Na]+ 258.1101 found 258.1110 
[𝜶]𝑫
𝟐𝟔 −11.6º (c 0.17, CHCl3) 
RF = 0.35 (1% MeOH in DCM) 
 
 
 
 
 
 
Tetramic acid 3.95. 
To a solution of phosphonate 3.74 (8.24 mg, 26.0 µmol, 1.50 equiv.) in THF (0.6 mL) at 0 ºC was added LiOt-
Bu (4.2 mg, 52 µmol, 3.0 equiv.). The orange suspension was stirred at 0 ºC for 30 min after which 3.98 (2.0 
µL, 17 µmol, 1.0 equiv.) in THF (120 µL) was added. The reaction was stirred at room temperature for 4 h. 
A saturated aqueous solution of NH4Cl (0.4 mL) was added and all solvents were evaporated under reduced 
pressure. To the remaining residue was added acetone (0.6 mL) and the resulting suspension was stirred 
for 20 min at room temperature. The mixture was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure and submitted to HPLC purification (H2O/ACN, gradient, 40 to 90%) 
yielding 3.95 (3.6 mg, 13.1 µmol, 75% yield) as yellow oil, 1H NMR shows two isomers in ratio 1:0.25. 
1H NMR (400 MHz, CDCl3, * denotes minor isomer) δ 13.66 (br s, 1H), 7.20–7.03 (m, 2H+2H*), 4.06 (dd, J = 
9.9, 6.9 Hz, 1H*), 3.96 (dd, J = 10.1, 6.8 Hz, 1H), 3.75 (dt, J = 11.3, 7.9 Hz, 1H+1H*), 3.27 (ddd, J = 11.4, 8.8, 
4.0 Hz, 1H), 3.21 (ddd, J = 11.9, 8.0, 3.9 Hz, 1H*), 2.37-2.2 (m, 1H+1H*), 2.23-2.00 (3H+3H*), 1.79 (td, J = 
13.2, 3.2 Hz, 4H+4H*), 1.69 (br d, J = 16.1, 1H+1H*), 1.53 (dtd, J = 11.6, 10.1, 8.4 Hz, 1H+1H*), 1.39-1.12 
(5H+5H*) 
13C NMR (100 MHz, CDCl3, * denotes minor isomer) δ 203.0*, 195.12, 194.81*, 177.49, 176.07*, 174.73, 
156.60*, 155.68, 119.05*, 116.1*, 105.8*, 101.36, 68.74, 66.42*, 43.37*, 43.11, 41.52, 31.69, 31.67, 31.61, 
31.58*, 27.14*, 27.04*, 26.88, 26.85, 25.86, 25.62, 25.60*. 
IR (ATR): 3320 (br w), 2924 (s), 2852 (m), 1702 (s), 1638 (s), 1575 (s), 1429 (s), 1352 (m), 1242 (m), 986(w), 
945 (w), 731 (w) 
HRMS (+ESI): calc. for C13H17NNaO3 [M+H]+ 298.1414 found 298.1401 
[𝜶]𝑫
𝟐𝟔 −35.08 (c 0.32, CHCl3) 
RF = 0.38 (1% MeOH in DCM) 
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8.6 Supporting Information for Chapter 6.1 
8.6.1 Experimental Procedures for Chapter 6.1 
 
 
 
 
The synthesis of Benzhydrol 6.27 was accomplished by a modification of the procedure by Knochel et 
al.[325]  
Benzhydrol 6.27. 
A dry flask was charged with 2-iodonitrobenzene (500 mg, 2.01 mmol, 1.00 equiv.). Dry THF (8.0 mL) was 
added and the mixture was cooled to −40°C. PhMgBr (0.74 mL, 2.21 mmol, 1.10 equiv., 3M in THF) was 
added dropwise. The I-Mg exchange was complete after 5 min. 2-nitrobenzaldehyde (364 mg, 2.41 mmol, 
1.20 equiv.) was added to the Grignard. The reaction was stirred for 30 min at −40°C.  
A saturated NH4Cl solution (2.0 mL) was added to the reaction mixture and the mixture was poured into 
water (25 mL). The aqueous phase was extracted five times with DCM and the combined organic layers 
were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. Purification 
of the crude material by flash column chromatography on silica gel (EtOAc/Hexanes 35%) afforded 
benzhydrol 6.27 as a brown solid, (480 mg, 1.75 mmol, 87% yield). 
1H NMR (400 MHz, CDCl3) δ 8.05 (dd, J = 8.1, 1.1 Hz, 2H), 7.66–7.57 (m, 4H), 7.50 (ddd, J = 8.7, 7.2, 1.8 Hz, 
2H), 6.93 (d, J = 4.2 Hz, 1H), 3.60 (d, J = 4.2 Hz, 1H) 
13C NMR (100 MHz, CDCl3) δ 148.00, 136.97, 133.77, 128.89, 128.79, 125.06, 67.47 
IR (ATR): 3525 (br w), 1750 (w), 1682 (w), 1608 (w), 1577 (w), 1520 (s), 1342 (s), 1297 (m), 1176 (m), 1078 
(w), 1024 (m), 933 (w), 855 (m), 737 (s) 
HRMS (+ESI): calc. for C13H9N2O4 [M-OH]+ 257.0557 found 257.0555 
RF = 0.51 (40% EtOAc in hexanes) 
 
Azobenzophenone 6.23. 
To a solution of benzhydrol 6.27 (100 mg, 0.365 mmol, 1.00 equiv.) in pyridine (3.7 mL) at 10 ºC was added 
TsCl (139 mg, 0.729 mmol, 2.00 equiv.) and the mixture was stirred at the same temperature for 34 hours 
before it was warmed up to room temperature and stirred for 54 additional hours. The solvent was 
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evaporated under reduced pressure at 22 ºC and the crude material containing 6.30 was immediately 
submitted to the following step. 
The crude material was dissolved in acetic acid (2.2 mL) and aniline (40 µL, 0.422 mmol, 1.00 equiv.) was 
added. The reaction mixture was stirred at room temperature for 48 h, after which more aniline (40 µL, 
0.422 mmol, 1.00 equiv.) was added and the reaction was stirred for additional 48 h. 
Water and DCM were added to the mixture. The phases were separated and the aqueous layer was 
extracted four times with DCM. The organic layers were combined, washed with saturated aqueous 
bicarbonate and brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to 
afford a red solid.  
Purification of the crude material by flash column chromatography on silica gel (EtOAc/Hexanes 15%) 
afforded benzhydrol 6.27 as an intense red solid (74 mg, 0.223 mmol, 54% yield). 
1H NMR (400 MHz, CDCl3) δ 8.08 (dd, J = 7.7, 1.5 Hz, 1H), 7.93 (dd, J = 8.2, 0.9 Hz, 1H), 7.70 – 7.55 (m, 4H), 
7.51 (dd, J = 7.6, 1.4 Hz, 1H), 7.47 (ddd, J = 8.3, 7.5, 1.5 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.36 – 7.27 (m, 4H) 
13C NMR (100 MHz, CDCl3) 193.38, 152.19, 151.21, 146.75, 138.65, 133.97, 133.61, 133.45, 131.65, 130.69, 
130.62, 130.05, 129.05, 128.79, 124.08, 123.09, 116.68 
HRMS (+ESI): calc. for C19H14N3O3 [M+H]+ 332.1030 found 332.1031 
 
 
Imidazole 6.33. 
To a solution of azobenzophenone 6.23 (47.0 mg, 0.142 mmol, 1.00 equiv.) in EtOH/Dioxane (1.2 mL each) 
at room temperature was added a solution of sodium sulfide nonahydrate (136 mg, 0.567 mmol, 4.00 
equiv.) in water (0.47 mL) and the mixture was stirred in a microwave at 130 ºC for 35 minutes.  
After cooling to room temperature the mixture was partitioned between water and Et2O. The organic layer 
was separated and the aqueous phase was extracted twice with Et2O. The organic layers were combined, 
washed with saturated aqueous bicarbonate, water, dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure to afford a yellowish solid containing pure 6.33 (30 mg, 0.105 mmol, 
74% yield). 
1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.50 (d, J = 7.8 Hz, 2H), 7.36 (dt, 
J = 10.6, 7.1 Hz, 4H), 7.22 (t, J = 8.4 Hz, 1H), 7.16 – 7.07 (m, 1H), 6.99 (dd, J = 7.6, 1.1 Hz, 1H), 6.78 (d, J = 8.1 
Hz, 1H), 6.73 (t, J = 7.5 Hz, 1H) 
HRMS (+ESI): calc. for C19H19N4 [M+NH4]+ 303.1604 found 303.1583 
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Benzophenone S6.1. 
MnO2 (8.350 g, 96.0 mmol, 10.3 equiv.) was added to a solution of 6.23 (2.56 g, 9.34 mmol, 1.00 equiv.) in 
DCM (44 mL) and the reaction mixture was refluxed for 22 h (40 °C) before more MnO2 (1.28 g, 14.8 mmol, 
1.5 equiv.) was added and the suspension was stirred for an additional 2 h. 
The suspension was filtered trough a pad of celite and washed with DCM. The filtrate was concentrated 
under reduced pressure affording a white solid (2.30 g, 8.45 mmol, 91% yield). 
1H NMR (400 MHz, CDCl3) δ 7.97 (dd, J = 5.9, 3.5 Hz, 1H), 7.70 (dd, J = 6.0, 3.4 Hz, 2H), 7.61 (dd, J = 5.8, 3.4 
Hz, 1H) 
13C NMR (100 MHz, CDCl3) δ 189.77, 148.24, 132.95, 132.72, 132.48, 130.51, 124.43 
HRMS (+APCI): calc. for C13H9N2O5 [M+H]+ 273.0506 found 273.0505 
RF = 0.36 (40% EtOAc in hexanes) 
 
 
Diamine 6.37. 
To a stirred solution of S6.1 (61 mg, 0.224 mmol, 1.00 equiv.) in DCM (9.8 mL) was added Pd/C (10% Pd on 
activated charcoal, 23.8 mg, 0.022 mmol, 0.10 equiv.) and the reaction vessel was backfilled three times 
with H2. The mixture was stirred under H2 atmosphere for 20 h before it was filtered through a pad of Celite 
washing with DCM. The solvent was evaporated under reduced pressure and submitted to purification by 
flash column chromatography on silica gel (EtOAc/Hexanes 20%), which delivered diamine 6.37 as an 
intense yellow solid (47 mg, 0.221 mmol, 99% yield). 
1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 7.9, 1.4 Hz, 2H), 7.26 (dd, J = 15.4, 1.5 Hz, 2H), 6.73 (dd, J = 8.2, 0.9 
Hz, 2H), 6.69 – 6.60 (m, 2H), 5.45 (br s, 4H) 
13C NMR (100 MHz, CDCl3) δ 200.18, 149.28, 133.26, 133.05, 120.92, 116.88, 115.90 
IR (ATR): 3469 (br m), 3355 (br m), 3026 (w), 2360 (w), 1604 (s), 1578 (s), 1542 (s), 1483 (s), 1450 (s), 1299 
(s), 1237 (s), 1158 (s), 1029 (w), 929 (s), 749 (s) 
HRMS (+APCI): calc. for C13H13N2O [M+H]+ 213.1022 found 213.1024 
RF = 0.28 (20% EtOAc in hexanes) 
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Azobenzophenone 6.15. 
6.37 (550 mg, 2.59 mmol, 1.00 equiv.) and nitrosobenzene (278 mg, 2.59 mmol, 1.00 equiv.) were dissolved 
in acetic acid  (18 mL). The reaction mixture was stirred at room temperature for 24 h before additional 
nitrosobenzene (55.6 mg, 0.518 mmol, 0.20 equiv.) were added. The mixture was further stirred for 24 
hours, after which additional nitrosobenzene (139 mg, 1.30 mmol, 0.50 equiv.) was added. The reaction was 
stirred for an additional 48 h before the solvent was evaporated under reduced pressure. The brown residue 
was submitted to purification by flash column chromatography on silica gel (EtOAc/hexanes, gradient, 10 
to 15%) affording azobenzophenone 6.15 as a red solid (630 mg, 1.61 mmol, 62% yield). 
1H NMR (400 MHz, CDCl3) δ 7.93 (dd, J = 7.9, 1.1 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.56 (td, J = 7.4, 1.5 Hz, 1H), 
7.50 (dd, J = 7.4, 1.6 Hz, 1H), 7.37 (dd, J = 5.2, 1.7 Hz, 3H), 7.20 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.14 (dd, J = 
8.1, 1.4 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.43 (t, J = 8.1 Hz, 1H), 6.37 (br s, 2H) 
13C NMR (100 MHz, CDCl3) δ 199.23, 152.17, 150.35, 149.66, 138.29, 134.42, 134.30, 131.17, 130.73, 129.97, 
128.89, 128.11, 122.95, 119.71, 119.35, 116.64, 115.68 
IR (ATR): 3475 (br m), 3345 (br m), 3060 (w), 2359 (w), 2342 (w), 1610 (s), 1583 (s), 1548 (s), 1479 (m), 1450 
(m), 1302 (s), 1244 (s), 1159 (m), 933 (m), 774 (s), 751 (s) 
HRMS (+ESI): calc. for C19H15N3NaO [M+Na]+ 324.1107 found 324.1111 
RF = 0.28 (15% EtOAc in hexanes) 
 
Azobenzophenone 6.38. 
To a solution of 6.15 (271 mg, 0.896 mmol, 1.00 equiv.) in toluene (2.0 mL) at 10 ºC was slowly added 
chloroacetyl chloride (76.0 µL, 0.953 mmol, 1.06 equiv.). The reaction mixture was stirred at room 
temperature for 3 h before the solvent was evaporated under reduced pressure. 
To the crude residue was added 96% ethanol (0.87 mL) and the resulting mixture was stirred at room 
temperature for 20 hours. The suspension was filtered and the remaining solid was washed with 96% 
ethanol (3 x 0.2 mL). The solid was dried under high vacuum over 3 days yielding 6.38 as a red solid (308 
mg, 0.815 mmol, 91% yield). 
1H NMR (400 MHz, CDCl3) δ 12.35 (s, 1H), 8.71 (d, J = 8.5 Hz, 1H), 8.00 (dd, J = 7.8, 0.9 Hz, 1H), 7.69 (td, J = 
7.6, 1.6 Hz, 1H), 7.61 (td, J = 7.4, 1.2 Hz, 1H), 7.56 (dd, J = 7.5, 1.4 Hz, 1H), 7.51–7.43 (m, 3H), 7.40–7.33 (m, 
3H), 7.31 (dd, J = 7.9, 1.5 Hz, 1H), 6.95 (t, J = 8.2 Hz, 1H), 4.26 (s, 2H) 
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13C NMR (100 MHz, CDCl3) δ 200.69, 165.71, 151.75, 150.08, 139.31, 135.78, 134.51, 133.29, 131.65, 131.05, 
130.89, 129.04, 128.41, 124.47, 123.24, 122.74, 121.79, 120.55, 43.32 
IR (ATR): 3201 (br w), 3060 (br w), 1685 (m), 1640 (m), 1582 (m), 1518 (s), 1446 (s), 1295 (m), 1275 (m), 
1247 (s), 1159 (m), 963 (w), 927 (m), 753 (s) 
HRMS (+ESI): calc. for C21H17ClN3O2 [M+H]+ 378.1004 found 378.1008 
RF = 0.52 (30% EtOAc in hexanes) 
 
 
Benzodiazepine 6.13. 
To a suspension of ammonium chloride (39.6 mg, 0.741 mmol, 3.00 equiv.) and urotropine (79.2 mg, 0.565 
mmol, 2.27 equiv.) in EtOH (950 µL) was added 6.38 (94.0 mg, 0.249 mmol, 1.00 equiv.) and the mixture 
was stirred in the microwave at 85 ºC for 10 h. 
The crude mixture was partitioned between water and ethyl acetate. The phases were separated and the 
aqueous phase was extracted twice with EtOAc. The organic layers were put together, dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure affording an orange solid. 
Purification by flash column chromatography on silica gel, (EtOAc/Hexanes, gradient 0 to 40%) afforded 
benzodiazepine 6.13 as an intense red crystalline solid (42.7 mg, 125 µmol, 50% yield). 
1H NMR (400 MHz, CDCl3) δ 9.06 (s, 1H), 7.81–7.75 (m, 1H), 7.70–7.65 (m, 1H), 7.61–7.54 (m, 2H), 7.34–7.27 
(m, 6H), 7.06 (dd, J = 16.4, 8.0 Hz, 2H), 6.94 (t, J = 7.6 Hz, 1H), 4.45 (s, 2H) 
13C NMR (100 MHz, CDCl3) δ 171.60, 171.48, 152.21, 150.30, 138.83, 136.98, 131.19, 131.16, 130.72, 
130.46, 130.17, 130.00, 128.78, 123.65, 122.71, 120.55, 116.93, 56.66. 
IR (ATR): 3063 (br w), 2969 (br w), 2922 (br w), 2359 (w), 1680 (s), 1611 (m), 1483 (m), 1370 (m), 1329 (w), 
1235 (w), 1017 (w), 774 (m), 756 (m) 
HRMS (+ESI): calc. for C21H17N4O [M+H]+ 341.1397 found 341.1395 
RF = 0.18 (50% EtOAc in hexanes) 
λmax = 325 nm 
t1/2 = 2.6 s 
PSS (Z/E, 5 min 365 nm) >33/66 (1H NMR spectroscopy in saturated CDCl3). The fast thermal relaxation 
greatly enriches the mixture with E-isomer. 
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8.6.2 Crystallographic Data for Chapter 6.1 
8.6.2.1 Azobenzophenone 6.23 
 
Identification code 18dtr5h 
Chemical formula C19H13N3O3 
Formula weight 331.32 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.150 x 0.260 x 0.450 mm 
Crystal habit red block 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 7.1461(6) Å  
 b = 13.1648(11) Å  
 
c = 16.4572(13) Å 
α = 90° 
β = 90° 
γ = 90° 
  
 
Volume 1548.2(2) Å3  
Z 4 
Density (calculated) 1.421 g/cm3 
Absorption coefficient 0.099 mm-1 
F(000) 688 
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, Mo 
Theta range for data collection 1.98 to 28.28° 
Index ranges -9<=h<=9, -17<=k<=17, -21<=l<=21 
Reflections collected 19353 
Independent reflections 3838 [R(int) = 0.0349] 
Coverage of independent 
reflections 
100.0% 
Absorption correction multi-scan 
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Max. and min. transmission 0.7457 and 0.7046 
Structure solution technique direct methods 
Structure solution program SHELXT (Sheldrick 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018 (Sheldrick 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3838 / 0 / 226 
Goodness-of-fit on F2 1.080 
Final R indices 
 
3583 data; I>2σ(I) R1 = 0.0352, wR2 = 
0.0918  
 
 all data R1 = 0.0381, wR2 = 0.0936  
Weighting scheme 
w=1/[σ2(Fo2)+(0.0580P)2+0.0567P] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter -0.2(4) 
Largest diff. peak and hole 0.324 and -0.203 eÅ-3 
R.M.S. deviation from mean 0.042 eÅ-3 
 
 
8.6.2.2 Azobenzodiazepine 6.13 
 
 
Identification code 19dtr4h 
Chemical formula C21H16N4O 
Formula weight 340.38 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.350 x 0.450 x 0.560 mm 
Crystal habit red prism 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 9.4667(6) Å  
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 b = 16.9844(10) Å  
 
c = 10.6023(6) Å 
α = 90° 
β = 93.5402(9)° 
γ = 90°  
 
Volume 1701.45(18) Å3  
Z 4 
Density (calculated) 1.329 g/cm3 
Absorption coefficient 0.085 mm-1 
F(000) 712 
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, MoKα 
Theta range for data collection 2.15 to 28.29° 
Index ranges -12<=h<=12, -22<=k<=22, -14<=l<=14 
Reflections collected 32741 
Independent reflections 4223 [R(int) = 0.0263] 
Coverage of independent reflections 100.0% 
Absorption correction multi-scan 
Max. and min. transmission 0.7457 and 0.7142 
Structure solution technique direct methods 
Structure solution program SHELXT (Sheldrick 2015) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018/3 (Sheldrick, 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4223 / 0 / 239 
Goodness-of-fit on F2 1.006 
Final R indices 
3772 
data; 
I>2σ(I) 
R1 = 0.0397, wR2 = 0.1104 
 all 
data 
R1 = 0.0440, wR2 = 0.1148 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0721P)2+0.4791P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.412 and -0.181 eÅ-3 
R.M.S. deviation from mean 0.046 eÅ-3 
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8.7 Supporting Information for Chapter 6.2 
8.7.1 Experimental Procedures for Chapter 6.2 
 
 
The synthesis Nicotinic hydrazide was accomplished by a modification of the procedure by Farag et al.[335]  
Nicotinic hydrazide. 
Hydrazine monohydrate (0.40 mL, 8.2 mmol, 2.0 equiv.) was added to a solution of nicotinamide (500 mg, 
4.09 mmol, 1.00 equiv.) in absolute ethanol (8.2 mL) and the resulting mixture was stirred at 80 ºC for 24 h.  
The mixture was allowed to cool down to room temperature and the solvent was removed under reduced 
pressure. The remaining solid was recrystallized from ethanol yielding nicotinic hydrazide (475 mg, 3.46 
mmol, 85% yield) as colourless crystals.  
1H NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 8.96 (d, J = 2.1 Hz, 1H), 8.69 (dd, J = 4.9, 1.5 Hz, 1H), 8.20–8.10 
(m, 1H), 7.49 (dd, J = 8.0, 4.8 Hz, 1H), 4.56 (s, 2H) 
HRMS (+ESI): calc. for C6H8N3O [M+H]+ 138.0662 found 138.0666 
 
 
Triazolopyridazine 6.41. 
A suspension of nicotinic hydrazide (500 mg, 3.65 mmol, 1.5 equiv.) and 2,6-dichloropyridazine (362 mg, 
2.42 mmol, 1.00 equiv.) in n-BuOH (22 mL) was stirred in the microwave at 125 ºC for 1 h. 
The solvent was removed under reduced pressure and the remaining residue was purified by flash column 
chromatography on silica gel (MeOH/DCM, gradient 0 to 4%), which afforded 6.41 as a pale brown solid 
(484 mg, 2.09 mmol, 86% yield). 
1H NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 8.78 (d, J = 4.8 Hz, 1H), 8.63 (d, J = 8.1 Hz, 1H), 8.60 (d, J = 9.7 
Hz, 1H), 7.69 (t, J = 7.9, 4.9 Hz, 1H), 7.62 (d, J = 9.7 Hz, 1H). 
HRMS (+ESI): calc. for C10H7ClN5 [M+H]+ 232.0384 found 232.0384 
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Triazolopyridazine 6.42. 
To a solution of 6.41 (65.0 mg, 0.280 mmol, 1.00 equiv.) and 3-chloro-phenylhydrazine (50.2 mg, 0.280 
mmol, 1.00 equiv.) in Et2O (1.2 mL) at −78 ºC was added n-BuLi (2.33 M in hexane, 0.48 mL, 4.0 equiv.) 
dropwise over 30 minutes. After stirring at room temperature for 12 hours, the reaction was quenched with 
MeOH and the solvent was removed under reduced pressure. The remaining residue was partitioned 
between water and DCM. The aqueous phase was extracted with DCM (3x10 mL) and the organic layers 
were combined, washed with brine (15 mL), dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. The crude material was purified by flash column chromatography on silica gel 
(MeOH/DCM, gradient 0 to 3%), delivering 6.42 as a pale white solid (60.5 mg, 1.79 mmol, 64% yield). 
1H NMR (400 MHz, CDCl3) δ 9.73 (s, 1H), 8.76–8.68 (m, 2H), 7.93 (d, J = 10.1 Hz, 1H), 7.49–7.44 (m, 2H), 7.41 
(t, J = 8.0 Hz, 1H), 7.31 (dddd, J = 7.9, 5.9, 2.2, 1.1 Hz, 2H), 7.18 (d, J = 10.1 Hz, 1H), 4.67 (br s, 2H) 
13C NMR (100 MHz, CDCl3) δ 155.44, 150.60, 148.04, 144.92, 144.06, 135.29, 134.61, 132.85, 130.55, 127.15, 
125.22, 124.89, 123.60, 122.76, 114.81, 113.91 
IR (ATR): 3671 (br w), 2975 (m), 2939 (m), 2867 (w), 2191 (w), 1631 (w), 1592 (m), 1545 (m), 1477 (s), 1413 
(m), 1382 (m), 1341 (m), 1246 (w), 1054 (s), 1034 (s), 994 (m), 962 (w), 810 (m), 759 (m), 705 (s) 
HRMS (+ESI): calc. for C16H13ClN7 [M+H]+ 338.0915 found 338.0908 
RF = 0.67 (4% MeOH in DCM) 
 
 
 
GALiZA-1 (6.40). 
The crude mixture containing an unknown proportion of hydrazines 6.42 and 6.43 (15.0 mg, 0.0445 mmol, 
1.00 equiv.) and KOt-Bu (1.0 mg, 9.4 µmol, 0.2 equiv.) was added to liquid ammonia (0.57 mL) at −33 °C. 
The mixture was stirred in an opened vial at −33 °C for 25 min and then the cooling bath was removed and 
the solvent was allowed to evaporate (about 5 min). The remaining residue was dissolved in Et2O, washed 
with water, brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude material was submitted to HPLC purification (H2O/ACN, gradient, 20 to 80%) yielding 6.40 as an 
orange solid (0.8 mg, 18 µmol, 5% yield). 
See below for full analytics. 
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Hydrazine 6.44. 
To a suspension of triazolopyridazine 6.41 (300 mg, 1.29 mmol, 1.00 equiv.) in toluene (2.0 mL) was added 
hydrazine monohydrate (0.490 mL, 98%, 9.90 mmol, 7.60 eq.) and the resulting mixture was heated at 70 
°C for 24 h. The volatile material was evaporated under reduced pressure and the remaining residue was 
recrystallized from MeOH. Hydrazine 6.44 (159 mg, 0.700 mmol, 54%) was obtained as a colourless solid. 
1H NMR (400 MHz, DMSO-d6): δ 9.64 (d, J = 2.3 Hz, 1H), 8.89 (d, J = 7.9 Hz, 1H), 8.69 (d, J = 4.7 Hz, 1H), 8.59 
(s, 1H), 8.02 (d, J = 9.9 Hz, 1H), 7.59 (dd, J = 8.1, 4.7 Hz, 1H), 6.87 (d, J = 9.9 Hz, 1H), 4.46 (br s, 2H) 
 
 
The synthesis Amine 6.45 was accomplished by following the procedure by Meiming et al.[338] 
To a stirred suspension of Mg powder (5.4 mg, 0.22 mmol, 2.5 equiv.) in degassed THF (0.90 mL) at 0 °C was 
added TiCl4 (3.9 µL, 35.2 mmol, 0.4 equiv.) dropwise. The resulting mixture was allowed to warm to room 
temperature and stirred for 2 hours. A solution of and hydrazine 6.44 (20.0 mg, 88 µmol, 1.00 equiv.) in THF 
(0.25 mL) was added and the mixture was stirred at room temperature for another 6 hours. 
A saturated aqueous solution of NaHCO3 was added and the resulting mixture was filtered through celite. 
The filtrate was extracted three times with DCM. The organic layers were combined, dried over MgSO4, 
filtered and concentrated under reduced pressure to yield a yellow crude which was purified by flash 
column chromatography on silica gel (MeOH/DCM, gradient, 0 to 15%) delivering 6.46 as a colourless solid 
(2.1 mg, 9.7 µmol, 11% yield). 
See below for analytics. 
 
 
Benzylamine 6.45. 
To a suspension of 6.41 (300 mg, 1.29 mmol, 1.00 equiv.) in toluene (2.0 mL) was added benzylamine (1.1 
mL, 9.9 mmol, 7.6 equiv.) and the solution was heated at 70 °C for 22 h. The volatile material was removed 
under reduced pressure. The crude residue was recrystallized from MeOH, yielding 6.45 (284 mg, 0.939 
mmol, 73%) as orange crystals. 
1H NMR (400 MHz, DMSO-d6): δ 9.47 (d, J = 2.1 Hz, 1H), 8.66 (dd, J = 4.9, 1.5 Hz, 1H), 8.57 (d, J = 8.1 Hz, 1H), 
8.17 (t, J = 5.6 Hz, 1H), 8.06 (d, J = 9.8 Hz, 1H), 7.55 (dd, J = 8.1, 4.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.37 (t, J 
= 7.5 Hz, 2H), 7.26 (t, J = 7.3 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 4.51 (d, J = 5.4 Hz, 2H) 
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Amine 6.45. 
A solution of benzylamine 6.45 (25.0 mg, 0.083 mmol, 1.00 equiv.) in concentrated sulfuric acid (0.23 mL, 
98%) was heated at 80 °C for 2 h. The reaction mixture was poured into ice-water (10 mL) and basified with 
aq. ammonia (5 mL, 30%). The aqueous phase was extracted with DCM (4 x 5.0 mL), AcOEt (4 x 5.0 mL) and 
the combined organic layers were washed with water (5.0 mL) and brine (5.0 mL). After drying with MgSO4, 
the solvent was removed under reduced pressure to yield amine 6.46 (16.0 mg, 0.075 mmol, 91%) as a 
colourless solid.  
1H NMR (400 MHz, DMSO-d6)  9.58 (d, J = 2.1 Hz, 1H), 8.72 (dd, J = 8.1, 2.1 Hz, 1H), 8.69 (dd, J = 4.8, 1.5 Hz, 
1H), 8.06 (d, J = 9.8 Hz, 1H), 7.60 (dd, J = 8.0), 7.00 (s, 2H), 6.86 (d, J = 9.8 Hz, 1H) 
 
The synthesis pyridazine 6.51 was accomplished following the method by Yamamoto et al.[339]  
Pyridazine 6.51. 
To a solution of 2,6-dichloropyridazine (998 mg, 6.70 mmol, 1.00 equiv.) and hydroxylamine hydrochloride 
(1.862 mg, 26.8 mmol, 4.00 equiv.) in EtOH (13.4 mL) was added Et3N (3.73 mL, 26.8 mmol, 4.0 equiv.). The 
reaction mixture was stirred at 80 ºC for 2 h.  
After cooling down to room temperature the solvent was evaporated under reduced pressure. The 
remaining residue was partitioned between water and EtOAc. The aqueous phase was separated and 
extracted thee times with EtOAc and the organic layers were combined, dried over anhydrous MgSO4, 
filtered and concentrated under reduced pressure delivering 6.51 as a yellow solid (950 mg, 6.53 mmol, 
97% yield). 
1H NMR (400 MHz, CDCl3) δ 12.14 (br s, 1H), 10.53 (br s, 1H), 7.25 (d, J = 9.6 Hz, 2H), 6.96 (d, J = 9.8 Hz, 1H) 
HRMS (+ESI): calc. for C4H5ClN3O [M+H]+ 146.0116 found 146.0117 
 
 
The synthesis nitrosopyridazine 6.51 was accomplished following the method by Yamamoto et al.[339] 
Azobenzene 6.49. 
To a round bottom flask charged with MnO2 (2.06 g, 23.7 mmol, 20 equiv.) was added dry DCM (30 mL) and 
the suspension was stirred for 20 min at rt. Then, MeOH (0.30 mL) was added, the mixture was cooled to 
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−10°C and 6.51 (172 mg, 1.18 mmol, 1.00 equiv.) was added in two equal portions. The mixture was stirred 
at −10°C for 30 min and at rt for 30 min before it was filtered through a pad of Celite and washed with DCM. 
The resulting solution was evaporated under reduced pressure below 20 ºC and immediately submitted to 
the next step. 
To the crude material containing 6.50 was added 3-chloroaniline (125 µL, 1.184 mmol, 1.00 equiv.) followed 
by AcOH (4.9 mL) and the mixture was stirred at rt for 3 h before water and DCM were added. The aqueous 
phase was extracted three times with DCM and the organic layers were combined, washed with brine, 0.5 
M aqueous HCl, water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure 
yielding a brown solid. 
Purification by flash column chromatography on silica gel (MeOH/DCM, gradient, 0 to 1%) delivered 6.49 as 
an orange solid (50.0 mg, 0.198 mmol, 17% yield for 2 steps). 
1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 8.00 (d, J = 7.7 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 9.0 Hz, 
1H), 7.60–7.49 (m, 2H) 
13C NMR (100 MHz, CDCl3) δ 164.88, 158.09, 152.73, 135.60, 133.13, 130.44, 130.37, 123.18, 123.15, 118.72 
IR (ATR): 3061 (br w), 2924 (m), 2852 (w), 1560 (m), 1460 (m), 1391 (s), 1179 (s), 1163 (m), 1073 (m), 885 
(m), 856 (m), 786 (m), 760 (m) 
HRMS (+ESI): calc. for C10H6Cl2N4Na [M+Na]+ 274.9862 found 274.9869 
RF = 0.45 (1% MeOH in DCM) 
λmax = 312 nm 
 
GALiZA-1 (6.40). 
A suspension of 6.49 (49.0 mg, 0.194 mmol, 1.00 equiv) and nicotinic hydrazide (39.8 mg, 0.290 mmol, 1.50 
equiv.) in n-BuOH (1.7 mL) was stirred in the microwave at 140 ºC for 1 h. 
The solvent was evaporated under reduced pressure yielding a brown residue which was purified by flash 
column chromatography on silica gel ((MeOH + 2% Et3N)/DCM, gradient, 0 to 10%) delivering GALiZA-1 as 
an orange solid (59.0 mg, 0.176 mmol, 91% yield). 
1H NMR (400 MHz, CDCl3, trans) δ 9.87 (s, 1H), 8.92 (d, J = 7.7 Hz, 1H), 8.81 (d, J = 4.6 Hz, 1H), 8.33 (d, J = 
9.9 Hz, 1H), 8.09 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.86 (d, J = 9.9 Hz, 1H), 7.59 (dt, J = 14.9, 7.7 Hz, 3H) 
1H NMR (400 MHz, CDCl3, cis) δ 9.37 (s, 1H), 8.74 (dd, J = 4.9, 1.6 Hz, 1H), 8.31 (dt, J = 8.0, 1.8 Hz, 1H), 8.25 
(d, J = 9.6 Hz, 1H), 7.47–7.43 (m, 1H), 7.26–7.20 (m, 2H), 7.13 (t, J = 1.8 Hz, 1H), 7.07 (d, J = 9.6 Hz, 1H), 6.70 
(dt, J = 7.0, 2.0 Hz, 1H) 
13C NMR (100 MHz, CDCl3) δ 159.82, 152.56, 151.34, 148.79, 146.97, 145.26, 135.76, 134.89, 133.60, 130.59, 
126.70, 123.64, 123.52, 123.00, 122.32, 112.18, 77.00 
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IR (ATR): 3428 (br w), 3.45 (br m), 2924 (w), 2853 (w), 2361 (w), 1576 (m), 1532 (m), 1471 (s), 1433 (s), 1417 
(s), 1375 (s), 1334 (s), 1281 (w), 1186 (s), 1154 (m), 1067 (w), 986 (m), 827 (m), 786 (m), 732 (m) 
HRMS (+ESI): calc. for C16H11ClN7 [M+H]+ 336.0759 found 336.0760 
RF = 0.45 (5% MeOH in DCM) 
λmax = 313 nm 
t1/2 = 40 min 
PSS (Z/E, 5 min 365 nm) = 25/75 (1H NMR spectroscopy in saturated CDCl3) 
 
 
Azobenzene 6.56. 
To the crude material containing 6.50 (run with 3.01 mmol of 6.51) was added 3-chloroaniline (328 µL, 3.01 
mmol, 1.00 equiv.) followed by AcOH (12 mL) and the mixture was stirred at rt for 3 h before water and 
DCM were added. The aqueous phase was basified by addition of sodium carbonate and extracted four 
times with DCM. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure yielding a brown solid. 
Purification by flash column chromatography on silica gel (MeOH/DCM, gradient, 0 to 1%) delivered 6.56 as 
an orange solid (214 mg, 0.719 mmol, 24% yield for 2 steps). 
1H NMR (400 MHz, CDCl3) δ 8.25 (t, J = 1.7 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 7.72 (d, J 
= 7.9 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H) 
13C NMR (100 MHz, CDCl3) δ 164.84, 158.09, 152.78, 136.02, 130.72, 130.37, 125.96, 123.75, 123.42, 118.70 
IR (ATR): 3057 (br m), 1558 (m),1457 (w), 1391 (s), 1177 (s), 1161 (m), 1140 (m), 1073 (w), 995 (w), 848 (m), 
790 (m), 752 (w) 
HRMS (+ESI): calc. for C10H6ClBrN4Na [M+Na]+ 318.9357 found 318.9366 
RF = 0.62 (1% MeOH in DCM) 
λmax = 314 nm 
 
GALiZA-2 (6.52). 
A suspension of 6.56 (60.0 mg, 0.202 mmol, 1.00 equiv) and nicotinic hydrazide (41.5 mg, 0.302 mmol, 1.50 
equiv.) in n-BuOH (2.4 mL) was stirred in the microwave at 145 ºC for 1 h. 
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The solvent was evaporated under reduced pressure yielding a brown residue which was purified by flash 
column chromatography on silica gel ((MeOH+ 2% Et3N)/DCM, gradient, 0 to 10%) delivering GALiZA-2 as 
an orange solid (75.0 mg, 0.197 mmol, 98% yield). 
1H NMR (400 MHz, CDCl3) δ 9.87 (d, J = 1.6 Hz, 1H), 8.92 (dt, J = 8.0, 1.8 Hz, 1H), 8.81 (dd, J = 4.8, 1.5 Hz, 1H), 
8.33 (d, J = 9.9 Hz, 1H), 8.25 (t, J = 1.7 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 9.9 Hz, 1H), 7.77 (d, J = 8.0 
Hz, 1H), 7.57 (dd, J = 8.0, 4.9 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H) 
13C NMR (100 MHz, CDCl3) δ 159.79, 152.64, 151.35, 148.81, 146.98, 145.26, 136.50, 134.89, 130.87, 126.71, 
125.83, 124.10, 123.64, 123.59, 122.32, 112.16 
IR (ATR): 3043 (br m), 2960 (m), 1574 (m), 1531 (m), 1466 (s), 1432 (s), 1416 (s), 1374 (s), 1333 (s), 1281 (w), 
1282 (s), 1153 (s), 1060 (m), 986 (s), 826 (m), 750 (s) 
HRMS (+ESI): calc. for C16H11BrN7 [M+H]+ 380.0254 found 380.0249 
RF = 0.45 (5% MeOH in DCM) 
λmax = 314 nm 
t1/2 = 62 min 
 
GALiZA-3 (6.53). 
A pressure vial was charged with 6.52 (14.8 mg, 38.9 µmol, 1.00 equiv), morpholine (10.2 µL, 117 µmol, 3.00 
equiv.), Cs2CO3 (19.1 mg, 58.5 mmol, 1.50 equiv.), XPhos (3.6 mg, 7.6 µmol, 0.19 equiv.) and degassed 
dioxane (20 min N2 sparging, 0.35 mL). The mixture was stirred at 95 ºC for 18 hours. 
Upon cooling down to room temperature the solvent was evaporated under reduced pressure and the 
remaining residue was partitioned between DCM and a half-saturated aqueous sodium carbonate solution. 
The phases were separated and the aqueous layer was extracted twice with DCM. The organic layers were 
combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure yielding a red solid which was purified by flash column chromatography on silica gel (MeOH/DCM, 
gradient, 0 to 10%) delivering GALiZA-3 as red solid (9.0 mg, 23 µmol, 60% yield). 
1H NMR (400 MHz, CDCl3, trans) δ 9.94 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.80 (d, J = 4.7 Hz, 1H), 8.30 (d, J = 
9.9 Hz, 1H), 7.89 (d, J = 9.9 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.59–7.54 (m, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.20 
(d, J = 8.3 Hz, 1H), 3.92 (dd, J = 9.3, 4.5 Hz, 4H), 3.31 (dd, J = 9.3, 4.7 Hz, 4H) 
1H NMR (400 MHz, CDCl3, cis) δ 9.43 (s, 1H), 8.74 (d, J = 4.8 Hz, 1H), 8.48 (d, J = 9.1 Hz, 1H), 8.14 (d, J = 9.6 
Hz, 1H), 7.47–7.42 (m, 1H), 7.10 (t, J = 8.3 Hz, 1H), 6.86 (d, J = 9.2 Hz, 1H), 6.78 – 6.73 (m, 2H), 6.10 (d, J = 
8.1 Hz, 1H), 3.82 (t, J = 4.8 Hz, 4H), 3.12 (t, J = 4.4 Hz, 4H) 
13C NMR (100 MHz, CDCl3) δ 160.13, 152.83, 152.16, 151.24, 148.72, 146.87, 145.38, 135.04, 130.06, 126.43, 
123.68, 122.48, 121.14, 118.60, 112.52, 107.42, 66.73, 48.82 
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IR (ATR): 2929 (br m), 2855 (m), 1595 (m), 1538 (w), 1485 (m), 1467 (m), 1449 (m), 1377 (s), 1333 (s), 1246 
(s), 1230 (s), 1153 (m), 1121 (s), 987 (m), 907 (m), 817 (w), 731 (w) 
HRMS (+ESI): calc. for C20H19N8O [M+H]+ 387.1676 found 387.1678 
RF = 0.39 (5% MeOH in DCM) 
λmax = 322 nm 
t1/2 = 22 min 
PSS (Z/E, 5 min 365 nm) = 17/83 (1H NMR spectroscopy in saturated CDCl3) 
 
 
GALiZA-3 (6.54). 
A microwave vial was charged with 6.52 (24.0 mg, 63.1 µmol, 1.00 equiv), Pd2(dba)3 (40.5 mg, 44.2 µmol, 
0.70 equiv), N-methylpiperazine (21.0 µL, 189 µmol, 3.00 equiv.), Cs2CO3 (30.9 mg, 94.8 mmol, 1.50 equiv.), 
XPhos (41.5 mg, 87.1 µmol, 1.38 equiv.) and degassed dioxane (freeze-pump-thaw, 3x10 min, 1.5 mL). The 
mixture was stirred in the microwave at 120 ºC for 1.5 hours. 
The reaction mixture was directly submitted to flash column chromatography on Brockman type I alumina 
(MeOH/DCM, 0% then 12%). The dark orange fractions were combined, washed with saturated ammonium 
chloride, brine and saturated aqueous sodium carbonate, then dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure yielding a red solid which was purified again by flash column 
chromatography on silica gel ((MeOH+2% Et3N)/DCM, gradient, 0 to 10%) delivering GALiZA-4 as an orange 
solid (7.6 mg, 19 µmol, 30% yield). 
1H NMR (400 MHz, CDCl3, trans) δ 9.93 (dd, J = 2.1, 0.7 Hz, 1H), 8.91 (dt, J = 8.0, 1.9 Hz, 1H), 8.80 (dd, J = 4.8, 
1.7 Hz, 1H), 8.30 (d, J = 9.9 Hz, 1H), 7.89 (d, J = 9.9 Hz, 1H), 7.62–7.58 (m, 2H), 7.56 (ddd, J = 8.0, 4.9, 0.8 Hz, 
1H), 7.49 (t, J = 8.0 Hz, 1H), 7.22 (dd, J = 8.2, 2.8 Hz, 1H), 3.37 (dd, J = 10.0, 4.9 Hz, 4H), 2.64 (dd, J = 9.5, 4.8 
Hz, 4H), 2.39 (s, 3H) 
1H NMR (400 MHz, CDCl3, cis) δ 9.49 (d, J = 2.2 Hz, 1H), 8.74 (dd, J = 4.8, 1.7 Hz, 1H), 8.47 (dt, J = 8.1, 2.0 Hz, 
1H), 8.12 (d, J = 9.6 Hz, 1H), 7.46–7.43 (m, 1H), 7.08 (t, J = 7.9 Hz, 1H), 6.81 (d, J = 9.6 Hz, 1H), 6.79–6.75 (m, 
2H), 6.10 (dd, J = 7.8, 2.2 Hz, 1H), 3.17 (t, J = 5.1 Hz, 4H), 2.51 (t, J = 5.1 Hz, 4H), 2.33 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 160.19, 152.86, 152.08, 151.22, 148.76, 146.87, 145.38, 135.01, 129.97, 126.39, 
123.65, 122.49, 121.38, 117.81, 112.59, 108.02, 54.91, 48.54, 46.13 
IR (ATR): 2924 (s), 2852 (m), 2361 (br w), 1729 (s), 1609 (s), 1465 (s), 1378 (m), 1333 (m), 1291 (w), 1251 
(m), 1153 (m), 1116 (w), 1000 (w), 821 (m) 
HRMS (+ESI): calc. for C21H22N [M+H]+ 400.1993 found 400.1997 
RF = 0.36 (10% MeOH in DCM) 
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λmax = 322 nm 
t1/2 = 155 min 
PSS (Z/E, 5 min 365 nm) = 13/87 (1H NMR spectroscopy in saturated CDCl3) 
 
 
GALiZA-3 (6.55). 
A microwave vial was charged with 6.52 (24.0 mg, 63.1 µmol, 1.00 equiv), Pd2(dba)3 (40.5 mg, 44.2 µmol, 
0.70 equiv), S6.2 (47 mg, 189 µmol, 3.00 equiv.), Cs2CO3 (123 mg, 379 µmol, 6.00 equiv.), XPhos (41.5 mg, 
87.1 µmol, 1.38 equiv.) and degassed dioxane (freeze-pump-thaw, 3x10 min, 1.5 mL). The mixture was 
stirred in the microwave at 125 ºC for 1 hour. 
The reaction mixture was directly submitted to flash column chromatography on Brockman type I alumina 
(MeOH/DCM, 0% then 12%). The dark orange fractions were combined, washed with saturated ammonium 
chloride, brine and saturated aqueous sodium carbonate, then dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure yielding a red solid which was purified again by flash column 
chromatography on silica gel ((MeOH+2% Et3N)/DCM, gradient, 0 to 10%) delivering GALiZA-5 as an orange 
solid (15.0 mg, 34.5 µmol, 30% yield). 
1H NMR (400 MHz, DMSO-d6, trans) δ 9.95 (d, J = 1.6 Hz, 1H), 8.89 (dt, J = 8.0, 1.9 Hz, 1H), 8.82 (dd, J = 4.8, 
1.6 Hz, 1H), 8.32 (d, J = 9.9 Hz, 1H), 7.89 (d, J = 9.9 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.61–7.54 (m, 3H), 7.21 
(dd, J = 8.1, 2.3 Hz, 1H), 4.01 (dd, J = 10.4, 5.2 Hz, 4H), 3.19 (dd, J = 10.2, 5.3 Hz, 4H) 
1H NMR (400 MHz, DMSO-d6, cis) δ 9.08 (s, 1H), 8.73 (d, J = 3.7 Hz, 1H), 8.54 (d, J = 9.7 Hz, 1H), 8.38 (d, J = 
7.9 Hz, 1H), 7.60 (dd, J = 8.0, 4.7 Hz, 1H), 7.37 (d, J = 9.7 Hz, 1H), 7.16–7.06 (m, 2H), 6.93 (dd, J = 8.2, 2.3 Hz, 
1H), 6.21 (d, J = 8.7 Hz, 1H), 3.92 (t, J = 5.2 Hz, 4H), 3.07 (t, J = 5.3, 4.6 Hz, 4H) 
13C NMR (100 MHz, DMSO-d6) δ 159.80, 152.67, 151.14, 148.84, 148.05, 146.12, 145.38, 134.94, 130.67, 
127.12, 124.12, 122.38, 121.03, 114.16, 112.98, 110.57, 49.95, 46.55, 29.05, 22.12 
IR (ATR): 3409 (br s), 2924 (s), 2853 (m), 2362 (m), 1702 (s), 1596 (s), 1494 (s), 1468 (s), 1433 (m), 1417 (m), 
1379 (s), 1334 (s), 1287 (w), 1220 (s), 1151 (w), 1054 (s), 1005 (s), 951 (m), 822 (w), 751 (s) 
HRMS (+ESI): calc. for C20H18N8NaO2S [M+Na]+ 457.1166 found 457.1166 
RF = 0.23 (5% MeOH in DCM) 
λmax = 322 nm 
t1/2 = 59 min 
PSS (Z/E, 5 min 365 nm) >17/83 (1H NMR spectroscopy in saturated DMSO-d6) 
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8.7.2 Crystallographic Data for Chapter 6.2
Triazolopyridazine 6.40 (Chapter 6.2)  
 
Identification code 19dtr6h 
Chemical formula C16H10ClN7 
Formula weight 335.76 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.020 x 0.060 x 0.460 mm 
Crystal habit yellow needle 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 4.1940(15) Å 
 b = 11.511(4) Å 
 
c = 15.759(6) Å 
 
α = 106.587(5)° 
β = 95.933(5)° 
γ = 94.986(6)° 
  
 
Volume 719.8(4) Å3  
Z 2 
Density (calculated) 1.549 g/cm3 
Absorption coefficient 0.279 mm-1 
F(000) 344 
Diffractometer Bruker APEX-II CCD 
Theta range for data collection 1.36 to 28.30° 
Index ranges -5<=h<=5, -15<=k<=15, -20<=l<=20 
Reflections collected 10872 
Independent reflections 3572 [R(int) = 0.0562] 
Coverage of independent 
reflections 
99.5% 
Absorption correction multi-scan 
Max. and min. transmission 0.7457 and 0.5649 
193 
 
Structure solution technique direct methods 
Structure solution program SHELXT (Sheldrick 2015) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018/3 (Sheldrick, 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3572 / 0 / 217 
Goodness-of-fit on F2 0.959 
Final R indices 
2452 data; I>2σ(I) R1 = 0.0543, wR2 = 0.1280 
R1 = 0.0833, wR2 = 0.1418 
 all data  
Weighting scheme 
w=1/[σ2(Fo2)+(0.0786P)2] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.408 and -0.439 eÅ-3 
R.M.S. deviation from mean 0.074 eÅ-3 
 
 
 
 
 
 
 
 
194 
 
8.8 NMR Spectra 
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8.8.2 NMR Spectra for Chapter 3.2 
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8.8.4 NMR Spectra for Chapter 3.4 
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8.8.5 NMR Spectra for Chapter 6.1 
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8.8.6 NMR Spectra for Chapter 6.2 
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